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GENERAL INTRODUC TION
Adult congenital heart disease
Worldwide each 2.3 seconds a child is born with a congenital heart defect, which 
corresponds to approximately 1.35 million newborns with congenital heart disease each 
year. This is based on a reported birth prevalence of congenital heart defects of ~1%, and 
4.3 births every second worldwide.1, 2 With the great advances in cardiothoracic surgery, 
postoperative care, and pediatric cardiology over the past decades, the survival of these 
patients has considerably improved and, consequently, the population of adults with 
congenital heart disease is steadily growing (Figure 1).3, 4 
 Adult congenital heart disease (ACHD) consist of a wide variety of diagnoses, 
based on the type of congenital heart defect and the type of corrective surgery that 
was performed. The complexity of the congenital diagnosis is a major determinant of 
clinical outcome.5, 6 At the most favorable end of the spectrum, patients with an isolated 
repaired atrial or ventricular septal defect and no hemodynamic residuals have an 
excellent prognosis with a life expectancy equal or close to the general population.5, 7-10 
In contrast, patients with moderate or severe lesions such as tetralogy of Fallot, a 
systemic right ventricle, or a univentricular heart are at increased risk of complications 
such as heart failure, arrhythmia, re-interventions and early demise.5, 11-15 These patients 
therefore require lifelong follow-up in specialized cardiac centers and are monitored 
by routine assessments including physical examination, ECG, echocardiography and 
exercise testing.16 
 A subset of patients with ACHD (~3%)17 develop pulmonary arterial hypertension, 
which is deﬁned as an elevated mean pulmonary artery pressure at rest (≥ 25 mmHg) 
with a low pulmonary capillary wedge pressure (≤ 15 mmHg) as measured by right 
heart catheterization.18 Pulmonary hypertension is usually the result of large systemic-
to-pulmonary shunts, such as an unrepaired atrial or ventricular septal defect. The 
subsequent chronic volume overload of the pulmonary vasculature causes adverse 
vascular remodeling and endothelial dysfunction.19 Other types of pulmonary 
hypertension can develop as a result of left heart disease, primarily non-cardiac diseases 
including obstructive sleep apnea or chronic obstructive pulmonary disease, or chronic 
pulmonary thromboembolism.20 Elevated pulmonary pressures have direct impact on 
the right ventricle, leading to right ventricular hypertrophy, dilatation, and dysfunction. 
Therefore, these patients are at increased risk of complications and most patients with 
pulmonary hypertension are followed-up and treated by a multidisciplinary team, 
including both cardiologists and pulmonologists.18
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FIGURE 1 - Increasing prevalence of ACHD in the European Union. Reprinted with permission from Eur Heart J 
2014;35:683-685; Baumgartner et al.
Risk prediction
Risk can be deﬁ ned as “a probability of damage, injury, liability, loss, or any other 
negative occurrence that is caused by external or internal vulnerabilities, and that may 
be avoided through preemptive action”.21 This general deﬁ nition directly explains the 
ultimate reason why physicians continuously strive to foresee a patients’ life path: in cases 
of presumed high risk, interventions will be considered, aimed at preventing adverse 
events. Moreover, risk prediction is essential to provide accurate patient information, to 
determine adequate follow-up strategies, and to optimize cost eﬃ  ciency of healthcare. 
Elements of the medical history, physical examination, and diagnostic tests (including 
ECG, echocardiography, cardiac magnetic resonance imaging, exercise testing, and blood 
biomarkers) may all provide information on which risk prediction can be based. Before 
the start of this thesis, cardiac function (measured with echocardiography or cardiac 
magnetic resonance imaging) and exercise capacity (measured with cardiopulmonary 
exercise testing or 6-minute walking test) were already known to be predictors of outcome 
in both patients with ACHD22-24 and in patients with pulmonary hypertension.25, 26 
Patients with an impaired ventricular function or a decreased exercise capacity are 
more likely to develop heart failure, which is the leading cause of death in both patient 
groups.27, 28 Other variables that correlate with cardiac function or exercise capacity may 
also be useful for risk stratiﬁ cation. To identify potential new prognostic parameters, it 
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can therefore be worthwhile to investigate the cross-sectional associations with these 
so-called ‘surrogate’ endpoints. Subsequently, longitudinal studies should relate these 
variables to the occurrence of adverse events during clinical follow-up.
 A biomarker can be deﬁned as “any substance, structure, or process that can be 
measured in the body or its products and inﬂuence or predict the incidence of outcome 
or disease”.29 Biomarkers, such as an echocardiographic measurement or a molecular 
substance, gene, enzyme, or hormone, can be used for the diagnosis and staging of 
disease, as indicators of disease prognosis, or to monitor treatment eﬀect.30 
Considering the established role of blood biomarkers such as N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) and high-sensitive Troponin-T in the general cardiology 
ﬁeld, the potential of these biomarkers in patients with ACHD is huge. Before the start 
of this thesis, both biomarkers were already part of the pulmonary hypertension 
guidelines in 2009.31 However, no prospective and longitudinal studies were available 
on the prognostic value of these biomarkers in patients with ACHD, and biomarkers did 
not play a role in the routine work-up of these patients. None of the guidelines that were 
available on patients with ACHD recommend the clinical use of any biomarker, due to 
the lack of substantial evidence.
This thesis
Most chapters in this thesis are based on analyses of the BioCon study: a single-center, 
prospective, observational follow-up study of 602 patients with ACHD, who were 
consecutively included during their routine visit at the outpatient clinic between 
2011 and 2013. At baseline and at four subsequent annual follow-up visits, patients 
underwent clinical assessment, ECG, echocardiography (every two years), and venous 
blood sampling for biomarker assessment (Figure 2). Before the start of this thesis, all 
patients had been included in this cohort, and at baseline measurements had been 
performed of NT-proBNP,32, 33 high-sensitive troponin-T,34 and growth-diﬀerentiation 
factor 15,35 which were found to be related to measurements of cardiac function and 
exercise capacity (thesis Jannet Eindhoven). During this thesis, the follow-up of all 
patients according to the study protocol was continued, and was completed in 2017. 
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FIGURE 2 - Schematic overview of the BioCon study protocol for inclusion and follow-up. 
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FIGURE 3 - Overview of the main congenital heart defects included in this thesis. Courtesy of dr. M.E. Menting, MD, 
PhD.
Atrial septal defect: closure of hemodynamically signiﬁcant defects can be performed either surgically or 
percutaneously. The repair is sometimes performed in adults, when the atrial septal defect is diagnosed at 
a later age. Without repair, the left-to-right shunt causes a chronic right-sided volume overload. This may 
eventually result in right ventricular enlargement, dysfunction and pulmonary arterial hypertension (PAH), 
which is associated with a worse prognosis. 
Congenital aortic stenosis: there may be an obstruction at the valvular level (mostly caused by a bicuspid 
aortic valve), at the supravalvular level, or at the subvalvular level. Repair can be performed surgically (e.g. 
resection, valve repair or replacement) or percutaneously (e.g. balloon dilatation or valve replacement).
Coarctation: aortic coarctation can be repaired surgically by an end-to-end anastomosis, subclavian ﬂap 
angioplasty, bypass graft or patch or percutaneously by an aortic stent.
Tetralogy of Fallot: this cyanotic heart defect is deﬁned by the combination of a ventricular septal defect, 
overriding aorta, pulmonary artery stenosis and right ventricular hypertrophy. It is repaired in childhood 
by an interventricular patch and resection of the pulmonary artery stenosis (and back in the days, often a 
transannular patch). 
Transposition of the great arteries: the systemic and pulmonary circulations are completely separated. 
Surgical repair in the neonatal period is essential, because without any possibility to mix oxygenated with 
unoxygenated blood (by e.g. a septal defect), this condition is not compatible with life. From the 1960s, 
surgical repair was performed by an atrial switch operation (Mustard/Senning): unoxygenated blood is 
redirected towards the left ventricle, and oxygenated blood is redirected to the right ventricle which pumps 
the blood into the systemic circulation. The current treatment of choice is anatomical correction by arterial 
switch operation, as described for the ﬁrst time in 1976.
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 The BioPulse study is an ongoing prospective observational cohort study of 
consecutive patients with pulmonary hypertension who were screened in our center 
from 2012 up to now. All patients underwent clinical assessment, ECG, echocardiography, 
computed tomography, right heart catheterization, and venous blood sampling at 
study inclusion and are two-yearly followed at the outpatient clinic. Before the start of 
this thesis, 53 patients had already been included. During this thesis, the inclusion and 
follow-up was continued and the analysis of multiple baseline biomarker measurements 
in the ﬁrst 104 patients was performed. Other projects which are embedded in this 
thesis are based on separate cross-sectional or retrospective cohort studies. In Figure 
3, an overview of the main congenital heart defects that are included in this thesis is 
shown.
Aim
The aim of this thesis is to establish novel prognostic tools that can be used for the risk 
stratiﬁcation of patients with ACHD or pulmonary hypertension. 
OUTLINE OF THE THESIS
Part I and II focus on separate tools that are of potential importance in the risk stratiﬁcation 
of patients with ACHD and/or pulmonary hypertension: imaging by echocardiography 
and cardiac magnetic resonance imaging (Part I), and blood biomarkers (Part II). The 
combination of multiple clinical characteristics, imaging ﬁndings and blood biomarkers 
in order to derive clinically useful risk predictions is described in Part III. A schematic 
overview of the study design, study cohorts, exposure and outcome of all chapters that 
are part of this thesis is provided in Table 1.
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TABLE 1 - Schematic outline of the thesis.
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Part I – Imaging
Right ventricular function and exercise capacity are established prognostic markers in 
ACHD or pulmonary hypertension; however, accurate measurements can be diﬃcult 
due to trabeculae.16, 18 Chapter 2 describes the impact of a novel method to deal with 
trabeculae in the measurement of right ventricular volumes and function with cardiac 
magnetic resonance imaging (CMR), in order to improve the accuracy and reproducibility 
of these measurements in patients with pressure overloaded right ventricles. The 
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potential prognostic value of speciﬁc imaging ﬁndings within congenital diagnostic 
groups is evaluated in Chapter 3; which focuses on the cross-sectional association 
between pulmonary artery size and exercise capacity in patients after arterial switch 
operation, and in Chapter 4; which focuses on the association of left atrial size and 
function with clinical outcome during prospective follow-up in adults with repaired 
tetralogy of Fallot. 
 Pulmonary arterial hypertension may develop in patients with an atrial septal defect 
and is associated with a worse prognosis. The prevalence of pulmonary hypertension 
before and after atrial septal defect closure at adult age is reviewed in Chapter 5, and 
is investigated using retrospective echocardiographic analysis of right ventricular 
pressures in Chapter 6. Echocardiographic ﬁndings and CMR ﬁndings that can be useful 
for the stratiﬁcation in patients with pulmonary arterial hypertension are reviewed in 
Chapter 7 and Chapter 8, respectively. 
Part II – Blood biomarkers
The cross-sectional association of matrix metalloproteinases with cardiac function and 
exercise capacity in patients with ACHD is described in Chapter 9. The prognostic value 
of N-terminal pro-B-type natriuretic peptide, troponin-T, and growth-diﬀerentiation 
factor 15, galectin-3, and red cell distribution width in patients with ACHD is 
prospectively investigated and described in Chapter 10, Chapter 11, and Chapter 12, 
respectively. In Chapter 13, we evaluate repeated N-terminal pro-B-type natriuretic 
peptide measurements in patients with ACHD and relate these to the occurrence of 
clinical events. Chapter 14 describes the prospectively investigated prognostic value 
of multiple biomarkers including N-terminal pro-B-type natriuretic peptide, troponin-T, 
growth-diﬀerentiation factor 15, and galectin-3 in adults with pulmonary hypertension 
due to diﬀerent etiologies. 
Part III – Risk prediction 
In Chapter 15, an overview is provided of the wide range of factors that could be useful 
to predict adverse clinical outcome in the entire cohort of patients with ACHD and within 
speciﬁc congenital subgroups, including components of the medical history, physical 
examination, ECG, echocardiography, presence of pulmonary arterial hypertension, 
cardiac magnetic resonance imaging, exercise testing, and biomarkers. In Chapter 16 
we combined a set of clinically relevant predictors into a validated risk prediction model 
for ACHD. Chapter 17 provides a summary and general discussion of all ﬁndings, and 
formulates implications for future research.
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ABSTRAC T
Background Cardiac magnetic resonance (CMR) imaging is the preferred method 
to measure right ventricular (RV) volumes and ejection fraction (RVEF). 
This study aimed to determine the impact of excluding trabeculae 
and papillary muscles on RV volumes and function in patients with 
RV pressure and/or volume overload and healthy controls and its 
reproducibility using semi-automatic software. 
Methods Eighty patients (pulmonary hypertension, transposition of the great 
arteries after arterial switch operation and after atrial switch procedure 
and repaired tetralogy of Fallot) and 20 controls underwent short-axis 
multislice cine CMR. End-diastolic volume (EDV), end-systolic volume 
(ESV), RV mass and RVEF were measured using 2 methods. First, manual 
contour tracing of RV endo- and epicardial borders was performed. 
Thereafter, trabeculae were excluded from the RV blood volume using 
semi-automatic pixel-intensity based software. Both methods were 
compared using a Student T test and 25 datasets were reanalyzed for 
reproducibility. 
Results  Exclusion of trabeculae resulted in signiﬁcantly decreased EDV, ranging 
from –5.7 ± 1.7 mL/m2 in controls to –29.2 ± 6.6 mL/m2 in patients 
after atrial switch procedure. RVEF signiﬁcantly increased in all groups, 
ranging from an absolute increase of 3.4 ± 0.8% in healthy controls 
to 10.1 ± 2.3% in patients after atrial switch procedure. Interobserver 
agreement of method 2 was equal to method 1 for RVEDV, RVESV and 
RVEF and superior for RV mass. 
Conclusions In patients with overloaded RVs exclusion of trabeculae from the blood 
volume results in a signiﬁcant change in RV volumes, RVEF and RV mass. 
Exclusion of trabeculae is highly reproducible when semi-automatic 
pixel-intensity based software is used.
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INTRODUC TION
Both in patients with pulmonary hypertension (PH) and in patients with diﬀerent types 
of congenital heart disease (CHD), the right ventricle (RV) performs under increased 
pressure loading. The RV adapts by hypertrophying, however at a certain point the RV 
is unable to cope with the increased pressures and RV failure will ensue. Consequently, 
RV function is an important determinant of prognosis and of therapeutic strategy in 
these patients. For instance, in patients with pulmonary valvular (PV) stenosis, timing 
of intervention is partly dependent on RV function.1  In patients with PH, deterioration 
of right ventricular ejection fraction (RVEF), increased RV end-diastolic volume (RVEDV) 
and stroke index are associated with poor outcome.2,3 Furthermore, for patients with 
transposition of the great arteries (TGA) after an atrial switch operation, in which the RV 
supplies the systemic circulation (i.e. systemic RV), decline in RV function is one of the 
most important clinical problems. Therefore, RV volumes and function are frequently 
used in follow-up of these patients, making accurate and reproducible measurements 
highly important.
 As both 2D and 3D echocardiography of the RV remain less reproducible than 
cardiac magnetic resonance imaging (CMR), the latter is still considered to be the 
reference standard for the quantiﬁcation of RV volumes and EF.4-7 Whether trabeculae 
and papillary muscles should be included or excluded from the blood volume is subject 
of debate. Throughout literature both methods are used.2,8-10 However, many studies 
have not clearly described whether trabeculae and papillary muscles were included or 
excluded from the RV blood volume.11-14 The impact of trabeculae is assumed to be small 
in healthy individuals, but Winter et al. showed that exclusion of trabeculae from the RV 
blood volume resulted in a substantial diﬀerence of RVEDV, RVESV and RVEF in patients 
with a systemic right ventricle.15 Although theoretically more accurate, Winter et al. also 
showed that manual tracing of trabeculae has low reproducibility and therefore can be 
considered less favorable for longitudinal follow-up.5,15
 Freling et al. recently reported that semi-automatic pixel-intensity based 
segmentation software is able to exclude trabeculae and papillary muscles from the 
RV blood volume with high reproducibility in tetralogy of Fallot (ToF) patients with 
predominantly volume overloaded RVs. Moreover, this resulted in a substantial diﬀerence 
in RV volumes and RVEF compared to the method that includes these structures in the 
RV blood volume.16 In patients with increased RV pressure the trabeculae are likely to be 
coarser. The impact and reproducibility of excluding trabeculae and papillary muscles 
with this semi-automatic software in patient groups with RV pressure overload has not 
been investigated up to now.
 The purpose of this multicenter study was to determine the impact of excluding 
trabeculae and papillary muscles, on RV volumes and function as assessed by CMR in 
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patients with pressure or combined pressure and volume overload of the RV and healthy 
controls. Secondly, we aimed to determine the reproducibility of this methodology 
when semi-automatic pixel-intensity based software is used.
METHODS
Study design and population
One hundred CMR studies were included in the analysis (median age 36.2 years, 51% 
male). Four groups of 20 adult patients with pressure overloaded RVs were analyzed: 
patients with pre-capillary PH, patients with right ventricular outﬂow tract obstruction 
(RVOTO) after arterial switch operation (ASO) for TGA, patients with repaired ToF and 
patients with TGA and atrial switch procedure (Mustard or Senning operation). A 
reference group of 20 healthy controls was also included.
 PH was deﬁned in accordance with the ESC/ESR guidelines as a mean pulmonary 
artery pressure of ≥ 25 mmHg and a pulmonary capillary wedge pressure of ≤ 15 mmHg.17 
Only patients with pre-capillary (i.e. with arterial vascular changes) PH were included, all 
were diagnosed with either chronic trombo-embolic or idiopathic PH. In all patients RV 
systolic pressure (RVSP) was measured using Doppler echocardiography on the day of 
CMR investigation. RVSP was measured using the peak velocity of tricuspid regurgitation 
plus estimated right atrial pressure. Patients with repaired ToF were included if a RVSP 
of ≥ 36 mmHg was measured by Doppler echocardiography.18 Patients after ASO were 
included if RVSP measured by Doppler echocardiography was ≥ 36 mmHg or if, using 
Doppler echocardiography, a mild or moderate RVOTO was measured, deﬁned as a 
maximum gradient of ≥ 25 mmHg. For patients with TGA and atrial switch procedure 
systolic blood pressure was used to determine RVSP. Basic patient characteristics for 
each patient group are illustrated in Table 1. Degree of pulmonary (PR) and tricuspid 
valve regurgitation (TR) were assessed semi-quantitatively with echocardiography, 
based on color-Doppler and continuous wave Doppler pattern and graded as: none or 
trace, mild, moderate or severe.
 In this retrospective study, CMR images from two tertiary referral hospitals were 
analyzed. One centre contributed 59 patient CMR datasets and 20 control subjects. The 
second centre provided the remaining 21 patient CMR datasets. The datasets in this 
study were obtained between May 2008 and July 2012. Prior to analysis, all patient and 
control data were encoded to preserve anonymity. All CMR datasets were acquired in 
a routine clinical setting and anonymized for analysis. The medical ethics committees 
waived the need for informed consent.
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TABLE 1 - Baseline characteristics of each patient group and healthy controls.
PH
n = 20
ASO
n = 20
TOF
n = 20
Atrial switch
n = 20
Controls
n = 20
Male gender 7 (35) 11 (55) 11 (55) 12 (60) 10 (50)
Age, year 55.0 ± 14.1 24.9 ± 4.0 29.1 ± 7.8 33.0 ± 6.3 36.7 ± 10.1
BSA, m2 1.93 ± 0.18 1.88 ± 0.18 1.87 ± 0.19 1.96 ± 0.21 1.88 ± 0.21
RVSP, mmHg 54 [37–65]
n = 20
40 [37–53]
n = 15
45 [41–50]
n = 20
120 [106–125]
n = 20
-
RVOT gradient, mmHg - 35 [29–42]
n = 8
33 [30–40]
n = 15
- 4 [3–8]
n = 20
TR grade
- No/trace
- Mild
- Moderate
- Severe
- Missing 
7 (35)
9 (45)
4 (20)
-
-
12 (60)
7 (35)
1 (5)
-
-
10 (50)
7 (35)
3 (15)
-
-
1 (5)
14 (70)
4 (20)
1 (5)
-
20 (100)
-
-
-
-
PR grade*
- No/trace
- Mild
- Moderate 
- Severe
- Missing
14 (70)
6 (30)
-
-
-
14 (70)
3 (15)
-
-
2 (10)
9 (45)
4 (20)
-
6 (30)
1 (5)
13 (65)
2 (10)
-
-
5 (25)
20 (100)
-
-
-
-
Data is presented as n (%), mean ± SD or median [IQR]. *Aortic regurgitation grade in patients after atrial 
switch. Abbreviations: ASO, arterial switch operation; BSA, body surface area; PH, pulmonary hypertension; 
PR, pulmonary regurgitation; RVOT, right ventricular outﬂow tract; RVSP, right ventricular systolic pressure; 
TOF, tetralogy of Fallot; TR, tricuspid regurgitation. 
CMR imaging protocol
Datasets were obtained using commercially available 1.5 T MR scanners (Ingenia 
R4.1.2; Philips Healthcare, Best, The Netherlands (n = 79); Magnetom Sonata, Siemens 
Healthcare; (n = 7) and Magnetom Avanto; Siemens Healthcare, Erlangen, Germany (n 
= 14)). For all studies dedicated chest or torso phased array parallel-imaging capable 
surface coils were used with 12–28 elements. CMR images were acquired during repeated 
end-expiratory breath holds. Cine images were acquired using a retrospectively gated 
balanced steady state free precession sequence with 25–30 cardiac phases per cardiac 
cycle. Slice thickness used were 6 mm with 4 mm gap (n = 21) and 8 mm with 0 mm gap 
(n = 79). Sequences included multi-slice, multi-phase cine short-axis, longitudinal four-
chamber, vertical two-chamber and RV outﬂow views. The multi-slice cine short-axis 
acquisitions were planned from above the mitral valve up to and including the cardiac 
apex. The following ranges of other scan parameters were used: TR 2.7–3.4 ms; TE 1.1–
1.7 ms; ﬂip angle 80º–90º; matrix 171–192; voxel size: 1.25 x 1.25 x 8.0 mm and 1.7 x 1.7 
x 6.0 mm. Parallel imaging factors varied between 0–3. 
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CMR image analysis
Image analysis was performed using Qmass MR Research edition version 7.4.14.0 (Medis, 
Leiden, the Netherlands).16 Segmentation was performed on end-diastolic and end-
systolic phases only. The end-diastolic and end-systolic phases were selected by visual 
assessment as the phases with the largest and smallest RV cavity sizes respectively, taking 
into account the longitudinal four-chamber, vertical two-chamber and RV outﬂow tract 
as reference views. If visual assessment was diﬃcult, multiple frames were contoured to 
determine the correct end-diastolic or end-systolic phase. Using a previously described 
RV analysis protocol the RV epicardial and endocardial contours were manually traced 
from the most apical to the most basal short-axis slice.19 Only the portion of the outﬂow 
tract below the pulmonary valve was included in the blood volume in the basal slice 
in which the pulmonary valve was visible. If more than 50% of the tricuspid annulus or 
atrium was visible in a basal slice the valve area was excluded from the blood volume. 
Epicardial and endocardial contours overlapped at valve borders and septum, as the 
septum was considered part of the left ventricle. For patients with a systemic RV, the 
septum was considered to be part of the RV and included in the RV myocardial volume.
 Based on the methodology described above, two methods were used for determining 
RV volumes, function and mass. With method 1 trabeculae and papillary muscles were 
included in the blood volume. With method 2, trabeculae and papillary muscles were 
excluded from the blood volume and added to the myocardial volume (Figure 1). For 
both methods the volume between the endo- and epicardial contour was considered as 
myocardial volume. Selection of trabeculae and papillary muscles was done using semi-
automatic pixel-intensity based segmentation software. The segmentation software is 
based on the signal intensity distribution of MR images and has been described in detail 
by Freling et al.16 In brief, voxels within the epicardial contour are classiﬁed as either 
blood volume or myocardial volume according to their signal intensity, taking into 
account spatial variations in signal intensity. Based on this algorithm, trabeculae and 
papillary muscles were excluded from the blood volume and included in the myocardial 
volume. The algorithm works similar for images generated by the diﬀerent scanners 
used in this study. It was possible to manually change the threshold for every slice, in 
order to select the same trabeculae in end-diastole and end-systole. Observers selected 
only trabeculae with a signal intensity similar to the intensity of the RV myocardium. 
Individual voxels could also be selected or deselected in case of artifacts due to 
nonlaminar ﬂow.
 For both methods, RV volumetric parameters were calculated by the sums of the 
traced contours multiplied by slice thickness in all short-axis slices. For method 1 the 
volume of trabeculae and papillary muscles was included in the RV blood volume and 
for method 2 this was excluded from the blood volume. Stroke volume (SV) was deﬁned 
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as the diﬀerence between end-diastolic volume (EDV) and end-systolic volume (ESV). All 
volumetric data were indexed for body surface area (BSA), which was calculated using 
the Dubois-Dubois formula (0.20247 x height(m)0.725 x weight(kg)0.425). EF was calculated 
by SV / EDV * 100%. For method 1 myocardial volume was deﬁned as epicardial minus 
the endocardial contour, for method 2 end-diastolic trabecular volume was added to 
the myocardial volume. RV mass was quantiﬁed by multiplying the speciﬁc density of 
myocardium (1.05 g/mL) with the end-diastolic myocardial volume.
FIGURE 1 - RV contour tracing only (A-1 and B-1) and with semiautomatic selection of trabeculae (A-2 and B-2).
Two methods of measuring RV volumes in a healthy control (A) and patient after atrial switch procedure (B). 
Method 1: inclusion trabeculae in the blood volume (A-1 and B-1); Method 2: exclusion of trabeculae from the 
blood volume, using identical endocardial contours (A-2 and B-2).
Reproducibility
Intraobserver reproducibility of both methods was assessed by reanalyzing 5 randomly 
selected CMR datasets from every patient group, as well as the healthy control 
subjects by the primary observer. In total 25 datasets were reanalyzed. To determine 
interobserver variability a second observer reanalyzed the same 25 datasets. Observers 
were unaware of the results of the ﬁrst analysis and there was an interval of at least two 
weeks between the ﬁrst and second analysis. The observers had equal experience in RV 
volumetric analysis and received the same training for Qmass MR research edition.
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Statistical analysis
Continuous data were expressed as median and interquartile range (IQR) or mean value 
± standard deviation (SD) as appropriate. Mean diﬀerences ± SD between method 1 
and 2 were calculated for RVEDV/m2, RVESV/m2, RVSV/m2, RVEF and RV mass/m2, using 
the paired Student’s T-test. Diﬀerences in RVEDV/m2, RVESV/m2 and RVEF found in the 
patient groups were compared to the healthy control group using a one-way ANOVA 
with posthoc Dunnett’s test. For the one-way ANOVA data underwent logarithmic 
transformation if necessary (i.e. if homogeneity of variances was inequal). Intra- and 
interobserver agreement were assessed using Bland-Altman plots and intraclass 
correlation coeﬃcients (ICC). Paired Student’s T-test was used to test for signiﬁcant 
diﬀerences between observer 1 and 2 and between the ﬁrst and second measurements 
of observer 1. Mean diﬀerences ± SD for all measurements were calculated. Lastly to 
compare reproducibility of both methods the inter- and intraobserver agreement 
coeﬃcient (AC) of method 1 and 2 were calculated for each measurement. The AC was 
calculated using the following formula: AC = 100 * (1 – 2 * |Obs
1
 – Obs
2
| / Obs
1
 + Obs
2
); 
in which Obs
1
 and Obs
2
 are the ﬁrst and the second observation (or observer). The AC 
calculated for method 1 and 2 were compared using a paired Wilcoxon signed rank 
test. Using a Bonferroni correction for multiple measurements p-values of < 0.01 were 
considered statistically signiﬁcant. Data analysis was performed in IBM SPSS statistics 
version 20.0 (IBM SPSS, Chicago, IL).
RESULTS
Exclusion of trabecular volume
RVEDV/m2, RVESV/m2, RVEF and RV mass/m2 measured including (method 1) and 
excluding (method 2) RV trabeculae from the RV blood volume (method 2) are listed 
in Table 2. For all patient groups and for healthy controls, exclusion of trabeculae and 
papillary muscles from the blood volume resulted in a signiﬁcantly decreased RVEDV/
m2 and RVESV/m2 and a signiﬁcantly increased RVEF and RV mass/m2 (Table 2). Of note, 
the diﬀerences in EDV/m2, ESV/m2, RVEF, and RV mass between both methods were 
most pronounced in the patients after atrial switch procedure and least pronounced 
in the PH patients, with mean absolute diﬀerences in EF of 10.1 ± 2.3% and 4.7 ± 1.6%, 
respectively. In healthy controls an absolute increase in RVEF of 3.4 ± 0.8% was measured. 
Of note, the diﬀerences in EDV/m2, EDV/m2, RVEF and RV mass were signiﬁcantly larger 
in all patient groups compared with the healthy controls (p < 0.01). 
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TABLE 2 - RV volumes and function.
PH
(mean ± SD)
ASO
(mean ± SD)
TOF
(mean ± SD)
Atrial switch
(mean ± SD)
Controls
(mean ± SD)
RVEDV (mL/m2)
Method 1 117.4 ± 31.8 99.4 ± 23.3 147.0 ± 42.5 139.9 ± 33.6 96.9 ± 18.9
Method 2 105.1 ± 28.4 88.3 ± 21.2 124.8 ± 38.0 110.7 ± 28.7 91.2 ± 17.8
Diﬀerence –12.3 ± 4.6† –11.1 ± 3.3† –22.2 ± 6.0† –29.2 ± 6.6† –5.7 ± 1.7†
RVESV (mL/m2)
Method 1 75.4 ± 30.0 50.1 ± 13.3 85.5 ± 27.8 85.9 ± 26.2 47.5 ± 11.5
Method 2 62.7 ± 25.9 39.2 ± 11.3 63.7 ± 23.2 57.1 ± 21.7 41.6 ± 10.5
Diﬀerence –12.7 ± 4.8† –10.9 ± 3.3† –21.8 ± 6.0† –28.8 ± 6.5† –5.9 ± 1.5†
RVSV (mL/m2)
Method 1 42.0 ± 7.9 49.3 ± 11.7 61.5 ± 19.4 54.0 ± 14.9 49.4 ± 8.6
Method 2 42.4 ± 8.0 –0.2 ± 0.6 61.0 ± 19.6 53.6 ± 14.7 49.6 ± 8.6
Diﬀerence –0.4 ± 0.6* –0.2 ± 0.6 –0.4 ± 0.8* –0.4 ± 0.9 0.2 ± 0.5
RV mass (gr/m2)
Method 1 18.5 ± 5.5 20.1 ± 5.0 25.4 ± 7.1 43.3 ± 9.1 13.0 ± 3.0
Method 2 31.4 ± 9.8 31.1 ± 7.5 48.7 ± 12.3 73.9 ± 15.4 19.0 ± 4.2
Diﬀerence 12.9 ± 4.9† 11.0 ± 4.8† 23.3 ± 6.3† 30.6 ± 6.9† 6.0 ± 1.8†
RVEF (%)
Method 1 37.2 ± 8.5 49.6 ± 5.0 42.1 ± 6.9 39.2 ± 7.8 51.3 ± 3.8
Method 2 41.9 ± 9.1 55.8 ± 5.1 49.4 ± 12.3 49.3 ± 9.7 54.7 ± 4.1
Diﬀerence 4.7 ± 1.6† 6.1 ± 1.7† 7.2 ± 1.7† 10.1 ± 2.3† 3.4 ± 0.8†
RV volume, mass and ejection fraction measured with inclusion (method 1) and exclusion of trabeculae from 
the RV blood volume (method 2). All volumetric data are indexed for BSA. Legend: *p < 0.05 using paired 
Student’s T-test; †p < 0.001 using paired Student’s T-test. Abbreviations: ASO, arterial switch operation; 
PH, pulmonary hypertension; RVEDV, right ventricular end-diastolic volume; RVEF; right ventricular ejection 
fraction; RVESV, right ventricular end-systolic volume; RVSV, right ventricular stroke volume; SD, standard 
deviation; TOF, tetralogy of Fallot.
Reproducibility
For both methods, inter- and intraobserver agreement was high in all measurements, 
as illustrated by high ICCs with small limits of agreement (Table 3; Figure 2). For both 
methods, RVEDV, RVESV and RV mass showed signiﬁcant diﬀerences between repeated 
measurements. However, mean diﬀerences were small and considered not clinically 
relevant. In Figure 2, Bland-Altman plots show interobserver variability for RVESV, RVEDV 
and RVEF for both methods. For RVEDV, RVESV and RV mass the limits of agreement 
were narrower when trabeculae and papillary muscles were excluded from the RV 
blood volume (method 2). The inter- and intraobserver AC of both methods was not 
C H A P T E R  2  -  I m p o r t a n c e  o f  t r a b e c u l a e  i n  P O R V
32 
statistically signiﬁ cantly diﬀ erent for RVEDV, RVESV and RVEF (p > 0.1). Method 2 had a 
signiﬁ cantly better interobserver AC than method 1 for RV mass measurement, with a 
median (IQR) interobserver AC of respectively 94.1 (92.1–97.1)% and 77.2 (72.1–82.6)%.
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FIGURE 2 - Bland-Altman plots for method 1 and method 2.
Bland-Altman plots showing the mean value of both observers on the x-axis and absolute diﬀ erences 
between the observers on the y-axis for each paired observation. Limits of agreement are deﬁ ned as the 
mean diﬀ erence ± 2 SD. 
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TABLE 3 - Inter- and intraobserver agreement.
Interobserver (Obs2 – Obs1
I) Intraobserver (Obs1
II – Obs1
I)
ICC Mean difference ± SD P-value ICC
Mean 
difference ± SD P-value
RVEDV (mL/m2)
   Method 1 0.981 –2.4 ± 6.7 0.089 0.990 2.8 ± 5.1 0.012
   Method 2 0.987 1.8 ± 4.5 0.059 0.985 3.0 ± 5.0 0.006
RVESV (mL/m2)
   Method 1 0.970 –2.3 ± 5.2 0.039 0.982 1.1 ± 4.2 0.209
   Method 2 0.974 1.7 ± 3.5 0.027 0.969 1.0 ± 3.8 0.194
RVEF (%)
   Method 1 0.934 0.9 ± 2.6 0.086 0.965 0.4 ± 1.8 0.241
   Method 2 0.934 –0.5 ± 2.6 0.354 0.954 0.6 ± 2.2 0.189
RV mass (gr/m2)
   Method 1 0.965 5.8 ± 3.5 0.000 0.983 0.5 ± 2.3 0.283
   Method 2 0.993 1.4 ± 2.6 0.012 0.990 0.3 ± 3.2 0.694
P-value obtained using paired student T-test. Abbreviations: ICC, intraclass correlation coeﬃcient; Obs 
2
 = 
second observer; Obs
1
I = ﬁrst measurement of the ﬁrst observer; Obs 
1
II = second measurement of the ﬁrst 
observer; RVEDV, right ventricular end-diastolic volume; RVEF; right ventricular ejection fraction; RVESV, right 
ventricular end-systolic volume; SD, standard deviation.
DISCUSSION
Exclusion of trabeculae and papillary muscles resulted in substantial alterations of RV 
volumes, RVEF and RV mass in a wide range of patient populations with pressure and 
volume overloaded RVs. Furthermore, we found that these diﬀerences in RV parameters 
vary widely depending on the exact condition underlying RV overload. Although 
prior studies already established this fact in general terms, the major impediment 
to widespread adoption of this method in clinical practice was the lack of a fast and 
reproducible way to measure the exact amount of RV trabeculae and papillary muscles. 
We found that exclusion of RV trabeculae using semi-automatic pixel-intensity based 
software resulted in fast and highly reproducible RV measurements. This is opposed 
to manual tracing of trabeculae which has previously been shown to be unreliable.15,20
 Accurate and reproducible measurement of RV volume and function is mandatory 
because of the prognostic and therapeutic implications in patients with PH and 
CHD.1,3,21,22 The current study underscores that exclusion of trabeculae has a signiﬁcant 
impact on RV volumes, RVEF and RV mass in both CHD and PH patients with overloaded 
RVs. Moreover, the impact of excluding trabeculae varied widely between patient 
groups, from a change in RVEDV of –12.3 ± 4.6 mL/m2 in PH patients to –29.2 ± 6.6 mL/
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m2   in patients with a systemic RV. Healthy controls also exhibited signiﬁcant diﬀerences 
in all RV measurements, but these were signiﬁcantly smaller (p < 0.01) compared to the 
diﬀerences observed in patient groups. Consequently, RV volume and function in most 
patients will be closer to or in the normal range after exclusion of trabeculae from the 
RV blood volume.
 Currently, there is no clear standard for RV volumetric analysis or consensus on 
how trabecular structures should be handled. Major obstacles to exclude trabeculae 
and papillary muscles from the RV blood volume have been the time investment of 
performing manual tracing of these structures and the low reproducibility.15,20 Several 
studies in CHD patients diﬀer on the point of in- or excluding RV trabeculae and papillary 
muscles from the RV blood volume3,4,11,12,20,22,23 or are not clear about the methodology 
used.13,14 In the current study we found that using semi-automatic pixel-intensity based 
segmentation software results in highly reproducible RV volumetric measurements. 
Because in- or exclusion of trabeculae has a major impact on RV parameters as measured 
with CMR, studies using diﬀerent methodologies are incomparable. Application of the 
method described in this study may be a step forward to achieve uniformity of RV 
volumetric measurements, which is important to compare the eﬀect of interventions 
aimed at preserving or improving RV function. However, there are only few reports using 
this new methodology and it is of great importance that new studies are undertaken to 
determine clinically relevant cut-oﬀ values using this semi-automated method.
 When comparing the current study to prior studies investigating the impact 
of trabeculae and papillary muscles on RV volume and function, some important 
diﬀerences can be observed. Winter et al. studied 29 patients with systemic right 
ventricles and found an increase in RVEF of 7.4 ± 3.9 % compared to 10.1 ± 2.3 % in our 
report. In contrast to our results, which are based on semi-automated pixel-intensity 
based segmentation, manual exclusion of trabeculae was substantially less reproducible 
in the study of Winter et al.15 Moreover, both our study and the study by Freling et al. 
even demonstrated a higher reproducibility for RVEDV and RV mass, using this semi-
automatic method to exclude trabeculae compared with only endocardial contour 
tracing.16 We attribute this ﬁnding to observer variation in handling of trabeculae 
adjacent to the endocardial border. This can result in small diﬀerences for endocardial 
contour tracing, which will be rectiﬁed if all trabeculae are excluded. Sievers et al. studied 
the eﬀect of trabeculae on RV volumes in healthy controls and reported a diﬀerence in 
RVEF of only 1.72% compared with 3.4 ± 0.8% in our study, however baseline RVEDV 
values also diﬀered considerably with ours, indicating that these study populations 
are not comparable.24 Freling et al. investigated a diﬀerent group of ToF patients with 
volume overloaded RVs, using the same software package as described in the current 
study, and found a similar increase in RVEF of 7 ± 4 % versus 7 ± 2% in our study.16 
02I m p o r t a n c e  o f  t r a b e c u l a e  i n  P O R V  -  C H A P T E R  2
35 
02
 The current study only focused on one of the possible sources of error in RV 
volumetric assessment with CMR. An important source of error remains basal slice 
selection and delineation of the tricuspid valve. In this study a short-axis orientation for 
RV volumetric measurement was used, as this is standard practice in our hospitals. Axial 
orientation, however, might result in higher reproducibility than short-axis orientation 
in CHD patients with severely dilated RVs, decreasing the diﬃculty of valve delineation 
in the basal slices.25,26 To minimize errors at the tricuspid and pulmonic valve, images 
were cross-linked to RV two-chamber, four-chamber and RV outﬂow tract views. 
Furthermore, only a small portion of the patients had severely dilated RVs, therefore 
it is unlikely that the slice orientation would have resulted in important diﬀerences for 
the current study. The impact and reproducibility of the semi-automatic software used 
in the current study will likely be similar in axial slice orientation, as the software is not 
restricted by geometric assumptions and uses signal intensity to select trabeculae. 
Finally, another source of error might be inadequate selection of the RV end-systolic 
frame. In daily practice both RV ESV and LV ESV are often assessed in the LV end-systolic 
frame. However, in patients with CHD, who often have a right bundle branch block, timing 
of the RV end-systolic frame can be delayed compared to the LV end-systolic frame.27 
Therefore RV end-diastolic and end-systolic phase was based solely on RV cavity size.
Study limitations
This study is unable to determine whether in- or excluding trabeculae best represents 
true RV volumes, as a gold standard in vivo is lacking. Because the stroke volume 
remains equal with both methodologies, other CMR measurements are unable to serve 
as a reference standard. However, theoretically exclusion of trabeculae is more accurate 
as these do not contribute to RV blood volumes in end-diastole or end-systole. 
 No invasive measurements were available to determine the true RV pressure in these 
patients. Therefore, estimations of RVESP and RVOT gradient based on Doppler-derived 
ﬂow velocities were used, which might not always be accurate and have limitations. 
Nonetheless these are the best available non-invasive alternatives to assess the degree 
of RV pressure overload or RVOT stenosis. 
CONCLUSIONS
Exclusion of trabeculae and papillary muscles has a signiﬁcant impact on measured 
RV volumes, mass and EF. The magnitude of the diﬀerences varies between patient 
groups and is signiﬁcantly larger in all investigated patient groups with overloaded 
RVs than in healthy controls. Importantly, exclusion of trabeculae with semi-automatic 
pixel-intensity based software is highly reproducible and superior compared to manual 
contour tracing for RV mass.
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ABSTRAC T
Background Despite excellent survival in patients after the arterial switch operation, 
re-intervention is frequently required and exercise capacity is decreased 
in a substantial number of patients. This study relates right-sided 
imaging features in patients long-term after the arterial switch operation 
to exercise capacity and ventilatory eﬃciency, in order to investigate 
which lesions are functionally important.
Methods Patients operated in the UMC Utrecht, the Netherlands (1976–2001) and 
healthy controls underwent cardiac magnetic resonance imaging and 
cardiopulmonary exercise testing within 1 week. We measured main, left 
and right pulmonary artery cross-sectional areas, pulmonary blood ﬂow 
distribution, peak oxygen uptake (VO
2 
peak%), and minute ventilation 
relative to carbon dioxide elimination (VE/VCO
2 
slope).
Results  A total of 71 patients (median age 20 [range 12–35] years, 73% male) and 
21 healthy controls (median age 26 [range 21–35] years, 48% male) were 
included. Main, left, and right pulmonary artery areas were decreased 
compared with controls (190 vs. 269 mm2/m2, 59 vs. 157 mm2/m2, 98 
vs. 139 mm2/m2, respectively, all p < 0.001); however, pulmonary blood 
ﬂow distribution was comparable (p = 0.722). VO
2 
peak% and VE/VCO
2 
slope were 88 ± 20% and 23.7 ± 3.8, respectively, with 42% and 1% of 
patients demonstrating abnormal results (≤ 84% and ≥ 34, respectively). 
The main pulmonary artery area signiﬁcantly correlated with VO
2 
peak% 
(r = 0.401, p = 0.001) and pulmonary blood ﬂow distribution with VE/
VCO
2
 slope (r = –0.329, p = 0.008). Sub-analysis (< 18, 18–25, > 25 years) 
showed that the main pulmonary artery area was smaller in older age 
groups. In multivariable analysis, the main pulmonary artery area was 
independently associated with VO
2 
peak% (p = 0.032).
Conclusion In adult patients after the arterial switch operation, narrowing of the main 
pulmonary artery is a common ﬁnding and is the main determinant of 
limitation in functional capacity, rather than pulmonary branch stenosis.
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INTRODUC TION
Transposition of the great arteries is the most common cyanotic congenital heart 
defect, occurring in 4.7 of 10.000 newborns.1 The current treatment of choice is neonatal 
arterial switch operation, as described in 1976 by Jatene and colleagues.2
Follow-up studies show excellent results with low perioperative mortality and high 
25-year survival (> 95%). However, the cumulative risk of re-intervention increases up 
to 25% in adult patients.3,4  Most of these patients have supravalvular neopulmonary 
artery or pulmonary branch stenosis and undergo balloon dilatation or stenting by 
catheter intervention or surgical pulmonary artery reconstruction.4 Apart from re-
intervention, long-term follow-up studies show that exercise capacity is decreased 
in a signiﬁcant subset of patients.5-7 Reduced exercise capacity has been associated 
with right-sided obstructive lesions.6,7 Still, long-term follow-up data are limited, and 
deﬁned management strategies for subclinical anatomic or physiologic abnormalities 
are lacking.8
 This study compared patients long-term after the arterial switch operation with 
healthy controls, focusing on right ventricular (RV) function, pulmonary artery and 
branch cross-sectional areas, pulmonary branch relative area change, and pulmonary 
blood ﬂow (PBF) distribution. Second, these imaging features were related to exercise 
capacity and ventilatory eﬃciency, in order to determine which lesions are functionally 
important and therefore potentially amenable to re-intervention.
METHODS
Study population
We performed a cross-sectional cohort study between August 2011 and February 2014. 
All patients who underwent an arterial switch operation in our center who were aged 
more than 12 years (1976-2001) were approached. Patients prospectively underwent 
cardiac magnetic resonance (CMR) imaging, echocardiography, and cardiopulmonary 
exercise testing within 1 week, without any change in clinical condition. Healthy control 
subjects (aged 18–35 years) underwent CMR and echocardiography with the same study 
protocol. Exercise testing was not performed in healthy controls because reference 
values are well established.9 The institutional review committee of the University 
Medical Center Utrecht approved this study. Informed consent was obtained from all 
patients, parents if aged less than 18 years, and healthy controls. Patient characteristics 
were obtained from the patient chart. Patients with a homograft, signs of myocardial 
ischemia during the exercise test, or claustrophobia were excluded.
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Cardiac magnetic resonance acquisition
Patients and controls were scanned according to a predeﬁned imaging protocol without 
anesthesia or sedation. A 1.5-T system (Ingenia R4.1.2, Philips Healthcare, Best, The 
Netherlands) was used with a dedicated chest phased-array parallel imaging-capable 
surface coil with a maximum of 36 active elements.
 Steady-state free precession cine images were acquired in various orientations 
(short axis, 4-chamber and 2-chamber long axis, right and left ventricular outﬂow tract 
views in 2 planes) during repeated end-expiratory breath holds. Multi-slice cine short-
axis acquisition was planned from the apex to well above the tricuspid and mitral valve: 
TR / TE 3.4 / 1.69 ms, voxel size 1.25 × 1.25 × 8 mm, ﬂip angle 90°, matrix 192 × 171 mm, 
30 frames / cycle. 
 Gadolinium-enhanced magnetic resonance angiography (MRA) images of the 
pulmonary vasculature were performed with non-electrocardiography gated time-
resolved 3-dimensional (3D) spoiled gradient echo sequence: TR / TE 5.2 / 1.49, voxel 
size 0.94 × 0.94 × 2 mm, 60 slices, ﬁeld of view 300, matrix 308 × 125, keyhole percentage 
25%, 3 dynamics, keyhole scan time 2.8 seconds. Gadopentetate dimeglumine (0.2 mL/
kg, injection rate 1.5 mL/s) was injected intravenously followed by saline ﬂush (25 mL).
 Quantitative through-plane ﬂow through the left pulmonary artery (LPA) and right 
pulmonary artery (RPA) was measured with a retrospectively electrocardiography 
gated, velocity encoded phase-contrast sequence: TR / TE 5.2 / 3.1 ms, voxel size 2.5 × 
2.5 × 8 mm, ﬂip angle 12°, ﬁeld of view 320, matrix 128 × 100, temporal resolution 20 
frames / cycle.10 In case of aliasing, the sequence was rescanned at a higher velocity 
encoding range. LPA and RPA ﬂow measurements were performed on the narrowest 
points identiﬁed on scout, black-blood, and MRA images.
Cardiac magnetic resonance analysis 
RV volumetric analysis was performed by manual tracing of endocardial and epicardial 
contours, using Qmass MR Research edition (version 7.4, Medis, Leiden, The Netherlands), 
with a previously described RV analysis protocol.11 Trabeculae and papillary muscles 
were selected and excluded from the blood volume using semiautomatic threshold-
based segmentation software, which is based on the signal intensity distribution of the 
voxels.12
 Diameters and areas of the main pulmonary artery (MPA), LPA, and RPA were 
measured on 3D MRA images in OsiriX Imaging Software for MacOS 10.7 (version 
5.5.2, 32-bit, Pixmeo, Geneva, Switzerland). Narrowest vessel lumina were selected in 
2 perpendicular views to obtain the smallest cross-sectional area in the third view. The 
full width at half maximum method was used to distinguish vessel from surrounding 
tissue.13
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 Velocity-encoded CMR data were analyzed using QFlow (version 5.6, Medis, Leiden, 
The Netherlands). Contours were manually traced for the LPA and RPA lumina in 
all phases. In this way, maximal and minimal areas of the pulmonary branches were 
obtained. Flow data were determined with a velocity analysis of each voxel in all phases. 
One researcher performed all CMR analyses and was blinded for the results of the 
cardiopulmonary exercise test.
Calculation of right-sided imaging features
All volumetric data were indexed for body surface area, calculated by the Dubois formula. 
Pulmonary branch relative area change was calculated by (maximal area – minimal 
area) / minimal area x 100%. To express the degree of unilateral pulmonary branch 
stenosis, relative branch area was calculated by smallest pulmonary branch area / (LPA 
+ RPA area) x 100%. Signiﬁcant unilateral pulmonary branch stenosis was deﬁned as a 
relative branch area of <30%. PBF distribution was calculated by relative eﬀective stroke 
volume (forward ﬂow – backward ﬂow per heart beat) to the left and right lung: LPA (or 
RPA) eﬀective stroke volume / (LPA + RPA eﬀective stroke volume) x 100%. Abnormal 
PBF distribution was deﬁned as a greater than 15% point deviation from normal 
(LPA 45 : RPA 55%, thus < 30% LPA relative ﬂow or < 40% RPA relative ﬂow).
Echocardiography
Doppler transthoracic echocardiography was performed on a Toshiba Artida (Toshiba, 
Tokyo, Japan) with a 5-MHz transducer. The greatest continuous-wave velocity of the 
tricuspid regurgitation jet was used to express RV systolic pressure, using the Bernoulli 
equation (4TR2). The greatest continuous-wave velocity measured across the pulmonary 
valve was used as an index of RV outﬂow tract (RVOT) obstruction.6
Exercise testing
Patients performed a cardiopulmonary exercise test using an electronically braked 
cycle ergometer (Lode Corrival, Lode BV, Groningen, The Netherlands). Before exercise, 
forced expiratory volume in the ﬁrst second (FEV 
1
) was measured. After a rest period of 
3 minutes and 3 minutes of unloaded cycling, the work rate was increased in a ramp-like 
protocol with 15, 20, or 25 Watts per minute. It was aimed to complete the test within 
8 to 12 minutes.14 Maximum eﬀort was deﬁned as a peak respiratory exchange ratio of 
greater than 1.0 for children and greater than 1.1 for adults. Indications for premature 
test termination are provided by the American Thoracic Society / American College of 
Chest Physicians.9
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 During exercise, oxygen uptake (VO
2
), carbon dioxide elimination (VCO
2
), and minute 
ventilation (VE) were recorded using a computerized breath-by-breath analyzer (ZAN 
600, ZAN Meßgeräte GmbH, Accuramed BVBA, Herk-de-Stad, Belgium). Respiratory 
exchange ratio was calculated by VCO
2
/VO
2
 and breathing reserve by (1 – peak VE 
/ [FEV
1
 x 40]) x 100%. Peak oxygen uptake (VO
2 
peak%) was expressed as percentage 
of the predicted value, based on age, sex, height, and body weight.15 Ventilatory 
eﬃciency (minute ventilation relative to carbon dioxide elimination; VE/VCO
2
 slope) was 
calculated using linear regression, up to the respiratory compensation point. Peak heart 
rate 85% or less, VO
2
 peak 84% or less, and VE/VCO
2
 slope 34 or greater were considered 
abnormal.9 Speciﬁc reference values for children were applied in patients aged 12 to 18 
years.16
Reproducibility
Intra- and interobserver reproducibility of RV function analysis was previously assessed 
and published.11 In addition, we assessed reproducibility of 3D MRA analysis by blinded 
re-analysis of 10 random datasets by a second observer. 
Statistical analysis
For all variables, the distribution was tested using the Shapiro-Wilk test. Continuous data 
were expressed as mean value ± standard deviation or median [interquartile range] as 
appropriate. Depending on the distribution of data, the independent-samples T-test 
or the Mann-Whitney U test was used to compare groups. For categorical data, the chi-
square test was used. Associations were evaluated using Pearson’s or Spearman’s rho (r) 
coeﬃcient as appropriate. 
 For the sub-analysis, we could not deﬁne clear changes in surgical strategies over 
time. Therefore, we chose to deﬁne three age groups (< 18, 18–25, > 25 years), based 
on approximately equal years and patients per subgroup. Sub-analysis for three pre-
deﬁned age groups was performed using chi-square Mantel-Haenszel tests and linear 
regression for dichotomous and continuous outcomes, respectively. 
 Associations were adjusted for age, sex and operative characteristics using 
multivariable linear regression. Reproducibility was tested with intraclass correlation 
coeﬃcients and paired-samples T-test. Mean relative diﬀerences were calculated with 
Obs
1
 – Obs
2
 / ((Obs
1
 + Obs
2
) / 2) x 100%. All data analysis was performed in IBM SPSS 
statistics (version 20.0, IBM, Chicago, IL). Two-sided P-values of < 0.05 were considered 
statistically signiﬁcant.
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RESULTS
Study population
Eighty-six perioperative survivors were approached, of whom 74 participated. Three 
patients with a homograft were excluded, because this predisposes to obstruction 
and decreased exercise capacity. None of the patients had ST-T–segment dynamics 
typical of myocardial ischemia. The remaining 71 patients represented the cohort 
as analyzed in the present study (median age, 20.1 [14.5–26.1] years; range, 12–35, 
52 male, 73%). Exercise testing was performed in 69 patients. Eight patients (11%) 
underwent pulmonary artery banding, and 48 patients (68%) underwent the Rashkind 
procedure. The median age at arterial switch operation was 7 (5–20) days (range, 0–755 
days). The Lecompte maneuver was performed in 63 patients (89%).17 Ventricular septal 
defect was surgically closed in 20 patients (28%), of whom 2 had Taussig-Bing anomaly; 
aortic coarctation was repaired in 5 patients (7%). Eleven patients (16%) underwent 1 
or multiple RVOT re-interventions, of whom 7 (10%) underwent a surgical procedure. 
Twenty-one healthy controls were included (median age, 26.4 [23.2–29.9] years; range, 
21–35, 10 men, 48%).
Patients after arterial switch operation compared with healthy controls
Doppler echocardiography and CMR measurements in patients after the arterial switch 
operation are compared with healthy controls in Table 1. All measured cross-sectional 
areas of the pulmonary tree (MPA, LPA, and RPA) were signiﬁcantly and substantially 
reduced in patients (p < 0.001). Signiﬁcant unilateral branch stenosis (relative branch 
area of < 30%) was present in 26 of 70 patients with available 3D MRA data (37%). 
Abnormal PBF distribution was present in only 5 of 66 patients with representative 
ﬂow data (7%), of whom 4 had less than 30% relative LPA ﬂow and 1 had less than 40% 
relative RPA ﬂow. PBF distribution and smallest relative and absolute pulmonary branch 
ﬂow in patients were not signiﬁcantly diﬀerent from those in controls (p = 0.722, p = 
0.444, and p = 0.210, respectively). 
 LPA and RPA relative area change did not signiﬁcantly diﬀer from controls; however, 
the range of data distribution was larger. The maximal ﬂow velocities across the 
pulmonary valve (echocardiography) and pulmonary branches (CMR phase-contrast) 
were increased compared with controls (p < 0.001).
Cardiopulmonary exercise testing
Exercise testing results are presented in Table 2. Patients achieved a median peak heart 
rate of 98% of predicted (interquartile range, 94–102), 4 out of 69 patients (6%) had an 
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inadequate increase of heart rate during exercise (range, 71 to 83% of predicted). Mean 
VO
2 
peak% was 88 ± 20%, and 29 patients (42%) demonstrated abnormal results (69 ± 
11%). Mean VE/VCO
2 
slope was 23.7 ± 3.8, and 1 patient (1%) had an abnormal VE/VCO
2 
slope (35). 
TABLE 1 - Patients after the arterial switch operation compared with healthy controls.
Patients (n = 71) Controls (n = 21) P-value
Age, years 20.1 [14.5–26.1] 26.4 [23.2–29.9] < 0.001
Sex, male n (%) 52 (73) 10 (48) 0.028
RV systolic pressure, mmHg 29 ± 10 - -
Maximal velocity across pulmonary valve, cm/s 207 ± 68 107 ± 15 < 0.001
RV function    
   RV end-diastolic volume, mL/m2 95 [85–104] 104 [91–116] 0.014
   RV end-systolic volume, mL/m2 41 [35–48] 50 [45–58] 0.003
   RV stroke volume, mL/m2 53 ± 9 56 ± 9 0.160
   RV ejection fraction, % 55 ± 5 53 ± 4 0.048
   RV mass, gr/m2 30 [27–35] 23 [21–26] < 0.001
Pulmonary artery cross-sectional areas    
   MPA area, mm2/m2 190 [137–238] 269 [242–301] < 0.001
   LPA area, mm2/m2 59 [41–86] 157 [141–186] < 0.001
   RPA area, mm2/m2 98 [63–147] 139 [123–175] < 0.001
   LPA + RPA area, mm2/m2 175 [109–228] 300 [272–343] < 0.001
   Smallest branch area, mm2/m2 51 [37–77] 139 [123–169] < 0.001
Qflow measurements    
   LPA relative area change, % 43 [31–61] 42 [35–53] 0.754
   RPA relative area change, % 56 [40–66] 51 [45–65] 0.966
   LPA : RPA ﬂow, % 45 : 55 ± 8 45 : 55 ± 4 0.722
   Smallest branch ﬂow, % 44 [39–47] 46 [41–47] 0.444
   Smallest branch ﬂow, mL/m2 21 [19–25] 23 [21–26] 0.210
   LPA peak ﬂow velocity, cm/s 168 [139–204] 73 [66–82] < 0.001
   RPA peak ﬂow velocity, cm/s 166 [140–207] 88 [77–97] < 0.001
   LPA regurgitation fraction, % 2.7 [0.6–10.0] 3.0 [2.2–7.0] 0.565
   RPA regurgitation fraction, % 5.8 [1.6–8.5] 1.7 [0.6–2.7] 0.001
Median [interquartile range] and Mann-Whitney U test; mean ± SD and independent-samples T-test; or n (%) 
and chi-square test. Abbreviations: RV, right ventricular; MPA, main pulmonary artery; LPA, left pulmonary 
artery; RPA, right pulmonary artery.
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TABLE 2 - Exercise testing results of patients after the arterial switch operation (n = 69).
Variable Mean ± SD or median [IQR]
Weight, kg 64.2 ± 17.7
Body surface area, m2 1.75 ± 0.29
Body mass index, kg/m2 21.4 ± 4.0
Peak minute ventilation, L/min 83.4 ± 24.1
Forced expiratory volume in first second, L 3.44 ± 0.91
Breathing reserve, % 37 [27–47]
Peak heart rate  
   Beats/min 184 [177–192]
   % predicted 98 [94–102]
Peak systolic blood pressure, mmHg 183 ± 27
Peak workload  
   Watt 208 ± 55
   % predicted 96 ± 19
Peak oxygen uptake  
   mL/kg/min 40.1 ± 10.8
   % predicted 88 ± 20
   Abnormal (≤ 84%), n (%) 29 (42)
   mL/peak heart rate 13.6 ± 3.9
   % predicted 90 ± 18
Minute ventilation/carbon dioxide elimination  
   Slope 23.7 ± 3.8
   Abnormal slope (≥ 34), n (%) 1 (1)
Peak respiratory exchange ratio 1.17 ± 0.10
Abbreviations: IQR, interquartile range; SD, standard deviation.
Age, sex and imaging features related to functional outcome
Univariable correlations of age, sex and imaging features with exercise capacity and 
ventilatory eﬃciency are presented in Table 3. Age negatively correlated with VO
2 
peak% (r = –0.315, p = 0.008) and male patients generally had a better exercise capacity 
(r = 0.318, p = 0.008). RV end-diastolic volume and stroke volume were both signiﬁcantly 
associated with exercise capacity and ventilatory eﬃciency. MPA area signiﬁcantly 
correlated with VO
2
 peak% (r = 0.401, p = 0.001), however the sum of LPA and RPA area, 
and smallest pulmonary branch area were not related to VO
2 
peak%. Smallest pulmonary 
branch area (mm2/m2) and smallest relative branch ﬂow (%) were signiﬁcantly associated 
with VE/VCO
2 
slope (r = –0.301, p = 0.013 and r = –0.307, p = 0.014 respectively). 
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 The MPA area was also signiﬁcantly related to RV stroke volume (r = 0.273, p = 0.022) 
and RV systolic pressure (r = -0.493, p = 0.001). We repeated all analyses with exclusion 
of patients after pulmonary artery banding, because this is usually not an accepted 
practice in the contemporary era. This did not yield diﬀerent conclusions.
TABLE 3 - Univariable correlations of age, sex and imaging features with exercise capacity and ventilatory efficiency in 
patients after the arterial switch operation.
VO2 peak% (r) VE/VCO2 slope (r) 
Age, years† −0.315** 0.073
Sex, male 0.318** −0.279*
RV systolic pressure, mmHg −0.112 −0.076
Maximal velocity across pulmonary valve, cm/s −0.304* 0.012
RV function   
   RV end-diastolic volume, mL/m2† 0.305* −0.306*
   RV end-systolic volume, mL/m2† 0.159 −0.200
   RV stroke volume, mL/m2 0.400** −0.347**
   RV ejection fraction, % 0.142 0.025
   RV mass, gr/m2† 0.208 −0.235
Pulmonary artery cross-sectional areas   
   MPA area, mm2/m2 0.401** −0.043
   LPA area, mm2/m2† 0.044 −0.249*
   RPA area, mm2/m2† 0.115 −0.182
   LPA + RPA area, mm2/m2† 0.093 −0.233
   Smallest branch area, mm2/m2† 0.109 −0.301*
Qflow measurements   
   LPA relative area change, %† −0.032 −0.178
   RPA relative area change, %† −0.051 0.152
   LPA : RPA ﬂow, % 0.141 : −0.141 −0.329** : 0.329**
   Smallest branch ﬂow, %† 0.105 −0.307*
   Smallest branch ﬂow, mL/m2† 0.260* −0.264*
   LPA peak ﬂow velocity, cm/s −0.070 0.154
   RPA peak ﬂow velocity, cm/s† −0.249* 0.288*
   LPA regurgitation fraction, %† −0.076 −0.156
   RPA regurgitation fraction, %† 0.002 0.245
*p < 0.05; **p < 0.01; †Spearman’s correlation; other Pearson’s correlation. Abbreviations: VE/VCO
2 
slope, 
minute ventilation relative to carbon dioxide elimination; VO
2 
peak%, percentage of predicted peak oxygen 
uptake; other as deﬁned in Table 1.
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Sub-analysis in three age groups
Results of the sub-analysis in 3 pre-deﬁned age groups (< 18, 18–25 and > 25 years) are 
presented in Figure 1 and Table 4. As presented in Figure 1, MPA area was not associated 
with exercise capacity in patients aged less than 18 years (β = –0.034, p = 0.635), who 
had the largest MPA areas, whereas it was signiﬁcantly related to exercise capacity both 
in patients aged 18 to 25 years and in patients aged more than 25 years (β = 0.134, p = 
0.008 and β = 0.219, p = 0.045, respectively).
 
FIGURE 1 - Association between MPA area and VO 2 peak% in different age groups.
MPA area is not associated with exercise capacity in patients < 18 years, who have largest MPA areas (β = 
–0.034, p = 0.635), while it is signiﬁcantly related to exercise capacity in patients 18–25 and > 25 years (β = 
0.134, p = 0.008 and β = 0.219, p = 0.045, respectively). Abbreviations: MPA, main pulmonary artery; VO
2 
peak%, exercise capacity reﬂected by percentage of predicted peak oxygen uptake.
Table 4 shows the operative characteristics and imaging features per age group. 
Pulmonary artery banding was almost exclusively performed in the oldest age group 
(p < 0.001). Patients from the earliest surgical era underwent repair at an older age 
(p < 0.001), and for the reconstruction of the MPA mostly separate patches were 
used (vs. pantaloon-type patch in younger patients) using pericardium treated with 
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glutaraldehyde (vs. untreated pericardium in younger patients). Oldest patients also had 
smallest MPA areas (229.6 ± 47.7 mm2/m2, 196.3 ± 77.7 mm2/m2, and 133.6 ± 51.2 mm2/
m2, p < 0.001), highest maximal velocity across the pulmonary valve (p < 0.001), highest 
RV mass (p = 0.035), highest RV systolic pressures (p < 0.001), and a trend towards a 
lower VO
2
 peak% (p = 0.051). Pulmonary branch areas, ﬂow, and VE/VCO
2
 slope were not 
signiﬁcantly diﬀerent among the 3 age groups.
TABLE 4 - Sub-analysis for operative characteristics, imaging features and functional outcome among three age groups.
Variable < 18 years(n = 25)
18−25 years
(n = 26)
> 25 years
(n = 20) P-value
Sex, male n (%) 18 (72) 20 (77) 14 (70) 0.910
Operative characteristics    
  Rashkind procedure, n (%) 22 (88) 14 (54) 12 (60) 0.089
  Pulmonary artery banding, n (%) 0 (0) 1 (4) 7 (35) < 0.001
  Age at surgical repair, days 9.2 ± 8.8 15.5 ± 26.9 125.8 ± 201.2 0.001
  Pantaloon-type patch, n (%) 23 (92) 10 (40)* 1 (8)† < 0.001
  Untreated pericardium, n (%) 25 (100) 14 (56)* 0 (0)† < 0.001
  Lecompte maneuver, n (%) 23 (92) 23 (89) 17 (85) 0.463
  Ventricular septal defect repair, n (%) 5 (20) 8 (31) 7 (35) 0.260
  Cardiopulmonary bypass time, min 153 ± 59 207 ± 53 187 ± 45 0.104
  Cross clamp time, min 92 ± 18 125 ± 34 106 ± 27 0.171
  RV outﬂow tract re-intervention, n (%) 0 (0) 2 (8) 9 (45) < 0.001
Imaging features  
  RV systolic pressure, mmHg 22.7 ± 9.6 29.2 ± 6.8 36.5 ± 9.9 < 0.001
  Maximal velocity across pulmonary valve, 
cm/s 183.7 ± 58.0 194.5 ± 72.4 254.6 ± 52.7 0.001
  RV end-diastolic volume, mL/m2 94.1 ± 12.0 96.9 ± 12.4 94.5 ± 23.7 0.909
  RV stroke volume, mL/m2 51.7 ± 8.3 53.3 ± 7.0 52.6 ± 10.5 0.690
  RV mass, gr/m2 29.6 ± 4.7 30.6 ± 6.0 34.1 ± 9.5 0.035
  MPA area, mm2/m2 229.6 ± 47.7 196.3 ± 77.7 133.6 ± 51.2 < 0.001
  LPA + RPA area, mm2/m2 171.0 ± 55.5 176.2 ± 81.4 184.5 ± 102.1 0.581
  Smallest pulmonary branch area, mm2/m2 57.7 ± 28.9 58.3 ± 35.0 67.6 ± 44.7 0.388
  Smallest pulmonary branch ﬂow, mL/m2 22.0 ± 4.5 21.0 ± 4.0 21.2 ± 4.3 0.494
  Smallest pulmonary branch ﬂow, % 43.7 ± 6.0 41.7 ± 5.9 42.5 ± 5.0 0.435
Functional outcome     
  VO
2 
peak, % 94.7 ± 16.1 84.4 ± 20.6 83.4 ± 21.9 0.051
  VE/VCO
2
 slope 23.0 ± 2.9 24.3 ± 3.6 24.0 ± 5.1 0.379
Mean ± SD and univariable linear regression; or n (%) and chi-square Mantel-Haenszel test. *Data available in 
25 of 26 patients; †data available in 12 of 20 patients. Abbreviations: as deﬁned in Table 1 and 3.
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Lecompte Maneuver
Pulmonary branch areas were smaller in patients who underwent the Lecompte 
maneuver compared with patients who did not (LPA 52 [39–75] mm2/m2 vs. 128 [91–
149] mm2/m2, p < 0.001 and RPA 89 [58–139] mm2/m2 vs. 145 [109–187] mm2/m2, p = 
0.053); however, this did not translate into an abnormal PBF distribution (mean LPA : 
RPA relative ﬂow 46 : 54 vs. 47 : 53%, p = 0.181). MPA area, VO
2
 peak%, and VE/VCO
2
 slope 
were comparable in both groups (p = 0.971, p = 0.216, and p = 0.555, respectively).
Multivariable analysis
MPA area remained signiﬁcantly associated with exercise capacity (β = 0.102, p = 0.032) 
after adjustment for age, sex and operative characteristics (age at repair, pulmonary 
artery banding, patch type and treatment, RVOT re-intervention). In this multivariable 
model, MPA area was the only signiﬁcant predictor of exercise capacity. 
Reproducibility 
Inter- and intraobserver variability for the measurement of the MPA area on MRA were 
reﬂected by intraclass correlation coeﬃcients of 0.993 and 0.997 and mean diﬀerences 
of 2.1 ± 10.7 mm2/m2 (p = 0.564) and 7.3 ± 8.0 mm2/m2 (p = 0.019), respectively. Mean 
relative diﬀerences for inter- and intraobserver variability were 0.7 ± 5.3% and –3.7 ± 
3.2%.
DISCUSSION
In this cross-sectional cohort study of patients long-term after arterial switch operation, 
both MPA and pulmonary branch areas were signiﬁcantly decreased compared with 
healthy controls, and abnormal exercise capacity was common (42%). Cross-sectional 
MPA area was independently associated with exercise capacity in patients aged more 
than 18 years and correlated with stroke volume at rest and RV systolic pressure.
 Signiﬁcant unilateral pulmonary branch stenosis was present in 37% of patients; 
however, this resulted in abnormal blood ﬂow distribution in only 7% of patients. 
Other factors that could inhibit exercise capacity in this group of patients, such as RV 
dysfunction or chronotropic incompetence, were uncommon in our cohort. These 
results indicate that narrowing of the MPA is a common ﬁnding in adult patients after 
the arterial switch operation and that it is the main right-sided lesion limiting functional 
capacity, rather than RV dysfunction or unilateral pulmonary branch stenosis.
 Although abnormal PBF distribution was uncommon in our cohort, smallest relative 
pulmonary branch ﬂow was associated with ventilatory eﬃciency. This was also reported 
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by Giardini and colleagues, who identiﬁed abnormal PBF distribution as an independent 
predictor of both decreased exercise capacity and ventilatory eﬃciency.7 In contrast to 
our results, abnormal PBF distribution was more common in their study (18%) and MPA 
area was not an independent predictor of exercise capacity. This is probably explained 
by the younger age of the patient group in their study (13.3 ± 3.4 years), because MPA 
area was not related to exercise capacity in the youngest patients of our cohort. 
Limitation of stroke volume increase during exercise
In normal subjects, the RV stroke volume increases during exercise with only mild 
elevation of RV pressures. This is a consequence of low pulmonary vascular resistance, 
mediated by recruitment of closed vessels and distension of already opened vessels.18,19 
We found that MPA area signiﬁcantly correlated with RV stroke volume at rest and RV 
systolic pressure. This may imply that in patients with pulmonary artery narrowing, RV 
systolic pressure increases disproportionately during exercise, limiting the increase in 
RV stroke volume during exercise, subsequently limiting exercise capacity. 
Relative area change
Decreased distensibility of the MPA or branches has been proposed as a possible 
mechanism for reduced exercise capacity in patients after the arterial switch operation. 
Grotenhuis and colleagues20 and Voges and colleagues21 demonstrated a reduced 
distensibility of the proximal aorta in these patients. This was potentially mediated 
by increased aortic wall stress of the dilated root, ﬁbrous tissue, and intrinsic wall 
abnormalities near the suture line and pulmonary artery branches embracing the aorta 
after the Lecompte maneuver.17 Most of these features could theoretically also aﬀect 
the distensibility of the MPA and branches, contributing to a functional stenosis on 
exercise.7,22 This study approximated distensibility of the pulmonary branches by relative 
area change, which is uncorrected for pulse pressure, because our study protocol did 
not include invasive measurements. To our knowledge, these measurements have not 
been performed in patients after the arterial switch operation. Our data do not provide 
evidence for a decreased relative area change of the LPA and RPA. However, relative 
area change of the MPA was not assessed in this study and could be altered because of 
diﬀerent elastic properties of the pericardial patch.
Smaller main pulmonary artery areas in older age groups
Patients aged more than 18 years had smaller MPA areas compared with younger 
patients. Because this is a cross-sectional study, it is uncertain whether this diminution 
of size is a reﬂection of learning curve and changing surgical techniques over time or 
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the result of rapid somatic growth with inadequate growth at the anastomotic site, 
as suggested by Prifti and colleagues.23 The operative characteristics of patients aged 
more than 25 years showed clear diﬀerences with both other age categories. Pulmonary 
artery banding was almost exclusively performed in this age group, patients were 
markedly older at time of surgical repair, and for the reconstruction of the MPA, mostly 
separate patches of pericardium treated with glutaraldehyde were used (vs. untreated 
pantaloon-type patch). Single pantaloon-type patch has been reported to result in less 
residual RVOT obstruction, and, in contrast to treated pericardium, untreated pericardial 
tissue potentially retains the ability to grow and adapt.23 Therefore, pulmonary artery 
banding and type of MPA reconstruction (separate patches, treated pericardium with 
inadequate growth) are probably important causes of MPA narrowing.
 Prolonged cyanosis and low PBF in patients who underwent the arterial switch 
operation at an older age also may adversely aﬀect the microscopic pulmonary 
vasculature, myocardium, and systemic circulation, leading to a reduced VO
2
 peak%.
 By using multivariable linear regression, we adjusted for the eﬀects of age, sex, 
and operative characteristics (age at repair, pulmonary artery banding, patch type 
and treatment, RVOT re-intervention). In multivariable analysis, MPA area was the only 
signiﬁcant predictor of exercise capacity.
Clinical implications
In this study, the importance of MPA narrowing as a determinant for exercise capacity is 
highlighted. This could imply that during the arterial switch operation, optimization of 
MPA size is important for functional outcomes. Moreover, this suggests that the long-
term follow-up of patients after the arterial switch operation should focus on presence 
or progression of MPA stenosis. Pulmonary branch re-interventions in patients with 
unilateral pulmonary branch stenosis might only improve functional capacity in the 
small subgroup of patients with an abnormal PBF distribution. This hypothesis requires 
further investigation in longitudinal studies.
Study limitations
Limitations of this study are inherent to its design, because this is a single-center, cross-
sectional study. Therefore, variance in operation procedures and surgical experience 
among surgical centers could result in diﬀerent outcomes in other patient cohorts. 
Second, we need longitudinal follow-up studies to assess the actual impact of RVOT re-
interventions on functional outcome in adult patients after the arterial switch operation. 
Individual follow-up data should elucidate whether the observation of decreased MPA 
areas in older age groups can be partially explained by rapid somatic growth. Finally, 
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patients and controls were not perfectly matched, because patients were younger than 
healthy controls and included more male patients. To account for this, all measurements 
were indexed for body surface area. Moreover, because patients aged less than 18 years 
exhibited the smallest diﬀerences compared with healthy controls and male patients 
generally had a better exercise capacity, age and sex matching would have only 
strengthened the diﬀerences found in this study.
CONCLUSIONS
In this cross-sectional study of patients long-term after the arterial switch operation, the 
MPA area was increasingly smaller in older age groups. The MPA area was signiﬁcantly 
related to exercise capacity, independently of age, sex and operative characteristics. 
Although branch pulmonary artery areas were smaller than in healthy controls, PBF 
at rest and ventilatory eﬃciency were generally not compromised. Therefore, our data 
suggest that MPA narrowing is an important and thus far underappreciated determinant 
in the limitation of functional capacity in adults after arterial switch operation.
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ABSTRAC T
Background  Left atrial (LA) size predicts cardiovascular outcome in chronic heart 
failure. Its prognostic value in adults with repaired tetralogy of Fallot 
(ToF) is unknown. This study therefore investigated the association of LA 
size and function with cardiovascular events in adults with ToF.
Methods  Clinically stable adults with ToF who visited the outpatient clinic between 
2011 and 2013 underwent echocardiography and were prospectively 
followed for the occurrence of death, heart failure, hospitalizations, 
arrhythmia, thromboembolic events, and re-interventions. LA maximal, 
minimal and pre-A wave volume, area and length were measured on the 
apical four-chamber view. Total, passive and active emptying fractions 
were calculated. 
Results  In total, 134 patients were included (median age 35 [IQR 29–45] years, 
65% male, 91% NYHA I). Median follow-up was 40 [IQR 32–47] months. 
Patients with a dilated LA (≥ 34 mL/m2, 43%) were at higher risk of 
cardiovascular events (n = 33, adjusted HR 2.48; 95% CI 1.09–5.62, p = 
0.030). Analysis of LA volumes as continuous variables yielded similar 
conclusions. In addition, LA length (adjusted HR 2.49; 95% CI 1.51–4.09, 
p < 0.001), total emptying fraction (adjusted HR 0.96; 95% CI 0.93–0.99, 
p = 0.008), and active emptying fraction (adjusted HR 0.92; 95% CI 0.87–
0.96, p = 0.001) were signiﬁcantly associated with cardiovascular events. 
Standardized HRs indicated that LA length was the strongest prognostic 
marker. In addition, none of the patients with a normally sized LA died or 
developed heart failure.
Conclusions  LA size and function can provide relevant prognostic information in 
clinically stable adults with repaired ToF. Especially LA length may be a 
valuable additional tool in the risk stratiﬁcation of these patients.
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INTRODUC TION
Tetralogy of Fallot (ToF) is the most common cyanotic heart defect.1,2 Thanks to successful 
repair at young age, the survival of patients with ToF has tremendously improved 
with current survival rates over 90% up to 30 years after surgical repair.3 Nevertheless, 
residual lesions are common. Especially older patients are at risk of complications such 
as heart failure, arrhythmia and early demise. Therefore, life-long follow-up is warranted. 
Identiﬁcation of patients with a high risk of adverse cardiovascular events is essential, in 
order to optimize patient information, follow-up and therapeutic strategies.3,4 
 Echocardiography is the cornerstone in the evaluation of cardiac function in patients 
with ToF. Right and left ventricular function are known as important prognostic markers 
in these patients.5 Atrial function has been largely neglected so far. The left atrium (LA) 
has multiple functions: it modulates as a reservoir, a conduit and as a pump.6 LA size can 
be reliably measured with two-dimensional echocardiography and reﬂects the average 
eﬀect of left ventricle (LV) ﬁlling pressures over time. It is known as a useful marker 
for both chronicity and severity of LV diastolic dysfunction.7-9 Larger LA volumes have 
been associated with an increased risk of adverse cardiovascular events in patients with 
chronic heart failure.10 To the best of our knowledge, the prognostic value of LA size or 
function in patients with ToF has not been evaluated. Therefore, the aim of this study 
was to investigate the association of LA size and function with a composite endpoint of 
cardiovascular events in clinically stable adults with repaired ToF.
METHODS
Study design and population
For the purpose of this study, all patients with repaired ToF were selected from a large 
prospective cohort of clinically stable adults with congenital heart disease. This cohort 
consisted of consecutive patients who routinely visited our adult congenital cardiology 
outpatient clinic and underwent echocardiography between April 2011 and April 2013. 
Patients with pulmonary valve atresia and ventricular septal defect and patients with 
isolated pulmonary stenosis were excluded. Other exclusion criteria were: age < 18 
years, pregnancy, incapability of understanding and signing informed consent, kidney 
failure (creatinine > 200 μmol/L), or insuﬃcient echocardiographic image quality. Image 
quality was deﬁned as insuﬃcient when the LA borders were not clearly visible and 
therefore could not be adequately traced in the apical four-chamber (A4C) view.
 At the time of study inclusion, all patients underwent physical examination by 
a cardiologist, 12-lead ECG, venous blood sampling, and echocardiography. Patient 
demographics, medical history, medication use, symptoms and signs of heart failure 
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(NYHA classiﬁcation), results of physical examination, associated lesions, surgical 
characteristics, re-interventions, electrocardiography, echocardiography, laboratory 
results and events were collected using an electronic CRF-based online system (© 2004–
2012 OpenClinica, LLC and collaborators). Details have been reported previously.11 
The institutional review board of the Erasmus MC approved the study protocol and all 
participants provided written informed consent.
Echocardiography
Two-dimensional transthoracic echocardiographic images were acquired using a 
commercially available ultrasound system iE33 (Philips Medical Systems, Best, the 
Netherlands) with a 1.5-MHz transducer. Echocardiographic measurements were 
performed in agreement with the current recommendations of the American Society 
of Echocardiography and European Association of Cardiovascular Imaging.12 LV end-
diastolic and end-systolic volumes were calculated using the biplane method of 
disks summation (modiﬁed Simpson’s rule). LV systolic function was quantiﬁed with 
LV ejection fraction, and visually graded as normal or impaired. LV diastolic function 
was assessed using pulsed waved Doppler of the mitral valve inﬂow (E/A-ratio and 
deceleration time) and septal tissue Doppler imaging (E’ wave and E/E’-ratio). RV systolic 
function was quantiﬁed with RV fractional area change and tricuspid annular plane 
systolic excursion. 
Left atrial size and function
LA volumetric measurements were performed on the A4C view in three diﬀerent phases 
during one cardiac cycle. LA maximal and minimal volume were measured on the 
frames with respectively the largest and smallest atrial cavities on visual assessment. 
LA pre-A-wave volume was measured one frame before the atrial contraction started 
(also based on the movement of the mitral valve leaﬂets, and the onset of the P-wave 
on the ECG). Contours were manually traced, the atrial appendage and pulmonary veins 
were excluded, and at the mitral valve level the contour was closed with a straight line. 
For the calculation of volumes, a single plane summation of disks method was used. In 
addition, left atrial maximal size was quantiﬁed using the LA anteroposterior dimension 
on the parasternal long axis view, the LA major axis on the A4C view (LA length), and the 
LA maximal area on the A4C view (Supplemental File 1). All LA volumes were indexed 
by body surface area.
 We separately considered LA reservoir, conduit and contractile function.6,7,13 Reservoir 
function was quantiﬁed with LA total emptying volume (TEV), LA total emptying fraction 
(TEF) and the expansion index. TEV was calculated by LA maximal volume – LA minimal 
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volume. TEF was calculated by (TEV / LA maximal volume) *100%. Expansion index was 
deﬁned as (TEV / LA minimal volume) *100%. Conduit function was quantiﬁed with 
LA passive emptying volume (PEV) and LA passive emptying fraction (PEF). PEV was 
calculated by LA maximal volume – LA pre-A-wave volume. PEF was calculated by (PEV / 
LA maximal volume) *100%. Contractile or active function was estimated with LA active 
emptying volume (AEV) and LA active emptying fraction (AEF). AEV was calculated by 
LA pre-A-wave volume – LA minimal volume. AEF was calculated by (AEV / LA pre-A-
wave volume) *100%. 
 One investigator (A.S.), who was blinded for clinical events and other patient data, 
performed all LA measurements. Reproducibility was assessed by blinded repeated 
analysis of 20 randomly selected patients by the ﬁrst and a second observer (V.B.). 
Laboratory testing
Peripheral venous blood samples were obtained from all patients after at least 30 
minutes of rest. Serum NT-proBNP was measured for research purposes only in 
our clinical chemistry laboratory using a commercial electrochemiluminescence 
immunoassay (Roche Diagnostics, Rotkreuz, Switzerland). The limit of detection was 0.6 
pmol/L. The upper limit of normal for NT-proBNP was 14 pmol/L (approximately 125 pg/
mL), based on the recommended low cut-oﬀ for the diagnosis of heart failure in patients 
presenting with non-acute symptoms.14
Definition and assessment of events
The primary endpoint was deﬁned prior to the collection of data as a composite of all 
adverse cardiovascular events: all-cause mortality, heart failure (requiring initiation or 
change in heart failure medication, or requiring hospital admission), hospitalization 
for cardiac reasons, arrhythmia (symptomatic and recorded, or requiring treatment), 
thromboembolic events (ischemic cerebrovascular accident, pulmonary embolism 
or myocardial infarction), or cardiac re-interventions (surgical or percutaneous). A 
secondary composite endpoint of all-cause mortality or heart failure was deﬁned. All 
patients were prospectively followed for fatal and non-fatal events by a yearly clinical 
evaluation at our institution. During the follow-up, patients were treated according to 
the physician’s discretion and the study protocol did allow for adjustment of cardiac 
medication. Where necessary, we retrieved information from electronic patient 
charts and correspondence with referring hospitals. Survival status of all patients was 
also checked in the Municipal Population Register. Events were adjudicated by two 
experienced investigators (V.B. and J.R.) without knowledge of LA measurements. 
The investigators had direct access to the patient clinical records and the events were 
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independently reviewed by each investigator. For patients with multiple events, event-
free survival was deﬁned as the time from enrollment to the occurrence of the ﬁrst event. 
Patients without any cardiovascular event were censored at the end of the follow-up 
duration (August 1, 2015).
Statistical analysis 
Continuous normally distributed data were presented as mean ± standard deviation (SD) 
and skewed data as median [IQ
1
–IQ
3
]. Categorical data were presented as frequencies and 
percentages. Following the guidelines, patients were stratiﬁed according to LA volume 
index < 34 mL/m2 (normal LA) and ≥ 34 mL/m2 (dilated LA).12 Continuous variables were 
compared between these two groups using the Student’s T-test or the Mann-Whitney U 
test, depending on the distribution of data. Categorical variables were compared using 
the chi-squared test or Fisher’s exact test when applicable. Cumulative endpoint free 
survival estimates and survival curves were derived by the Kaplan-Meier method; the 
log-rank test was used to compare groups. Cox proportional hazards regression was 
used to investigate the associations between LA measurements and endpoints. LA 
measurements were analyzed as continuous and as standardized variables (created by 
calculating z-scores). The association of LA measurements with the primary endpoint 
was adjusted for age and NYHA functional class, using a minimum of ten endpoints 
per degree of freedom to prevent overﬁtting. Inter- and intraobserver agreement of 
LA maximal volume, area and length was presented by Bland-Altman plots. Limits of 
agreement were deﬁned as the mean diﬀerence of the two repeated measurements ± 
1.96 SD. The coeﬃcient of variation (COV) was deﬁned as the SD of the diﬀerences of 
two measurements divided by the mean of two measurements *100%. Mean relative 
diﬀerences were calculated by dividing the diﬀerence of two measurements by the 
mean of two measurements *100%. All data analysis was performed using IBM SPSS 
Statistics Version 21.0.0.1 (IBM Corp., Armonk, NY, USA). Two-sided p-values of < 0.05 
were considered statistically signiﬁcant. 
RESULTS
Baseline measurements
Of the 179 patients that were included in the initial cohort, 31 patients with pulmonary 
valve atresia and 1 patient with isolated pulmonary stenosis were excluded. In addition, 
13 patients were excluded because of insuﬃcient image quality. These patients did 
not have signiﬁcant or clinically relevant diﬀerences in age, NYHA classiﬁcation, body 
mass index, use of cardiac medication or number of re-interventions compared to the 
134 adult patients with repaired ToF who were included in this study. Median age at 
04L A  s i z e  a n d  f u n c t i o n  i n  Fa l l o t  p a t i e n t s  -  C H A P T E R  4
63 
04
inclusion was 35 [29–45] years and 87 patients (65%) were male. Median age at initial 
repair was 3.3 [1.0–6.7] years and in 87 patients (67%) a transannular patch was used. 
Baseline characteristics are further detailed in Table 1. 
 The LA was dilated (≥ 34 mL/m2) in 58 patients (43%). Clinical characteristics and 
results of electrocardiography and echocardiography are compared between patients 
with a normal and a dilated LA in Tables 1 and 2. Patients with a dilated LA were 
signiﬁcantly older and were in a higher NYHA functional class. In addition, 22 patients 
(38%) with a dilated LA used cardiac medication compared with 9 patients (12%) with 
a normal LA (p < 0.001). The majority of patients were in sinus rhythm (n = 111, 83%) 
and had a prolonged QRS interval (n = 91, 75%). None of the patients fulﬁlled criteria of 
heart failure at baseline. Patients with a dilated LA had signiﬁcantly larger LV volumes, 
impaired diastolic function (expressed by a lower E’ wave and a higher E/E’-ratio), a 
larger RV end-diastolic annulus dimension and a higher NT-proBNP level. No signiﬁcant 
diﬀerences in rhythm or valvular function were found between both subgroups. 
TABLE 1 - Baseline characteristics of the study cohort.
LA volume index, mL/m2
Valid cases, 
n (%)
All 
patients
< 34 
(normal, n = 76)
≥ 34  
(dilated, n = 58) P-value
Clinical Characteristics
Age, years 134 (100) 35 [29–45] 31 [26–39] 42 [34–49] < 0.001
Sex, male n (%) 134 (100) 87 (65) 49 (65) 38 (66) 0.900
NYHA class II-III, n (%) 134 (100) 12 (9) 3 (4) 9 (16) 0.020
Body mass index, kg/m2 134 (100) 24 ± 4 24 ± 4 25 ± 4 0.046
Body surface area, m2 134 (100) 1.89 ± 0.20 1.89 ± 0.22 1.89 ± 0.18 0.918
Systolic blood pressure, mmHg 131 (98) 126 ± 17 124 ± 15 127 ± 19 0.355
O
2
 saturation < 90%, n (%) 126 (94) 1 (1) 1 (1) 0 (0) -
Cardiac medication, n (%) 134 (100) 31 (23)* 9 (12) 22 (38) < 0.001
    ACE-inhibitor 134 (100) 10 (8) 4 (5) 6 (10) -
    Beta blocker 134 (100) 17 (13) 3 (4) 14 (24) -
    Anti-arrhythmic 134 (100) 10 (8) 2 (3) 8 (14) -
    Aspirin 134 (100) 10 (8) 2 (3) 8 (14) -
    Anticoagulants 134 (100) 16 (12) 1 (1) 15 (26) -
    Diuretics 134 (100) 7 (5) 0 (0) 7 (12) -
Associated lesions, n (%) 134 (100) 31 (23) 15 (20) 16 (28) 0.286
    Atrial septal defect 134 (100) 16 (12) 7 (9) 9 (16) -
    Patent ductus arteriosus 133 (99) 11 (8) 7 (9) 4 (7) -
    Aortic valve stenosis 134 (100) 8 (6) 4 (5) 5 (7) -
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TABLE 1 - Continued.
LA volume index, mL/m2
Valid cases, 
n (%)
All 
patients
< 34 
(normal, n = 76)
≥ 34  
(dilated, n = 58) P-value
Surgical Characteristics
Age at repair, years 134 (100) 3.3 [1.0–6.7] 1.6 [0.8–4.1] 5.8 [2.2–9.7] < 0.001
Prior aortopulmonary shunt, n (%) 134 (100) 39 (29) 14 (18) 25 (43) 0.002
    Blalock shunt 134 (100) 20 (15) 5 (7) 15 (26) -
    Waterston shunt 134 (100) 16 (12) 7 (9) 9 (16) -
    Other shunt 134 (100) 3 (2) 2 (2) 1 (2) -
Transannular patch used, n (%) 129 (96) 87 (67) 52 (71) 35 (63) 0.294
Re-intervention, n (%) 134 (100) 86 (64) 48 (63) 38 (66) 0.778
    More than two re-interventions 134 (100) 14 (10) 4 (5) 10 (17) 0.025
    Surgical, n (%) 134 (100) 75 (56) 46 (61) 29 (50) 0.224
       Pulmonary valve replacement 134 (100) 67 (50) 42 (55) 25 (43) -
       Residual VSD repair 134 (100) 19 (14) 8 (11) 11 (19) -
    Catheter-based, n (%) 134 (100) 19 (14) 11 (15) 8 (14) 0.911
       Pulmonary valve balloon 
       dilatation 134 (100) 11 (8) 7 (9) 4 (7) -
       Pulmonary valve replacement 134 (100) 4 (3) 2 (3) 2 (3) -
       Ablation 134 (100) 4 (3) 2 (3) 2 (3) -
    Other, n (%) 134 (100) 22 (16) 9 (12) 13 (22) 0.102
Continuous variables are reported as mean ± SD or as median [IQ
1
–IQ
3
], categorical variables are reported as 
n (%). P-values are given for the comparison between patients with a normal (< 34 mL/m2) and dilated (≥ 34 
mL/m2) left atrium. Signiﬁcant p-values are printed in bold. Comparisons were not made between subgroups, 
in order to avoid multiplicity of comparisons. *In 13 patients, the cardiac medication was changed during 
the follow-up. Abbreviations: ACE, angiotensin converting enzyme; LA, left atrial; NYHA, New York Heart 
Association; VSD, ventricular septal defect.
Follow-up
At the end of the follow-up (August 1, 2015), survival status and detailed follow-up data 
were complete in 134 patients (100%). During a median follow-up period of 40.4 [31.9–
46.7] months, the primary endpoint occurred in 33 patients (25%) and the secondary 
endpoint occurred in 8 patients (6%). None of the patients with a normally sized LA died 
or developed heart failure. Kaplan-Meier estimates of event-free survival (the primary 
endpoint) were 88% at year one, 83% at year two and 77% at year three. Heart-failure-
free survival (the secondary endpoint) was 96% at year one, 96% at year two and 94% 
at year three. All components of the primary and secondary endpoint are separately 
displayed in Supplemental File 2 for exploratory purposes.
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TABLE 2 - Baseline electrocardiography, echocardiography and laboratory results of the study cohort.
LA volume index, mL/m2
Valid cases, 
n (%)
All 
patients
< 34 
(normal, n = 76)
≥ 34 
(dilated, n = 58) P-value
Electrocardiography
Heart rate, beats/minute 134 (100) 75 ± 13 76 ± 14 73 ± 13 0.298
Rhythm, n (%)
   Sinus rhythm 134 (100) 111 (83) 67 (88) 44 (76) 0.061
   Pacemaker rhythm 134 (100) 12 (9) 4 (5) 8 (14) 0.087
   Other* 134 (100) 11 (8) 5 (7) 6 (10) 0.531
QRS duration, ms† 122 (91) 144 [120–169] 139 [119–164] 158 [122–170] 0.286
QRS duration >120 ms, n (%)† 122 (91) 91 (75) 52 (72) 39 (78) 0.471
   RBBB 91 (100) 82 (90) 50 (96) 32 (82) -
   LBBB 91 (100) 1 (1) 0 (0) 1 (3) -
   Other 91 (100) 8 (9) 2 (4) 6 (15) -
PR interval, if sinus rhythm, ms 111 (83) 165 [146–180] 163 [146–173] 173 [148–187] 0.053
Echocardiography
LV end diastolic volume, mL/m2 122 (91) 56 [49–66] 54 [45–64] 59 [51–71] 0.027
LV end systolic volume, mL/m2 121 (90) 25 [20–32] 24 [21–30] 28 [21–34] 0.048
LV ejection fraction, % 122 (91) 53 ± 8 54 ± 5 53 ± 10 0.446
Normal LV function, n (%) 134 (100) 58 (43) 33 (43) 25 (43) 0.971
E/A-ratio 128 (95) 1.5 [1.1–2.1] 1.5 [1.1–2.1] 1.4 [1.1–2.0] 0.338
E’ wave, cm/s 129 (96) 7.7 [6.2–9.2] 8.1 [6.6–9.6] 7.0 [5.8–8.8] 0.023
E/E’-ratio 127 (95) 10.0 [8.1–13.6] 8.9 [7.7–11.9] 11.3 [8.4–15.8] 0.005
Deceleration time, ms 124 (93) 192 [158–235] 192 [158–237] 192 [159–235] 0.835
RV end-diastolic annulus, mm 119 (89) 45.7 ± 7.9 43.7 ± 7.7 48.4 ± 7.4 0.001
TAPSE, mm 124 (93) 17.4 ± 4.5 17.1 ± 4.4 17.8 ± 4.8 0.432
RV fractional area change, % 105 (78) 41 ± 9 41 ± 9 42 ± 9 0.443
Valvular function
   AV peak velocity, m/s 117 (87) 1.07 [0.94–1.21] 1.05 [0.91–1.16] 1.12 [0.96–1.24] 0.078
   AR ≥ moderate, n (%) 89 (66) 3 (3) 0 (0) 3 (7) 0.101
   PV peak velocity, m/s 131 (98) 2.20 ± 0.75 2.24 ± 0.73 2.15 ± 0.78 0.519
   PR ≥ moderate, n (%) 124 (93) 47 (38) 25 (37) 22 (39) 0.773
   TR ≥ moderate, n (%) 124 (93) 11 (9) 5 (7) 6 (11) 0.536
   TR peak velocity, m/s 107 (80) 2.8 ± 0.5 2.8 ± 0.5 2.9 ± 0.6 0.276
   MR ≥ moderate, n (%) 82 (61) 1 (1) 0 (0) 1 (2) 1.000
C H A P T E R  4  -  L A  s i z e  a n d  f u n c t i o n  i n  Fa l l o t  p a t i e n t s
66 
TABLE 2 - Continued.
LA volume index, mL/m2
Valid cases, 
n (%)
All 
patients
< 34 
(normal, n = 76)
≥ 34 
(dilated, n = 58) P-value
Laboratory results
Hemoglobin, mmol/L 93 (69) 9.2 ± 0.9 9.3 ± 0.8 9.0 ± 1.0 0.181
Creatinine, μmol/L 134 (100) 78.4 ± 19.5 76.7 ± 13.7 80.7 ± 25.2 0.237
NT-proBNP, pmol/L 133 (99) 14.5 [6.4–27.4] 9.3 [4.9–17.0] 23.4 [14.6–42.4] < 0.001
As deﬁned in Table 1. *Three patients were in atrial ﬁbrillation (one with LA volume index < 34 mL/m2 and 
two with LA volume index ≥ 34 mL/m2). †Patients with a pacemaker rhythm were excluded. Abbreviations: 
AR, aortic regurgitation; AV, aortic valve; LA, left atrial; LBBB, left bundle branch block; LV, left ventricle; MR, 
mitral regurgitation; NT-pro-BNP, N-terminal pro-B-type natriuretic peptide; PR, pulmonary regurgitation; PV, 
pulmonary valve; RBBB, right bundle branch block; RV, right ventricle; TAPSE, tricuspid annular plane systolic 
excursion; TR, tricuspid regurgitation.
Prognostic value of left atrial measurements
In Figure 1, Kaplan-Meier curves show the proportion of patients free of the primary 
and secondary endpoint for patients with a normal and a dilated LA. In patients with 
a normally sized LA, the cumulative proportion of death and heart failure was 0%. In 
Table 3, the association between all LA measurements and the primary endpoint is 
shown. Except for the anteroposterior dimension on the parasternal long-axis view, all 
other LA size measurements (length, area, and volume) were signiﬁcantly associated 
with the primary endpoint, also when adjusted for age and NYHA functional class. The 
standardized adjusted hazard ratios (HRs) show that among the various LA size indices, 
LA length was most strongly associated with the primary endpoint (HR 2.05; 95% CI 
1.38–3.02, p < 0.001). 
FIGURE 1 - Cardiovascular event-free survival and heart failure-free survival, stratified according to LA maximal 
volume index (< 34 mL/m2 and ≥ 34 mL/m2).
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In addition, a lower reservoir function (TEF) and a lower contractile function (AEF) were 
signiﬁcantly associated with the primary endpoint, whereas a lower conduit function 
(PEF) was not. 
Reproducibility of left atrial measurements
Bland-Altman plots of the intra- and interobserver agreement of LA maximal volume, 
area and length are presented in Supplemental File 3. Mean diﬀerences of the 
intraobserver measurements were –0.3 ± 0.9 mL/m2 (COV = 2.5), 0.0 ± 0.4 cm2/m2 (COV 
= 3.4) and 0.0 ± 0.2 cm/m2 (COV = 5.7), and mean relative diﬀerences were –0.7 ± 2.8%, 
–0.2 ± 3.5% and –0.4 ± 5.7% for LA maximal volume, area, and length, respectively. 
Mean diﬀerences of the interobserver measurements were –0.3 ± 5.2 mL/m2 (COV = 
14.2), 0.0 ± 1.0 cm2/m2 (COV = 8.4) and 0.0 ± 0.2 cm/m2 (COV = 5.8), and mean relative 
diﬀerences were –0.5 ± 15.1%, –0.2 ± 8.9% and –0.8 ± 5.6% for LA maximal volume, area, 
and length, respectively.
DISCUSSION
To the best of our knowledge, this is the ﬁrst study that evaluates the prognostic value 
of LA size and function in ToF patients. In our cohort of clinically stable adults with 
repaired ToF, the LA was enlarged in 43% of patients. Larger LA size, lower LA reservoir 
function, and lower LA contractile function were signiﬁcantly associated with the 
primary endpoint of any cardiovascular event. None of the patients with a normally 
sized LA died or developed heart failure. Among the diﬀerent indices of LA size, LA 
length was most strongly associated with adverse cardiovascular events, and had the 
best reproducibility. 
Diastolic dysfunction
A potential association of LA size and clinical outcomes in patients with repaired ToF has 
been suggested earlier, but this association has not further been described.15 However 
from other cardiac conditions, as well as in the general population, it is known that LA 
size is a marker of LV diastolic dysfunction and that it is associated with adverse clinical 
outcome.7-10,16,17 In our cohort, patients with a dilated LA were signiﬁcantly older, had 
larger LV volumes, and indeed had an impaired diastolic function. Of note, the accuracy 
of LV diastolic parameters such as the E’ wave is questioned in patients with ToF because 
of the presence of the interventricular septal patch. Evaluation of LA size may therefore 
be a more reliable alternative, or valuable addition to the set of LV diastolic function 
parameters.
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 Cardiac magnetic resonance studies have evaluated the extent of ventricular ﬁbrosis 
in patients with ToF using late gadolinium enhancement.18,19 In this relatively young 
patient group, more prominent LV regional and diﬀuse myocardial ﬁbrosis was observed, 
which was related to both abnormal systolic and diastolic function. Increased myocardial 
ﬁbrosis may explain why LV diastolic dysfunction and accompanied LA enlargement 
already develops at a relatively young age in patients with ToF.18,19 However, the normal 
aging process is also likely to play a role in the development of diastolic dysfunction, 
which was reﬂected in our cohort by increased LA volumes in older patients.
 In this study, a decreased LA active emptying fraction was associated with 
cardiovascular events, whereas the passive emptying fraction was not. This association 
has also been described in the general population, in chronic hypertension, and 
in ischemic heart disease.13,20 When LV diastolic dysfunction progresses, adequate 
diastolic ﬁlling of the LV becomes more dependent on the contractile function of the 
LA.20 This might explain why the contribution of the LA active emptying fraction seems 
to be of clinical importance in patients with ToF, in contrast to the passive emptying 
fraction. This is in line with a previous study in asymptomatic young patients after ToF 
repair, in which earlier and increased LA active contraction was suggested to indicate 
adaptive compensatory mechanisms to overcome latent and asymptomatic altered LV 
performance.21
Left atrial enlargement and clinical worsening
RV dilatation and dysfunction have always been the major concern in patients with 
repaired ToF.1 More recently, LV systolic dysfunction has also shown to predict adverse 
outcomes in ToF patients.5,22,23 Several studies showed an association between RV 
and LV systolic dysfunction in ToF patients, suggesting an unfavorable ventricular 
interaction.5,24,25 For instance, RV dilatation – secondary to RV volume overload – may 
shift the interventricular septum to the left, changing LV geometry, mechanics and 
ﬁlling.26 More speciﬁc, speckle-tracking echocardiography studies have suggested that 
RV dilatation impedes LV apical rotation in patients with repaired ToF. The subsequent 
reduced LV twist resulted in global LV systolic dysfunction.24,25,27 Interestingly, the 
abnormal systolic LV twist was also related to LV diastolic dysfunction in these 
patients.24 Diastolic dysfunction can lead to an increase in LA pressure, reﬂected by 
LA enlargement. The resulting increase in pulmonary artery pressure may augment 
pulmonary regurgitation, which is a common problem in ToF patients.1 The subsequent 
RV dilatation may create one of the vicious circles that can tilt a stable ToF patient 
towards progressive clinical deterioration. 
 Atrial ﬁbrillation and mitral regurgitation are also known to inﬂuence the LA size.28 In 
patients with ToF, atrial ﬁbrillation is an important cause of morbidity and poor clinical 
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outcome.15,28,29 LA dilatation in patients with mitral regurgitation has been described as 
a compensatory mechanism and predictor of cardiovascular events.28,29 Both conditions 
could in theory explain the association of LA enlargement and clinical deterioration. 
However, in our cohort they do not seem to play a major role, since we found no 
signiﬁcant diﬀerences in rhythm and heart rate between patients with a normal and 
a dilated LA, only three patients were in atrial ﬁbrillation, and only one patient had 
moderate mitral regurgitation. 
Comparison of left atrial size measurements
According to the guidelines, the most reliable and accurate method to estimate LA size 
and function is provided by LA volume or by multiple linear dimensions. A single linear 
measurement of the LA may underestimate the LA size, considering the asymmetrical 
shape and the possibility of foreshortening.8,12,16,30 In order to compare the prognostic 
value of the diﬀerent measurements of LA size (volume, area, length, and anteroposterior 
dimension), we evaluated each measurement as a standardized variable, which 
allows comparison of the HRs across all variables. Interestingly, a single measurement 
of LA length appeared to be more predictive than LA volume, reﬂected by a higher 
standardized HR. This could be explained by the observation that LA dilatation mainly 
develops in the craniocaudal direction. Anatomic factors such as a dilated right ventricle, 
the sternum and the spine may limit LA dilatation in the anteroposterior direction.31 As 
a result, LA length possibly provides a better reﬂection of LA enlargement. In addition, 
LA length showed to be the most reproducible measurement, reﬂected by a smaller 
interobserver variation than the LA area or volume measurement.
Clinical implications
In patients with ToF, accurate risk prediction is of paramount importance in order to 
optimize individual follow-up strategies, pharmacological treatment and timing of 
interventions.1 This study shows that one-dimensional LA length is a simple and 
reliable measurement, which is associated with cardiovascular events in clinically stable 
adults with repaired ToF. This measurement comes at no extra costs, as it is quick and 
can be performed on the A4C view of routinely acquired echocardiographic images. 
Although other imaging techniques such as CT, CMR or 3D echocardiography could 
provide a more accurate estimation of LA size, this simple linear dimension can be easily 
implemented in day-to-day clinical practice. Patients with LA dilatation may require 
more vigilant follow-up, initiation or expansion of medical therapy, or earlier timing of 
a re-intervention. Importantly, LA size seems to have a very high negative predictive 
value for death and heart failure, which makes it particularly valuable as a screening 
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tool. Patients with a normally sized LA may be reassured, and may need less frequent 
evaluation at the outpatient clinic. 
Study limitations 
The most important limitation of this study is that LA volumes were measured using 
a single plane approach of the A4C only, because the two-chamber views were of 
insuﬃcient quality in the majority of patients. Because of this limitation, the LA volumes 
measured in our study could be slightly underestimated.31 Second, due to the limited 
number of events, we could only adjust for the variables age and NYHA functional 
class, which may have resulted in residual confounding. Age at initial repair and prior 
palliative shunts were associated with LA dilatation, and may also play a crucial role. 
Larger studies are warranted to investigate the prognostic value of LA size and function 
in addition to multiple clinical, echocardiographic and biochemical markers.
CONCLUSIONS
In this cohort of clinically stable adults with repaired ToF, the LA was enlarged 
in a substantial number of patients. LA size and function, measured on routine 
echocardiographic examination, were signiﬁcantly associated with cardiovascular 
events. A normally sized LA could accurately rule out the risk of death and heart failure 
with a high negative predictive value. LA length was most strongly associated with 
cardiovascular events, and had the best reproducibility. This free, quick and simple one-
dimensional echocardiographic measurement may therefore be a valuable additional 
tool in the management and risk stratiﬁcation of adults with repaired ToF.
C H A P T E R  4  -  L A  s i z e  a n d  f u n c t i o n  i n  Fa l l o t  p a t i e n t s
72 
REFERENCES
1. Apitz C, Webb GD, Redington AN. Tetralogy of 
Fallot. Lancet. 2009;374:1462-1471.
2. van der Linde D, Konings EE, Slager MA et al. 
Birth prevalence of congenital heart disease 
worldwide: a systematic review and meta-
analysis. J Am Coll Cardiol. 2011;58:2241-2247.
3. Cuypers JA, Menting ME, Konings EE et 
al. Unnatural history of tetralogy of Fallot: 
prospective follow-up of 40 years after surgical 
correction. Circulation. 2014;130:1944-1953.
4. Hickey EJ, Veldtman G, Bradley TJ et al. Late risk 
of outcomes for adults with repaired tetralogy 
of Fallot from an inception cohort spanning four 
decades. Eur J Cardiothorac Surg. 2009;35:156-
164.
5. Geva T, Sandweiss BM, Gauvreau K, Lock JE, 
Powell AJ. Factors associated with impaired 
clinical status in long-term survivors of tetralogy 
of Fallot repair evaluated by magnetic resonance 
imaging. J Am Coll Cardiol. 2004;43:1068-1074.
6. Boyd AC, Schiller NB, Leung D, Ross DL, Thomas L. 
Atrial dilation and altered function are mediated 
by age and diastolic function but not before 
the eighth decade. JACC Cardiovasc Imaging. 
2011;4:234-242.
7. Leung DY, Boyd A, Ng AA, Chi C, Thomas L. 
Echocardiographic evaluation of left atrial 
size and function: current understanding, 
pathophysiologic correlates, and prognostic 
implications. Am Heart J. 2008;156:1056-1064.
8. To AC, Flamm SD, Marwick TH, Klein AL. Clinical 
utility of multimodality LA imaging: assessment 
of size, function, and structure. JACC Cardiovasc 
Imaging. 2011;4:788-798.
9. Pritchett AM, Mahoney DW, Jacobsen SJ, 
Rodeheﬀer RJ, Karon BL, Redﬁeld MM. Diastolic 
dysfunction and left atrial volume: a population-
based study. J Am Coll Cardiol. 2005;45:87-92.
10. Melenovsky V, Hwang SJ, Redﬁeld MM, Zakeri 
R, Lin G, Borlaug BA. Left atrial remodeling 
and function in advanced heart failure with 
preserved or reduced ejection fraction. Circ 
Heart Fail. 2015;8:295-303.
11. Eindhoven JA, van den Bosch AE, Ruys TP et al. 
N-terminal pro-B-type natriuretic peptide and 
its relationship with cardiac function in adults 
with congenital heart disease. J Am Coll Cardiol. 
2013;62:1203-1212.
12. Lang RM, Badano LP, Mor-Avi V et al. 
Recommendations for cardiac chamber 
quantiﬁcation by echocardiography in 
adults: an update from the American Society 
of Echocardiography and the European 
Association of Cardiovascular Imaging. J Am Soc 
Echocardiogr. 2015;28:1-39 e14.
13. Hoit BD. Left atrial size and function: role in 
prognosis. J Am Coll Cardiol. 2014;63:493-505.
14. McMurray JJ, Adamopoulos S, Anker SD et al. 
ESC Guidelines for the diagnosis and treatment 
of acute and chronic heart failure 2012: The 
Task Force for the Diagnosis and Treatment of 
Acute and Chronic Heart Failure 2012 of the 
European Society of Cardiology. Developed in 
collaboration with the Heart Failure Association 
(HFA) of the ESC. Eur Heart J. 2012;33:1787-1847.
15. Roos-Hesselink J, Perlroth MG, McGhie J, Spitaels 
S. Atrial arrhythmias in adults after repair of 
tetralogy of Fallot. Correlations with clinical, 
exercise, and echocardiographic ﬁndings. 
Circulation. 1995;91:2214-2219.
16. Abhayaratna WP, Seward JB, Appleton CP et 
al. Left atrial size: physiologic determinants 
and clinical applications. J Am Coll Cardiol. 
2006;47:2357-2363.
17. Nagueh SF, Appleton CP, Gillebert TC et 
al. Recommendations for the evaluation 
of left ventricular diastolic function by 
echocardiography. Eur J Echocardiogr. 
2009;10:165-193.
18. Babu-Narayan SV, Kilner PJ, Li W et al. Ventricular 
ﬁbrosis suggested by cardiovascular magnetic 
resonance in adults with repaired tetralogy of 
fallot and its relationship to adverse markers of 
clinical outcome. Circulation. 2006;113:405-413.
19. Kozak MF, Redington A, Yoo SJ, Seed M, Greiser 
A, Grosse-Wortmann L. Diﬀuse myocardial 
ﬁbrosis following tetralogy of Fallot repair: a T1 
mapping cardiac magnetic resonance study. 
Pediatr Radiol. 2014;44:403-409.
20. Kaminski M, Steel K, Jerosch-Herold M et al. 
Strong cardiovascular prognostic implication 
of quantitative left atrial contractile function 
assessed by cardiac magnetic resonance 
imaging in patients with chronic hypertension. 
J Cardiovasc Magn Reson. 2011;13:42.
04L A  s i z e  a n d  f u n c t i o n  i n  Fa l l o t  p a t i e n t s  -  C H A P T E R  4
73 
04
21. Koenigstein K, Raedle-Hurst T, Hosse M, Hauser 
M, Abdul-Khaliq H. Altered diastolic left atrial 
and ventricular performance in asymptomatic 
patients after repair of tetralogy of Fallot. Pediatr 
Cardiol. 2013;34:948-953.
22. Ghai A, Silversides C, Harris L, Webb GD, Siu 
SC, Therrien J. Left ventricular dysfunction is 
a risk factor for sudden cardiac death in adults 
late after repair of tetralogy of Fallot. J Am Coll 
Cardiol. 2002;40:1675-1680.
23. Diller GP, Kempny A, Liodakis E et al. Left 
ventricular longitudinal function predicts life-
threatening ventricular arrhythmia and death 
in adults with repaired tetralogy of fallot. 
Circulation. 2012;125:2440-2446.
24. Cheung YF, Wong SJ, Liang XC, Cheung EW. 
Torsional mechanics of the left ventricle in 
patients after surgical repair of tetralogy of 
Fallot. Circ J. 2011;75:1735-1741.
25. Menting ME, Eindhoven JA, van den Bosch AE et 
al. Abnormal left ventricular rotation and twist in 
adult patients with corrected tetralogy of Fallot. 
Eur Heart J Cardiovasc Imaging. 2014;15:566-
574.
26. Haddad F, Doyle R, Murphy DJ, Hunt SA. Right 
ventricular function in cardiovascular disease, 
part II: pathophysiology, clinical importance, 
and management of right ventricular failure. 
Circulation. 2008;117:1717-1731.
27. Kempny A, Diller GP, Orwat S et al. Right 
ventricular-left ventricular interaction in adults 
with Tetralogy of Fallot: a combined cardiac 
magnetic resonance and echocardiographic 
speckle tracking study. Int J Cardiol. 
2012;154:259-264.
28. Le Tourneau T, Messika-Zeitoun D, Russo A et al. 
Impact of left atrial volume on clinical outcome 
in organic mitral regurgitation. J Am Coll Cardiol. 
2010;56:570-578.
29. Borg AN, Pearce KA, Williams SG, Ray SG. Left 
atrial function and deformation in chronic 
primary mitral regurgitation. Eur J Echocardiogr. 
2009;10:833-840.
30. Aurigemma GP, Gottdiener JS, Arnold AM, 
Chinali M, Hill JC, Kitzman D. Left atrial 
volume and geometry in healthy aging: the 
Cardiovascular Health Study. Circ Cardiovasc 
Imaging. 2009;2:282-289.
31. Russo C, Hahn RT, Jin Z, Homma S, Sacco RL, Di 
Tullio MR. Comparison of echocardiographic 
single-plane versus biplane method in the 
assessment of left atrial volume and validation by 
real time three-dimensional echocardiography. J 
Am Soc Echocardiogr. 2010;23:954-960.
C H A P T E R  4  -  L A  s i z e  a n d  f u n c t i o n  i n  Fa l l o t  p a t i e n t s
74 
SUPPLEMENTAL MATERIAL
SUPPLEMENTAL FILE 1 - Left atrial length, area and volume measurement on the apical four chamber view
A, tetralogy of Fallot patient with a dilated left atrium (84 mL/m2). B, tetralogy of Fallot patient with a normal 
left atrium (26 mL/m2).
SUPPLEMENTAL FILE 2 - Patients with the primary and secondary composite endpoint.  
 
 
  LA volume index, mL/m2    
All patients
(n = 134)
< 34 
(normal, n = 76)
≥ 34 
(dilated, n = 58)
P-value
Cardiovascular event 33 (25) 10 (13) 23 (40) < 0.001
Death or heart failure 8 (6) 0 (0) 8 (14) 0.001
   Death 4 (3) 0 (0) 4 (7)
   Heart failure* 6 (5) 0 (0) 6 (10)
   Hospitalization 26 (19) 9 (12) 17 (29)
   Arrhythmia 19 (14) 4 (5) 15 (26)
   Thromboembolic event 5 (4) 1 (1) 4 (7)
   Cardiac re-intervention 18 (13) 8 (11) 10 (17)
For patients with multiple events, event-free and heart failure-free survival was deﬁned as the time from 
enrollment to the occurrence of the ﬁrst event. All components of the primary and secondary endpoint are 
separately displayed in this table for exploratory purposes (in which patients are not censored at the time of 
another endpoint than the endpoint of interest). P-value is calculated using the chi-squared test. Comparisons 
were not made between subgroups, in order to avoid multiplicity of comparisons. *Due to RV dysfunction (n = 
3), LV dysfunction (n = 2) or both RV and LV dysfunction (n = 1). Abbreviations: LA, left atrial.
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SUPPLEMENTAL FILE 3 - Bland-Altman plots demonstrating intraobserver (left) and interobserver agreement (right) 
for LA maximal volume (A), area (B) and length (C).
The solid lines represent the mean diﬀerence of two measurements. The dotted lines represent the limits of 
agreement (mean ± 1.96 SD). Abbreviations: COV, coeﬃcient of variation; LA, left atrial.
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ABSTRAC T
Background The development or persistence of pulmonary arterial hypertension 
(PAH) after atrial septal defect (ASD) closure at adult age is associated 
with a poor prognosis. The objective of this review was to investigate the 
prevalence of PAH before and after ASD closure and to identify factors 
that are associated with PAH.
Methods EMBASE and MEDLINE databases were searched for publications 
until March 2017. All studies reporting the prevalence of PAH or data 
on pulmonary artery pressures both before and after surgical or 
percutaneous ASD closure in an adult population (≥ 16 years of age) 
were included. Papers were methodologically checked and data was 
visualized in tables, bar charts and plots.
Results  A total of 30 papers were included. The prevalence of PAH ranged from 
29 to 73% before ASD closure and from 5 to 50% after closure; being 
highest in older studies, small study cohorts, and studies with high rates 
of loss to follow-up. The pooled systolic pulmonary artery pressure (PAP) 
was 43 ± 13 before ASD closure and 32 ± 10 after closure. The overall 
mean PAP was 34 ± 10 before closure and 28 ± 8 after closure. Studies 
with a higher mean PAP before closure and a higher mean age of the 
study cohort reported greater PAP reductions.
Conclusions The prevalence of PAH and mean pulmonary pressures decreased in 
all studies, regardless of the mean age or pulmonary pressures of the 
cohort. The reported prevalence of PAH after ASD closure is substantial, 
although widely varying (5–50%), which is likely aﬀected by selection of 
the study cohort.
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INTRODUC TION
Atrial septal defect (ASD) is the second most common congenital heart defect with 
an estimated worldwide birth prevalence of 1.6 per 1000 live births.1 ASDs are usually 
detected and closed during childhood, but can also be discovered at adult age. When 
left untreated, chronic volume overload of the pulmonary vasculature can cause 
structural and mechanical changes in the pulmonary vascular bed. Eventually, patients 
may develop pulmonary arterial hypertension (PAH), accompanied by progressive right 
ventricular dilatation and dysfunction.2 Therefore, it has been shown that ASD closure of 
a hemodynamically signiﬁcant shunt is indicated at all ages.
 Patients with PAH related to congenital heart disease suﬀer from substantial 
morbidity and mortality, with ﬁve-year mortality rates ranging from 5 to 23%.3, 4 After 
ASD repair, it is unclear what proportion of patients continues to have high pulmonary 
pressures and which factors are associated with the persistence of PAH. It is also still 
under debate whether very high pulmonary artery pressures (PAP) are reversible after 
closure.5-7 In addition, it has been reported that even patients with low pulmonary 
pressures before ASD repair may develop PAH after the procedure.5, 8
 The objective of this systematic review was to investigate the prevalence of PAH both 
before and after ASD repair. In addition, we aimed to identify factors that are associated 
with the development or persistence of PAH after ASD closure.
METHODS
Protocol and registration
The systematic review was conducted in accordance with the PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses) statement.9 A pre-deﬁned 
review protocol of this study can be accessed through PROSPERO (registration number: 
CRD42016034199). No extramural funding was used to support this work.
Information sources and search strategy
We performed a literature search on the 20th of March 2017 in EMBASE and MEDLINE 
online databases. The following search terms (including their synonyms and MeSH 
terms) were combined: (“pulmonary arterial hypertension” or “right ventricular pressure” 
or “tricuspid valve regurgitation”) and “atrial septal defect” and “closure”. The exact 
search syntax is shown in Supplemental File 1. Duplicates were identiﬁed and removed 
using Endnote X7.1 (New York, Thomson Reuters, 2013), which was manually checked.  
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Eligibility criteria
We included articles that reported the prevalence of PAH or data on PAP both before 
and after percutaneous or surgical ASD closure (both secundum ASD and sinus venosus 
defect) in an adult population (≥ 16 years of age at ASD closure). We only focused on the 
adult population, because these patients have a more long-term volume overload and 
are therefore more at risk of developing PAH. When the data for children and adults were 
separately described, the study was included and only the data of the adult population 
was used in this review. The following exclusion criteria were used: non-original data 
(reviews and comments) or non-clinical data (animal and in vitro studies), case series 
(study population of less than ﬁve participants), less than 95% secundum ASD or sinus 
venosus defect, follow-up shorter than three months, pulmonary pressure before and 
after ASD closure measured on diﬀerent modalities, and articles written in languages 
other than English or Dutch. In addition, studies that only investigated patients with 
patent foramen ovale (PFO) closure were excluded. 
Study selection
A ﬂow diagram of the selection procedure is shown in Figure 1. Three authors (R.Z., L.G., 
K.V.) independently performed screening on title and abstract. In case of disagreement, 
a fourth author was consulted to achieve consensus. All references in reviews and in 
the remaining papers were crosschecked to identify possible relevant papers missed 
in the original search syntax. Subsequently, two authors (R.Z., V.B.) performed full-text 
screening based on the eligibility criteria as described above. 
Methodological quality assessment 
For the methodological quality assessment of the included studies we applied a modiﬁed 
version of the Newcastle-Ottawa Scale.10 We used the items that were applicable for this 
review as described in Figure 2. The quality of the studies was assessed on the following 
main groups: selection of the study cohort, ascertainment of PAH before and after ASD 
closure, comparability of the cohort, and missing data. 
Data extraction and analysis
Data was collected using a standardized form. This included study design, age, sex, type 
of procedure (surgical or percutaneous), New York Heart Association (NYHA) functional 
class, ASD diameter, prevalence of PAH and/or mean pulmonary artery pressures before 
and after ASD closure, modality and cut-oﬀ point used for the diagnosis of PAH, mean 
ASD diameter, mean follow-up time, and missing data.
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2193 records identified through database 
searches in MEDLINE (1320) and EMBASE 
(873) in March 2017
1469 potentially relevant records identified
165 full-text articles assessed for eligibility
30articles included in systematic review
724 duplicates removed
1304 records excluded based on title 
and abstract
137 articles excluded based on:
- No PAH measurement before 
and/or after ASD closure 
mentioned (46)
- Article not available in English or 
Dutch (46)
- Full text not available (13)
- Minimum follow-up <3 months 
or not reported (9)
- No separate analysis for adults 
(8)
- Less than 95% ASD2 or SVD (7)
- Study population <5(2)
- Non-original data (2)
- PAH measurements done with 
different modalities (1)
- Type ASD not reported (1)
- Same cohort as other study (1)
- Retracted from journal 
publication (1)
2reference cross-checking of 
selected articles
3 studies
report PAH 
prevalence 
before and 
after
5 studies report 
PAH prevalence 
before and after 
+ mean 
pulmonary 
pressures
17 studies 
report mean 
pulmonary
pressures
5 studies 
includeda
population with 
100% PAH 
before ASD 
closure
FIGURE 1 - Flow diagram of literature search and selection of studies.
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 To explore which factors could be associated with the development or persistence of 
PAH, we plotted the average age at closure, percentage women, and percentage NYHA 
class III-IV of the separate studies against the pulmonary pressures. Other study baseline 
characteristics were overall insuﬃ  ciently reported to aggregate the results in plots. 
Because of the heterogeneity in modality of PAH measurement and result presentation, 
a formal meta-analysis was not conducted. 
 The pooled pulmonary pressure was calculated by the following formula: 
∑ N * pulmonary pressure / ∑ N.  The pooled standard deviation (SD) was calculated by 
the following formula:  ∑ N − 1 * SD / ∑ N . Studies that included a patient population with 
100% PAH before ASD closure were excluded when calculating the overall prevalence 
of PAH and mean pulmonary pressures before and after ASD closure, because these 
studies will cause a false-increased overall prevalence.
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PH measurement aŌer closure
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FIGURE 2 - Methodological quality of the included studies.
Selection of study cohort: Consecutive patients reported ( + yes, - no), Type of patients included (+ all patients 
with ASD, - only PAH patients), Ascertainment of PAH prior to ASD closure: Modality of PAH measurement (+ 
RHC, ± TTE/TEE, - Not deﬁ ned), PAH cutoﬀ  deﬁ ned (+ yes, - no, NA not applicable (study did not describe the 
prevalence of PAH), Comparability of cohort: Description of baseline characteristics: age, sex, comorbidities 
(+ all 3 items described, ± 2 items described - ≤ 1 item described), Ascertainment of PAH after ASD closure: 
Modality of PAH measurement (+ RHC, ± TTE/TEE, - Not deﬁ ned), PAH cutoﬀ  deﬁ ned (+ yes, - no, NA not 
applicable (study did not describe the prevalence of PAH), Missing data: PAH measurement before and after 
closure (+ < 5%, ± 5–10%, - > 10%, NR not reported).
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RESULTS
Search results
The literature search identiﬁed 1469 potential relevant records, of which 1304 were 
excluded based on title and abstract (Figure 1). After comprehensive full-text screening 
and reference cross-checking, 30 articles were included in this systematic literature 
review.5, 6, 11-38 Three studies15, 17, 25 reported only PAH prevalence before and after ASD 
closure, ﬁve studies11-14, 30 reported both PAH prevalence and average pulmonary 
pressures before and after ASD closure, 17 studies16, 19-21, 23, 24, 26-29, 31-34, 36-38 only reported 
average pulmonary pressures before and after ASD closure, and ﬁve studies5, 6, 18, 22, 35 
included a patient population with 100% PAH before ASD closure. In eight studies, only 
a subpopulation met the inclusion criteria, which was used for this review.5, 6, 16, 19, 27, 30, 32, 35 
Two studies reported their data for two separate groups instead of for the total cohort, 
so we maintained these two groups in this review.24, 33
 Study and patient characteristics of the included studies are shown in Table 1. The 
total number of study participants varied from 12 to 274, with a mean age ranging from 
32 to 76 years (53–91% female). The mean follow-up duration ranged from 13 to 98 
months.
Methodological aspects
The quality assessment per category is presented in Figure 2. The results of the quality 
assessment for the individual studies can be found in Supplemental Table 1. In 90% of 
the studies patients were included consecutively, in the other 10% this was not reported. 
 Pulmonary pressures before and after ASD closure were measured using right 
heart catheterization (RHC) in 9 studies (30%) and using echocardiography in 21 
studies (70%). Some studies determined PAP before ASD closure with both RHC and 
echocardiography, but after closure with only echocardiography. Accordingly, we 
then also used the echocardiographic measurement of PAP before closure in order to 
compare these results.
 Three studies reported the PAH prevalence both before and after ASD closure 
assessed by RHC with a cutoﬀ of mean PAP ≥ 20 mmHg13-15 and one study5 did not report 
a cutoﬀ for PAH. According to the current guidelines for the diagnosis of pulmonary 
hypertension the cutoﬀ of mean PAP ≥ 25 mmHg assessed by RHC should be used.39 
D’Alto et al.,5 Dave et al.14 and Saksena et al.13 presented the data of individual patients, 
so we were able to adjust the PAH cutoﬀ for these studies to mean PAP ≥ 25 mmHg. 
 The percentage of patients who were lost to follow-up after ASD closure (i.e., no 
information available on pulmonary pressures) was between 5 and 10% in one study 
(3%), more than 10% in eight studies (27%) and not reported in eight studies (27%). 
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Prevalence of PAH after ASD closure
Eight out of the 30 studies reported the proportion of patients with PAH before and 
after ASD closure, according to a cut-oﬀ  level of pulmonary arterial pressure. As shown 
in Figure 3, the prevalence of PAH varied between 29 and 73% before ASD closure, and 
between 5 and 50% after closure. When pooling these results, the overall prevalence 
was 48% before and 18% after the ASD repair. In all studies, the prevalence of PAH after 
closure decreased with absolute 16 to 54%.
 We conducted a sensitivity analysis in which all studies with a loss to follow-up of 
> 20% (n = 4) were excluded. This yielded a pooled PAH prevalence of 42% before and 
16% after ASD closure.
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FIGURE 3 - PAH prevalence before and after ASD closure.
PAH prevalence before and after ASD closure presented per study. The number of patients shown in this 
bar chart is the number that had a measurement of pulmonary pressures (right heart catheterization or 
echocardiography).
Pulmonary pressures before and after ASD closure
In Figure 4, the pulmonary pressures before and after ASD closure are visualized. In all 
studies, the average pulmonary pressure of the study cohort decreased after closure. 
In 16 studies, a statistically signiﬁ cant reduction was found. In the remaining studies, 
only one described no signiﬁ cant diﬀ erence27 and the other ﬁ ve (of which two studies 
reported the results for two diﬀ erent subgroups24, 33) did not report any p-values. 
Considering that this is paired data, the individual reduction per patient would be 
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needed to derive the appropriate p-value, and these studies provided only the mean 
and standard deviation before and after ASD closure in the entire group. Therefore, the 
p-value could not be calculated from the data provided by the studies. 
 When pooling these results, the overall systolic PAP was 43 ± 13 before ASD closure 
and 32 ± 10 after closure. The overall mean PAP was 34 ± 10 before closure, and 28 ± 8 
after closure. A sensitivity analysis with the exclusion of studies with loss to follow-up 
> 20% (n = 3) resulted in an overall systolic PAP of 39 ± 11 before and 31 ± 10 after ASD 
closure.
FIGURE 4 - Pulmonary pressures before and after ASD closure.
SPAP and MPAP before and after ASD closure shown as mean±SD. The number of patients displayed is the 
number that underwent measurement of PAP before closure. *Signiﬁ cant reduction of p < 0.05; NR, not 
reported. †SD before and/or after was not available and therefore also not included in the pooled pulmonary 
pressures.
Studies that included 100% PAH
Five studies had only selected patients with PAH before ASD closure, resulting in a PAH 
prevalence of 100% before closure.5, 6, 18, 22, 35 All ﬁ ve studies presented PAP before and after 
closure (Supplemental Figure 1). The reduction in PAP after ASD closure was statistically 
signiﬁ cant in all ﬁ ve studies. Two studies additionally reported a PAH prevalence after 
ASD closure.5, 22 Balint et al.22 reported a prevalence of 56% and D’Alto et al.5 100% after 
ASD closure. Thus, in the latter study, although the average PAP decreased, all patients 
continued to have pulmonary pressures that were above the cutoﬀ  for PAH; therefore, no 
reduction in the prevalence of PAH was found. Of note, this study included only 12 patients. 
C H A P T E R  5  -  P r e v a l e n c e  o f  PA H  b e f o r e  a n d  a f t e r  A S D  c l o s u r e
88 
 When pooling the results of these ﬁ ve studies, the overall systolic PAP was 60 ± 15 
before and 39 ± 13 after ASD closure. The overall mean PAP was 46 ± 8 before and 30 ± 
8 after ASD closure.
Increase of PAP after ASD closure among individual patients
Although the average pulmonary pressures in the entire cohort decreased after ASD 
closure in all studies, ﬁ ve studies reported that the pulmonary pressure increased after 
ASD closure in a small subset of patients.5, 13, 14, 22, 35 An increase in PAP was found in one 
to maximum four patients per study (5 to 17% of the study cohort). In three out of ﬁ ve 
studies, all patients with a rise in PAP were already diagnosed with PAH before ASD 
closure.5, 22, 35 In the two other studies, only a very mild increase in PAP was present: 
in the study of Saksena et al. two patients who did not have pulmonary hypertension 
before ASD closure had an increase in PAP (mean PAP increased from 14 to 26 mmHg in 
one patient, and from 18 to 26 mmHg in the other) and another patient had an increase 
in mean PAP from 17 to 23 mmHg. In the study of Dave et al., only one patient had an 
increase in mean PAP from 21 to 27 mmHg. The patients with an increase in PAP were 
not signiﬁ cantly older, or could not be clearly distinguished based on other baseline 
characteristics from the patients with a decrease in PAP.
 Three studies described that not any patient had an increase in PAP.11, 12, 16 Importantly, 
all other studies have not explicitly stated whether or not there were individual patients 
with an increase in PAP.
FIGURE 5 - Association of PAP before closure with PAP after closure and reduction in PAP.
Each symbol illustrates one study cohort. 
Associations with pulmonary pressures
As shown in Figure 5, studies with a higher PAP before ASD closure also reported greater 
absolute PAP reductions. It may also be concluded that studies with a higher mean age 
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also have a higher PAP before ASD closure, with a corresponding larger PAP reduction (Figure 
6). We did not observe any associations for sex and NYHA class (Supplemental Figure 2). 
FIGURE 6 - Association of age with PAP before closure, PAP after closure, and reduction in PAP.
Each symbol illustrates one study cohort. The green symbol illustrates studies that reported the median age 
instead of the mean age.
DISCUSSION
To the extent of our knowledge, this is the ﬁrst systematic review that provides an 
overview of all studies that investigated the prevalence of PAH or the pulmonary 
arterial pressures before and after ASD closure. In addition, we explored factors that 
were possibly associated with higher pulmonary pressures before or after ASD closure. 
The most important ﬁnding of this review is that the PAH prevalence and the mean 
pulmonary pressures decreased in all studies after ASD closure, regardless the mean 
age of the study cohort or pulmonary pressures. In addition, studies with the highest 
pulmonary pressures before closure generally also reported the largest reduction in 
pulmonary pressures. The proportion of patients with PAH after ASD closure remained 
substantial, although widely varying (5–50%).
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PAH prevalence
The widely varying prevalence of PAH after ASD closure may be partly explained by 
diﬀerent selection criteria of the studies. The main studies with the highest proportion 
of patients with PAH after closure are published over 30 years ago, and included a small 
number of patients.11, 13, 14 Accordingly, studies with the lowest percentage of PAH after 
ASD closure included the highest number of patients (Figure 3). In addition, a high 
proportion of patients was lost to follow-up in the studies that reported a high PAP 
after ASD closure. Hanlon et al.11 and Dave et al.14 reported a proportion of 79% and 
41% loss to follow-up after ASD closure, respectively. Because healthy patients without 
complaints may be more likely to withdraw from follow-up, the prevalence in these 
studies may be overestimated. The “true” prevalence of PAH after closure is therefore 
likely to be more towards the lower limit of the reported range (i.e., 5–20%). This is 
also in line with two other large studies that only assessed the prevalence of PAH after 
ASD closure, reporting a prevalence of 8%40 and 12%3 in 717 and 377 adults after ASD 
closure, respectively.
Studies with 100% PAH included
Of the ﬁve studies that selected only patients with PAH before ASD closure, the study 
of D’Alto et al. additionally selected patients based on whether they had PAH after 
ASD closure.5 In addition, the study population existed of patients with a very high 
pulmonary vascular resistance (PVR) and ratio between PVR and systemic vascular 
resistance (SVR). Therefore, this is actually a highly-selected group with irreversible PAH. 
This explains why this study showed no change in the PAH prevalence after ASD closure 
and thus remained to be 100%, whereas all others did report a reduction. Nonetheless, 
although the PAH prevalence after ASD closure did not decrease, ASD closure may still 
be beneﬁcial in these patients because the overall mean PAP signiﬁcantly decreased.
Increase of PAP after ASD closure
This systematic review shows that the PAP may increase in individual patients after 
ASD closure. However, this increase in PAP was mainly observed in patients who had 
already been diagnosed with PAH before the closure. In other patients, there was only a 
negligible increase in PAP. One study that was not included in this review because they 
also studied patients with ASD closure in their childhood, did describe a large group of 
patients (n = 20, 10%) that had a normal PAP before ASD closure, but developed PAH 
during follow-up.41 Furthermore, most studies did not report if there were individual 
patients who had an increase of PAP after closure. This could have resulted in under-
reporting and therefore underestimation of this number. For future research, it is 
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advisable to report individual results of pulmonary pressure changes to provide more 
insight in this topic. 
Association between age and pulmonary pressures
Some previous studies have also investigated which factors were associated with 
PAH after ASD closure.25, 41 In the study of Yong and colleagues, age at closure was 
signiﬁcantly associated with PAH in a multivariable analysis.25 Humenberger et al. 
reported that although a reduction in systolic PAP was observed in all age groups, older 
patients ended up with higher PAP after the ASD closure.29 Although not included in this 
review because also children were included, the study of Gabriels et al. reported that 
age at closure was signiﬁcantly associated with PAH in the multivariable analysis, when 
adjusted for mean PAP before repair, body mass index and systolic blood pressure.41 In 
this review, the mean age of the study cohort seemed to be positively associated with 
the mean PAP reduction, and possibly with the mean PAP before ASD closure (Figure 6). 
However, we could not demonstrate a clear association between the mean age of the 
study cohort and the mean PAP after ASD closure. These diﬀerences may be explained 
by the fact that this review only studied aggregated data (i.e., mean age of the study 
cohort), as opposed to individual patient data in the original studies.
Clinical implications
In the ESC guidelines for the management of grown-up congenital heart disease,42 it 
is recommended that patients with elevated PAP and with ASD closure at adult age 
(especially over 40 years of age) should be checked periodically. Advised is regular 
follow-up during the ﬁrst two years and then, depending on the results, every 2–4 years. 
Given the substantial percentage of patients with PAH after closure, this review conﬁrms 
that long-term follow-up with monitoring of RV pressures is mandatory. 
 A long-standing discussion is whether ASD closure is still useful in elderly patients.43-45 
Importantly, in this review we found a decrease in PAP in all studies, regardless of the 
mean age of the study cohort. On top of that, the reduction in PAP may even be higher 
in studies that included older patients. Therefore, the results from this review show that 
ASD closure leads to decreased pulmonary pressures in all investigated study cohorts 
and may thus be considered beneﬁcial at any age.
Study limitations
We included studies that measured PAP with either echocardiography or RHC. 
Although RHC is the reference standard to obtain hemodynamic measurements,46 
echocardiography is non-invasive and easy to use in clinical practice. Including both 
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modalities in this review is one cause of the heterogeneity of the results. Moreover, 
diﬀerent cutoﬀ values for PAH were used, even among studies that measured PAP with 
the same modality. We have tried to improve this by using the cutoﬀ value for mean 
PAP ≥ 25 mmHg (measured with RHC) in studies where individual patient data were 
reported.
 Second, there was a high number of patients lost to follow-up in a large subset of 
studies, which might have introduced selection bias. It is diﬃcult to indicate in what 
direction this may have biased the results. The prevalence of PAH can be underestimated 
if patients with the highest pulmonary pressures are lost to follow-up, or overestimated 
if more healthy people with low pulmonary pressures are being discharged from follow-
up and do not receive a second echocardiogram or RHC after ASD closure. We believe 
that the latter is more likely to have occurred. Nonetheless, in a sensitivity analysis with 
the exclusion of studies with > 20% loss to follow-up, there was only a slight decrease in 
the pooled PAH prevalence and pooled systolic PAP, both before and after ASD closure.
CONCLUSIONS
This systematic review shows that the reported prevalence of PAH after ASD closure 
varies between 5 and 50%, and was highest in older studies with small study cohorts 
and studies with a large proportion of patients lost to follow-up. The prevalence of PAH 
and mean pulmonary pressures decreased in all studies, regardless of the mean age or 
pulmonary pressures of the cohort. In addition, studies with a higher mean PAP before 
closure and a higher mean age of the study cohort reported greater PAP reductions. 
Still, long-term follow-up of pulmonary artery pressures is warranted, as the proportion 
of patients with PAH after ASD remains substantial, and the pulmonary pressure may 
increase in individual patients.
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SUPPLEMENTAL MATERIAL
SUPPLEMENTAL FILE 1 - Search syntax used to identify publications of interest. Search date March 20, 2017.
MEDLINE
“pulmonary hypertension”[tiab] OR “pulmonary arterial hypertension”[tiab] OR “pulmonary artery 
hypertension”[tiab] OR PAH[tiab] OR (pulmonary[tiab] AND (artery[tiab] OR arterial[tiab]) AND (pressure[tiab] 
OR pressures[tiab])) OR (right[tiab] AND (ventricular[tiab] OR ventricle[tiab]) AND (pressure[tiab] OR 
pressures[tiab])) OR ((tricuspid[tiab] OR tricuspidalis[tiab] OR tricuspidal[tiab] OR tricuspide[tiab]) AND 
(regurgitant[tiab] OR regurgitation[tiab] OR insuﬃciency[tiab] OR velocity[tiab] OR velocities[tiab] OR 
gradient[tiab] OR gradients[tiab])) OR “Hypertension, Pulmonary”[MeSH Terms]
AND
ASD[tiab] OR ((atrial[tiab] OR atrium[tiab] OR atria[tiab] OR interatrial[tiab]) AND (septum[tiab] OR septal[tiab]) 
AND (defect[tiab] OR defects[tiab])) OR (ostium[tiab] AND primum[tiab] AND (defect[tiab] OR defects[tiab])) 
OR (ostium[tiab] AND secundum[tiab] AND (defect[tiab] OR defects[tiab])) OR (sinus[tiab] AND venosus[tiab] 
AND (defect[tiab] OR defects[tiab])) OR “Heart Septal Defects, Atrial”[MeSH Terms]
AND
closure[tiab] OR closed[tiab] OR surgery[tiab] OR repair[tiab] OR repaired[tiab] OR occlusion[tiab] OR 
occluder[tiab] OR occluded[tiab] OR “Septal Occluder Device”[MeSH Terms]
NOT 
(animals[MeSH] NOT humans[MeSH])
EMBASE
“pulmonary hypertension”:ti,ab OR “pulmonary arterial hypertension”:ti,ab OR “pulmonary artery 
hypertension”:ti,ab OR PAH:ti,ab OR (pulmonary:ti,ab AND (artery:ti,ab OR arterial:ti,ab) AND (pressurev OR 
pressures:ti,ab)) OR (right:ti,ab AND (ventricular:ti,ab OR ventricle:ti,ab) AND (pressure:ti,ab OR pressures:ti,ab)) 
OR ((tricuspid:ti,ab OR tricuspidalis:ti,ab OR tricuspidal:ti,ab OR tricuspide:ti,ab) AND (regurgitant:ti,ab 
OR regurgitation:ti,ab OR insuﬃciency:ti,ab OR velocity:ti,ab OR velocities:ti,ab OR gradient:ti,ab OR 
gradients:ti,ab)) 
AND
ASD:ti,ab OR ((atrial:ti,ab OR atrium:ti,ab OR atria:ti,ab OR interatrial:ti,ab) AND (septum:ti,ab OR septal:ti,ab) 
AND (defect:ti,ab OR defects:ti,ab)) OR (ostium:ti,ab AND primum:ti,ab AND (defect:ti,ab OR defects:ti,ab)) OR 
(ostium:ti,ab AND secundum:ti,ab AND (defect:ti,ab OR defects:ti,ab)) OR (sinus:ti,ab AND venosus:ti,ab AND 
(defect:ti,ab OR defects:ti,ab)) 
AND
closure:ti,ab OR closed:ti,ab OR surgery:ti,ab OR repair:ti,ab OR repaired:ti,ab OR occlusion:ti,ab OR 
occluder:ti,ab OR occluded:ti,ab 
NOT 
([conference abstract]/lim OR [conference paper]/lim OR [conference review]/lim OR [editorial]/lim OR 
[erratum]/lim OR [letter]/lim OR [note]/lim OR [animals]/lim) 
AND 
[embase]/lim
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SUPPLEMENTAL FIGURE 1 - Pulmonary pressures before and after ASD closure for the studies that included 100% 
PAH before closure.
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ABSTRAC T
Background Atrial septal defect (ASD) closure is performed to prevent pulmonary 
hypertension (PH), which is associated with poor outcome. This study 
investigates the prevalence of PH in adults before and after ASD closure 
and explored associations between patient characteristics and PH after 
ASD closure.
Methods Consecutive adult patients who underwent surgical or percutaneous ASD 
closure (2000–2014) in the Erasmus MC, the Netherlands, were included. 
Echocardiograms before and after ASD closure were retrospectively 
assessed. Patients were categorized into three groups (no, possible, and 
likely PH) based on tricuspid regurgitation velocity (< 2.9, 2.9–3.4, and 
≥ 3.4 m/s) or mean pulmonary arterial pressure (< 20, 20–24, and ≥ 25 
mmHg). Cox regression was performed to identify associations between 
patient characteristics and PH after ASD closure.
Results  Of the 244 eligible patients who underwent ASD closure, 198 (81%) had 
echocardiograms both before and median 15 [IQR 12–35] months after 
ASD closure (median age at closure 45 [IQR 30–57] years, 75% female). 
The prevalence of PH was 13.1% (n = 26) before ASD closure and 5.0% (n 
= 10) after closure. NYHA III–IV (HR 11.07, 95% CI 3.12–39.29, p < 0.001), 
pulmonary disease (HR 10.43, 95% CI 2.12–51.21, p = 0.004), cardiac 
medication use (HR 3.96, 95% CI 1.02–15.34, p = 0.047), right ventricular 
fractional area change (HR 0.87, 95% CI 0.81–0.93, p < 0.001), and 
tricuspid annular plane systolic excursion (HR 0.75, 95% CI 0.59–0.95, p = 
0.018) were signiﬁcantly associated with PH.
Conclusions Adults with low pulmonary pressures before ASD closure are not at risk 
of PH after closure. Especially in patients with risk factors for PH after 
ASD closure close follow-up is warranted.
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INTRODUC TION
Atrial septal defect (ASD) is a common congenital cardiac anomaly and accounts for 
approximately 10% of congenital cardiac anomalies.1 Increased pulmonary ﬂow 
caused by left-to-right shunting can lead to right ventricular failure and/or pulmonary 
hypertension (PH).2 Left untreated, the consequent increase in pulmonary vascular 
resistance can cause progressive deterioration of right ventricular (RV) function, 
right heart failure, and eventually death.3, 4 Therefore, in patients with a signiﬁcant 
hemodynamic shunt causing RV volume overload, ASD closure is indicated, unless 
speciﬁc contra-indications are present.5
 The reported prevalence of PH in adult patients with a closed ASD is widely varying 
from 5% up to 50% in older studies.6-15 Some studies even suggest that pulmonary 
pressures can further increase after ASD closure in individual patients.16 The persistence 
or development of PH after ASD closure is probably due to less reversible changes 
in extracellular matrix and endothelial dysfunction, accompanied with increased 
pulmonary vascular resistance. PH associated with congenital heart disease is associated 
with high mortality and morbidity.4 Identiﬁcation of patient characteristics associated 
with the persistence or development of PH after ASD closure, as well as further 
delineation of the clinical course of patients with PH after ASD closure is important, as 
it aﬀects individual patient follow-up and therapeutic management, and contributes to 
the general understanding of PH pathophysiology.
 The objective of this study is to estimate the prevalence of PH before and after ASD 
closure. In addition, this study aims to investigate the association between patient 
characteristics and the presence of PH after ASD closure.
METHODS
Study population
All consecutive adult patients who underwent surgical or percutaneous closure of an 
ASD ostium secundum or sinus venosus defect between 2000 and 2014 in our center 
were identiﬁed. We excluded patients with a patent foramen ovale (PFO), signiﬁcant 
pulmonary stenosis (> 2.0 m/s or requiring surgery), Ebstein’s anomaly, left heart surgery 
or PCI during the procedure, lung transplantation before ASD closure, and patients with 
other identiﬁable causes for PH such as chronic thromboembolic PH. 
 Patient characteristics such as age at ASD closure, sex, height, weight, blood pressure, 
saturation, New York Heart Association (NYHA) functional class, cardiac medication, 
known pulmonary disease (chronic obstructive pulmonary disease (COPD) or obstructive 
sleep apnea syndrome (OSAS)), type of procedure (percutaneous or surgical), residual 
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lesions, and cardiac (re-)interventions were obtained from the electronic patient charts. 
The Erasmus MC medical ethics committee approved the study protocol and waived the 
need for written informed consent.
Echocardiography
All transthoracic echocardiograms before and after ASD closure were retrospectively 
assessed. Right atrial pressure was estimated from the inferior vena cava size and the 
response to inspiration.17 Right atrial (RA) and right ventricular (RV) dimensions and 
area were primarily measured on a RV focused view. If this view was not available, these 
measurements were performed on the apical four-chamber view. Cardiac dimensions 
were measured in agreement with the current recommendations of the American Society 
of Echocardiography and European Association of Cardiovascular Imaging.17 Tricuspid 
regurgitation (TR) and pulmonary regurgitation (PR) were quantiﬁed on color Doppler 
echocardiography and right ventricular systolic pressure; mean and diastolic pulmonary 
arterial pressures were calculated in accordance with the current recommendations of 
the American Society of Echocardiography and European Association of Cardiovascular 
Imaging. 
PH assessment
Patients were categorized into three groups based on TR velocity (no PH: < 2.9 m/s, 
possible PH: 2.9–3.4 m/s, and likely PH: ≥ 3.4 m/s) according to the ESC/ERS guidelines 
for the diagnosis and treatment of pulmonary hypertension.18 When this measurement 
was not available, categorization was based on mean pulmonary arterial pressure 
(mPAP) (pulmonary regurgitation maximal velocity and estimated right atrial pressure; 
< 20, 20–24, and ≥ 25 mmHg, respectively). When both TR velocity and mPAP could not 
be measured, patients were categorized as possible PH based on evaluation of enlarged 
RV dimensions, decreased RV function and signs of PH (systolic and diastolic septal 
ﬂattening on the parasternal short axis image at midventricular level19) by a cardiologist 
expert in the ﬁeld of echocardiography and pulmonary hypertension (A.E.v.d.B.). RV 
function was quantiﬁed with tricuspid annular plane systolic excursion (TAPSE) and RV 
fractional area change (FAC).
Mid-term and long-term follow-up
The mid-term follow-up was deﬁned as the ﬁrst echocardiogram that was performed 
≥6 months after the ASD closure and was collected in all patients. We actively invited 
the high-risk subset of patients (patients categorized as likely PH before ASD closure, or 
possible or likely PH after closure) to visit our outpatient clinic for a long-term follow-
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up visit. Mid- and long-term follow-up was performed by non-invasive examinations 
(clinical examination, electrocardiography and transthoracic echocardiography). If 
patients were followed up in another hospital and were not able to come to the Erasmus 
Medial Center Rotterdam, we contacted the patients and asked for their consent for 
retrieving their data from the local hospital. 
Statistical analysis
Continuous variables were reported as mean ± standard deviation (SD), or as 
median [interquartile range (IQR)] if data was skewed. Categorical data were presented 
as frequencies and percentages. Comparisons across the diﬀerent PH categories (no PH, 
possible PH, and likely PH) were performed using the Chi-Square Mantel-Haenszel test 
for trend for categorical variables and linear regression for continuous variables. Cox 
proportional hazards regression was performed to identify associations between patient 
characteristics and PH after ASD closure. Proportional hazards assumption was checked 
in R (version 3.4.1) using log-minus-log plots for categorical variables and Schoenfeld 
residuals for continuous variables. Because of the limited number of patients with PH 
after ASD closure, multivariable Cox regression analysis was not performed. Statistical 
analysis was performed using SPSS version 21.0.0.1 (IBM Corp., Armonk, NY, USA). Two-
sided p-values of < 0.05 were considered statistically signiﬁcant.
RESULTS
Study population
We identiﬁed 281 adult patients with an ASD closure in our center, of whom 37 patients 
were excluded based on pre-deﬁned criteria (Figure 1). Of the 244 eligible patients, 6 
had missing echocardiographic data on RV pressures before the ASD closure and 40 
patients had missing echocardiographic data on RV pressures after the ASD closure. 
Therefore, 198 patients were included in the ﬁnal study cohort. The 46 patients with 
missing RV pressures did not have signiﬁcant diﬀerences in age at closure, body mass 
index, use of cardiac medication, NYHA class, type of procedure, or PH classiﬁcation 
before ASD closure compared to the 198 patients included in the analysis. 
Baseline patient characteristics
Of the 198 patients, the ASD was closed percutaneously in 110 patients and surgically 
in 88 patients. The median age at closure was 45 [IQR 30–57] years and 75% was female. 
Baseline characteristics of the study population (and for the separate PH classiﬁcation 
groups) are further speciﬁed in Table 1. 
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 Patients who were classiﬁed as likely PH before ASD closure were signiﬁcantly older, 
a larger proportion was in NYHA class III–IV, used cardiac medication, had a higher 
body mass index, a higher systolic blood pressure, a larger proportion had a saturation 
under 95%, had more often loss of sinus rhythm, a longer QRS duration, a larger defect 
diameter, more often RA pressure ≥ 10 mmHg, a larger RA end-systolic area, higher TR 
maximum velocity, decreased RV FAC, and larger RV end-diastolic diameter.
244 patients with ASD closure included 
in this study 
37 patients excluded: 
- ASD + left heart 
surgery/PCI       (n = 12) 
- ASD + right sided cardiac 
malformations    (n = 23) 
- ASD after LOTX   (n = 1) 
- ASD + CTEPH      (n = 1) 
198 patients included in the analysis 
46 patients excluded because 
of missing echocardiographic 
data on RV pressures 
281 adult patients with ASD closure in 
the Erasmus MC (2000൞2014) 
Sinus venosus defect 
n = 21 
ASD secundum 
n = 177 
Percutaneous closure 
n = 110 
Surgical closure 
n = 88 
FIGURE 1 - Flowchart of the patient selection.
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TABLE 1 - Baseline characteristics of the study cohort (n = 198).
 
PH classification before ASD closure
Valid 
cases, 
n (%)
All, 
n = 198
No PH       
(n = 121)
Possible 
PH (n = 51)
Likely PH 
(n = 26)
P for 
trend
Clinical characteristics     
Age at closure, years* 198 (100) 45 [30–57] 42 [27–52] 53 [44–64] 50 [36–66] < 0.001
Sex, female n (%) 198 (100) 148 (75) 91 (75) 39 (77) 18 (69) 0.650
NYHA class III–IV, n (%) 198 (100) 24 (12) 7 (6) 6 (12) 11 (42) < 0.001
Sinus venosus defect, n (%) 198 (100) 21 (11) 15 (12) 5 (10) 1 (4) 0.207
Surgical repair, n (%) 198 (100) 88 (44) 52 (43) 21 (41) 15 (58) 0.298
Pulmonary disease, n (%) 198 (100) 8 (5) 4 (3) 2 (4) 2 (8) 0.355
   COPD 198 (100) 7 (4) 4 (3) 2 (4) 1 (4) -
   OSAS 198 (100) 2 (1) 0 (0) 0 (0) 2 (8) -
Cardiac medication, n (%) 198 (100) 66 (33) 27 (22) 23 (45) 16 (62) < 0.001
   ACE-inhibitor 198 (100) 12 (6) 5 (4) 4 (8) 3 (12) -
   Beta blocker 198 (100) 49 (25) 19 (16) 20 (39) 10 (39) -
   Diuretic 198 (100) 33 (17) 10 (8) 14 (28) 9 (35) -
   Anti-arrhythmic 198 (100) 12 (6) 2 (2) 6 (12) 4 (15) -
Body mass index, kg/m2 198 (100) 25 ± 5 24 ± 4 27 ± 5 25 ± 5 0.016
Systolic blood pressure, mmHg 197 (99) 133 ± 19 123 ± 16 142 ± 21 139 ± 19 < 0.001
O
2
 saturation < 95%, n (%) 126 (64) 16 (8) 4 (6) 6 (17) 6 (32) 0.002
Electrocardiography      
Heart rate, beats/min 197 (99) 73 ± 12 73 ± 12 74 ± 14 73 ± 11 0.998
Loss of sinus rhythm, n (%) 198 (100) 30 (15) 13 (11) 9 (18) 8 (31) 0.009
QRS duration, ms 198 (100) 109 ± 19 107 ± 18 110 ± 19 116 ± 24 0.021
PR interval, ms 173 (87) 164 ± 24 169 ± 23 171 ± 25 168 ± 31 0.114
Echocardiography      
Defect diameter, mm 163 (82) 21.5 ± 9.4 20.4 ± 8.6 21.2 ± 9.7 27 ± 11 0.007
RA pressure, mmHg 177 (90) 6.5 ± 2.8 6.1 ± 2.5 6.6 ± 2.8 7.8 ± 3.9 0.012
RA pressure ≥ 15 mmHg 177 (90) 10 (6) 4 (4) 2 (5) 4 (17) 0.025
RA end-systolic area 159 (80) 29 ± 11 26 ± 8 33 ± 13 38 ± 14 < 0.001
RA end-systolic area > 18 cm2, n (%) 159 (80) 151 (76) 95 (93) 37 (97) 19 (100) 0.144
TR maximum velocity, m/s 187 (94) 2.8 ± 0.5 2.4 ± 0.3 3.0 ± 0.2 3.8 ± 0.4 < 0.001
RV FAC, % 154 (78) 38 ± 8 39 ± 7 39 ± 10 31 ± 8 0.001
RV FAC < 35%, n (%) 154 (78) 55 (28) 27 (27) 14 (38) 14 (78) < 0.001
RVEDD basal, mm 154 (78) 5.6 ± 0.9 5.4 ± 0.8 5.8 ± 1.0 6.2 ± 0.9 0.001
RVEDD basal > 41 mm, n (%) 154 (78) 146 (95) 94 (95) 34 (92) 18 (100) 0.680
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TABLE 1 - Continued.
 
PH classification before ASD closure
Valid 
cases, 
n (%)
All, 
n = 198
No PH       
(n = 121)
Possible 
PH (n = 51)
Likely PH 
(n = 26)
P for 
trend
Echocardiography
LV FS, % 187 (94) 38 ± 9 37 ± 9 40 ± 8 39 ± 9 0.205
LV systolic function, n (%) 190 (96) 0.412
   Normal 190 (96) 159 (84) 100 (83) 43 (91) 16 (70)
   Mildly impaired 190 (96) 28 (14) 18 (15) 4 (9) 6 (26)
   Moderately impaired 190 (96) 3 (2) 2 (2) 0 (0) 1 (4)
   Severely impaired 190 (96) 0 (0) 0 (0) 0 (0) 0 (0)
TAPSE, mm 106 (54) 28.4 ± 6.3 28.7 ± 5.7 29.0 ± 6.9 25.4 ± 8.0 0.262
TAPSE < 17 mm 106 (54) 3 (3) 2 (3) 0 (0) 1 (10) 0.503
P-value for trend was calculated using the Chi-Square Mantel-Haenszel test for categorical variables and 
linear regression for continuous variables. For pulmonary disease en cardiac medication: no comparisons 
were made between subgroups. Legend: *Median [IQ
1
–IQ
3
], other n (%) or mean ± SD. Abbreviations: ASD, 
atrial septal defect; NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease; OSAS, 
obstructive sleep apnea syndrome; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; 
PH, pulmonary hypertension; RA, right atrial; TR; tricuspid regurgitation, RVFAC, right ventricular fractional 
area change; RVEDD, right ventricle end-diastolic dimension; LV, left ventricular; FS, fractional shortening; 
TAPSE, tricuspid annular plane systolic excursion.
Echocardiographic follow-up after ASD closure
Figure 2 provides an overview of the PH classiﬁcation before and after ASD closure. 
Before ASD closure, the majority of patients (n = 121, 61.1%) was categorized as no PH. 
After ASD closure, in 174 patients (87.9%) no signs of PH were present. The prevalence 
of PH was 13.1% (n = 26) before and 5.0% (n = 10) after ASD closure. Median mid-term 
follow-up time was 15 [IQR 12–35] months. Of the ten patients with likely PH after 
closure, seven were suspected to have PAH and the other three were suspected of PH 
due to left ventricular diastolic dysfunction according to the ESC/ERS guidelines for the 
diagnosis and treatment of pulmonary hypertension.18
 Figure 2 shows that RV pressures decreased in almost all patients after ASD closure. 
Only one patient (ASD closed at age of 63 years) had an increase in the pulmonary 
pressure, but this patient also had left ventricular diastolic dysfunction.
 Before ASD closure, the classiﬁcation of PH was based on TR velocity in 187 patients 
(94%), on PR velocity in 4 patients (2%), and on a combination of RV dimensions, RV 
function and signs of PH in 7 patients (4%). In 29 patients (15%) the PH classiﬁcation 
after ASD closure was based on diﬀerent variables (i.e., TR before ASD closure, and PR 
velocity or right ventricular function after ASD closure), because reliable measurements 
of the TR maximal velocity were not always available.
06R i s k  f a c t o r s  f o r  PA H  a f t e r  A S D  c l o s u r e  -  C H A P T E R  6
111 
06
11 
120 
10 
   Before ASD closure                          After ASD closure  
 
 
  
 
 
 
 
  
 
No PH 
n = 121 (61.1%) 
Possible PH 
n = 51 (25.8%) 
No PH 
n = 174 (87.9%) 
Possible PH 
n = 14 (7.1%) 
Likely PH 
n = 10 (5.0%) 
Likely PH 
n = 26 (13.1%) 
FIGURE 2 - Classifi cation of pulmonary hypertension before and after ASD closure.
No PH: TR velocity < 2.9 m/s or mPAP < 20 mmHg; Possible PH: TR velocity 2.9–3.4 m/s or mPAP 20–24 mmHg; 
Likely PH: TR velocity ≥ 3.4 m/s or mPAP ≥ 25 mmHg. Abbreviations: ASD, atrial septal defect; mPAP; mean 
pulmonary artery pressure; PH, pulmonary hypertension, TR, tricuspid regurgitation.
PH medication use
Before ASD closure, four patients used PH medication. Three patients used 
a phosphodiesterase-5 inhibitor and one patient used a combination of a 
phosphodiesterase-5 inhibitor, an endothelin antagonist, and a prostacyclin analogue. 
Of the ten patients classiﬁ ed as likely PH after ASD closure, seven patients used a 
combination of a phosphodiesterase-5 inhibitor and an endothelin antagonist. Two 
patients only used a phosphodiesterase-5 inhibitor. 
Associations between baseline characteristics and PH after ASD closure
In Table 2, the results of the Cox proportional hazards regression are displayed. Of 
all clinical, electrocardiographic and echocardiographic measurements that were 
evaluated, we found that NYHA functional class, presence of pulmonary disease, use 
of cardiac medication, TR maximum velocity, RV FAC, TAPSE and PH before ASD closure 
were signiﬁ cantly associated with PH at mid-term follow-up. Of note, age at closure and 
the diameter of the ASD or sinus venosus defect were not found to be associated with 
PH after ASD closure.
Long-term follow-up
Long-term follow-up was complete in 25 patients (66%) and not available in 13 patients 
(34%) due to loss to follow-up (n = 10) and death (n = 3). The 13 patients with missing 
long-term follow-up did not have signiﬁ cant diﬀ erences in age at closure, body mass 
index, cardiac medication use, NYHA class, type of procedure, or PH classiﬁ cation before 
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ASD closure compared to the 25 patients that had completed the long-term follow-up. 
The median time from ASD closure to long-term follow-up was 52 [IQR 31–95] months. 
Except for one patient, all patients were in the same PH category as they were at the 
mid-term follow-up after ASD closure. One patient who initially changed from no to 
possible PH at mid-term follow-up, changed back to no PH at long-term follow-up.
TABLE 2 - Associations between patient characteristics and classification of “likely PH” after ASD closure.
 
Valid cases 
(n%)
Hazard 
ratio 95% CI P-value
Clinical characteristics    
Age at closure, years 198 (100) 1.02 0.98–1.07 0.241
Sex, female 198 (100) 1.16 0.30–4.50 0.828
NYHA class III–IV 198 (100) 11.07 3.12–39.3 < 0.001
Sinus venosus defect 198 (100) 0.04 0.00–166 0.450
Surgical repair 198 (100) 1.34 0.39–4.63 0.644
Pulmonary disease, yes 198 (100) 10.43 2.12–51.2 0.004
Cardiac medication, yes 198 (100) 3.96 1.02–15.3 0.047
Body mass index, kg/m2 198 (100) 1.03 0.92–1.16 0.589
Systolic blood pressure, mmHg 197 (99) 0.99 0.96–1.03 0.601
O
2
 saturation < 95% 126 (64) 1.98 0.38–10.3 0.416
Electrocardiography    
Heart rate, beats/min 197 (99) 1.02 0.98–1.07 0.368
Loss of sinus rhythm 198 (100) 1.24 0.26–5.85 0.788
QRS duration, ms 198 (100) 1.01 0.98–1.04 0.600
PR interval, ms 173 (87) 1.00 0.97–1.04 0.863
Echocardiography      
Defect diameter, per mm 163 (82) 1.03 0.96–1.10 0.382
RA pressure, per mmHg 177 (90) 1.10 0.92–1.32 0.293
RA end-systolic area, per cm2 159 (80) 1.01 0.97–1.06 0.516
TR maximum velocity, per m/s 187 (94) 7.36 2.92–18.5 < 0.001
RV FAC, per % 154 (78) 0.87 0.81–0.93 < 0.001
RVEDD basal, per mm 154 (78) 1.44 0.70–2.94 0.318
LV FS, per % 187 (94) 1.02 0.95–1.10 0.580
LV systolic function, mild/moderately impaired 190 (96) 3.40 0.85–13.7 0.085
TAPSE, per mm 106 (54) 0.75 0.59–0.95 0.018
PH likely before ASD closure 198 (100) 23.03 3.39–157 0.001
CI, conﬁdence interval; others as deﬁned in Table 1.
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Clinical outcome
Information on survival was available in all patients using the municipal registry. Overall 
nine patients died during follow-up, of whom ﬁve were categorized as no PH, one 
patient as possible PH and three patients as likely PH after ASD closure. The median 
time from ASD closure to death was 69 [IQR 20–92] months. Causes of death were end 
stage heart failure (n = 4), sudden death (suspected cardiac) (n = 1), malignancy (n = 1), 
gastro-intestinal bleeding, presumably due to anticoagulants use (n = 1), euthanasia (in 
a patient with an infaust prognosis due to malignancy) (n = 1), and unknown (n = 1). 
Re-intervention after the ASD closure because of a signiﬁcant rest shunt was performed 
in two patients (1%). 
DISCUSSION
The prevalence of PH in adult patients before ASD closure in our study was 13.1% and 
decreased to 5% after ASD closure. Factors associated with PH after ASD closure were PH 
before ASD closure, NYHA functional class III–IV, presence of pulmonary disease, cardiac 
medication use, RV FAC and TAPSE. Patients with one or more of these risk factors need 
careful follow-up after ASD closure. Patients with low pulmonary pressures before ASD 
closure have a low risk of developing PH after closure, can be reassured, and require less 
frequent follow-up.
Prevalence of PH before and after ASD closure
Although pulmonary artery pressure (PAP) decreased after ASD closure in the majority 
of patients, 10 patients showed no change in PAP resulting in an overall PH prevalence 
median 15 months after ASD closure of 5%. This number is consistent with some 
previous studies, who also reported a prevalence of 5% in the adult population after 
ASD closure.20, 21 Other studies have reported a higher prevalence ranging from 12 to 
50%.6-8, 10, 11, 22, 23 These studies were mainly published between 1970–1990 and consisted 
of a small study population with the majority having surgical ASD closure. In these 
studies, before ASD closure the PH prevalence and NYHA functional class was also 
higher;6, 7, 11, 22 therefore, it is likely that this is a selection of more severe cases. There is no 
documentation on the type of patients who were lost to follow-up, but the percentage 
of patients lost to follow-up was clearly higher in these older studies (> 25%) and 
selection bias could have occurred. 
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Associations between patient characteristics and PH after ASD closure
According to the guidelines of pulmonary hypertension and the literature, the most 
recognized predictors of poor clinical outcome in patients with PH are TAPSE, pericardial 
eﬀusion and RA area.18, 24 In our study, only one patient had signiﬁcant pericardial eﬀusion 
so this variable was not further analyzed in our study. RA area was not associated with the 
presence of PH in adults after ASD closure. Our study did show an association between 
the presence of pulmonary disease, NYHA class, RV FAC, TAPSE, pulmonary pressures 
before closure, and PH classiﬁcation of “likely PH” after ASD closure. These variables have 
also been reported as predictors for PH in previous studies.10, 16, 23, 25 Cardiac medication 
use (ACE inhibitors, diuretics, beta blockers or anti-arrhythmia) has not been described 
previously as a predictor for PH after ASD closure. This medication is mostly used for 
problems with the left side of the heart. Because of these left-sided problems, patients 
can also develop higher pulmonary pressures, which may explain the association with 
PH after ASD closure in our study population.
 Various studies have identiﬁed age at ASD closure as a predictor for PH.16, 23, 26 
Interestingly, in our study age at closure was not found to be associated with PH after 
ASD closure. In the study of Gabriels et al., besides adult patients, also patients with an 
ASD closure in their childhood were included.16 Yong et al.23 and Humenberger et al.26 
only included patients with an ASD repair at adult age, but these patients were much 
older than in our study cohort (mean age 54 ± 16 and 49 ± 18 years, respectively). The 
wider age range compared with our study may explain why these studies did ﬁnd an 
association between age at closure and PH after ASD closure, in contrast to our study.
Clinical implications
 Patients with an ASD repair at adult age, especially those repaired at 40 years of age 
and older, should be followed on a regular basis during the ﬁrst 2 years and then 
depending on the results every 2–4 years, according to the 2010 European Society of 
Cardiology guidelines for the management of grown-up congenital heart disease.5 No 
speciﬁc recommendations are made with regard to patient characteristics that further 
diﬀerentiate the need for clinical follow-up. The results of our study show that adult 
patients without signs of PH before ASD closure are not at risk for the development 
of PH after the repair and therefore follow-up is needed only with long intervals. 
In contrast, a substantial proportion of the patients with signs of PH before closure 
continued to have high right ventricular pressures. Moreover, results of the long-term 
follow-up demonstrate that the pulmonary pressures do not change after median 
15 months after ASD c losure. Therefore, it is indeed important to regularly follow-up 
patients with elevated PAP or signs of PH before closure, while patients without PH can 
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be checked with a low frequency. Special attention is warranted for those patients who 
have speciﬁc risk factors such as NYHA class III–IV, cardiac medication use, presence of 
pulmonary disease and right ventricular dysfunction before the ASD closure as they 
have an increased risk of PH after ASD closure.
Limitations
This study is vulnerable to diﬀerent types of bias because of its observational and 
retrospective design. We attempted to avoid selection bias by including all consecutive 
patients that underwent ASD closure between 2000 and 2014 in our center; however, 
echocardiographic data on RV pressures was not available in 46 patients. Because 
the baseline characteristics of these patients were not signiﬁcantly diﬀerent from the 
included study population, we have no indication that a selective loss to follow-up has 
occurred, but it is important to take this into account when interpreting the results. 
 Secondly, patients were categorized into PH groups based on echocardiographic 
measurements, which are less accurate for the diagnosis of PH than the reference 
standard, right heart catheterization. This was not routinely performed in all patients, 
because it is unethical to perform these invasive measurements in asymptomatic 
patients.18 Some patients have been classiﬁed with diﬀerent echocardiographic variables 
before and after ASD closure, but these were mostly patients without any signs of PH, 
and we expect that this has not largely inﬂuenced our conclusions.
 Finally, multivariable Cox regression could not be performed in this study, because 
of the limited number of patients with PH after ASD closure.
CONCLUSIONS
Adult patients with low pulmonary pressures before ASD closure are not at risk for the 
development of PH after ASD closure during a follow-up period of 15 months. These 
patients can be reassured and need less frequent follow-up. Nevertheless, PH is prevalent 
in approximately 5% of adult patients after ASD closure. Especially those patients with 
PH before ASD closure, high NYHA functional class, presence of pulmonary disease, 
cardiac medication use and impaired RV function at baseline are at risk and therefore 
require close follow-up after ASD closure.
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ABSTRAC T
Background Identiﬁcation of patients at risk of deterioration is essential to guide 
clinical management in pulmonary arterial hypertension (PAH). This 
study aims to provide a comprehensive overview of well-investigated 
echocardiographic ﬁndings that are associated with clinical deterioration 
in PAH.
Methods MEDLINE and EMBASE databases were systematically searched for 
longitudinal studies published by April 2015 that reported associations 
between echocardiographic ﬁndings and mortality, transplant or clinical 
worsening. Meta-analysis using random eﬀect models was performed 
for echocardiographic ﬁndings investigated by four or more studies. In 
case of statistical heterogeneity, a sensitivity analysis was conducted.
Results  Thirty-seven papers investigating 51 echocardiographic ﬁndings were 
included. Meta-analysis of univariable hazard ratios (HRs) and sensitivity 
analysis showed that presence of pericardial eﬀusion (pooled HR 1.70; 
95% CI 1.44–1.99), right atrial area (pooled HR 1.71; 95% CI 1.38–2.13) 
and tricuspid annular plane systolic excursion (TAPSE; pooled HR 1.72; 
95% CI 1.34–2.20) were the most well-investigated and robust predictors 
of mortality or transplant.
Conclusions This meta-analysis substantiates the clinical yield of speciﬁc 
echocardiographic ﬁndings in the prognostication of PAH patients in 
day-to-day practice. In particular, pericardial eﬀusion, right atrial area 
and TAPSE are of prognostic value.
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INTRODUC TION
The ongoing research on pulmonary arterial hypertension (PAH) has led to increased 
awareness of the pathophysiological, hemodynamic and clinical consequences of 
this devastating disease.1 Without intervention, progressive remodeling of the distal 
pulmonary arteries leads to elevated pulmonary vascular resistance, eventually resulting 
in right heart failure and death.1,2 Fortunately, advances in therapeutic modalities have 
greatly improved the survival and quality of life in patients with PAH.3 However, the 
natural course of the disease varies widely between individuals, as some patients live for 
decades while others die within months of diagnosis.4 In order to guide optimal clinical 
management, it is therefore essential to accurately monitor disease progression and 
estimate prognosis in PAH.
 Previously reported predictors of mortality include etiology of PAH, gender and 
several functional, hemodynamic and biochemical variables.5-8 Echocardiography 
is the most readily available cardiac imaging modality and is universally used in the 
follow-up of patients with PAH. Current literature reports several echocardiographic 
ﬁndings that may provide important prognostic information. The goal of this study is 
to provide a comprehensive overview of the most thoroughly investigated baseline 
echocardiographic ﬁndings that are associated with adverse clinical outcome in PAH. 
Separately, this study evaluates the prognostic value of a change in echocardiographic 
ﬁndings during a follow-up period.
METHODS
This systematic review was conducted in accordance with the PRISMA statement.9 A pre-
deﬁned review protocol, as adopted by this study, can be accessed through PROSPERO 
(registration number: CRD42014009231).
Literature search strategy
A comprehensive systematic search was performed in MEDLINE (via PubMed interface) 
and EMBASE electronic databases on 29 April 2015 using combinations of all synonyms 
for: PAH, echocardiography and relevant clinical outcomes (components of the Dana 
Point Time to Clinical Worsening composite endpoint).1 A validated prognostic search 
ﬁlter with the highest sensitivity (98%) was added to the search syntax.10 No language or 
publication period restrictions were applied. The full original search syntax is provided 
in Supplemental File 1.
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Selection of papers
A ﬂow diagram of the selection process is shown in Figure 1.2 After deduplication, one 
author performed screening and selection of articles based on title and abstract, using 
the following exclusion criteria: inappropriate study type (cross-sectional or trial design, 
reviews, case reports with < 10 patients, editorials or congress abstracts), non-clinical 
data (technical, animal and in-vitro studies), study population without PAH (e.g. acute 
pulmonary embolism, exercise-induced pulmonary hypertension), studies that included 
children < 12 years, and studies that did not relate echocardiographic ﬁndings to clinical 
outcome. Full-text screening was performed by two authors; reasons for exclusion are 
described in Figure 1. All references of the excluded reviews and included articles were 
cross-checked to identify possible relevant articles missed in the original search syntax. 
Assessment of methodological quality
Study quality was critically appraised using previously developed criteria for prognostic 
studies.11 We assessed study design, missing data and loss to follow-up (selection bias), 
adequate description and measurement of imaging features and outcome (information 
bias), reported eﬀect size, treatment of continuous risk predictors and multivariable 
adjustment for possible confounders. 
Data extraction and analysis
Study characteristics and hazard ratios (HRs) for all investigated echocardiographic 
ﬁndings with accompanying 95% conﬁdence intervals were extracted using a 
standardized form. Meta-analysis was performed for all echocardiographic ﬁndings that 
were investigated as continuous parameters by four or more studies, using random eﬀect 
models. In order to unify the extracted data to allow more studies to be pooled, HRs were 
recalculated to one uniform clinically applicable number of units change. Heterogeneity 
was assessed using Cochran’s Q test and the I2 statistic. Imaging ﬁndings investigated 
as dichotomous variables were additionally presented below the corresponding forest 
plots. For all echocardiographic measurements with signiﬁcant heterogeneity (I2 > 50% 
or Cochran’s Q p-value < 0.10) a sensitivity analysis was performed by excluding speciﬁc 
patient subgroups.
 If study data were used in multiple papers and the same echocardiographic ﬁndings 
were evaluated, only the study with the largest sample size was used to exclude the risk 
of using duplicate data in our meta-analysis. The risk of publication bias was assessed 
using visual inspection of funnel plots and the Egger’s test.
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RESULTS
Search results
The systematic literature search in MEDLINE and EMBASE and extensive reference cross-
checking retrieved 2733 potentially relevant records, of which 2610 were excluded 
based on title and abstract (Figure 1). After full-text review of the remaining 123 articles, 
37 papers were ﬁ nally selected.6, 12-47 Study and patient characteristics of the included 
studies are shown in Table 1. 
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> 30% other than WHO group
I PAH included (n = 26), no
Cox regression analysis 
performed (n = 6), children  
(n = 5), outcome after surgery 
or thrombectomy (n = 4), 
cross-sectional study design 
(n = 4), identical study cohort 
(n = 1) 
Studies included in qualitative synthesis  
(n = 44): CMR findings (n = 8), ĞĐŚŽĐĂƌĚŝŽŐƌĂƉŚŝĐ
ĨŝŶĚŝŶŐƐ;Ŷсϯϳ͕ƚŚŝƐƌĞǀŝĞǁͿΎ
Studies included in 
quantitative synthesis (this 
meta-analysis) 
(n = 27) 
FIGURE 1 - PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2009 fl ow diagram.
*, one study investigated both echocardiographic and cardiac magnetic resonance imaging ﬁ ndings.
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TABLE 1 - Study characteristics.
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s
Ev
en
ts
, n
 (%
)
[11] 26 41 [16–70] 69 NR 100 _ _ _ _ _ _ _ 24 ± 14 16 (62)
[12] 26 43 ± 17 73 58 100 _ _ _ _ _ _ _ NR 6 (23)
[13] 53 45 ± 14 72 70 100 _ _ _ _ _ _ _ 35 [NR] 32 (60)
[14] 43 37 [14–67] 70 86 100 _ _ _ _ _ _ _ 21 ± 16 12 (28)
[15] 25 38 ± 13 76 100 100 _ _ _ _ _ _ _ 12 [0–84] 13 (52)
[16] 81 40 ± 15 73 100 100 _ _ _ _ _ _ _ 36 ± 15 41 (51)
[17] 63 55 ± 15 83 70 37 _ 38 _ _ _ 21 5 19 [10–22]* 23 (37)
[18] 54 52 ± 11 76 76 100 _ _ _ _ _ _ _ 50 [NR] 12 (22)
[19] 50 46 ± 13 78 42 46 _ 22 _ _ 4 _ 28 14 [12–18] 19 (38)
[6] 2716 50 ± 17 79 54 49 5 24 5 12 5 _ _ 17 [0–24] 340 (13)
[20] 76 61 ± 11 84 53 _ _ 100 _ _ _ _ _ 36 [NR–113] 42 (55)
[21] 32 53 ± 16 66 91 69 16 6 _ 9 _ _ _ 21 [NR] 17 (53)
[22] 59 46 ± 16 63 66 100 _ _ _ _ _ _ _ 52 [28–79]* 23 (39)
[23] 72 52 ± 16 72 76 100 _ _ _ _ _ _ _ 38 [14–71]* 22 (31)
[24] 484 52 ± 15 75 71 56 _ 24 11 9 _ _ _ 38 [16–60] 264 (55)
[25] 50 61 ± 11 98 70 _ _ 100 _ _ _ _ _ 16 [9–39] 25 (50)
[26] 80 56 ± 14 76 72 43 _ 41 10 _ 6 _ _ 24 [NR] 33 (41)
[27] 95 31 ± 10 64 56 100 _ _ _ _ _ _ _ 21 ± 15 27 (28)
[28] 57 52 ± 14 28 100 63 _ 18 11 _ 5 _ 3 25 ± 29 29 (51)
[29] 181 39 ± 13 67 67 _ _ _ _ 100 _ _ _ 16 [7–46] 19 (10)
[30] 154 54 ± 9 84 NR 46 1 40 5 6 3 _ _ 36 [17–71]* 71 (46)
[31] 61 48 ± 18 84 69 100 _ _ _ _ _ _ _ NR NR
[32] 142 59 ± 15 65 44 31 9 19 4 9 1 _ 27 11 [6–39] 28 (20)
[33] 577 53 ± 15 75 70 _ _ _ _ _ 100 _ _ 57 ± 50 NR
[34] 406 59 ± 16 65 46 _ _ _ _ _ 74 14 12 16 [8–20]* 73 (18)
[35] 32 39 ± 15 69 59 22 _ 16 _ 53 _ _ 9 14 [8–21] 15 (47)
[36] 124 54 ± 16 70 92 _ _ _ _ _ 84 _ 16 36 ± 22 31 (25)
[37] 71 57 ± 14 76 75 46 _ 41 6 _ 7 _ _ 24 [NR] 20 (28)
[38] 50 56 ± 12 84 72 42 _ 38 14 _ 6 _ _ 48 [NR] NR
[39] 102 54 ± 16 84 NR 47 _ 24 _ _ 29 _ _ 44 [22–79]* 43 (42)
[40] 37 46 ± 14 76 35 65 _ 5 _ 24 5 _ _ 16 [13–18]* 7 (19)
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TABLE 1 - Continued.
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[41] 48 44 ± 14 83 100 67 _ 21 6 6 _ _ _ 53 [21–80]* 18 (38)
[42] 91 42 ± 14 60 73 _ _ _ _ 100 _ _ _ 46 [4–64] 24 (26)
[43] 79 48 [24–65] 66 92 92 _ 8 _ _ _ _ _ NR [12–92] 27 (34)
[44] 121 60 ± 14 66 63 39 _ 36 18 _ 6 _ _ 37 ± 36 49 (40)
[45] 200 54 ± 15 71 50 47 1 33 7 12 _ _ _ 43 ± 31 106 (53)
[46] 51 60 ± 15 73 71 33 _ 55 6 6 _ _ _ 36 ± 24 8 (16)
 *interquartile range, otherwise reported as median [range] or mean ± SD.
Abbreviations: CHD, congenital heart disease; CTD, connective tissue disease; CTEPH, chronic 
thromboembolic pulmonary hypertension; HF, heart failure; IPAH, idiopathic pulmonary arterial hypertension; 
NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; SD, 
standard deviation; NR, not reported; WHO, World Health Organization.
 The total number of patients per study ranged from 25 to 2716, with a mean age 
ranging from 31–61 years (60–98% female) and 35–100% of patients in New York Heart 
Association (NYHA) class III–IV. Twelve studies included patients with congenital heart 
disease (CHD) (6–100% of patients)6,22,25,30,31,33,36,41-43,46,47 and seven studies included a 
subset of patients with pulmonary hypertension group III or IV (< 30% of total study 
population).18,20,29,33,35-37 The majority of studies used death or transplant as primary 
outcome; only ﬁve studies (14%) used a composite outcome, additionally including 
hospitalization for heart failure,20,35,41,47 need for a second vasodilator drug or worsening 
of functional class.36 Mean follow-up duration varied between 11 and 53 months, 
with the primary outcome event occurring in 6–340 patients (10–62% of the study 
population).
Methodological aspects
In Figure 2, an overview of the methodological quality of all included studies is 
presented. Individual bias assessment per study is provided in Supplemental File 2. 
Studies prospectively included consecutive patients diagnosed with the disease (43% of 
studies) or retrospectively reviewed echocardiographic images. Information on missing 
values and loss to follow-up was not reported in 16 (43%) and 21 (57%) of the 37 studies, 
respectively. It is therefore important to recognize the possible impact of selection bias 
on individual study outcomes.
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 All studies used right heart catheterization for the diagnosis of PAH in 100% of 
the included patients, except for one study that used right heart catheterization in 
87% and echocardiography in 13% of patients.35 Deﬁ nition and measurement of 
echocardiographic ﬁ ndings and study outcome was appropriate and consistent in the 
majority of studies; therefore, the impact of information bias is assumed to be small.
 Cox regression analysis was performed in all studies; however large diﬀ erences 
for predictors included in the multivariable analysis were found. Twenty-nine studies 
performed some form of multivariable adjustment, of which only 15 adjusted for age 
and gender. Only nine studies (24%) used more than ten events per predictor. Because 
of this large variety between studies and overall poor methodological quality of 
multivariable adjustment, it was chosen to present only the univariable HRs in forest plots.
Ϭй ϮϬй ϰϬй ϲϬй ϴϬй ϭϬϬй
DƵůƚŝǀĂƌŝĂďůĞĂŶĂůǇƐŝƐ
ĂƉƉƌŽƉƌŝĂƚĞ
DƵůƚŝǀĂƌŝĂďůĞĂĚũƵƐƚŵĞŶƚ
dƌĞĂƚŵĞŶƚŽĨĐŽŶƚŝŶƵŽƵƐ
ƉƌĞĚŝĐƚŽƌƐ
ĨĨĞĐƚƐŝǌĞ͗ŚĂǌĂƌĚƌĂƚŝŽƐ
ĞĐƌŝƉƚŝŽŶŽĨƐƚĂƚŝƐƚŝĐĂůĂŶĂůǇƐŝƐ
ĞĨŝŶŝƚŝŽŶĂŶĚŵĞĂƐƵƌĞŵĞŶƚŽĨ
ŽƵƚĐŽŵĞ
DĞĂƐƵƌĞŵĞŶƚŽĨ
ĞĐŚŽĐĂƌĚŝŽŐƌĂƉŚŝĐĨŝŶĚŝŶŐƐ
ĞĐƌŝƉƚŝŽŶŽĨĞĐŚŽĐĂƌĚŝŽŐƌĂƉŚǇ
ƉƌŽƚŽĐŽů
>ŽƐƐƚŽĨŽůůŽǁͲƵƉ
DŝƐƐŝŶŐĚĂƚĂ
^ƚƵĚǇĚĞƐŝŐŶ
WƌŽƐƉĞĐƚŝǀĞĚĞƐŝŐŶ͕
фϱйŵŝƐƐŝŶŐƐ͕
ƐƵĨĨŝĐŝĞŶƚ͕ǇĞƐ͕ĂůůŬĞƉƚ
ĐŽŶƚŝŶƵŽƵƐ͕ĨŽƌĂŐĞ
ĂŶĚŐĞŶĚĞƌ͕хϭϬ
ĞǀĞŶƚƐͬƉƌĞĚŝĐƚŽƌ
ϱͲϭϬйŵŝƐƐŝŶŐƐ͕
ŵŽĚĞƌĂƚĞ͕ŶŽŚĂǌĂƌĚ
ƌĂƚŝŽΖƐ͕ƐŽŵĞ
ĐĂƚĞŐŽƌŝǌĞĚ͕
ĂĚũƵƐƚŵĞŶƚĨŽƌŽƚŚĞƌ
ĨĂĐƚŽƌƐ
ZĞƚƌŽƐƉĞĐƚŝǀĞĚĞƐŝŐŶ͕
хϭϬйŵŝƐƐŝŶŐƐ͕
ŝŶƐƵĨĨŝĐŝĞŶƚ͕Ăůů
ĐĂƚĞŐŽƌŝǌĞĚ͕ŶŽƚ
ƉĞƌĨŽƌŵĞĚ͕фϭϬ
ĞǀĞŶƚƐͬƉƌĞĚŝĐƚŽƌ
EŽƚƌĞƉŽƌƚĞĚ͕ŶŽƚ
ĂƉƉůŝĐĂďůĞ
FIGURE 2 - Methodological quality of the included studies.
Methodological quality of the included studies was assessed on the following domains of potential bias: 
completeness of data (selection bias), standardization of prognostic factors and study outcome (information 
bias) and statistical calculation of eﬀ ect size (study outcome).
Prognostic value of baseline echocardiographic findings
In 37 studies, in total 51 echocardiographic ﬁ ndings were evaluated (Supplemental File 
3). Meta-analysis was performed for ten echocardiographic ﬁ ndings that were suitable 
for pooling of results among four or more studies: presence of pericardial eﬀ usion, right 
07E c h o c a r d i o g r a p h i c  f i n d i n g s  i n  PA H  -  C H A P T E R  7
127 
07
atrial area, right ventricular (RV) pressure estimates, severity of tricuspid regurgitation, 
estimated right atrial pressure, left ventricular (LV) eccentricity index (Figure 3 A), 
tricuspid annular plane systolic excursion (TAPSE), RV fractional area change, Tei index 
(RV myocardial performance index) and RV free wall longitudinal peak systolic strain 
(LPSS; Figure 3 B).
 Although not included in the meta-analysis, RV end-diastolic basal dimension24,30,33,36 
or area17,25,36,37 and tissue Doppler velocity (S’) of the tricuspid valve annulus30,33,35,36,41 were 
investigated by several studies and could be of prognostic importance. Less investigated 
echocardiographic measurements such as pulmonary artery capacitance,19,35 several 
strain values,27,38,44 RV diastolic dysfunction,12,20,30 LV end-diastolic volume,23 systolic 
pulmonary artery pressure increase during exercise37 and RV load adaptation index44 
seem promising but require further evaluation.
Serial echocardiographic evaluation
Five studies included in this review investigated the prognostic value of a change in 
echocardiographic ﬁndings during a follow-up period, rather than their absolute 
baseline values, as indicated in Supplemental File 3.39,42,44,46,47 Patients with ≥ 5% 
improvement in RV free wall LPSS on PAH treatment at 6 ± 2 months follow-up had a 
signiﬁcantly reduced mortality risk at four years (HR 0.13; 95% CI 0.03–0.50).39 Tonelli et 
al. showed that overall mortality was associated with a 10% increase in RV end-diastolic 
area (HR 1.37; 95% CI 1.08–1.75), tricuspid regurgitation velocity (HR 1.72; 95% CI 1.12–
2.70) and diﬀerence in qualitative RV function (HR per unit of improvement 0.55; 95% CI 
0.31–0.96) at one-year follow-up.42 Sano et al. recently reported that a mid-term change 
in RV end-systolic area (HR 0.92; 95% CI 0.86–0.98) and in right atrial area (HR 0.95; 95% 
CI 0.92–0.99) were signiﬁcantly related to long-term outcome.47 In addition, changes in 
RV load-adaptation index and pericardial eﬀusion have been associated with clinical 
outcomes in PAH.44,46
Risk of bias assessment
Heterogeneity statistics (Cochran’s Q and I2) are presented in the corresponding forest 
plots in Figure 3. For all echocardiographic measurements with signiﬁcant statistical 
heterogeneity, we performed a sensitivity analysis to evaluate possible sources for 
heterogeneity (Table 2). We excluded speciﬁc studies (< 70% in NYHA class III–IV, < 
100% PAH, inclusion of CHD, < 50% on PAH medication at baseline, other endpoints 
than mortality or transplant used) to investigate whether this impacted the pooled 
HR. For presence of pericardial eﬀusion, right atrial area and TAPSE, sensitivity analysis 
did not change the overall conclusions. These results can therefore be regarded with a 
higher degree of certainty (Figure 4).
C H A P T E R  7  -  E c h o c a r d i o g r a p h i c  f i n d i n g s  i n  PA H
128 
P
re
se
nc
e 
o
f 
p
er
ic
ar
d
ia
l e
ff
u
si
o
n
0.
1
1
10
=
 4
2%
)
2 
To
ta
l (
Q
 =
 2
5.
7,
 I
Sh
im
on
y 
20
13
C
ia
rk
a 
20
10
Ba
d
ag
lia
cc
a 
20
12
A
us
ti
n 
20
15
Fi
ne
 2
01
3
R
ay
m
on
d
 2
00
2
Fo
rf
ia
 2
00
6 
(g
ra
d
e 
0-
4)
C
am
p
o 
20
10
Ey
sm
an
n 
19
89
 (g
ra
d
e 
0-
3)
Ka
ne
 2
01
1
Fe
ns
ta
d
 2
01
3
Er
na
nd
e 
20
13
Be
nz
a 
20
10
M
at
ha
i 2
01
1 
(g
ra
d
e 
0-
4)
G
hi
o 
20
10
M
iy
am
ot
o 
20
00
 (g
ra
d
e 
0-
2)
0.
37
 (0
.0
2-
5.
53
)
0.
79
 (0
.1
8-
3.
40
)
1.
11
 (0
.7
5-
1.
64
)
1.
35
 (1
.1
0-
1.
80
)
1.
47
 (0
.6
2-
3.
47
)
1.
50
 (1
.2
3-
1.
83
)
1.
54
 (1
.1
7-
2.
02
)
1.
66
 (0
.9
9-
2.
78
)
1.
69
 (0
.9
0-
3.
32
)
1.
69
 (1
.1
2-
2.
54
)
2.
08
 (1
.1
2-
3.
86
)
2.
19
 (1
.5
1-
3.
09
)
2.
49
 (1
.3
4-
4.
63
)
2.
97
 (1
.2
5-
7.
06
)
3.
49
 (1
.1
2-
10
.9
)
6.
85
 (2
.6
0-
18
.1
)
1.
70
 (
1.
44
-1
.9
9)
p
<
0.
00
1
H
az
ar
d
 r
at
io
0.
1
1
10
G
ru
ni
g
 2
01
3 
(>
20
 c
m
2)
A
us
ti
n 
20
15
 (
>
18
 c
m
2)
Ka
ne
 2
01
1 
(s
ev
er
e 
en
la
rg
em
en
t)
Er
na
nd
e 
20
13
 (>
14
 c
m
2/
m
)
Sc
hu
ur
in
g
 2
01
4 
(>
25
 c
m
2)
 =
 5
5%
)
2
To
ta
l (
Q
 =
 8
.9
, I
Fo
rf
ia
 2
00
6 
(c
m
2/
m
)
M
oc
er
i 2
01
2 
(c
m
2)
M
at
ha
i 2
01
1 
(c
m
2/
m
)
Bu
st
am
an
te
 2
00
2 
(c
m
2)
R
ay
m
on
d
 2
00
2 
(c
m
2/
m
)
R
ig
ht
 a
tr
ia
l a
re
a 
(p
er
 5
 c
m
2
 in
cr
ea
se
)
1.
33
 (1
.0
6-
1.
66
)
1.
61
 (1
.2
0-
2.
16
)
1.
69
 (1
.1
5-
2.
48
)
1.
89
 (1
.3
9-
2.
59
)
2.
93
 (1
.7
4-
4.
94
)
1.
71
 (
1.
38
-2
.1
3)
p
<
0.
00
1
1.
10
 (0
.4
0-
3.
20
)
1.
17
 (0
.4
4-
3.
08
)
1.
84
 (1
.3
9-
2.
41
)
2.
60
 (1
.3
2-
5.
14
)
10
.2
0 
(1
.3
0-
76
.9
2)
H
az
ar
d
 r
at
io
0.
1
1
10
C
ho
 2
01
4 
(R
V
SP
 >
73
 m
m
H
g
)
Er
na
nd
e 
20
13
 (S
PA
P 
>
78
 m
m
H
g
)
G
ru
ni
g
 2
01
3 
(S
PA
P 
>
95
 m
m
H
g
)
=
 7
6%
)
2 
To
ta
l (
Q
 =
 2
5.
1,
 I
M
ah
ap
at
ra
 2
00
6 
(R
V
SP
)
M
at
ha
i 2
01
1 
(R
V
SP
)
Fi
ne
 2
01
3 
(S
PA
P)
C
ia
rk
a 
20
10
 (R
V
SP
)
G
iu
sc
a 
20
13
 (S
PA
P)
R
ay
m
on
d
 2
00
2 
(R
V
SP
)
G
hi
o 
20
10
 (R
V
SP
)
 R
V
 p
re
ss
ur
e 
es
ti
m
at
es
 (
p
er
 1
0 
m
m
H
g
 in
cr
ea
se
)
0.
90
 (0
.7
4-
1.
10
)
1.
00
 (0
.7
6-
1.
32
)
1.
00
 (0
.7
4-
1.
35
)
1.
10
 (0
.9
5-
1.
28
)
1.
30
 (1
.2
2-
1.
39
)
1.
81
 (1
.2
0-
2.
73
)
1.
97
 (1
.2
3-
3.
14
)
1.
18
 (
1.
01
-1
.3
8)
p
=
0.
04
3
0.
34
 (0
.1
5-
0.
75
)
1.
05
 (0
.5
0-
2.
21
)
1.
43
 (0
.3
2-
6.
48
)
H
az
ar
d
 r
at
io
0.
1
1
10
=
39
%
)
2
To
ta
l (
Q
=
9.
8,
 I
G
hi
o
 2
01
0 
(m
o
d
er
at
e/
se
ve
re
)
Ka
ne
 2
01
1 
(s
ev
er
e)
A
us
ti
n 
20
15
 (m
od
er
at
e/
se
ve
re
)
Fo
rf
ia
 2
00
6 
(g
ra
d
e 
0-
3)
B
us
ta
m
an
te
 2
00
2 
(g
ra
d
e 
0-
3)
Ye
o
 1
99
8 
(g
ra
d
e 
0-
4)
 
R
ay
m
o
nd
 2
00
2 
(T
R
/R
A
 p
er
 0
.2
)
TR
 s
ev
er
it
y
1.
37
 (0
.9
6-
1.
97
)
1.
67
 (0
.6
7-
4.
15
)
2.
52
 (1
.0
1-
6.
30
)
2.
59
 (1
.3
9-
4.
81
)
2.
62
 (1
.3
4-
5.
13
)
2.
82
 (1
.9
4-
3.
98
)
3.
11
 (1
.2
0-
9.
48
)
2.
20
 (
1.
64
-2
.9
5)
p
<
0.
00
1
H
az
ar
d
 r
at
io
0.
1
1
10
=
76
%
)
2
To
ta
l (
Q
=
20
.7
, I
M
o
ce
ri
 2
01
2 
(>
15
 m
m
H
g
)
A
us
tin
 2
01
5 
(>
15
 m
m
H
g
)
Fi
ne
 2
01
3 
(>
15
 m
m
H
g
)
G
hi
o
 2
01
0 
(>
15
 m
m
H
g
)
Ka
ne
 2
01
1 
(>
10
 m
m
H
g
)
M
ah
ap
at
ra
 2
00
6 
(>
15
 m
m
H
g
)
Es
ti
m
at
ed
 R
A
 p
re
ss
ur
e
0.
90
 (0
.5
2-
1.
58
)
1.
95
 (1
.4
7-
2.
63
)
2.
94
 (1
.1
9-
7.
26
)
3.
32
 (2
.3
7-
4.
62
)
4.
20
 (1
.8
1-
9.
77
)
4.
52
 (1
.7
3-
11
.8
2)
2.
45
 (
1.
56
-3
.8
5)
p
<
0.
00
1
H
az
ar
d
 r
at
io
0.
1
1
10
1.
7)
t
G
hi
o
 2
01
0 
(E
D
 
1.
4)
t
Er
na
nd
e 
20
13
 (E
D
 0
.8
1)
t
C
ho
 2
01
4 
(E
S 
 =
 0
%
)
2
To
ta
l (
Q
 =
 3
.0
, I
Fo
rf
ia
 2
00
6
M
at
ha
i 2
01
1
R
ay
m
o
nd
 2
00
2
M
iy
am
o
to
 2
00
0
LV
 e
cc
en
tr
ic
it
y 
in
d
ex
1.
60
 (0
.3
2-
8.
10
)
2.
10
 (1
.2
7-
3.
49
)
5.
39
 (1
.4
2-
20
.4
)
6.
14
 (1
.0
3-
36
.4
8)
2.
43
 (
1.
57
-3
.7
5)
p
<
0.
00
1
0.
26
 (0
.0
5-
1.
42
)
1.
65
 (0
.7
5-
3.
65
)
3.
68
 (1
.5
5-
8.
74
)
H
az
ar
d
 r
at
io
A
FI
GU
RE
 3A
 - P
ro
gn
os
tic
 va
lue
 of
 ec
ho
ca
rd
iog
ra
ph
ic 
fi n
din
gs
 in
ve
sti
ga
te
d i
n f
ou
r o
r m
or
e s
tu
die
s.
G
en
er
al
 e
ch
oc
ar
di
og
ra
p
hi
c 
ﬁ n
di
ng
s
07E c h o c a r d i o g r a p h i c  f i n d i n g s  i n  PA H  -  C H A P T E R  7
129 
07
TA
P
SE
 (
p
er
 5
 m
m
 d
ec
re
as
e)
0.
1
1
10
14
 m
m
)
d
Sc
hu
ur
in
g
 2
01
4 
(
19
 m
m
)
d
G
ru
ni
g
 2
01
3 
(
17
 m
m
)
d
Er
na
nd
e 
(
14
 m
m
)
d
C
ho
 2
01
4 
(
 =
 7
7%
)
2
To
ta
l (
Q
 =
 2
6.
1,
 IFo
rf
ia
 2
00
6
M
o
ce
ri
 2
01
2
M
at
ha
i 2
01
1
G
iu
sc
a 
20
13
Fi
ne
 2
01
3
G
hi
o
 2
01
0
D
an
d
el
 2
01
4
1.
20
 (1
.0
9-
1.
31
)
1.
60
 (1
.0
3-
2.
49
)
1.
69
 (1
.4
3-
2.
00
)
1.
89
 (1
.0
4-
3.
44
)
2.
01
 (1
.1
9-
3.
37
)
2.
50
 (1
.5
2-
4.
11
)
2.
54
 (1
.0
7-
6.
01
)
1.
72
 (
1.
34
-2
.2
0)
p
<
0.
00
1
0.
47
 (0
.0
9-
2.
43
)
2.
62
 (1
.1
0-
6.
19
)
2.
83
 (1
.1
7-
6.
85
)
3.
50
 (1
.4
0-
8.
60
)
H
az
ar
d
 r
at
io
R
V
 f
ra
ct
io
na
l a
re
a 
ch
an
g
e 
(p
er
 5
%
 d
ec
re
as
e)
0.
1
1
10
Sh
im
o
ny
 2
01
2 
(n
o
 R
V
 d
ys
f)
A
us
tin
 2
01
5 
(<
35
%
)
Ka
ne
 2
01
1 
(n
o
 R
V
 d
ys
f)
 =
 6
0%
)
2
To
ta
l (
Q
 =
 1
0.
1,
 I
G
iu
sc
a 
20
13
Fo
rf
ia
 2
00
6
Fi
ne
 2
01
3
R
ay
m
o
nd
 2
00
2
M
at
ha
i 2
01
1
1.
05
 (0
.8
6-
1.
29
)
1.
08
 (0
.8
8-
1.
32
)
1.
15
 (0
.9
9-
1.
35
)
1.
52
 (1
.1
5-
2.
00
)
1.
89
 (1
.2
4-
2.
90
)
1.
23
 (
1.
04
-1
.4
4)
p
=
0.
03
9
1.
45
 (1
.2
3-
1.
87
)
2.
32
 (1
.1
8-
4.
53
)
3.
03
 (0
.8
6-
11
.1
1)
H
az
ar
d
 r
at
io
0.
1
1
10
0.
47
)
t
C
ho
 2
01
4 
( =
 7
3%
)
2
To
ta
l (
Q
 =
 2
2.
3,
 I
Sh
im
on
y 
20
12
G
hi
o 
20
10
M
ah
ap
at
ra
 2
00
6
Te
i 1
99
6
Ye
o 
19
98
Fi
ne
 2
01
3
Ka
ne
 2
01
1
Te
i i
nd
ex
 (
p
er
 0
.1
 in
cr
ea
se
)
1.
06
 (1
.0
1-
1.
11
)
1.
25
 (1
.1
6-
1.
35
)
1.
30
 (1
.0
9-
1.
56
)
1.
30
 (1
.0
0-
1.
70
)
1.
66
 (1
.0
5-
2.
60
)
2.
61
 (0
.5
2-
13
.0
3)
3.
25
 (0
.2
4-
44
.9
0)
1.
23
 (
1.
09
-1
.4
0)
p
=
0.
00
1
1.
02
 (0
.2
3-
4.
59
)
H
az
ar
d
 r
at
io
0.
1
1
10
-1
8.
7%
)
t
Er
na
nd
e 
20
13
 (
=
0%
)
2
To
ta
l (
Q
=
3,
0,
 I
Sa
ch
d
ev
 2
01
1
Sa
no
 2
01
5
G
iu
sc
a 
20
13
Fi
ne
 2
01
3
R
V
 f
re
e 
w
al
l l
o
ng
it
ud
in
al
 p
ea
k 
sy
st
o
lic
 s
tr
ai
n 
(p
er
 5
%
 d
ec
re
as
e) 1.6
5
 (
1
.4
6
-1
.8
8
)
2
.1
0
 (
1
.2
3
-3
.6
0
)
2
.1
6
 (
1
.2
0
-3
.9
1
)
2
.4
0
 (
1
.4
5
-4
.2
1
)
1
.7
2
 (
1
.5
3
-1
.9
3
)
p
<
0
.0
0
1
2
.1
7
 (
0
.9
7
-4
.8
4
)
H
az
ar
d
 r
at
io
B
FI
GU
RE
 3B
 - P
ro
gn
os
tic
 va
lue
 of
 ec
ho
ca
rd
iog
ra
ph
ic 
fi n
din
gs
 in
ve
sti
ga
te
d i
n f
ou
r o
r m
or
e s
tu
die
s.
Ec
ho
ca
rd
io
gr
ap
hi
c 
m
ea
su
re
m
en
ts
 o
f r
ig
ht
 v
en
tr
ic
ul
ar
 fu
nc
tio
n.
C H A P T E R  7  -  E c h o c a r d i o g r a p h i c  f i n d i n g s  i n  PA H
130 
TABLE 2 - Sensitivity analysis for all echocardiographic measurements with significant statistical heterogeneity (I2 > 
50% or p-value < 0.10) in specific study subgroups.
 No. of studies HR 95% CI p-value I
2, % Cochran’s Q (p-value)
Presence of pericardial effusion 16 1.70 1.44–1.99 < 0.001 42 25.7 (0.041)
   > 70% NYHA class III-IV 8 1.56 1.31–1.86 < 0.001 23 9.0 (0.249)
   100% PAH 12 1.62 1.34–1.96 < 0.001 45 20.1 (0.045)
   Exclusion of CHD 12 1.81 1.45–2.25 < 0.001 49 21.5 (0.028)
   > 50% on PAH medication / NR 10 1.86 1.40–2.47 < 0.001 60 22.3 (0.008)
   Mortality / transplant as outcome 15 1.64 1.39–1.94 < 0.001 38 22.5 (0.069)
Right atrial area, per 5 cm2 increase 5 1.71 1.38–2.13 < 0.001 55 8.9 (0.063)
   > 70% NYHA class III-IV 4 1.69 1.29–2.21 < 0.001 61 7.8 (0.051)
   100% PAH 4 1.56 1.33–1.84 < 0.001 17 3.6 (0.306)
   Exclusion of CHD 4 1.69 1.29–2.21 < 0.001 61 7.8 (0.051)
   > 50% on PAH medication / NR 3 1.77 1.17–2.68 0.007 74 7.7 (0.021)
   Mortality / transplant as outcome 5 1.71 1.38–2.13 < 0.001 55 8.9 (0.063)
RV pressure, per 10 mmHg increase 7 1.18 1.01–1.38 0.043 76 25.1 (< 0.001)
   > 70% NYHA class III-IV 4 1.33 1.00–1.77 NS 72 10.9 (0.012)
   100% PAH 5 1.20 0.95–1.52 NS 75 15.8 (0.003)
   Exclusion of CHD 5 1.26 1.00–1.59 NS 81 20.6 (< 0.001)
   > 50% on PAH medication / NR 5 1.19 1.02–1.38 0.024 66 11.8 (0.019)
   Mortality / transplant as outcome 5 1.20 0.95–1.52 NS 75 15.8 (0.003)
Right atrial pressure, >15 mmHg 6 2.45 1.56–3.85 < 0.001 76 20.7 (< 0.001)
   > 70% NYHA class III-IV 2 1.38 0.65–2.92 NS 82 5.7 (0.017)
   100% PAH 6 2.45 1.56–3.85 < 0.001 76 20.7 (< 0.001)
   Exclusion of CHD 4 2.41 1.16–4.98 0.018 82 17.0 (< 0.001)
   > 50% on PAH medication / NR 0 - - - - -
   Mortality / transplant as outcome 5 2.28 1.33–3.92 0.003 72 14.2 (0.007)
TAPSE, per 5 mm decrease 7 1.72 1.34–2.20 < 0.001 77 26.1 (< 0.001)
   > 70% NYHA class III-IV 3 1.63 1.01–2.63 0.047 69 6.5 (0.039)
   100% PAH 4 1.67 1.15–2.44 0.007 77 12.8 (0.005)
   Exclusion of CHD 5 1.58 1.22–2.06 < 0.001 79 18.7 (< 0.001)
   > 50% on PAH medication / NR 4 3.24 1.92–5.45 < 0.001 0 1.2 (0.756)
   Mortality / transplant as outcome 5 1.76 1.22–2.52 0.002 74 15.4 (0.004)
RV FAC, per 5 % decrease 5 1.23 1.04–1.44 0.039 60 10.1 (0.039)
   > 70% NYHA class III-IV 3 1.18 0.96–1.44 NS 60 5.0 (0.080)
   100% PAH 2 1.06 1.04–1.09 < 0.001 0 0.0 (0.863)
   Exclusion of CHD 4 1.16 1.02–1.32 0.026 41 5.0 (0.168)
   > 50% on PAH medication / NR 5 1.23 1.04–1.44 0.039 60 10.1 (0.039)
   Mortality / transplant as outcome 3 1.18 0.96–1.44 NS 60 5.0 (0.080)
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TABLE 2 - Continued.
 
No. of 
studies HR 95% CI p-value I
2, % Cochran’s Q (p-value)
Tei index, per 0.1 unit increase 7 1.23 1.09–1.40 0.001 73 22.3 (0.001)
   > 70% NYHA class III-IV 3 1.22 0.99–1.51 NS 76 8.3 (0.016)
   100% PAH 6 1.25 1.05–1.48 0.012 58 12.0 (0.035)
   Exclusion of CHD 5 1.46 1.24–1.72 < 0.001 0 2.3 (0.677)
   > 50% on PAH medication / NR 2 1.25 1.16–1.35 < 0.001 0 0.5 (0.775)
   Mortality / transplant as outcome 6 1.25 1.05–1.48 0.012 58 12.0 (0.035)
Abbreviations: CHD, congenital heart disease; CI, conﬁdence interval; FAC, fractional area change; HR, hazard 
ratio; NR, not reported; NS, non-signiﬁcant; NYHA, New York Heart Association; PAH, pulmonary arterial 
hypertension; RV, right ventricular; TAPSE, tricuspid annular plane systolic excursion. 
FIGURE 4 - Prognostic value of pericardial effusion, TAPSE and right atrial area.
Key message: Echocardiography is useful in prognostication in pulmonary arterial hypertension. Presence 
of pericardial eﬀusion, lower TAPSE and enlarged right atrial area are the most robust predictors for mortality 
and transplant. This is important, since accurate prognostication can aid in adequate expansion of PAH-
speciﬁc therapy and timely listing for transplantation.
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 No sensitivity analysis was performed for severity of tricuspid regurgitation, LV 
eccentricity index and RV free wall LPSS; however, the forest plots show that especially 
tricuspid regurgitation severity and LV eccentricity index have relatively large standard 
errors, and thus provide imprecise risk estimations.
 A combination of visual assessment of funnel plots and the Egger’s test provided 
statistical evidence of publication bias for TAPSE (p = 0.026), right atrial area (p = 0.027) 
and the Tei index (p = 0.076 and based on the funnel plot). This may indicate that 
studies with a positive result are overrepresented, subsequently leading to a relative 
overestimation of the pooled HR in the meta-analysis.
DISCUSSION
To our knowledge, this is the ﬁrst systematic review and meta-analysis on the 
prognostic value of speciﬁc echocardiographic ﬁndings in patients with PAH. Among 
51 echocardiographic ﬁndings investigated in 37 studies, meta-analysis and additional 
sensitivity analysis showed that presence of pericardial eﬀusion, right atrial area and 
TAPSE were the most robust predictors of mortality or transplant in patients with PAH.
Right ventricular decompensation
Most deaths in patients with PAH are due to right heart failure.7 Once the right ventricle 
starts to fail, it is no longer able to overcome the high pulmonary arterial pressures. This 
will cause a progressive rise in RV diastolic pressure and right atrial pressure, generally 
accompanied by right atrial enlargement. It is thought that elevated right atrial pressure 
causes impaired lymphatic and venous drainage, subsequently leading to pericardial 
ﬂuid accumulation.17 These insights into the mechanistic course tilting a stable PAH state 
towards death clearly explain why pericardial eﬀusion, right atrial area, estimated right 
atrial pressure and RV dysfunction measured on echocardiography are associated with 
mortality in PAH.
 Studies investigating RV function and right atrial pressure as assessed with other 
diagnostic modalities, such as cardiac magnetic resonance imaging and right heart 
catheterization, report comparable ﬁndings.6,7,48,49 However, as echocardiography 
is more widely applied, non-invasive and less expensive, it is more suitable for the 
evaluation of PAH patients in day-to-day practice.
Serial measurements
The majority of the included studies investigated the prognostic value of baseline imaging 
ﬁndings, evaluated at the time of diagnosis. Complementary information on changes in 
hemodynamic, functional and biochemical variables may better reﬂect an individual’s 
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response to PAH-targeted therapy – or progression of disease.50 Interestingly, although 
the ﬁrst study included in this review originates from 1989, serial echocardiographic 
evaluation in PAH has only recently gained scientiﬁc attention, as Hardegree and 
colleagues were the ﬁrst ones to publish on this topic in 2013.12,39 Thus far, changes 
in pericardial ﬂuid accumulation, right atrial area, tricuspid regurgitation velocity, RV 
free wall LPSS and qualitative RV function, RV dimensions and RV load-adaptation 
index have been associated with clinical outcomes in PAH.39,42,44,46,47 This is in line with 
the conclusions reached by the international working group of Vonk-Noordegraaf et 
al., who stated that changes in RV imaging parameters after treatment reﬂect altered 
exercise capacity and predict subsequent survival.51 Advantages of echocardiography 
over more expensive or invasive imaging modalities become especially important in the 
serial evaluation of individual patients.
Heterogeneity
PAH prognosis depends largely on the underlying etiology, as the right ventricle can 
show rapid deterioration after initial diagnosis in patients with idiopathic or connective 
tissue disease-PAH, while it may cope successfully with pressure overload for decades 
in patients with congenital heart disease.4,6 Still, most studies in this review investigated 
the World Health Organization (WHO) group I PAH as a whole. Moreover, some studies 
in this review additionally included small subsets (< 30%) of patients with WHO group 
III (pulmonary hypertension due to lung disease) or IV (chronic thromboembolic 
pulmonary hypertension), which further increases the heterogeneity of the study 
population. The heterogeneity of pulmonary hypertension etiologies among studies in 
this review likely plays a major role in the observed variation between the reported study 
results. Along the same line, disease severity and changing available treatment options 
over time likely contribute to this observed heterogeneity across studies. We therefore 
conducted a sensitivity analysis in which we excluded studies with other than WHO 
group I PAH, patients with CHD, < 70% patients in NYHA class III-IV (thus investigating 
a sicker patient population) or < 50% on PAH medication (representing other available 
treatment options). Importantly, this clearly reduced the statistical heterogeneity in 
speciﬁc study subgroups; however, the overall conclusions for presence of pericardial 
eﬀusion, right atrial area and TAPSE remained unchanged.
Study limitations
We presented only univariable HRs in this study, because of the large variety between 
studies in which multivariable adjustment was performed (regarding the type and 
number of predictors per event used). Second, formal tests for publication bias retrieved 
signiﬁcant results for the variables right atrial area, TAPSE and Tei index. Theoretically, 
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publication bias may cause underreporting of non-signiﬁcant HRs, leading to a relative 
overestimation of the pooled HRs. Exact results of the random eﬀect models as 
presented in this review should be therefore interpreted with caution.
Clinical implications
In order to adequately expand PAH-speciﬁc therapy and timely list patients for 
transplantation, accurate prognostication is highly important. The data in this review 
imply that especially pericardial eﬀusion, enlarged right atrial area and decreased TAPSE 
are useful echocardiographic markers to predict mortality or transplantation. This is 
largely concordant with the 2015 European Society of Cardiology / European Respiratory 
Society Guidelines for the diagnosis and treatment of pulmonary hypertension, in 
which right atrial area and pericardial eﬀusion are recommended as determinants of 
prognosis.2 Controversy continues to exist about the use of TAPSE; it has been suggested 
that progressive RV dysfunction is associated with a decline in TAPSE until a certain 
ﬂoor eﬀect is reached.52 Of note, considering the multi-faceted nature of this disease, 
accurate prognostication should always be based on a combination of hemodynamic, 
functional, biochemical and echocardiographic ﬁndings, and should not rely on just 
one single parameter according to the current guidelines.2
CONCLUSIONS
This meta-analysis substantiates the clinical yield of speciﬁc echocardiographic ﬁndings 
in the prognostication of PAH patients in day-to-day practice. Although accurate 
prognostication should not rely on just one single parameter, presence of pericardial 
eﬀusion, enlarged right atrial area and decreased TAPSE are the most ﬁrmly established 
echocardiographic tools that can be of important additional value.
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SUPPLEMENTAL MATERIAL
SUPPLEMENTAL FILE 1 - Search syntax used to identify publications of interest (search date April 29, 2015).
Population #1 “pulmonary hypertension”[tiab] OR “pulmonary arterial 
hypertension”[tiab] OR “pulmonary artery hypertension”[tiab]
Predictive variable #2 echocardiograph*[tiab] OR echocardiogram[tiab] OR ultrasound[tiab] 
OR ultrasonograph*[tiab] OR ultrasonogram[tiab] OR ultrasonic[tiab] OR 
“M-Mode”[tiab] OR “M Mode”[tiab] OR doppler[tiab] OR “cardiac magnetic 
resonance”[tiab] OR imaging[tiab] OR MRI[tiab] OR “magnetic resonance 
angiography”[tiab] OR “magnetic resonance angiographies”[tiab]
Outcome #3 death[tiab] OR mortality[tiab] OR survival[tiab] OR fatal[tiab] OR 
fatality[tiab] OR transplant*[tiab] OR graft*[tiab] OR hospitalization[tiab] 
OR hospitalisation[tiab] OR admission[tiab] OR readmission[tiab] OR 
transcatheter[tiab] OR intervention[tiab] OR intravenous[tiab] OR 
infusion*[tiab] OR “new york heart association”[tiab] OR “functional 
class”[tiab] OR “functional status”[tiab] OR function[tiab] OR exercise[tiab] 
OR endurance[tiab] OR ((“6-minute”[tiab] OR “6 minute”[tiab] OR 
“6-min”[tiab] OR “6 min”[tiab] OR “six-minute”[tiab] OR “six minute”[tiab]) 
AND walk[tiab] AND (test[tiab] OR distance[tiab])) OR VO2max[tiab] 
OR “VO2 max”[tiab] OR VO2peak[tiab] OR “VO2 peak”[tiab] OR 
“aerobic capacity”[tiab] OR (oxygen[tiab] AND (uptake[tiab] OR 
consumption[tiab])) OR symptom*[tiab] OR morbidity[tiab] OR 
outcome[tiab] OR outcomes[tiab]
Prognostic studies #4 predict*[tiab] OR clinical*[tiab] OR outcome*[tiab] OR risk*[tiab] OR 
prognos*[tiab]
Search results  
(#1 AND #2 AND #3 AND #4) 
MEDLINE: 2371 
EMBASE: 2228 (replace [tiab] by :ti,ab)
Other limits (added search strings): 
PubMed: NOT (animals[MeSH] NOT humans[MeSH]) 
Embase: NOT ([conference abstract]/lim OR [conference paper]/lim OR [conference review]/lim OR 
[editorial]/lim OR [erratum]/lim OR [letter]/lim OR [note]/lim) AND [embase]/lim
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SUPPLEMENTAL FILE 2 - Risk of bias assessment in individual studies.
    Selection bias
Information bias: 
defined and measured 
appropriately?
Statistical calculation of 
effect size
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Eysmann 1989 + nr + + + + + ± + - NA
Tei 1996 - + nr + + + + + - - NA
Yeo 1998 - - ± + + + + + + + -
Miyamoto 2000 + nr + ± ± + + + + + -
Bustamante 2002 + + - + + + ± + ± + -
Raymond 2002 - - ± + + ± + + - + -
Forﬁa 2006 + + nr + + + + + + ± -
Mahapatra 2006 - - nr + + + + + + ± -
Utsunomiya 2009 - nr + + + ± + + + - NA
Benza 2010 + - + - ± + + + NA + -
Campo 2010 - + + - ± + + + NA - NA
Ciarka 2010 + nr + + + + + + + ± -
Ghio 2010 + nr nr + + ± + + ± - NA
Ghio 2011 + nr nr + + ± + + - ± +
Kane 2011 - + + ± - + + + - + +
Mathai 2011 + nr nr + + ± + + + ± -
Sachdev 2011 - - nr + + + + + - + +
Zeng 2011 - nr nr + + + + + - ± -
Badagliacca 2012 - nr nr ± + + + + NA ± -
Moceri 2012 + nr + + + + + + ± ± -
Shimony 2012 - + nr - - ± + + + - NA
Tonelli 2012 - nr nr + + + + + ± + -
Ernande 2013 + nr nr + + + + + - + -
Fenstad 2013 + + nr + + ± + + NA + -
Fine 2013 + - + + + + + + - + -
Giusca 2013 + - nr ± + ± + + + ± -
Grunig 2013 + - + + + + + + - + +
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SUPPLEMENTAL FILE 2 - Continued.
    Selection bias
Information bias: 
defined and measured 
appropriately?
Statistical calculation of 
effect size
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Hardegree 2013 - - + + + ± + + - ± -
Hardegree 2013 - ± + + + ± + + - + +
Shimony 2013 - + nr ± + ± + + NA ± +
Cho 2014 - nr nr + + + ± + - - NA
Tonelli 2014 - nr nr + + + + + ± + -
Schuuring 2014 + ± - ± + + + + - ± +
Dandel 2014 - nr nr + + ± + + ± - NA
Austin 2015 - nr nr + + + + + - ± +
Batal 2015 - - nr + + ± + + + + +
Sano 2015 - ± nr + + + + + + ± -
nr, not reported; NA, not applicable. Study design: +, prospective cohort study; -, retrospective cohort study. 
Missing data: +, <5%; ±, 5-10% or <5% selective missing data; -, >10% or >5% selective missing data. Loss to 
follow-up: +, <5%; ±, 5-10% or <5% selective loss to follow-up; -, >10% or >5% selective loss to follow-up. 
Echocardiography protocol and statistical analysis: +, well deﬁned; ±, moderately deﬁned; -, poorly deﬁned. 
Echocardiographic findings and outcome: +, well deﬁned and measured appropriately; ± moderately deﬁned or 
moderately measured; -, poorly deﬁned or poorly measured. Effect size: +, Cox regression model and outcomes 
presented as HR [95% CI]; ± Cox regression model, outcomes not presented as HR [95% CI]; -, independent-
samples T-test or outcomes presented as OR/RR. Treatment of continuous predictors: +, all kept continuous; 
±, some categorised/dichotomised, some not; -, all categorised/dichotomised. Multivariable adjustment: +, 
yes, at least for age and gender; ± multivariable adjustment for other factors; -, no multivariable analysis 
performed or not described. Multivariable analysis appropriate: +, ≥10 events per predictor used; -, <10 events 
per predictor used.
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SUPPLEMENTAL FILE 3 - Overview of investigated echocardiographic findings per study.
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Pericardial effusion 17 16 x x x x x x x x x x x x x x x x x*
TAPSE 12 7 x x x x x x x x x x* x x
RA area 12 5 x x x x x x x x x* x x x*
RVSP, SPAP, TR Vmax 11 7 x x x x x x x x x x x*
RV fractional area change 9 5 x x x x x x x x* x
Tei index (RIMP) 8 7 x x x x x x x x
TR severity 8 7 x x x x x x x* x
Estimated RA pressure 7 6 x x x x x x* x
LV eccentricity index 7 4 x x x x x x x
RV longitudinal peak systolic strain 6 4 x x x x x* x
RV end-diastolic basal diameter 5 3 x x x x x*
RV end-diastolic area 5 2 x x x x x*
TDI TV lat S' 5 2 x x x x x
LV cardiac output or index 4 3 x x x x
MV E/A ratio 4 2 x x x x*
MV E velocity 3 x x x*
RVOT time velocity integral 3 x x x*
PA acceleration time 2 x x
RV ejection time 2 x x
PA capacitance 2 x x
RV free wall thickness 2 x x
RV free wall strain rate 2 x x
RV/LV end-diastolic basal diameter  2 x x
LV ejection fraction 2 x x*
RA/LA area ratio 2 x x
TR deceleration 1 x
TV E/e' ratio 1 x
LV end-diastolic volume 1 x
RV free wall time to peak syst strain 1 x
RV free wall early diast strain rate 1 x
MV e' velocity 1 x
TV e'/a' ratio 1 x
Total isovolumic time 1 x
Isovolumic contraction peak velocity x
Isovolumic acceleration 1 x
Isovolumic relaxation time 1 x
sPAP 1 x
LV free wall LPSS 1 x
LV circumferential strain 1 x
TR duration (heart rate adjusted) 1 x
RV midcavity diameter 1 x*
RV longitudinal diameter 1 x*
LV end-diastolic diameter 1 x*
LV end-systolic diameter 1 x*
RV outflow tract acceleration time 1 x*
1
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SUPPLEMENTAL FILE 3 - Continued. 
abnormal end-diastolic septal curve x*
S wave velocity 1 x*
D wave velocity 1 x*
LV dysfunction (0-1) 1 x
RV load adaptation index 1 x*
RV end-systolic area 1 x*
1
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*imaging ﬁnding is longitudinally investigated (change between baseline and follow-up).
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Objectives To provide a comprehensive overview of all reported cardiac magnetic 
resonance (CMR) ﬁndings that predict clinical deterioration in pulmonary 
arterial hypertension (PAH). 
Methods MEDLINE and EMBASE electronic databases were systematically 
searched for longitudinal studies published by April 2015 that reported 
associations between CMR ﬁndings and adverse clinical outcome in 
PAH. Studies were appraised using previously developed criteria for 
prognostic studies. Meta-analysis using random eﬀect models was 
performed for CMR ﬁndings investigated by three or more studies.
Results  Eight papers (539 patients) investigating 21 diﬀerent CMR ﬁndings were 
included. Meta-analysis showed that right ventricular (RV) ejection 
fraction was the strongest predictor of mortality in PAH (pooled HR 
1.23; 95% CI 1.07–1.41, p = 0.003) per 5% decrease. In addition, RV end-
diastolic volume index (pooled HR 1.06; 95% CI 1.00–1.12, p = 0.049), 
RV end-systolic volume index (pooled HR 1.05; 95% CI 1.01–1.09, p = 
0.013) and left ventricular end-diastolic volume index (pooled HR 1.16; 
95% CI 1.00–1.34, p = 0.045) were of prognostic importance. RV and LV 
mass did not provide prognostic information (p = 0.852 and p = 0.983, 
respectively).
Conclusion This meta-analysis substantiates the clinical yield of speciﬁc CMR 
ﬁndings in the prognostication of PAH patients. Decreased RV ejection 
is the strongest and most well established predictor of mortality.
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INTRODUC TION
Pulmonary Arterial Hypertension (PAH) is deﬁned as a mean pulmonary arterial 
pressure ≥ 25 mmHg in the presence of a pulmonary capillary wedge pressure ≤ 15 
mmHg as assessed by right heart catheterization, and is characterized by progressive 
remodeling of the distal pulmonary arteries.1 PAH includes apparent heterogeneous 
conditions (idiopathic, heritable, induced by drugs or toxins, associated with connective 
tissue diseases, HIV infection, portal hypertension and congenital heart disease), but 
is characterized by similar clinical, hemodynamic and pathological pictures.1, 2 Left 
untreated, the resultant increase in pulmonary vascular resistance leads to progressive 
deterioration of right ventricular (RV) function and eventually death in 45% of 
incident cases within 3 years.2, 3 Although recent advances in therapeutic modalities 
have signiﬁcantly improved the outcomes of this devastating disease, the course 
of the disease widely varies between individuals.4-6 In order to guide optimal clinical 
management of patients with PAH, accurate prognostication and monitoring of disease 
progression is therefore of great importance.5
 Previously reported predictors of mortality include etiology of PAH, sex, and several 
functional, biochemical and hemodynamic variables.3, 7-10 Although it is inferred that 
cardiac magnetic resonance imaging (CMR) could be of important additional value, 
evidence for the prognostic merit of speciﬁc imaging ﬁndings is still far from robust. This 
study therefore aims to provide a comprehensive overview of commonly investigated 
CMR ﬁndings that are predictive of adverse clinical outcome in PAH.
METHODS
This systematic review was conducted in accordance with the PRISMA statement.11 
A pre-deﬁned review protocol as adopted by this study can be accessed through 
PROSPERO (registration number: CRD42014009231). 
Literature search strategy
CMR studies as described in this review were identiﬁed through a general search syntax 
that was designed to aggregate all studies concerning the prognostic value of non-
invasive imaging in PAH. A comprehensive systematic search was performed on 29 
April 2015 in MEDLINE (via PubMed interface) and EMBASE electronic databases using 
combinations of all synonyms for: population (PAH), non-invasive imaging and relevant 
clinical outcomes (components of the Dana Point Time To Clinical Worsening composite 
endpoint).2, 12 A validated prognostic search ﬁlter with the highest sensitivity (98%) was 
added to the search syntax.13, 14 No language or publication period restrictions were 
applied. The full original search syntax is supplied in Supplemental File 1.
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Selection of papers
A ﬂow diagram of the selection process is shown in Figure 1.11 After deduplication, 
one author (V.B.) performed screening and selection of articles based on title and 
abstract, using the following exclusion criteria: cross-sectional study design, study 
population without PH (e.g. acute pulmonary embolism, exercise-induced PH), > 30% 
study population with other than WHO group I PAH, inclusion of children < 12 years of 
age, CMR ﬁndings not investigated as potential predictor for clinical outcome, lack of 
Cox regression analysis. Full-text screening was performed by two authors (V.B., J.H.); 
exclusion criteria are described in Figure 1. All references of the excluded reviews and 
included articles were cross-checked to identify possible relevant articles missed in the 
original search syntax. 
Assessment of methodological quality
Study quality was critically appraised using previously developed criteria for prognostic 
studies.15 We assessed study design, missing data and loss to follow-up (selection bias), 
adequate description and measurement of imaging features and outcome (information 
bias), reported eﬀect size, treatment of continuous risk predictors, and multivariable 
adjustment for possible confounders. 
Data extraction and analysis
Study characteristics and hazard ratios (HRs) for all investigated CMR ﬁndings with 
accompanying 95% conﬁdence intervals were extracted using a standardized form. 
Meta-analysis was performed for all CMR ﬁndings investigated by three or more 
studies, using random eﬀect models. HRs for speciﬁc ﬁndings were recalculated to 
one uniform clinically applicable number of units change. Heterogeneity was assessed 
using Cochran’s Q test and the I2 statistic.16 CMR ﬁndings investigated as dichotomous 
variables were additionally presented in the corresponding forest plots. To determine 
the eﬀect of individual study data, sensitivity analyses were performed by recalculating 
pooled HRs after excluding the results of one study. If study data were used in multiple 
papers and the same CMR ﬁndings were evaluated, only the study with the largest 
sample size was selected, thus excluding the risk of using duplicate data in our meta-
analysis. The risk of publication bias was assessed using visual inspection of funnel plots 
and the Egger’s test.17
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RESULTS
Search results
Through a systematic literature search in MEDLINE and EMBASE and extensive reference 
cross-checking, 2733 potentially relevant records were retrieved, of which 2610 were 
excluded based on title and abstract. After full-text review of the remaining 123 articles, 
44 papers were ﬁ nally selected, of which 8 studies in 539 patients described CMR 
ﬁ ndings (Figure 1).18-25
Records identified through 
database searching  
(n = 4599) 
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Additional records identified 
through other sources  
(n = 1) 
Records after duplicates removed  
(n = 2733) 
Records screened  
(n = 2733) 
Records excluded  
(n = 2610) 
Full-text articles assessed 
for eligibility  
(n = 123) 
Full-text articles excluded  
(n = 79): 
No non-invasive cardiac 
imaging parameters related 
to clinical outcome (n = 33), 
> 30% other than WHO 
group I PAH included  
(n = 26), no Cox regression 
analysis performed (n = 6), 
children (n = 5), outcome 
after surgery/thrombectomy 
(n = 4), cross-sectional study 
design (n = 4), identical 
study cohort (n = 1) 
Studies included in qualitative synthesis  
(n = 44): DZĨŝŶĚŝŶŐƐ;Ŷсϴ͕ƚŚŝƐƌĞǀŝĞǁͿ, 
echocardiographic findings (n = 37)* 
Studies included in 
quantitative synthesis 
(this meta-analysis) 
(n = 4) 
FIGURE 1 - PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2009 fl ow diagram.
*, one study investigated both echocardiographic and cardiac magnetic resonance imaging ﬁ ndings. 
Abbreviations:  CMR, cardiac magnetic resonance; PAH, pulmonary arterial hypertension; WHO, World Health 
Organization.
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 Study and patient characteristics of the included studies are presented in Table 1. 
The studies were published between 2007 and 2014; study size ranged from 37 to 110 
patients, mean age ranged from 39 to 62 years, and 60–79% of the population was female. 
The majority of patients was diagnosed with idiopathic PAH (41–100%), two studies 
included a subset of patients with congenital heart disease (9 and 24%, respectively)23, 
25 and one study included patients with PH group III, IV or V (24% of patients).21 Two 
studies did not report information on the use of PAH-speciﬁc mediation,24, 25 in all other 
studies > 60% of patients were on PAH-speciﬁc therapy at baseline. 
 The majority of studies used death (or transplant) as primary outcome; two studies 
used a composite outcome, additionally including hospitalization for heart failure.21, 23 
Mean follow-up duration varied between 10 and 45 months, and the primary outcome 
event occurred in 4–25 patients (10–33% of the study population).
Methodological aspects
The individual bias assessment per study is detailed in Table 2. Five out of eight studies 
had a retrospective study design. Information on missing values and loss to follow-up 
was not reported in two studies. It is therefore important to recognize the possible 
impact of selection bias.
 Right heart catheterization was used for the diagnosis of PAH in 100% of the included 
patients. The majority of studies used short-axis segmentation for the measurement of 
RV volumes;19-21, 23, 24 one study used a transverse segmenting method22 and none of 
the studies used axial slice segmentation. Slice thickness varied between 5 and 10 mm 
and temporal resolution between 20 and 25 frames/cycle or 35–45 ms. Two studies did 
not report spatial or temporal resolution.19, 21 None of the studies explicitly described if 
the valvular planes were taken into account in the segmentation and how the tricuspid 
valve was delineated; however, most studies did mention that both ventricles were 
covered from base to apex. Most studies were not clear about the methodology used 
for the selection of the trabeculae. The technical details regarding the CMR acquisition 
and analysis are described in more detail in Supplemental File 2. 
 Although all studies reported HRs using Cox regression analysis, large diﬀerences 
were found regarding the type and number of predictors per event used in the 
multivariable analysis. Five studies performed some form of multivariable adjustment, of 
which only one study adjusted for age and sex. Only one study used ten or more events 
per predictor. Because of this large variety between studies and overall suboptimal 
methodological quality of multivariable adjustment, it was decided to present only 
univariable HRs in the forest plots. 
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TABLE 1 - Study characteristics.
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Study population         
  Size, n 70 64 110 58 41 37 80 79
  Age, mean ± SD 50 ± 15 43 ± 13 53 ± 15 53 ± 14 39 ± 14 46 ± 14 59 ± 17 62 ± 16
  Sex, % female 79 73 76 74 71 76 60 61
  NYHA class III–IV, % nr 89 52 nr 51 35 66 nr
PH subclassification
  Idiopathic PAH 70 100 66 41 100 65 100 44
  Hereditary PAH - - 6 - - - - -
  Drug- or toxin-induced PAH - - 3 - - - - -
  PAH-CTD 23 - 18 - - 5 - 47
  PAH-HIV 3 - 2 - - - - -
  Po-PAH - - 5 - - - - -
  PAH-CHD - - - - - 24 - 9
  WHO I PAH (other/not speciﬁed) 4 - - 34 - 5 - -
  WHO II (left heart disease) - - - 14 - - - -
  WHO III (lung disease) - - - 2 - - - -
  WHO IV (CTEPH) - - - 3 - - - -
  WHO V (unclear/multifactorial) - - - 5 - - - -
PAH medication, %
  Calcium antagonist 4 8 3 31 22 8 nr nr
  Phosphodiesterase 5-inhibitor 6 6 15 88 21 nr nr
  Endothelin receptor antagonist 51 39 35 54 62 nr nr
  Prostacyclin analog 29 47 14 31 34 14 nr nr
Outcome
  Endpoint
Death Death, 
Tx
Death Death, 
Tx, HF
Death Death, 
HF
Death Death
  Follow-up, months,  
  mean ± SD or median [IQR]
nr 32 ± 16 12 [10–16] 10 ± 6 45 ± 26 16 [13–18] 32 ± 14 nr
  Events, n (%) 18 (26) 19 (30) 13 (12) 19 (33) 4 (10) 7 (19) 23 (29) 25 (32)
CHD, congenital heart disease; CTD, connective tissue disease; CTEPH, chronic thrombo-embolic pulmonary 
hypertension; HF, admission for heart failure; HIV, human immunodeﬁciency virus; IQR, interquartile range; 
NYHA, New York Heart Association; nr, not reported; PAH, pulmonary arterial hypertension; Po-PAH, PAH 
associated with portal hypertension; SD, standard deviation; Tx, transplant; WHO, World Health Organization.
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TABLE 2 - Methodological quality of the included studies.
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Selection bias
   Study design – + + + – – – –
   Missing data nr + ± ± + nr + +
   Loss to follow-up + + + + + nr + nr
Information bias: defined and measured appropriately?
   Description of CMR protocol + ± + ± + ± ± +
   Measurement of CMR ﬁndings + ± + + ± + + +
   Deﬁnition and measurement of outcome + + + + + + ± ±
   Description of statistical analysis + ± + + ± ± + +
Statistical calculation of effect size
   Eﬀect size: hazard ratios + + + + + + + +
   Treatment of continuous predictors + + + + + – + +
   Multivariable adjustment ± ± ± ± – – – +
   Multivariable analysis appropriate – – – – NA NA NA +
nr, not reported; NA, not applicable. Study design: +, prospective cohort; –, retrospective cohort. Missing data: 
+, < 5%; ±, 5–10% or < 5% selective. Loss to follow-up: +, < 5%. CMR protocol and statistical analysis: +, well 
deﬁned; ±, moderately deﬁned. CMR findings and outcome: +, well deﬁned and measured appropriately; ± 
moderately deﬁned or moderately measured. Effect size: +, Cox regression model and outcomes presented 
as HR (95% CI). Treatment of continuous predictors: +, all kept continuous; –, all categorized/dichotomized. 
Multivariable adjustment: +, yes, at least for age and gender; ± multivariate adjustment for other factors; –, 
no multivariate analysis performed or not described. Multivariable analysis appropriate: +, ≥ 10 events per 
predictor used; –, < 10 events per predictor used.
Prognostic value of baseline CMR findings
Eight studies evaluated 21 diﬀerent CMR ﬁndings, as shown in Table 3. Meta-analysis was 
performed for nine CMR ﬁndings that were evaluated by three or more studies. Forest 
plots and pooled HRs are presented in Figure 2. The strongest predictor of mortality was 
RV ejection fraction: pooled HR 1.23 (95% CI 1.07–1.41, p = 0.003) per 5% decrease. In 
addition, RV end-diastolic volume index (p = 0.049) and end-systolic volume index (p = 
0.013) and left ventricular (LV) end-diastolic volume index (p = 0.045) were of prognostic 
importance. Notably, measurements of RV and LV mass did not provide prognostic 
information in PAH (p = 0.852 and p = 0.983, respectively).
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 Although RV stroke volume index as measured by the summation of disks method 
did not have signiﬁcant prognostic value (pooled HR 1.05, p = 0.242),21, 22, 24 the 
pulmonary artery (PA) ﬂow stroke volume index as measured by CMR phase-contrast 
imaging predicted mortality in two studies.19, 24 Less investigated CMR measurements 
such as LV stroke volume,20, 24 pulmonary artery relative area change,18 left atrial volume, 
late gadolinium enhancement at RV insertion points21 and two novel dynamic contrast-
enhanced CMR measurements (full width at half maximum of the bolus passage and 
pulmonary transit time)25 seem promising but require further evaluation.
TABLE 3 - Overview of investigated cardiac magnetic resonance imaging findings per study.
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RV ejection fraction 6 x* x* x x x x
RV end-diastolic volume 5 x* x* x x x
RV end-systolic volume 4 x* x x x
RV stroke volume 3 x x x
PA ﬂow stroke volume index 2 x* x
PA ﬂow cardiac index 2 x* x
RV mass 3 x* x x
LV ejection fraction 5 x* x* x x x
LV end-diastolic volume 5 x* x* x x x
LV end-systolic volume 4 x* x x x
LV stroke volume 2 x* x
LV mass 3 x* x x
RV wall thickness 1 x*
LV wall thickness 1 x*
Ventricular mass index (RV/LV mass) 1 x
RA volume 1 x
LA volume 1 x
PA relative area change 1 x
RV insertion points late gadolinium enhancement 1 x
Full width at half maximum of the bolus passage 1 x
Pulmonary transit time 1 x
*additional serial investigation (change between baseline and follow-up). Abbreviations: LV, left ventricular; 
PA, pulmonary artery; RV, right ventricular.
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FIGURE 2 - Prognostic value of cardiac magnetic resonance imaging findings evaluated by three or more studies.
Values are presented as mean (95% conﬁdence interval). Abbreviations: EDVI, end-diastolic volume index; 
EF, ejection fraction; ESVI, end-systolic volume index; LV, left ventricular; MI, mass index; RV, right ventricular; 
SVI, stroke volume index.
Serial CMR evaluation
Two studies included in this review additionally quantiﬁed the individual change in 
speciﬁc CMR ﬁndings during a follow-up period and directly associated these with 
patient outcomes. Van Wolferen et al. showed that overall mortality was associated with 
a decrease in RV ejection fraction (p = 0.015) and PA ﬂow stroke volume index (p = 0.006) 
at 1-year follow-up.19 Van de Veerdonk’s group reported a 1-year change in RV ejection 
fraction (p = 0.014), RV end-diastolic and end-systolic volume index (both p < 0.001) as 
signiﬁcant predictors of long-term outcome.20 
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Risk of bias assessment
A combination of visual assessment of funnel plots and the Egger’s test did not provide 
statistical evidence for publication bias for any of the CMR ﬁndings included in the 
meta-analysis. Statistical heterogeneity among studies was generally low, as presented 
by Cochran’s Q and I2 statistics in Figure 2 in the corresponding forest plots. We noted 
a discrepancy between the values that were reported in the study of van Wolferen et 
al. compared with the other studies, as eﬀect sizes and standard errors were extremely 
large in this study.19 We therefore conducted sensitivity analyses by excluding the results 
of this study. This did not result in signiﬁcantly diﬀerent HRs and did thus not change 
our conclusions.
DISCUSSION
To our knowledge, this is the ﬁrst systematic review and meta-analysis that substantiates 
the clinical yield of CMR ﬁndings in the prognostication of PAH patients. Among eight 
studies (539 patients) that investigated 21 diﬀerent CMR ﬁndings, RV ejection fraction 
was found to be the strongest and most well established predictor of mortality in PAH. 
In addition, increased RV volumes and decreased LV end-diastolic volume at baseline 
were found to be associated with a higher mortality risk in PAH patients.
Right heart failure
The primary cause of death in PAH is right heart decompensation.8 This is congruent 
with the observation that a decrease in RV function is such an important prognostic 
factor, as it indicates that the right ventricle is no longer able to cope with the high 
pulmonary pressures, leading to increased RV diastolic pressures and RV dilatation. RV 
cardiac output as invasively assessed during right heart catheterization has similarly 
shown to predict mortality in PAH.7, 8 Studies that have investigated echocardiographic 
measurements of RV function, such as TAPSE or RV longitudinal strain, report similar 
ﬁndings.26, 27 RV ejection fraction assessed with equilibrium radionuclide angiography 
also showed to be of prognostic importance.28 Nevertheless, CMR is currently considered 
as the reference standard for the assessment of RV volumes and function.29 RV function 
as measured with CMR may therefore be the most accurate and thus most reliable 
predictor. However, it has to be acknowledged that direct comparisons between the 
diﬀerent imaging modalities are not reported yet.
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Ventricular-ventricular interaction
Whereas CMR-derived RV volumes are increased in high-risk PAH patients, LV 
end-diastolic volume is decreased. Similar results have been reported in several 
echocardiographic studies.30-32 These ﬁndings emphasize once more the inextricable 
connection between the two ventricles. Although often considered as separate entities, 
the two ventricles share common myoﬁbers, a noncompliant pericardium and of course 
the interventricular septum.33 The pressure-overloaded RV will alter LV geometry by a 
leftward septal shift, resulting in a D-shaped LV, which is generally considered as one of 
the hallmarks of pulmonary hypertension. This so-called systolic D-sign is primarily an 
expression of RV pressure overload, in contrast to a diastolic D-sign which is considered 
a sign of a volume-overloaded RV.34 Interestingly, previous studies have shown that 
the diastolic leftward septal shift is associated with mortality in PAH, in contrast to the 
systolic leftward septal shift.35 Accordingly, we found decreased LV end-diastolic volume 
to be of prognostic value, in contrast to LV end-systolic volume. 
 The overall observation that systolic LV geometry is not associated with mortality 
may be explained by the fact that RV systolic pressures are generally high in a stable 
PAH state. However, once the RV starts to fail, LV preload will decrease due to lower 
transpulmonary ﬂow, and RV diastolic pressures will rise. The accompanied altered 
diastolic LV geometry can therefore be seen as a direct expression of RV failure.35 
Subsequently, this altered shape could impair LV ﬁlling and function, further leading 
to increased pulmonary pressures, which may create a vicious circle tilting a stable PAH 
state towards clinical deterioration and, ultimately, death.
Serial measurements
Apart from baseline ﬁndings evaluated at the time of diagnosis, changes in several 
hemodynamic, functional, biochemical and imaging variables could carry incremental 
prognostic information, as they conceivably better reﬂect an individual’s course of 
disease.19, 20, 36, 37 Thus far, only two studies have directly related subject-speciﬁc changes 
in CMR measurements to clinical outcome using Cox regression.19, 20 Both studies report 
the prognostic importance of a decrease in RV ejection fraction over time. In addition, 
van de Veerdonk et al. recently published the results of repeated CMR measurements 
during a follow-up period of 10 years, in patients with initially stable idiopathic PAH 
for 5 years.38 Although no HRs were presented, this study showed that late disease 
progression is also accompanied by increased RV volumes and decreased RV ejection 
fraction. 
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RV mass
Based on three studies, our results showed that RV mass does not provide prognostic 
information in PAH.19, 21, 22 This is probably because concentric RV hypertrophy is an 
adaptive response to increased RV pressures that serves to maintain wall stress as low 
as possible, as is also seen in the LV.39, 40
 RV mass-to-volume ratio allows the distinction between RV concentric and eccentric 
hypertrophy, which might better reﬂect the RV’s adaptive or maladaptive response. 
A recently published cross-sectional study in patients with idiopathic PAH showed 
that eccentric hypertrophy, reﬂected by a lower RV mass-to-volume ratio, was clearly 
related to worse RV systolic function, right ventricular to arterial coupling, and clinical 
impairment.40 Moreover, in patients with tetralogy of Fallot, lower RV mass-to-volume 
ratio was predictive of death.41 Therefore, it may be more prudent to focus on RV mass-
to-volume ratios rather than on RV mass alone.
Study limitations
Although we calculated pooled eﬀect estimates in our review, the results of the random 
eﬀect models should be interpreted with caution, as we included only univariable HRs 
in the meta-analysis, due to the large variability between studies in which multivariable 
adjustment was performed (regarding the type and number of predictors per event 
used). Second, although formal tests for publication bias yielded mainly non-signiﬁcant 
results, the relative lack of power of the Egger’s test in detecting publication bias for 
imaging ﬁndings investigated in less than ten studies should be recognized. Theoretically, 
publication bias can cause underreporting of non-signiﬁcant HRs, leading to a relative 
overestimation of the pooled HRs. Finally, although diﬀerences within studies regarding 
the CMR acquisition and analysis probably reﬂect the normal variance in day-to-day 
practice, they may lead to less precise measurements (independent of the outcome). 
While the vast majority of the studies used short-axis segmentation, it has been 
suggested that axial segmentation results in higher reproducibility, as it may decrease 
the diﬃculty of valve delineation in the basal slices.42, 43 Incomplete segmentation of the 
tricuspid plane, inaccurate delineation of the basal slice and the methodology used to 
deal with the trabeculae can substantially impact the measurements of RV volumes.44, 45 
The subsequent ‘random noise’ would dilute the eﬀect and thus could cause a relative 
underestimation of the actual hazard ratios.
Clinical implications
This review substantiates the clinical yield of speciﬁc CMR ﬁndings in the identiﬁcation 
of patients with PAH at higher risk of clinical deterioration. This is important, as timely 
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intensiﬁcation of PAH-speciﬁc therapy could prevent further clinical worsening and 
death. In addition, CMR-derived RV ejection fraction could be of additional value for the 
longitudinal assessment of PAH. More research is needed to investigate the prognostic 
value of other serial CMR measurements, and baseline measurements such as and RV 
mass-to-volume ratio, LV stroke volume, pulmonary artery relative area change and left 
atrial volume. In addition, it would be worthwhile to directly compare the prognostic 
value of RV function measured using CMR with RV function measured using other non-
invasive imaging modalities, such as echocardiography.
CONCLUSIONS
CMR is useful and accurate in the prognostication of PAH patients. RV ejection fraction 
at baseline and during follow-up is the strongest and most well investigated predictor 
of mortality in patients with PAH. In addition, increased RV volumes and decreased LV 
end-diastolic volume are of prognostic importance.
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SUPPLEMENTAL MATERIAL
SUPPLEMENTAL FILE 1 - Search syntax used to identify publications of interest (search date 29 April 2015).
Population #1 “pulmonary hypertension”[tiab] OR “pulmonary arterial 
hypertension”[tiab] OR “pulmonary artery hypertension”[tiab]
Predictive variable #2 echocardiograph*[tiab] OR echocardiogram[tiab] OR ultrasound[tiab] 
OR ultrasonograph*[tiab] OR ultrasonogram[tiab] OR ultrasonic[tiab] OR 
“M-Mode”[tiab] OR “M Mode”[tiab] OR doppler[tiab] OR “cardiac magnetic 
resonance”[tiab] OR imaging[tiab] OR MRI[tiab] OR “magnetic resonance 
angiography”[tiab] OR “magnetic resonance angiographies”[tiab]
Outcome #3 death[tiab] OR mortality[tiab] OR survival[tiab] OR fatal[tiab] OR 
fatality[tiab] OR transplant*[tiab] OR graft*[tiab] OR hospitalization[tiab] 
OR hospitalisation[tiab] OR admission[tiab] OR readmission[tiab] OR 
transcatheter[tiab] OR intervention[tiab] OR intravenous[tiab] OR 
infusion*[tiab] OR “new york heart association”[tiab] OR “functional 
class”[tiab] OR “functional status”[tiab] OR function[tiab] OR exercise[tiab] 
OR endurance[tiab] OR ((“6-minute”[tiab] OR “6 minute”[tiab] OR 
“6-min”[tiab] OR “6 min”[tiab] OR “six-minute”[tiab] OR “six minute”[tiab]) 
AND walk[tiab] AND (test[tiab] OR distance[tiab])) OR VO2max[tiab] 
OR “VO2 max”[tiab] OR VO2peak[tiab] OR “VO2 peak”[tiab] OR 
“aerobic capacity”[tiab] OR (oxygen[tiab] AND (uptake[tiab] OR 
consumption[tiab])) OR symptom*[tiab] OR morbidity[tiab] OR 
outcome[tiab] OR outcomes[tiab]
Prognostic studies #4 predict*[tiab] OR clinical*[tiab] OR outcome*[tiab] OR risk*[tiab] OR 
prognos*[tiab]
Search results (#1 AND #2 
AND #3 AND #4) 
MEDLINE: 2371
EMBASE: 2228 (replace [tiab] by :ti,ab)
Other limits (added search strings): 
Pubmed: NOT (animals[MeSH] NOT humans[MeSH]) 
Embase: NOT ([conference abstract]/lim OR [conference paper]/lim OR [conference review]/lim OR 
[editorial]/lim OR [erratum]/lim OR [letter]/lim OR [note]/lim) AND [embase]/lim
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ABSTRAC T
Background Matrix metalloproteinases (MMPs) are associated with diastolic 
dysfunction and heart failure in acquired heart disease.
Objective To investigate the role of MMPs as novel biomarkers in clinically stable 
adults with congenital heart disease.
Methods We measured serum MMP-2, -3, -9 and tissue inhibitor of matrix 
metalloproteinase-1 in 425 patients and analyzed the association with 
cardiac function and exercise capacity.
Results  MMP-2 was signiﬁcantly associated with exercise capacity, ventilatory 
eﬃciency and left ventricular deceleration time, independently of age, 
sex, body surface area and NT-proBNP.
Conclusions MMP-2 may provide new information in the clinical evaluation of adults 
with congenital heart disease.
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INTRODUC TION
Since Jerome Gross and Charles Lapiere initially described the enzyme collagenase 
while observing the metamorphosis of the tadpole in 1962, much research has been 
performed on what is nowadays known as matrix metalloproteinase-1.1 Many other 
members of the family of matrix metalloproteinases (MMPs) and their tissue inhibitors 
(TIMPs), consisting of structurally and functionally related extracellular proteolytic 
enzymes, have been described since.2 Together, these enzymes are capable of degrading 
all kinds of extracellular matrix protein components.3, 4 A disruption of the balance 
between MMPs and TIMPs is observed in a wide variety of pathological conditions, such 
as acute and chronic cardiovascular diseases, cancer progression and diﬀerent types of 
arthritis.4-7 More speciﬁc, altered MMP-2, MMP-9 and TIMP-1 levels have been associated 
with left ventricular (LV) hypertrophy, chronic heart failure and diastolic dysfunction 
in hypertensive heart disease and coronary artery disease.8-12 In patients with thoracic 
aortic aneurysms, speciﬁc MMP-2, -9 and TIMP-1 proﬁles have been described; however, 
the majority of research in this ﬁeld is based on histology of the aortic wall rather than 
circulating blood biomarker levels.13-15
 To date, little is known about circulating MMP proﬁles in patients with adult 
congenital heart disease (ACHD). As biventricular ﬁbrosis, hypertrophy and dysfunction 
are important causes of morbidity and mortality, the evaluation of MMPs may well 
prove to be important in this setting. Therefore, the goal of this study was to evaluate 
MMP proﬁles in patients with ACHD and to investigate its relation with exercise capacity 
and echocardiographic ﬁndings, in order to explore the potential role of MMPs as new 
biomarkers.
METHODS
Study design
This is a cross-sectional, observational study. Patients who routinely visited our adult 
congenital cardiology outpatient clinic between May 2011 and April 2013 were 
approached and prospectively enrolled. At the same day, patients underwent physical 
examination by a cardiologist, 12-lead electrocardiography, echocardiography and 
venous blood sampling. A minority of patients underwent exercise testing for routine 
clinical follow-up during the same week as the other study investigations. According to 
the study protocol, these exercise testing results were collected if performed as routine 
clinical care. The study protocol was approved by the institutional review board of the 
Erasmus MC and written informed consent was obtained from all subjects.
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 The following congenital cardiac diagnoses were included: repaired tetralogy of Fallot 
(including pulmonary atresia with ventricular septal defect), congenital aortic stenosis, 
aortic coarctation, transposition of the great arteries (TGA) corrected by atrial switch 
operation (Mustard/Senning), TGA corrected by arterial switch operation, congenitally 
corrected TGA and functionally univentricular hearts palliated by Fontan procedure. 
Exclusion criteria were: age < 18 years, severe renal impairment (creatinine > 200 μmol/L), 
pregnancy, and mild cardiac lesions (isolated atrial or ventricular septal defect).
Data collection
Patients were anonymized using a central online coding system. Data collection was 
performed using an electronic CRF-based online system (© 2004–2012 OpenClinica, 
LLC and collaborators, Waltham, MA; www.OpenClinica.com). This included patient 
demographics, medical history, medication use, symptoms and signs of heart failure 
(New York Heart Association (NYHA) classiﬁcation), results of physical examination, 
electrocardiography, echocardiography, exercise capacity, and laboratory results.
Echocardiography
Patients underwent two-dimensional transthoracic echocardiography using a 
commercially available ultrasound system (iE33, Philips Medical Systems, Best, the 
Netherlands) with a 1.5-MHz transducer. Cardiac dimensions and function were 
measured in accordance with the most recent recommendations of the American 
Society of Echocardiography and the European Association of Cardiovascular Imaging.16 
Left ventricular (LV) and right ventricular (RV) dimensions were measured in end-
diastolic phase from the parasternal long-axis and RV-focused apical four-chamber 
view, respectively. LV ejection fraction was calculated using the biplane method of disc 
summation (modiﬁed Simpson’s rule). RV systolic function was quantiﬁed by tricuspid 
annular plane systolic excursion (TAPSE) and RV fractional area change. Additionally, LV 
and RV systolic function was qualitatively graded as normal or abnormal. LV diastolic 
function was measured using pulsed wave Doppler echocardiography of the mitral 
valve inﬂow (E, A and deceleration time) and tissue Doppler imaging of the medial 
mitral annulus velocity from the apical four-chamber view (E’). Echocardiographic 
measurements of patients with a systemic (sub-aortic) RV were assessed similar to 
patients with a sub-pulmonary RV.
Exercise capacity
Exercise testing was performed on an electrically braked cycle ergometer (Ergoselect 
200 P, Ergoline GmbH, Bitz, Germany), using a gradually increasing workload of 20 Watts 
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per minute. It was aimed to complete the test within 8–12 minutes. Minute ventilation, 
oxygen uptake and carbon dioxide elimination were measured using a computerized 
breath-by-breath analyzer. Maximum eﬀort was deﬁned as a peak respiratory 
exchange ratio of > 1.10. Peak workload, heart rate and oxygen uptake were expressed 
as percentage of the predicted value, based on age, sex, body height and weight. 
Ventilatory eﬃciency was expressed as carbon dioxide equivalent (minute ventilation 
relative to carbon dioxide elimination).
Biomarkers
Venous blood samples were obtained after 30 minutes of rest. Plasma N-terminal-pro-
B-type natriuretic peptide (NT-proBNP) was assessed by electrochemiluminescence 
immunoassays (Roche Diagnostics, Basel, Switzerland) in our clinical chemistry laboratory, 
as part of routine patient care. Other blood samples were coded, processed and stored 
at –80 degrees Celsius within two hours, until further analysis. Serum MMP-2, MMP-3 and 
MMP-9 were measured by batch analysis using the ProcartaPlexTM Multiplex Immunoassay, 
with sample dilution factor 50 (eBioscience, Vienna, Austria). Serum TIMP-1 was measured 
using two-site enzyme-linked immunosorbent assays, with sample dilution factor 100 
(BMS2018CE, eBioscience, Vienna, Austria). Lower limits of detection were < 34 pg/mL, 
< 0.83 pg/mL and < 39 ng/mL for MMP-2, MMP-9 and TIMP-1, respectively. As all blood 
samples were coded, laboratory staﬀ was blinded for patient data. 
Statistical analysis
The distribution of data was checked using histograms and the Shapiro-Wilk test. Patient 
characteristics were presented as mean ± standard deviation or median [interquartile 
1-3 (IQ
1
–IQ 
3
)], depending on the distribution of data. Skewed biomarker distributions 
were log-transformed.
 Univariable associations were evaluated using Pearson’s correlation. MMP values 
below the limit of detection were analyzed as the lowest detectable value. We performed 
a stratiﬁed analysis in the three main diagnostic groups (left sided heart disease, right 
sided heart disease and systemic RV). 
 Multivariable linear (for continuous outcomes) and logistic (for dichotomous 
outcomes) regression analyses were only performed for MMP-2, as all other biomarker 
values yielded non-signiﬁcant results in the univariable analysis. Unstandardized 
β-coeﬃcients were adjusted for the potential confounders age, sex and body surface 
area (BSA). Based on the results of the univariable analysis, β-coeﬃcients were 
additionally adjusted for other covariates. Data analysis was performed using IBM SPSS 
Statistics for Windows, Version 21.0 (IBM Corp., Armonk, NY, USA). Two-sided p-values < 
0.05 were considered statistically signiﬁcant.
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RESULTS
We prospectively included 425 patients (median age 33.3 years [IQ
1
-IQ
3
 25.9–42.1 years], 
244 males, 57%). Echocardiography and measurement of serum MMPs was performed 
in all patients. Bicycle ergometry was performed in 126 patients, of whom 40 patients 
underwent measurement of oxygen uptake en carbon dioxide elimination. Clinical 
characteristics and medication use are detailed in Table 1. MMP and TIMP proﬁles were 
not diﬀerent when comparing all patient subgroups based on the congenital cardiac 
diagnosis (Figure 1). 
TABLE 1 - Characteristics of the study population (n = 425).
Variable
Mean ± SD, median 
[IQ1−IQ3] or n (%)
Surgical repair / 
intervention, n (%)
Age, years 33.3 [25.9−42.1]
Sex, male n (%) 244 (57)
Diagnosis, n (%)
   Tetralogy of Fallot 167 (39) 167 (100)
   Congenital aortic stenosis 112 (26) 80 (71)
   Aortic coarctation 40 (10) 39 (98)
   TGA corrected by atrial switch 60 (14) 60 (100)
   TGA corrected by arterial switch 18 (4) 18 (100)
   Congenitally corrected TGA 18 (4) 9 (50)
   Univentricular heart (Fontan) 10 (3) 10 (100)
Age at surgical repair / intervention, years 3.9 [0.8−11.9]
Systolic blood pressure, mmHg 125 ± 16
Diastolic blood pressure, mmHg 79 ± 11
Heart rate, beats/minute 74 ± 14
Saturation < 90%, n (%) 9 (2)
Cardiac medication, n (%)
   ACE-inhibitor 61 (14)
   Angiotensin receptor blocker 21 (5)
   Betablocker 58 (14)
   Diuretics 44 (10)
NT-proBNP, pmol/L 16.6 [7.9−34.3]
NYHA functional class, II−III n (%) 40 (9)
Abbreviations: ACE, angiotensin converting enzyme; IQ, interquartile; NT-proBNP, N-terminal brain natriuretic 
peptide; NYHA, New York Heart Association; SD, standard deviation; TGA, transposition of the great arteries.
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FIGURE 1 - MMP-2, MMP-3, MMP-9 and TIMP-1 values were comparable among the diagnostic groups.
P-values are obtained by comparing the actual MMP-2, MMP-3, MMP-9 and TIMP-1 values across the 
diagnostic groups using the Kruskal-Wallis test. Comparison of log
10
 values across diagnostic groups using 
one-way ANOVA did not yield diﬀ erent conclusions.
Univariable analysis
In Table 2 the correlations of log
10
 MMP-2, MMP-3, MMP-9 and TIMP-1 with patient 
characteristics, exercise testing results and echocardiographic data are presented. 
MMP-2 and MMP-9 were signiﬁ cantly related to BSA, diastolic blood pressure and 
decreased saturation. MMP-2 signiﬁ cantly correlated with peak workload % (r = –0.233, 
p = 0.009), peak oxygen uptake (r = –0.411, p = 0.008) and carbon dioxide equivalent (r = 
0.396, p = 0.034), of which scatterplots are additionally shown in Figure 2. Furthermore, 
MMP-2 signiﬁ cantly correlated to NT-proBNP, NYHA functional class, aortic valve peak 
velocity, LV and RV systolic dysfunction, E’ wave velocity < 8 cm/s, E/E’ ratio ≥ 13 and LV 
deceleration time. MMP-9 was only related to peak oxygen uptake (r = –0.350, p = 0.027). 
MMP-3, MMP-9, TIMP-1 and MMP-9/TIMP-1 ratios (ratios are not presented in Table 2) 
were not signiﬁ cantly associated with any other parameters of functional outcome. 
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TABLE 2 - Univariable associations (Pearson’s correlation, n = 425).
Variable log10 MMP-2 log 10 MMP-3 log10 MMP-9 log10 TIMP-1
Patient characteristics
Age, years 0.027 0.093 −0.049 −0.063
Sex, male 0.066 −0.151** 0.086 −0.011
Body surface area, m2 −0.173** 0.073 −0.137** 0.048
Diagnosis: systemic right ventricle 0.009 −0.018 −0.043 0.097*
Surgical repair 0.080 −0.039 −0.069 0.005
Systolic blood pressure, mmHg −0.083 0.067 −0.022 0.077
Diastolic blood pressure, mmHg −0.100* 0.017 −0.111* 0.051
Heart rate, beats/minute 0.042 −0.018 −0.012 0.003
Saturation <90% 0.136** 0.073 0.104* 0.074
Use of angiotensin receptor blocker −0.006 0.054 0.110* 0.038
log
10
 NT-proBNP 0.147** 0.035 0.081 −0.004
NYHA functional class, II−III 0.102* 0.064 −0.018 −0.034
Exercise testing
Peak heart rate, % of target (n = 126) −0.205* −0.024 0.001 −0.088
Peak workload, % of target (n = 126) −0.233** 0.032 −0.080 −0.047
Peak oxygen uptake, mL/min (n = 40) −0.411** 0.004 −0.350* −0.038
Peak oxygen uptake, % of target (n = 40) −0.230 −0.141 −0.056 −0.119
Carbon dioxide equivalent (n = 40) 0.396* 0.214 0.270 0.148
Echocardiography
LV end-diastolic dimension, mm −0.100 0.005 −0.072 0.022
Aortic STJ end-diastolic diameter, mm 0.056 0.070 −0.051 −0.085
Aortic valve peak velocity, m/s −0.110* −0.001 0.045 −0.040
Interventricular septum, mm (PLAX) −0.028 0.092 −0.010 −0.020
RV end-diastolic annulus, mm 0.069 0.071 0.003 0.022
RV end-diastolic area, cm2 0.061 0.065 −0.009 0.087
RV end-systolic area, cm2 0.096 0.061 0.002 0.078
Systolic function
   LV ejection fraction, % −0.065 −0.027 0.050 −0.057
   LV systolic dysfunction, 0−1 0.102* 0.093 −0.073 0.011
   RV fractional area change, % −0.112 −0.017 −0.019 −0.022
   RV systolic dysfunction, 0−1 0.115* 0.047 −0.039 0.018
   TAPSE, mm 0.017 0.079 0.081 −0.018
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TABLE 2 - Continued.
Variable log10 MMP-2 log 10 MMP-3 log10 MMP-9 log10 TIMP-1
LV diastolic function
   E/A ratio 0.012 −0.044 0.049 0.019
   E’ wave < 8 cm/s 0.132* 0.050 −0.014 0.002
   E/E’ ratio ≥ 13 0.128* 0.103 0.051 −0.033
   Deceleration time, ms −0.137* −0.085 0.017 −0.061
*p < 0.05, **p < 0.01. Abbreviations: LV, left ventricular; MMP, matrix metalloproteinase; NT-proBNP, 
N-terminal brain natriuretic peptide; NYHA, New York Heart Association; PLAX, parasternal long-axis view; 
RV, right ventricular; STJ, sinotubular junction; TAPSE, tricuspid annular plane systolic excursion; TIMP, tissue 
inhibitor of matrix metalloproteinase.
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FIGURE 2 - Scatterplots demonstrating the correlation of MMP-2 with peak workload %, peak oxygen uptake and 
carbon dioxide equivalent.
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As 46% of MMP-2 values were < 34 pg/mL (lower limit of detection), all analyses were 
repeated with exclusion of these values. Also non-parametric tests were performed 
(Spearman’s correlation). These did not yield diﬀerent conclusions.
TABLE 3 -Unstandardized ß-coefficients of log10 MMP-2 values (n = 425).
 
 
Adjusted for age, sex, BSA
β P-value
NYHA functional class, II−III 0.57 0.152
Exercise testing    
Peak heart rate, % of target (n = 126) −5.08 0.046
Peak workload, % of target (n = 126) −11.86 0.007
Peak oxygen uptake, mL/min (n = 40) −238.7 0.175
Peak oxygen uptake, % of target (n = 40) −12.79 0.046
Carbon dioxide equivalent (n = 40) 3.69 0.117
Echocardiography    
LV end-diastolic dimension, mm −0.78 0.362
Aortic STJ end-diastolic diameter, mm 1.80 0.098
Aortic valve peak velocity, m/s −0.26 0.074
Interventricular septum, mm (PLAX) −0.00 0.997
RV end-diastolic annulus, mm 2.24 0.051
RV end-diastolic area, cm2 3.40 0.025
RV end-systolic area, cm2 3.49 0.010
Systolic function    
   LV ejection fraction, % −1.64 0.410
   LV systolic dysfunction, 0−1 1.00 0.040
   RV fractional area change, % −3.99 0.036
   RV systolic dysfunction, 0−1 0.67 0.027
   TAPSE, mm 0.39 0.627
LV diastolic function    
   E/A ratio 0.03 0.735
   E’ wave < 8 cm/s 0.56 0.107
   E/E’ ratio ≥ 13 0.51 0.129
   Deceleration time, ms −22.33 0.009
Analysed using linear (for continuous outcome) or logistic regression (for categorical outcome). Signiﬁcant 
p-values are printed in bold. Abbreviations: as deﬁned in Table 2.
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Stratified analysis
The associations of echocardiographic measurements with MMP-2 as presented in 
Table 2 were additionally analyzed in three main diagnostic subgroups: left sided 
heart disease (congenital aortic stenosis, aortic coarctation and TGA corrected by 
arterial switch operation), right sided heart disease (repaired tetralogy of Fallot), and 
systemic RV (TGA corrected by atrial switch operation and congenitally corrected TGA). 
In patients with repaired tetralogy of Fallot, LV dysfunction (r = 0.184, p = 0.018), RV 
dysfunction (r = 0.190, p = 0.014), E/E’ ratio ≥ 13 (r = 0.165, p = 0.042) and LV deceleration 
time (r = –0.178, p = 0.028) were signiﬁcantly associated with MMP-2. These associations 
were not present in the two other diagnostic groups, and LV diastolic function was not 
measured in patients with a systemic RV.
Multivariable analysis
In Table 3, the results of the multivariable analysis are presented. ß-coeﬃcients 
represent the increase in patient characteristic per 10-fold increase in MMP-2, adjusted 
for age, sex and BSA. Based on the results of the univariable analysis, we additionally 
adjusted for diastolic blood pressure, decreased saturation and NT-proBNP (not shown 
in the table). After adjustment for all variables, MMP-2 was signiﬁcantly associated with 
peak workload (β = –10.96, p = 0.022), carbon dioxide equivalent (β = –6.86, p = 0.016) 
and LV deceleration time (β = –22.4, p = 0.012); however, not with RV dilatation and RV 
or LV systolic function. MMP-2 was not signiﬁcantly associated with aortic sinotubular 
junction end-diastolic diameter, although a trend was observed (β = 1.89, p = 0.087).
DISCUSSION
In our cohort of clinically stable adults with congenital heart disease, MMP-2 was 
signiﬁcantly associated with decreased exercise capacity (n = 126, peak workload %), 
decreased ventilatory eﬃciency (n = 40, carbon dioxide equivalent) and decreased LV 
deceleration time (n = 425), independently of NT-proBNP and other clinical variables. In 
addition, MMP-2 was related to LV and RV systolic dysfunction (adjusted for age, sex and 
BSA) and several echocardiographic markers of diastolic dysfunction in the univariable 
analysis. MMP-3, MMP-9 and TIMP-1 were not consistently related with exercise capacity 
or cardiac function. Nor did we observe speciﬁc MMP proﬁles among the varying 
underlying congenital diagnoses.
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Cardiac function
Although this is the ﬁrst study that reports a modest association of MMP-2 with systolic 
ventricular function, independently of age, sex and BSA, extracellular matrix remodeling 
processes have been previously related to systolic ventricular function in other patient 
groups. In patients with hypertension, serum TIMP-1 levels were independently related 
to LV longitudinal strain and torsion.10 Moreover, TIMP-1 was elevated in patients with 
congestive heart failure.8
 Increased extracellular matrix remodeling within the myocardium has been more 
frequently associated with diastolic ventricular dysfunction. In our cohort, diastolic 
dysfunction (as expressed by E’ wave velocity < 8 cm/s, E/E’ ratio ≥ 13 and LV deceleration 
time) was related to MMP-2 in the univariable analysis. Martos et al. showed that in 
hypertensive heart disease, serum levels of MMP-2 were elevated in those patients 
with diastolic heart failure, suggesting increased degradation of myocardial collagen 
and other components of the extracellular matrix.11 Subsequently, Gardin et al. showed 
that echocardiographic markers of diastolic dysfunction were independently related to 
peak oxygen uptake and ventilatory eﬃciency.17 In line with these results, Chen et al. 
recently reported that a serum biomarker of collagen type I synthesis (carboxy-terminal 
propeptide of procollagen type I, PICP) was related to higher RV late gadolinium 
enhancement scores (indicating myocardial ﬁbrosis) and lower peak oxygen uptake 
in patients with repaired tetralogy of Fallot.18 Diastolic function is often impaired 
in patients with ACHD.19 Diastolic dysfunction is especially common in patients with 
congenital aortic stenosis.20, 21 In addition, abnormal LV diastolic indices are known to 
be prevalent in a substantial proportion of patients with tetralogy of Fallot.22 The most 
important association found in our study, directly linking increased serum MMP-2 values 
with decreased exercise capacity and ventilatory eﬃciency, may therefore be partially 
explained by increased diastolic dysfunction.
 Importantly, the patients in our study were all clinically stable, with 91% of patients 
in NYHA class I. This probably explains some of the only modest or absent correlations. 
The stratiﬁed analysis in three main diagnostic groups showed that the associations 
of echocardiographic measurements with MMP-2 as found in the entire study cohort 
probably largely originate from the group of patients with repaired tetralogy of Fallot. 
This is possibly explained by a wider variance in ventricular systolic and diastolic function 
in this patient group. 
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Aortic stenosis and dilatation
In our study, serum MMP-2, -3, -9 and TIMP-1 levels were similar in patients with aortic 
stenosis or coarctation compared with all other congenital cardiac diagnoses. As we 
know patients with aortic stenosis or coarctation often have diastolic dysfunction, we 
had expected higher MMP-2 levels in these patients.19 Neither did we ﬁnd signiﬁcant 
relations with aortic dimensions as measured by echocardiography, although a trend 
was observed for MMP-2 (adjusted p-value 0.087). Previous studies have reported altered 
plasma MMP-2, -9 and TIMP-1 levels in patients with aortic valve stenosis and ascending 
aorta dilatation, both in bicuspid valves and in chronic thoracic aortic dissection.13-15 It 
may therefore be worthwhile to evaluate MMPs in speciﬁc patient subgroups with a 
high risk of aortic dilatation, in combination with more detailed imaging modalities of 
the aorta, such as CT or MRI. 
Matrix metalloproteinases as peripheral markers
As circulating blood biomarkers proﬁles can be aﬀected by processes throughout the 
entire body, altered MMP proﬁles may not entirely reﬂect the actual histological changes 
in the myocardium or aortic wall. The interaction between MMPs and other biologically 
active substrates is highly complex. We constructed a conceptual model of the MMP-
TIMP interactions with TGF-β, IL-1β, TNF-α and other substrates as described by the 
available literature on this topic (Figure 3).3, 7, 23-25 Due to these complex interactions, it 
is likely that the underlying disease and patient comorbidities inﬂuence MMP levels. In 
this study, MMP-9 and TIMP-1 were not found to be associated with echocardiographic 
data, in contrast to previous reports.8, 11, 12 This might be explained by the diﬀerence in 
patient cohorts, the selection of stable patients visiting the outpatient clinic and the 
type of MMP analysis performed.
Clinical implications
Previous studies have shown that exercise capacity and ventilatory response to exercise 
are important prognostic markers in ACHD.26, 27 Our data provide evidence for a modest 
association of MMP-2 with several measures of functional outcome, independently of 
NT-proBNP. Correlations were not strong, indicating that MMP-2 only partially explains 
the variance in echocardiographic ﬁndings and exercise capacity. Nevertheless, these 
ﬁndings indicate that MMP-2 provides new information, incremental to clinical variables 
and NT-proBNP, even in a clinically stable patient group. MMP-2 may therefore be useful 
as novel biomarker in patients with ACHD. It would be worthwhile to further evaluate 
the prognostic value of MMP-2 in longitudinal studies.
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MMP-2 MMP-3 MMP-9 
TIMP-1 TNF-ɲ 
TGF-ɴ(1) 
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FIGURE 3 - Conceptual model illustrating the highly complex interactions between MMPs, TIMP-1 and other 
biologically active substrates.
Dashed lines indicate enzyme inhibition. Abbreviations: ARBs, angiotensin receptor blockers; CTGF, 
connective tissue growth factor; EGF, epidermal growth factor; ET-1, endothelin-1; IL-1β, interleukin-1beta; 
PDGF, platelet derived growth factor; TGF-β, transforming growth factor-beta; TNF-α, tumor necrosis factor-
alpha; uPA, urokinase-type plasminogen activator.
Study limitations
Bicycle ergometry was performed in a subset of 126 patients. Of these, in 40 patients 
oxygen uptake and carbon dioxide elimination were recorded. The consistency and 
strength of these data should therefore be further evaluated in multiple studies 
from diﬀerent centers and laboratories, in accordance with previously formulated 
benchmarks for the assessment of novel cardiovascular biomarkers by Morrow and de 
Lemos.28 To be clinically useful, the pre-analytical and analytical performance of the 
MMP assays need to be thoroughly investigated and robust reference values have to be 
assessed in healthy controls. 
CONCLUSIONS
Serum MMP-2 was signiﬁcantly related to exercise capacity, ventilatory eﬃciency and LV 
deceleration time in a diverse cohort of stable adults with congenital heart disease, also 
after adjustment for NT-proBNP and other clinical variables. In contrast, MMP-3, MMP-9 
and TIMP-1 were not consistently related to exercise testing results or cardiac function. 
Prospective longitudinal studies are warranted to determine the clinical usefulness and 
prognostic value of MMP-2 as candidate biomarker.
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ABSTRAC T
Background The number of patients with adult congenital heart disease (ACHD) is 
rapidly increasing. In order to optimize patient management, there is a 
great need to accurately identify high-risk patients. Still, no biomarker has 
been ﬁrmly established as a clinically useful prognostic tool in this group. 
We studied the association of N-terminal pro-B-type natriuretic peptide 
(NT-proBNP), high-sensitive troponin-T, and growth-diﬀerentiation factor 
15 with cardiovascular events in ACHD. 
Methods Clinically stable patients with ACHD who routinely visited the outpatient 
clinic between April 2011 and April 2013 underwent clinical assessment, 
electrocardiography, echocardiography and biomarker measurement (NT-
proBNP, high-sensitive troponin-T, and growth-diﬀerentiation factor 15) at 
the time of study inclusion. Patients were prospectively followed for the 
occurrence of cardiovascular events (death, heart failure, hospitalization, 
arrhythmia, thromboembolic events, and re-intervention). Survival curves 
were derived by the Kaplan-Meier method, and Cox regression was 
performed to investigate the relation between biomarkers and events 
with adjustment for multiple clinical and echocardiographic variables. 
Results  In total, 595 patients were included (median age 33 [IQR 25–41] years; 
58% male; 90% New York Heart Association class I). Patients were followed 
during a median of 42 [IQR 37–46] months. Of the three evaluated 
biomarkers, NT-proBNP in the upper quartile (> 33.3 pmol/L) was most 
strongly associated with cardiovascular events (n = 165, adjusted HR 
9.05; 95% CI 3.24–25.3, p < 0.001) and with death or heart failure (n = 
50, adjusted HR 16.0; 95% CI 2.04–126, p < 0.001). When NT-proBNP 
was analyzed as a continuous variable, similar ﬁndings were retrieved. 
The cumulative proportion of patients with death and heart failure was 
only 1% in the lowest two NT-proBNP quartiles. Elevated NT-proBNP (> 
14 pmol/L), elevated high-sensitive troponin-T (> 14 ng/L), and elevated 
growth-diﬀerentiation factor 15 (> 1109 ng/L) identiﬁed those patients at 
highest risk of cardiovascular events (log-rank p < 0.0001).
Conclusions NT-proBNP provides prognostic information beyond a conventional risk 
marker model in patients with ACHD and can reliably exclude the risk 
of death and heart failure. Elevated levels of NT-proBNP, high-sensitive 
troponin-T, and growth-diﬀerentiation factor 15 identify patients at 
highest risk of cardiovascular events. These biomarkers therefore may 
play an important role in the monitoring and management of patients 
with ACHD.
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INTRODUC TION
The surgical treatment of children with moderate and complex types of congenital 
heart disease has tremendously improved during the past ﬁve decades. Today, over 
90% of these children survive into adulthood.1-3 Subsequently, the number of patients 
with adult congenital heart disease (ACHD) is rapidly increasing, which is estimated 
to only begin to plateau around the year 2050.4 The majority of these patients carry 
residual cardiac abnormalities, which inevitably predispose to complications such as 
heart failure, arrhythmia, and early demise.5 
 To adequately manage the growing number of patients with ACHD, accurate 
prognostication is of paramount importance. It enables optimization of patient 
information, follow-up and diagnostic testing strategies, pharmacological treatment, 
and timing of re-interventions.6 Current clinical tools such as echocardiography fail 
to identify early changes that precede adverse cardiac remodeling and heart failure. 
Therefore, there is a great need to identify additional measures that can be combined 
with existing tools to monitor subtle changes in the heart that reﬂect and possibly 
predict disease progression before it becomes clinically apparent.7, 8 
 Natriuretic peptides are ﬁrmly established diagnostic and prognostic tools in a 
variety of chronic cardiovascular conditions, such as heart failure and coronary heart 
disease.9-11 Cardiac troponins and growth-diﬀerentiation factor 15 (GDF-15) also oﬀer 
prognostic information in these groups.12-18 Cross-sectional studies in patients with 
various types of ACHD have shown that natriuretic peptides, high-sensitive troponin-T 
(hs-TnT), and GDF-15 are related to intermediate prognostic markers, such as ventricular 
function or exercise capacity.19-22 Prospective follow-up data are clearly needed in 
this patient group. The aim of this study was to investigate the association between 
circulating concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP), hs-
TnT, and GDF-15 and a composite endpoint of cardiovascular events in a large cohort of 
stable patients with ACHD.
METHODS
Study design and population
In this prospective cohort study, we aimed to include all consecutive patients 
who routinely visited our adult congenital cardiology outpatient clinic with an 
echocardiogram between April 2011 and April 2013. Moderate and complex types 
of congenital heart defects23 were considered eligible for inclusion: congenital aortic 
stenosis, aortic coarctation, repaired tetralogy of Fallot (including pulmonary atresia 
with ventricular septal defect), transposition of the great arteries corrected by atrial 
switch operation (Mustard), transposition of the great arteries corrected by arterial 
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switch operation, congenitally corrected transposition of the great arteries, complex 
transposition of the great arteries with ventricular septal defect or double-outlet right 
ventricle corrected with a Rastelli type repair, functionally univentricular hearts, or 
pulmonary arterial hypertension after a (corrected) atrial or ventricular septal defect. 
Exclusion criteria were: age < 18 years, pregnancy, mild cardiac lesion (isolated atrial or 
ventricular septal defect), not capable of understanding and signing informed consent, 
or kidney failure (creatinine > 200μmol/L, corresponding to 2.26 mg/dL). The study 
protocol was approved by the Erasmus MC medical ethics committee and all patients 
provided written informed consent.
Data collection
At the same day, patients underwent physical examination by a cardiologist, 12-lead 
electrocardiography, echocardiography, and venous blood sampling. Data collection 
and storage was performed using an electronic case report form-based online system (© 
2004-2012 OpenClinica, LLC and collaborators).24 This included patient demographics, 
medical history, medication use, results of physical examination, electrocardiography, 
echocardiography, laboratory results, and events. New York Heart Association (NYHA) 
functional class was used to classify symptoms and signs of heart failure. Patients who 
reported no limitation in ordinary physical activity were considered to be in NYHA 
functional class I. Other details have been described previously.19
Biomarkers
Venous blood samples were obtained after 30 minutes of rest. All biomarker values were 
measured for research purposes only, and all decisions regarding patient management 
(including re-interventions) were made independently of any biomarker level. 
Serum NT-proBNP was directly measured in our clinical chemistry laboratory using a 
commercial electrochemiluminescence immunoassay (Roche Diagnostics). Other blood 
samples were left in room temperature during a maximum of two hours. Samples were 
centrifuged at 1700g for 10 minutes at 4°C. Serum and EDTA plasma samples were stored 
at –80°C until batch analysis. The median storage period at –80°C was 22.0 [IQR 16.4–
26.2] months for hs-TnT and 28.7 [IQR 23.3–32.7] months for GDF-15. All samples were 
subjected to one freeze-thaw cycle. Serum hs-TnT was measured using a commercial 
electrochemiluminescence immunoassay (Roche Diagnostics). Plasma GDF-15 was 
measured using a precommercial electrochemiluminescence immunoassay (Roche 
Diagnostics). Reproducibility of the GDF-15 assay has been described previously.22 For 
NT-proBNP, hs-TnT, and GDF-15, the limits of detection were 0.6 pmol/L, 5 ng/L, and 400 
ng/L, respectively. For NT-proBNP and GDF-15, all values below the limit of detection 
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were reported as < 0.6 pmol/L and < 400 ng/L, and for hs-TnT the limit of blank (the 
highest measured test result likely to be observed for a sample containing no analyte) 
was 3 ng/L. The upper limit of normal for NT-proBNP was 14 pmol/L (≈ 125 pg/mL), on 
the basis of the recommended low cutoﬀ for the diagnosis of heart failure in patients 
presenting with non-acute symptoms.25 The upper limit of normal for hs-TnT and GDF-
15 level were deﬁned as 14 ng/L and 1109 ng/L, on the basis of the 99th and 97.5th 
percentile value in the normal population, respectively.18, 22, 26
Echocardiography
Patients underwent extensive two-dimensional transthoracic echocardiography, 
using a commercially available ultrasound system iE33 (Philips Medical Systems) with 
a 1.5-MHz transducer. Images were acquired according to a standardized sequential 
segmental analysis protocol. Cardiac dimensions were measured in agreement with the 
current recommendations of the American Society of Echocardiography and European 
Association of Cardiovascular Imaging and were indexed for body surface area.27 Left 
ventricular ejection fraction was measured using the modiﬁed Simpson rule. Right 
ventricular systolic function was quantiﬁed with fractional area change. Systemic 
ventricular function was also visually graded as normal, mildly, moderately or severely 
impaired. Measurements were performed without knowledge of biomarker levels and 
before the assessment of events.
Definition and assessment of events
The primary endpoint was deﬁned before the collection of data as a composite of all 
adverse cardiovascular events: all-cause mortality, heart failure (requiring initiation or 
change in heart failure medication, or requiring hospital admission), hospitalization 
for cardiac reasons, arrhythmia (symptomatic and recorded, or requiring treatment), 
thromboembolic events (ischemic cerebrovascular accident, pulmonary embolism, 
or myocardial infarction), or cardiac re-interventions (surgical or percutaneous). A 
secondary composite endpoint of all-cause mortality or heart failure was deﬁned. All 
patients were prospectively and systematically followed for fatal and nonfatal events 
by a yearly clinical evaluation at our institution according to a standard protocol. Where 
necessary, we retrieved information from electronic patient charts and correspondence 
with referring hospitals. Survival status of all patients was also checked in the Municipal 
Population Register. Events were adjudicated by two experienced investigators (V.B. 
and J.R.) without knowledge of biomarker levels. The investigators had direct access 
to the patient clinical records and the events were independently reviewed by each 
investigator. For patients with multiple events, event-free survival was deﬁned as the 
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time from enrollment to the occurrence of the ﬁrst event. All components of the primary 
endpoint were also separately assessed as tertiary endpoints for exploratory purposes 
(in which patients were not censored at the time of another endpoint than the endpoint 
of interest). Patients without any cardiovascular event were censored at the end of the 
follow-up duration (August 1, 2015).
Statistical analysis
At the end of the study duration, 25% of the cohort was expected to reach the primary 
composite endpoint, based on 2.4% cardiovascular deaths and 22.8% major adverse 
cardiac events such as heart failure, re-intervention, arrhythmia and hospital admission 
in the Euro Heart Survey.28 To collect at least 150 events, we therefore estimated that 
inclusion of ≈ 600 patients would be suﬃcient to permit appropriate adjustment for 
potential confounders. 
 Patient characteristics are presented as mean ± standard deviation or median 
[interquartile range, IQR], depending on the distribution of data. Comparisons across 
quartiles of the biomarker distribution were performed using the chi-square Mantel-
Haenszel test for trend (for categorical variables) or linear regression (for continuous 
variables). Associations of baseline characteristics with biomarker levels were also 
expressed using Pearson or Spearman correlation, depending on the distribution of data. 
Cumulative end-point free survival estimates and survival curves were derived by the 
Kaplan-Meier method; groups were compared using the log-rank test. Cox proportional 
hazards regression was performed to identify associations with the primary and 
secondary composite endpoint. We analyzed the biomarkers as both categorical and 
continuous variables (in quartiles, and using a log 
2
-transformation and expressed per 
one standard deviation increase in biomarker level, respectively). In the multivariable 
analysis, we adjusted for potential confounders by selecting age, sex, and other 
variables that were associated with the primary endpoint in the univariable analysis. 
The multivariable models were used with a minimum of ten endpoints per degree of 
freedom.29 Combinations of biomarkers were investigated by evaluating the number 
of elevated biomarkers, using the cutoﬀs as described previously, and as continuous 
variables in multivariable models. A sensitivity analysis was performed by excluding 
congenital diagnostic subgroups with the highest NT-proBNP levels. Data analysis was 
performed by two authors (V.B. and E.B.) using IBM SPSS Statistics for Windows, Version 
21.0 (IBM Corp., Armonk, NY, USA). Discrimination was described with the concordance 
(C)-index and the integrated discrimination improvement, calculated using R, Version 
3.3.0, packages survC1 and survIDINRI.30 Two-sided p-values of < 0.05 were considered 
statistically signiﬁcant. No corrections were made for multiplicity of comparisons.
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RESULTS
Baseline measurements
NT-proBNP, hs-TnT, and GDF-15 measurements were performed in 595, 589, and 589 
patients, respectively. A ﬂowchart of the patient selection is shown in Supplemental Figure 
1. Median age was 33 [IQR 25–41] years and 346 (58%) were men. Baseline characteristics 
are detailed in Table 1. The vast majority of patients (n = 540, 91%) underwent surgical 
repair at young age (median 3.7 [IQR 0.8–11.9] years) and was in NYHA functional class 
I (n = 534, 90%). NT-proBNP was signiﬁcantly higher in older patients, women, patients 
with initial repair at older age, patients with a complex type of congenital heart defect 
(tetralogy of Fallot, Rastelli, systemic right ventricle, univentricular heart or pulmonary 
arterial hypertension), patients who used cardiac medication, patients with low arterial 
oxygen saturation, and patients in NYHA class II–III. In addition, NT-proBNP was higher in 
patients with loss of sinus rhythm, longer QRS duration, higher left atrial volume, higher 
left ventricular volumes, and impaired ventricular systolic and diastolic function (Table 
1). Baseline characteristics stratiﬁed according to quartiles of hs-TnT and GDF-15 are 
further detailed in Supplemental Tables 1 and 2, and the correlation of NT-proBNP, hs-
TnT and GDF-15 with baseline characteristics is presented in Table 2. Biomarker values 
in the diagnostic subgroups are shown in Supplemental Figure 2.
Follow-up
At the end of the follow-up (August 1, 2015), survival status was known in 593 patients 
(99.7%) and unknown in two patients (0.3%) who emigrated. Detailed follow-up data 
were available in 587 patients (98.7%). During a median follow-up period of 41.8 [IQR 
36.6–46.1] months, the primary composite endpoint of a cardiovascular event occurred 
in 165 patients (28%) and the secondary composite endpoint of death or heart failure 
in 50 patients (8%). In total, 12 patients died. Causes of death were end-stage heart 
failure (n = 6), cardiac arrest (n = 3), sudden death, presumed cardiac (n = 2), and other 
(n = 1). Forty-six patients developed heart failure requiring hospitalization (n = 23) or 
medication change or initiation (n = 23). A total of 125 patients were hospitalized 157 
times for cardiac reasons: percutaneous (n = 55) or surgical (n = 38) re-intervention, 
heart failure (n = 23), arrhythmia (n = 11), thromboembolic event (n = 9), endocarditis 
(n = 8), and other (n = 13). A total of 90 patients had an arrhythmia: supraventricular 
tachycardia (n = 64), ventricular tachycardia (n = 14), ventricular ﬁbrillation (n = 6), and 
other (n = 6). Twenty patients had a thromboembolic event: ischemic cerebrovascular 
accident (n = 11), pulmonary embolism (n = 3), myocardial infarction (n = 3), and other 
(n = 3). Kaplan-Meier estimates of event-free survival were 87% at year one, 79% at year 
two and 74% at year three. Heart-failure-free survival was 96% at year one, 94% at year 
two and 92% at year three. 
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FIGURE 1 - Cardiovascular event-free survival and heart failure-free survival, stratified according to quartiles of NT-
proBNP, hs-TnT, and GDF-15.
NT-proBNP: ﬁrst quartile < 6.8 pmol/L (n = 150), second quartile 6.8–15.2 pmol/L (n = 148), third quartile 15.2–
33.3 pmol/L (n = 148), fourth quartile > 33.3 pmol/L (n = 149). Hs-TnT: ﬁrst quartile < 3 ng/L (n = 196), second 
quartile 3–4.8 ng/L (n = 131), third quartile 4.8–7.7 ng/L (n = 131), fourth quartile > 7.7 ng/L (n = 131). GDF-15: 
ﬁrst quartile < 487 ng/L (n = 148), second quartile 487–618 ng/L (n = 147), third quartile 618–867 ng/L (n = 
147), fourth quartile > 867 ng/L (n = 147).
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N-terminal pro-B-type natriuretic peptide
In Figure 1, Kaplan-Meier curves show the cardiovascular event-free survival and heart-
failure free survival stratiﬁed according to NT-proBNP quartiles. These Kaplan-Meier 
curves are presented including 95% conﬁdence intervals in Supplemental Figure 3. 
In patients with a NT-proBNP level below the median (< 15.2 pmol/L) the cumulative 
proportion of death and heart failure was 1%. Table 3 further details the number of 
events, person-years and hazard ratios per NT-proBNP quartile. Figure 2 shows the 
HRs for the primary and secondary endpoint when NT-proBNP was analyzed as a 
logarithmically transformed continuous variable (per standard deviation increase). 
These crude estimates did not materially change after multivariable adjustment for 
potential confounders. Besides age and sex, we considered age at surgical repair, 
congenital diagnosis, cardiac medication use, saturation, NYHA class, sinus rhythm, left 
atrial volume, left ventricular end-systolic volume, interventricular septum thickness, 
systemic ventricular function, and E’ wave as potential confounders, because these 
variables were also associated with the primary endpoint (Supplemental Table 3). 
Exploratory analysis of tertiary endpoints showed that NT-proBNP was signiﬁcantly 
associated with each separate component of the primary endpoint, with the exception 
of thromboembolic events (Supplemental Figure 4). A sensitivity analysis in which 
patients with the highest NT-proBNP values were excluded (patients with a systemic 
right ventricle, functionally univentricular heart or pulmonary arterial hypertension) did 
not yield diﬀerent conclusions.
TABLE 2 - Correlations coefficients (r) of NT-proBNP, hs-TnT and GDF-15 with clinical characteristics, electrocardiography, 
echocardiography and other laboratory measurements.
 NT-proBNP hs-TnT GDF-15
 r P-value r P-value r P-value
Clinical characteristics       
Age, years* 0.41 < 0.001 0.36 < 0.001 0.37 < 0.001
Sex, male −0.30 < 0.001 0.25 < 0.001 −0.23 < 0.001
Surgical repair 0.14 0.001 0.01 0.732 0.04 0.288
Age at surgical repair, years* 0.19 < 0.001 0.21 < 0.001 0.25 < 0.001
Congenital diagnosis† 0.35 < 0.001 0.13 0.002 0.16 < 0.001
Cardiac medication use 0.35 < 0.001 0.29 < 0.001 0.34 < 0.001
Body mass index, kg/m2 0.05 0.278 0.07 0.072 0.01 0.849
Heart rate, beats/minute −0.01 0.865 −0.04 0.306 0.10 0.015
Systolic blood pressure, mmHg −0.06 0.182 0.07 0.09 0.00 0.942
O
2
 saturation < 90% 0.19 < 0.001 0.09 0.040 0.13 0.003
NYHA class, II–III 0.37 < 0.001 0.23 < 0.001 0.32 < 0.001
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TABLE 2 - Continued.
 NT-proBNP hs-TnT GDF-15
 r P-value r P-value r P-value
Electrocardiogram       
Sinus rhythm −0.32 < 0.001 −0.25 < 0.001 −0.25 < 0.001
QRS duration, ms‡ 0.15 < 0.001 0.27 < 0.001  −0.00 0.947
Echocardiogram       
LA volume, mL/m2*‡ 0.30 < 0.001 0.22 < 0.001 0.15 0.002
LV end-diastolic volume, mL/m2‡ 0.18 < 0.001 0.21 < 0.001 0.00 1.00
LV end-systolic volume, mL/m2‡ 0.28 < 0.001 0.25 < 0.001 0.06 0.223
LV ejection fraction, %‡ −0.26 < 0.001 −0.19 < 0.001 −0.13 0.012
Interventricular septum, mm 0.11 0.022 0.27 < 0.001 0.04 0.436
Posterior wall, mm 0.02 0.647 0.17 < 0.001 −0.07 0.144
RV fractional area change, % −0.30 < 0.001  −0.21 < 0.001  −0.10 0.042
Systemic ventricular function, 0–3 0.43 < 0.001 0.24 < 0.001 0.18 < 0.001
E/A ratio  −0.01 0.882  −0.16 0.001 −0.13 0.007
E’ wave, cm/s −0.30 < 0.001  −0.21 < 0.001  −0.24 < 0.001
E/E’ ratio 0.36 < 0.001 0.13 0.011 0.17 < 0.001
Deceleration time, ms −0.09 0.056 0.06 0.266 −0.02 0.713
Laboratory results       
Hemoglobin, mmol/L −0.11 0.013 0.17 < 0.001 −0.10 0.026
Creatinine, μmol/L 0.07 0.112 0.34 < 0.001 0.26 < 0.001
NT-proBNP, pmol/L 0.42 < 0.001 0.50 < 0.001
hs-TnT, ng/L 0.42 < 0.001 0.31 < 0.001
GDF-15, ng/L 0.50 < 0.001 0.31 < 0.001   
*Spearman’s correlation coeﬃcient, other Pearson’s correlation coeﬃcient. †Congenital diagnosis of aortic 
stenosis, aortic coarctation or arterial switch operation (0) versus tetralogy of Fallot, Rastelli, systemic 
RV or univentricular heart (1). ‡Left sided volumes were not measured in patients with a systemic right 
ventricle, functionally univentricular heart, pulmonary hypertension (n = 137) or a poor acoustic window. 
Abbreviations: GDF-15, growth-diﬀerentiation factor 15, hs-TnT, high-sensitive troponin-T; LA, left atrial; LV, 
left ventricular; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; RV, 
right ventricular.
High-sensitive troponin-T
The risk of the primary and secondary composite endpoint for patients in the fourth 
hs-TnT quartile (> 7.7 ng/L) was signiﬁcantly higher compared with patients in the ﬁrst 
quartile (< 3 ng/L) (Figure 1 and Table 3). Similar results were obtained when hs-TnT 
was analyzed as a logarithmically transformed continuous variable (Figure 2). When 
adjusted for potential confounders in the multivariable analysis, hs-TnT, as a categorical 
and continuous variable, was only predictive of the secondary endpoint.
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FIGURE 2 - Risk of the primary composite endpoint (any adverse cardiovascular event) and secondary composite 
endpoint (death or heart failure) for NT-proBNP, hs-TnT, and GDF-15, analyzed continuously.
Skewed biomarker distributions were log transformed. Hazard ratios are expressed per one standard 
deviation increase of the biomarker. *Adjusted for age (years), sex, congenital diagnosis (aortic stenosis, aortic 
coarctation or arterial switch operation (0) versus tetralogy of Fallot, Rastelli, systemic RV, univentricular heart 
or pulmonary arterial hypertension (1)), systemic ventricular function (0–3), age at surgical repair (years), 
cardiac medication use (yes/no), saturation < 90%, NYHA class II–III, sinus rhythm (yes/no), LA volume (mL/m2), 
LV end-systolic volume (mL/m2), E’ wave (cm/s), and interventricular septum thickness (mm). †Adjusted for 
age (years), sex, congenital diagnosis (aortic stenosis, aortic coarctation or arterial switch operation (0) versus 
tetralogy of Fallot, Rastelli, systemic RV or univentricular heart (1)), and systemic ventricular function (0–3).
Growth-differentiation factor 15
As presented in Figure 1 and Table 3, patients in the fourth GDF-15 quartile (> 867 
ng/L) had a signiﬁcantly higher risk of the primary and secondary composite endpoint 
compared with patients in the ﬁrst quartile (< 487 ng/L). Each standard deviation increase 
in GDF-15 was also associated with a higher risk of the primary and secondary endpoint 
(Figure 2). Multivariable adjustment yielded similar results, both in the categorical and 
continuous analysis. GDF-15 was signiﬁcantly related to each separate component 
of the primary endpoint, and was the only biomarker that was also associated with 
thromboembolic events (Supplemental Figure 4).
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TABLE 3 - Risk of the primary composite endpoint (cardiovascular event) and secondary composite endpoint (death or 
heart failure) according to NT-proBNP, hs-TnT and GDF-15 quartiles.
 
NT-proBNP (n = 595)
Q1 
(< 6.8 pmol/L, 
n = 150)
Q2 
(6.8–15.2 pmol/L, 
n = 148)
Q3 
(15.2–33.3 pmol/L, 
n = 148)
Q4 
(> 33.3 pmol/L, 
n = 149)
P for 
trend*
Cardiovascular event
   No. cases 17 26 33 89
   Person-months 5641 5247 5114 3801
   Crude HR (95% CI) Reference 1.63 (0.89–3.01) 2.14 (1.19–3.84) 7.31 (4.35–12.3) < 0.001
   Adjusted HR (95% CI)† Reference 1.63 (0.59–4.54) 2.93 (1.12–7.68) 9.05 (3.24–25.3) < 0.001
Death or heart failure
   No. cases 1 1 9 39
   Person-months 6053 6004 5741 5121
   Crude HR (95% CI) Reference 1.00 (0.06–16.1) 9.47 (1.20–74.7) 44.7 (6.14–326) < 0.001
   Adjusted HR (95% CI)‡ Reference 0.82 (0.05–13.1) 5.60 (0.69–45.4) 16.0 (2.04–126) < 0.001
 
hs-TnT (n = 589)  
Q1 
(< 3 ng/L, 
n = 196)
Q2 
(3–4.8 ng/L, 
n = 131)
Q3 
(4.8–7.7 ng/L, 
n = 131)
Q4 
(> 7.7 ng/L, 
n = 131)
P for 
trend*
Cardiovascular event
   No. cases 34 33 34 61
   Person-months 7070 4513 4391 3697
   Crude HR (95% CI) Reference 1.52 (0.94–2.45) 1.59 (0.99–2.56) 3.27 (2.15–4.97) < 0.001
   Adjusted HR (95% CI)† Reference 1.24 (0.54–2.87) 1.11 (0.46–2.69) 1.80 (0.75–4.35) 0.191
Death or heart failure
   No. cases 2 8 9 30
   Person-months 7951 5175 5050 4542
   Crude HR (95% CI) Reference 6.14 (1.30–28.9) 7.00 (1.51–32.4) 25.3 (6.05–106) < 0.001
   Adjusted HR (95% CI)‡ Reference 7.60 (1.59–36.2) 6.60 (1.39–31.5) 14.4 (3.21–64.4) < 0.001
 
GDF-15 (n = 589)  
Q1 
(< 487 ng/L,
n = 148)
Q2 
(487–618 ng/L, 
n = 147)
Q3 
(618–867 ng/L, 
n = 147)
Q4 
(> 867 ng/L, 
n = 147)
P for 
trend*
Cardiovascular event
   No. cases 23 32 41 66
   Person-months 5386 5231 4939 4134
   Crude HR (95% CI) Reference 1.44 (0.84–2.46) 1.94 (1.17–3.24) 3.63 (2.26–5.84) < 0.001
   Adjusted HR (95% CI)† Reference 1.03 (0.43–2.49) 1.15 (0.49–2.74) 2.77 (1.12–6.85) 0.007
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TABLE 3 - Continued. 
 
GDF-15 (n = 589)  
Q1 
(< 487 ng/L,
n = 148)
Q2 
(487–618 ng/L, 
n = 147)
Q3 
(618–867 ng/L, 
n = 147)
Q4 
(> 867 ng/L, 
n = 147)
P for 
trend*
Death or heart failure
   No. cases 1 6 12 30
   Person-months 5992 5849 5692 5244
   Crude HR (95% CI) Reference 6.14 (0.74–51.0) 12.6 (1.64–97.2) 33.7 (4.60–247) < 0.001
   Adjusted HR (95% CI)‡ Reference 4.33 (0.52–36.2) 6.58 (0.84–51.7) 12.4 (1.63–94.9) 0.001
*Computed by assigning the median level in each quartile to participants and evaluating this variable 
continuously. †The primary endpoint was adjusted for age (years), sex, congenital diagnosis (aortic stenosis, 
aortic coarctation or arterial switch operation (0) versus tetralogy of Fallot, Rastelli, systemic RV or univentricular 
heart (1)), systemic ventricular function (0–3), age at surgical repair (years), cardiac medication use (yes/no), 
saturation < 90%, NYHA class II–III, sinus rhythm (yes/no), LA volume (mL/m2), LV end-systolic volume (mL/
m2), E’ wave (cm/s), and interventricular septum thickness (mm). ‡The secondary endpoint was adjusted for 
age (years), sex, congenital diagnosis (aortic stenosis, aortic coarctation or arterial switch operation (0) versus 
tetralogy of Fallot, Rastelli, systemic RV, univentricular heart or pulmonary arterial hypertension (1)), and 
systemic ventricular function (0–3). Abbreviations: CI, conﬁdence interval; GDF-15, growth-diﬀerentiation 
factor 15; HR, hazard ratio; hs-TnT, high-sensitive Troponin-T; NT-proBNP, N-terminal pro-B-type natriuretic 
peptide.
Combination of NT-proBNP, hs-TnT, and GDF-15
To determine the prognostic value of a combination of the three biomarkers, patients 
were divided into four groups: no biomarkers elevated (n = 256), one biomarker 
elevated (n = 234), two biomarkers elevated (n = 70), and three biomarkers elevated 
(n = 22). In Figure 3, Kaplan-Meier curves stratiﬁed according to these four groups are 
presented. These Kaplan-Meier curves are presented including 95% conﬁdence intervals 
in Supplemental Figure 5. Patients with elevated levels of all three biomarkers were at 
highest risk of the primary and secondary composite endpoint. The number of events, 
person-months and hazard ratios in each group are also indicated in Table 4. In Figure 
4, the Kaplan-Meier estimates of cardiovascular event-free survival and heart-failure 
free survival according to more detailed subgroups are presented, also including the 
number of patients per cell. In patients with a low NT-proBNP level, hs-TnT and GDF-15 
were elevated only in a small number of patients. In patients with a high NT-proBNP 
level, hs-TnT and GDF-15 could further stratify the risk of the primary and secondary 
endpoint. When all three biomarkers were analyzed as logarithmically transformed 
continuous variables in a multivariable model, one standard deviation increase in NT-
proBNP (adjusted HR 1.85; 95% CI 1.51–2.25, p < 0.001) and GDF-15 (adjusted HR 1.20; 
95% CI 1.04–1.40, p = 0.014) was independently associated with the primary endpoint, 
but hs-TnT was not (adjusted HR 1.09; 95% CI 0.93–1.29, p = 0.286).
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TABLE 4 - Risk of the primary composite endpoint (cardiovascular event) and secondary composite endpoint (death or 
heart failure) according to the number of elevated biomarkers.
 
Combination of NT-proBNP, hs-TnT and GDF-15 (n = 582)  
No 
biomarkers 
elevated 
(n = 256)
One biomarker 
elevated 
(n = 234)
Two 
biomarkers 
elevated 
(n = 70)
Three 
biomarkers 
elevated 
(n = 22)
P for 
trend*
Cardiovascular event
   No. cases 33 75 37 15
   Person-months 9522 7668 1795 456
   Crude HR (95% CI) Reference 2.78 (1.85–4.19) 5.64 (3.52–9.02) 8.48 (4.59–15.7) < 0.001
   Adjusted HR (95% CI)† Reference 3.15 (1.54–6.43) 4.88 (1.67–14.3) 6.24 (1.57–24.8) 0.001
Death or heart failure
   No. cases 1 18 19 10
   Person-months 10401 9178 2296 611
   Crude HR (95% CI) Reference 20.4 (2.72–153) 83.4 (11.2–623) 157 (20.1–1230) < 0.001
   Adjusted HR (95% CI)‡ Reference 12.0 (1.56–92.4) 34.0 (4.26–272) 44.4 (5.05–391) < 0.001
No biomarkers elevated (n = 256): NT-proBNP < 14 pmol/L, hs-TnT < 14 ng/L and GDF-15 < 1109 ng/L. One 
biomarker elevated (n = 234): NT-proBNP > 14 pmol/L (n = 217) or hs-TnT > 14 ng/L (n = 4) or GDF-15 > 1109 
ng/L (n = 13).  Two biomarkers elevated (n = 70): NT-proBNP > 14 pmol/L (n = 70) and hs-TnT > 14 ng/L (n = 20) or 
GDF-15 > 1109 ng/L (n = 50). Three biomarkers elevated (n = 22): NT-proBNP > 14 pmol/L and hs-TnT > 14 ng/L 
and GDF-15 > 1109 ng/L. *Computed by evaluating the number of elevated biomarkers (0–3) as continuous 
variable. Others as deﬁned in Table 2.
 Receiver Operating Characteristic-curves present the discriminatory value of 
NT-proBNP, hs-TnT, and GDF-15 separately for the primary and secondary endpoint 
in Supplemental Figure 6. The sensitivity and 1–speciﬁcity for cut-oﬀs according to 
quartiles of distribution are indicated. A clinical risk marker model including only clinical 
variables (age, sex, age at surgical repair, congenital diagnosis, cardiac medication 
use, saturation, and NYHA class) yielded a C-index of 0.69 (95% CI 0.64–0.73) for the 
primary endpoint. Adding electrocardiography and echocardiography variables (sinus 
rhythm, left atrial volume, left ventricular end-systolic volume, interventricular septum 
thickness, systemic ventricular function, and E’ wave) led to a similar improvement in the 
C-index in comparison with adding biomarker variables (NT-proBNP, hs-TnT, and GDF-
15): 0.74 (95% CI 0.66–0.82) in comparison with 0.74 (95% CI 0.70–0.79), respectively. 
The full model including all variables yielded the highest C-index: 0.80 (95% CI 0.74–
0.87). The diﬀerences between the clinical model and the biomarker updated model (p 
= 0.001), the clinical model and the full model (p < 0.001), and the echocardiography 
updated model and the full model (p = 0.019) were statistically signiﬁcant, whereas 
the diﬀerence between the clinical model and the echocardiography updated model 
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was not (p = 0.057). In comparison with the clinical risk marker model, the integrated 
discrimination improvement (reﬂecting the change in discrimination slope) was 0.07 
(95% CI –0.01 to 0.17) for the echocardiography updated model, 0.08 (95% CI 0.00–0.21) 
for the biomarker updated model, and 0.12 (95% CI 0.02–0.27) for the full model.
FIGURE 3 - Cardiovascular event-free survival and heart failure-free survival, stratified according to the number of 
elevated biomarkers.
No biomarkers elevated (n = 256): NT-proBNP < 14 pmol/L, hs-TnT < 14 ng/L and GDF-15 < 1109 ng/L. One 
biomarker elevated (n = 234): NT-proBNP > 14 pmol/L (n = 217) or hs-TnT > 14 ng/L (n = 4) or GDF-15 > 1109 
ng/L (n = 13).  Two biomarkers elevated (n = 70): NT-proBNP > 14 pmol/L (n = 70) and hs-TnT > 14 ng/L (n = 20) 
or GDF-15 > 1109 ng/L (n = 50). Three biomarkers elevated (n = 22): NT-proBNP > 14 pmol/L and hs-TnT > 14 
ng/L and GDF-15 > 1109 ng/L.
 Cardiovascular event-free survival       
 NTproBNP low NTproBNP high   
 hs-TnT low hs-TnT high hs-TnT low hs-TnT high   
GDF-15 high 69 (n=13) NA (n=0) 38 (n=50) 27 (n=22)   
GDF-15 low 86 (n=256) 75 (n=4) 65 (n=217) 47 (n=20)   
    
  Heart failure-free survival   
  NTproBNP low NTproBNP high Legend:   
  hs-TnT low hs-TnT high hs-TnT low hs-TnT high   < 50% 
GDF-15 high 100 (n=13) NA (n=0) 71 (n=50) 51 (n=22)   50-85% 
GDF-15 low 100 (n=256) 100 (n=4) 91 (n=217) 67 (n=20)   >85% 
FIGURE 4 - Kaplan-Meier estimates of cardiovascular event-free survival and heart-failure free survival at the end of 
the follow-up duration, stratified according to elevated versus non-elevated levels of NT-proBNP, hs-TnT, and GDF-15.
The number of patients in each cell is indicated. Abbreviations: GDF-15, growth-diﬀerentiation factor 15; 
hs-TnT, high-sensitive troponin-T; NA, not applicable; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
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DISCUSSION
This study evaluated the prognostic value of NT-proBNP, hs-TnT, and GDF-15 in clinically 
stable patients with ACHD. NT-proBNP was strongly associated with cardiovascular 
events, independently of clinical characteristics and electrocardiographic and 
echocardiographic measurements. Especially the risk of death or heart failure was 
extremely low in patients in the lowest two NT-proBNP quartiles (< 15.2 pmol/L). The 
risk of patients with a high level of NT-proBNP could be further diﬀerentiated by the 
combined use of hs-TnT and GDF-15. Patients with elevated levels of all three biomarkers 
were at highest risk of cardiovascular events.
Previous reports
This is the ﬁrst large and prospective cohort study investigating the association of NT-
proBNP with a combined endpoint of cardiovascular events in patients with ACHD. 
Because the detection of early deterioration is of particular interest, it is important 
that, apart from mortality, other endpoints are also investigated. In this study, NT-
proBNP was analyzed both as a categorical and as a continuous variable. Furthermore, 
the completeness of data due to the prospective design and the adequate event size 
allowed us to adjust for multiple clinical and echocardiographic variables, which has 
not previously been performed. All these diﬀerent analyses yielded similar results with 
a high degree of certainty. 
 The results of this study are concordant with the recently published paper by 
Popelová et al., who reported that a NT-proBNP value of > 630 pg/mL (corresponding 
to 74 pmol/L)31 was associated with mortality in a large cohort of patients with stable 
ACHD (n = 646).32 B-type natriuretic peptide (BNP) was also associated with mortality 
in two smaller cohorts of patients with ACHD.33, 34 In 83 patients with tetralogy of Fallot, 
Heng et al.35 recently showed that BNP was a strong predictor of death and sustained 
arrhythmia in univariable analysis. Westhoﬀ-Bleck et al.36 and Haberger et al.37 both 
found a signiﬁcant association of natriuretic peptides with a combined endpoint 
(‘hospitalization for any clinical event’ and ‘heart failure, transplant and death’) in 
patients with a systemic right ventricle (n = 116 and n = 89, respectively). In contrast, 
two earlier studies in small cohorts of patients with a systemic right ventricle or Fontan 
circulation did not ﬁnd a prognostic merit of NT-proBNP and BNP.38, 39 
 What makes our study unique and innovative is that we found a predictive value 
of hs-TnT and GDF-15 on top of NT-proBNP in patients with ACHD. To our knowledge, 
hs-TnT has only been reported as a predictor of mortality in patients with pulmonary 
arterial hypertension due to congenital heart disease.40 Prospective data on hs-TnT in 
other types of ACHD and prospective data on GDF-15 are not available. 
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Comparison of NT-proBNP, hs-TnT and GDF-15
Signiﬁcant correlations were present between NT-proBNP and GDF-15 (r = 0.50), and NT-
proBNP and hs-TnT (r = 0.42). This reﬂects a moderate overlap between the biomarkers, 
and may also explain why hs-TnT was not predictive of the primary endpoint when 
analyzed in a multivariable model including NT-proBNP and GDF-15. Notably however, 
the biomarker concentrations were signiﬁcantly diﬀerent among speciﬁc patient 
subgroups. For instance, NT-proBNP and GDF-15 were higher in women, while hs-
TnT was higher in men. These diﬀerences have also been described in the general 
population.41, 42 We observed that NT-proBNP and GDF-15 values were high in patients 
with a Fontan circulation, whereas hs-TnT was much lower. NT-proBNP and hs-TnT were 
related to QRS duration, left ventricular volumes, and interventricular septum thickness, 
and GDF-15 was not. Last, GDF-15 was the only biomarker that was also associated 
with thromboembolic events. Considering NT-proBNP (myocardial wall stress) and hs-
TnT (cardiomyocyte damage) primarily as cardiac markers, GDF-15 may therefore also 
reﬂect extra-cardiac pathophysiological mechanisms that are involved in the heart 
failure syndrome.22 These diﬀerences could also explain why these biomarkers seem to 
provide incremental prognostic information when used in combination.
Clinical implications
Measurement of natriuretic peptides should be considered to diagnose heart failure and 
to obtain prognostic information, according to the 2012 European Society of Cardiology 
guidelines for the diagnosis and treatment of acute and chronic heart failure25 and the 
2013 American College of Cardiology/American Heart Association guideline for the 
management of heart failure.43 In the 2010 European Society of Cardiology guidelines for 
the management of grown-up congenital heart disease, no recommendations are made 
regarding the use of any biomarker.44 This is not surprising as no substantial evidence 
was available at that time. It is important to note that the results of our study imply that 
NT-proBNP may play an important role in the risk stratiﬁcation of patients with stable 
ACHD who are seen at the outpatient clinic, independently of other currently used tools 
such as echocardiography. Considering the high negative predictive value, NT-proBNP 
may be particularly valuable as a screening tool. Patients with a low NT-proBNP can be 
reassured and will need less frequent monitoring and diagnostic examinations at the 
outpatient clinic. This could lead to important cost reductions in healthcare. High-risk 
patients may be more accurately identiﬁed by the combined use of NT-proBNP, hs-TnT, 
and GDF-15. These biomarkers therefore may play an important role in the monitoring 
and management of the rapidly growing population of patients with ACHD. 
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Future perspectives
In order to be clinically useful, a biomarker should meet three fundamental criteria, 
according to previously formulated benchmarks for the assessment of novel 
cardiovascular biomarkers.45 Analytical methods should allow reliable measurement 
at a reasonable cost; the biomarker should be consistently and strongly associated 
with outcomes (independent of, or superior to established tools); and it should help 
the clinician to manage patients. NT-proBNP and hs-TnT assays are known to have a 
good analytic performance and precision,26, 46, 47 and this study provides evidence for 
a strong association with clinical outcomes in patients with ACHD. To satisfy the last 
criterion, there should be evidence that the associated risk is modiﬁable with speciﬁc 
therapy or that biomarker-based therapy enhances care. In non-congenital patients 
with heart failure, it has been shown that biomarker-guided treatment results in 
better outcome than clinically guided therapy, although conﬂicting data have been 
reported.48 Such studies have not yet been performed in patients with ACHD and will be 
the next step to further unravel the value of biomarker-based therapy and to improve 
the clinical management of these patients. It could also be worthwhile to investigate 
the value of these biomarkers in other forms of structural heart disease, such as 
hypertrophic cardiomyopathy. Future research should investigate whether individual 
changes in biomarkers over time can reﬂect progression of disease or response to 
successful interventions, and if serial biomarker assessment can further enhance the 
prognostication of patients with ACHD.  
Study limitations
Patients with ACHD obviously compose a heterogeneous group. Due to the limited 
number of events, it was not possible to perform a stratiﬁed analysis in all diagnostic 
subgroups. The secondary composite endpoint could not be adjusted for the complete 
set of potential confounders. Some potential confounders were categorized, such as 
systemic ventricular function. All of this may have resulted in residual confounding. In 
addition, patients with mild cardiac lesions were not included in this study, which may 
aﬀect the external validity of these results. This study reports follow-up data during a 
median of 42 months, which may be considered relatively short. Therefore, it is important 
that these results are conﬁrmed in other cohorts with a longer follow-up duration. 
CONCLUSIONS
NT-proBNP provides prognostic information beyond a conventional risk marker model 
in patients with ACHD. Of particular importance, patients with a low risk of death and 
heart failure can be accurately identiﬁed with a high negative predictive value. This can 
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reassure patients and could lead to important cost reductions in healthcare. In patients 
with high NT-proBNP levels, hs-TnT and GDF-15 assessment further identiﬁes those 
patients at highest risk of cardiovascular events. This will enable further optimization 
of individual follow-up strategies and timely initiation or expansion of therapeutic 
measures.
CLINIC AL PERSPEC TIVE
What is new?
% This is the ﬁrst large and prospective study showing that N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) is associated with a composite endpoint of 
cardiovascular events in patients with adult congenital heart disease, independently 
of multiple clinical and echocardiographic variables. 
% Patients with a low risk of death and heart failure can be accurately identiﬁed with a 
high negative predictive value. 
% The risk of patients with a high level of NT-proBNP could be further diﬀerentiated by 
adding high-sensitive troponin-T and growth-diﬀerentiation factor 15. 
% Accordingly, patients with elevated levels of all three biomarkers were at highest risk 
of cardiovascular events.
What are the clinical implications?
% The results of our study suggest that NT-proBNP may play an important role in the 
risk stratiﬁcation of patients with adult congenital heart disease, independently of 
other currently used tools such as echocardiography. 
% The high negative predictive value makes NT-proBNP particularly valuable as a 
screening tool. 
% Patients with a low NT-proBNP can be reassured and will need less frequent 
monitoring and diagnostic examinations at the outpatient clinic, which could lead 
to important cost reductions in healthcare. 
% The combined use of NT-proBNP, high-sensitive troponin-T, and growth-
diﬀerentiation factor 15 may further aid in the optimization of follow-up strategies 
and timing of re-interventions.
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SUPPLEMENTAL MATERIAL
SUPPLEMENTAL TABLE 1 - Baseline characteristics of the study cohort according to hs-TnT quartiles.
 
hs-TnT quartiles (n = 589)
Q1 
(< 3 ng/L, 
n = 196)
Q2 
(3–4.8 ng/L, 
n = 131)
Q3 
(4.8–7.7 ng/L, 
n = 131)
Q4 
(> 7.7 ng/L, 
n = 131)
P for 
trend
Clinical characteristics      
Age, years 29 [23–34] 33 [24–40] 34 [26–45] 40 [33–51] < 0.001
Sex, male n (%) 71 (36) 87 (66) 97 (74) 86 (66) < 0.001
Surgical repair, n (%) 175 (89) 122 (93) 118 (90) 120 (92) 0.616
Age at surgical repair, years 2.0 [0.5–6.6] 4.4 [0.8–15.1] 5.1 [0.8–12.4] 6.3 [1.8–17.0] < 0.001
Congenital diagnosis, n (%)* 97 (49) 63 (48) 77 (59) 83 (63) 0.005
Cardiac medication use, n (%) 42 (21) 38 (29) 54 (41) 76 (58) < 0.001
Body mass index, kg/m2 24.4 ± 4.2 24.8 ± 4.6 25.1 ± 3.8 25.0 ± 5.0 0.126
Heart rate, beats/minute 75 ± 13 74 ± 14 72 ± 12 73 ± 15 0.078
Systolic blood pressure, mmHg 124 ± 14 125 ± 17 128 ± 15 128 ± 19 0.017
O
2
 saturation < 90%, n (%) 3 (2) 2 (2) 5 (4) 6 (5) 0.054
NYHA class, II–III n (%) 8 (4) 11 (8) 11 (8) 30 (23) < 0.001
Electrocardiogram      
Sinus rhythm, n (%) 184 (94) 113 (86) 119 (91) 92 (70) < 0.001
QRS duration, ms 105 [95–121] 113 [101–133] 121 [105–152] 124 [103–157] < 0.001
Echocardiogram      
LA volume, mL/m2† 20 [14–27] 20 [15–27] 21 [16–28] 28 [18–45] < 0.001
LV end-diastolic volume, mL/m2† 60 ± 15 62 ± 16 65 ± 22 70 ± 23 < 0.001
LV end-systolic volume, mL/m2† 26 ± 8 27 ± 12 29 ± 13 34 ± 18 < 0.001
LV ejection fraction, %† 57 ± 6 56 ± 8 56 ± 7 53 ± 11 0.001
Interventricular septum, mm 8.5 ± 1.5 9.1 ± 2.0 9.8 ± 2.4 9.9 ± 2.3 < 0.001
Posterior wall, mm 8.4 ± 1.3 9.0 ± 1.4 9.3 ± 1.8 9.0 ± 1.8 < 0.001
RV fractional area change, % 40 ± 11 40 ± 10 38 ± 11 34 ± 12 < 0.001
Systemic ventricular function, n (%) < 0.001
   Normal 166 (59) 66 (50) 66 (50) 49 (38)
   Mildly impaired 64 (33) 53 (40) 43 (33) 46 (35)
   Moderately impaired 14 (7) 10 (8) 20 (15) 24 (18)
   Severely impaired 2 (1) 2 (2) 2 (2) 12 (9)
E/A ratio 1.8 ± 0.8 1.6 ± 0.5 1.6 ± 0.6 1.5 ± 0.6 0.001
E’ wave, cm/s 8.8 ± 2.5 8.5 ± 2.3 7.8 ± 2.6 7.3 ± 2.7 < 0.001
E/E’ ratio 11.0 ± 4.7 11.0 ± 4.3 12.1 ± 5.2 13.0 ± 6.2 0.004
Deceleration time, ms 200 ± 59 202 ± 58 206 ± 56 212 ± 60 0.153
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SUPPLEMENTAL TABLE 1 - Continued.
 
hs-TnT quartiles (n = 589)
Q1 
(< 3 ng/L, 
n = 196)
Q2 
(3–4.8 ng/L, 
n = 131)
Q3 
(4.8–7.7 ng/L, 
n = 131)
Q4 
(> 7.7 ng/L, 
n = 131)
P for 
trend
Laboratory results      
Hemoglobin, mmol/L 9.0 ± 0.8 9.3 ± 1.0 9.4 ± 0.9 9.4 ± 1.2 < 0.001
Creatinine, μmol/L 71 ± 12 77 ± 13 78 ± 13 85 ± 28 < 0.001
SUPPLEMENTAL TABLE 2 - Baseline characteristics of the study cohort according to GDF-15 quartiles.
GDF-15 quartiles (n = 589)
 
Q1 
(< 487 ng/L, 
n = 148)
Q2 
(487–618 ng/L, 
n = 147)
Q3 
(618–867 ng/L, 
n = 147)
Q4 
(> 867 ng/L, 
n = 147)
P for 
trend
Clinical characteristics      
Age, years 28 [22–34] 32 [25–40] 34 [26–42] 40 [30–50] < 0.001
Sex, male n (%) 98 (66) 106 (72) 81 (55) 59 (40) < 0.001
Surgical repair, n (%) 135 (91) 129 (88) 134 (91) 137 (93) 0.382
Age at surgical repair, years 1.7 [0.3–7.3] 2.8 [0.8–12.3] 4.0 [0.6–12.0] 7.5 [2.5–15.9] < 0.001
Congenital diagnosis, n (%)* 71 (48) 72 (49) 85 (58) 93 (63) 0.003
Cardiac medication use, n (%) 20 (14) 49 (33) 55 (37) 85 (58) < 0.001
Body mass index, kg/m2 24.3 ± 4.1 25.1 ± 4.3 24.6 ± 4.1 25.0 ± 4.8 0.338
Heart rate, beats/minute 71 ± 14 73 ± 12 74 ± 13 75 ± 13 0.012
Systolic blood pressure, mmHg 125 ± 15 127 ± 15 125 ± 17 128 ± 18 0.332
O
2
 saturation < 90%, n (%) 2 (1) 1 (1) 7 (5) 7 (5) 0.024
NYHA class, II–III n (%) 7 (5) 7 (5) 14 (10) 33 (22) < 0.001
Electrocardiogram      
Sinus rhythm, n (%) 138 (93) 134 (91) 127 (86) 109 (74) < 0.001
QRS duration, ms 111 [99–130] 117 [103–136] 111 [98–140] 114 [98–144] 0.183
Echocardiogram      
LA volume, mL/m2† 19 [15–27] 21 [15–27] 22 [16–31] 23 [16–37] < 0.001
LV end-diastolic volume, mL/m2† 65 ± 20 63 ± 19 61 ± 18 65 ± 19 0.904
LV end-systolic volume, mL/m2† 29 ± 13 28 ± 12 27 ± 11 31 ± 15 0.401
LV ejection fraction, %† 56 ± 7 57 ± 8 57 ± 7 54 ± 9 0.045
Interventricular septum, mm 8.9 ± 1.7 9.6 ± 2.2 9.1 ± 2.3 9.2 ± 2.2 0.453
Posterior wall, mm 8.8 ± 1.6 9.1 ± 1.6 8.9 ± 1.8 8.5 ± 1.3 0.130
RV fractional area change, % 39 ± 10 39 ± 11 39 ± 13 36 ± 11 0.205
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SUPPLEMENTAL TABLE 2 - Continued.
GDF-15 quartiles (n = 589)
 
Q1 
(< 487 ng/L, 
n = 148)
Q2 
(487–618 ng/L, 
n = 147)
Q3 
(618–867 ng/L, 
n = 147)
Q4 
(> 867 ng/L, 
n = 147)
P for 
trend
Echocardiogram
Systemic ventricular function, n (%) < 0.001
   Normal 86 (58) 80 (54) 75 (51) 57 (39)
   Mildly impaired 50 (34) 45 (31) 51 (35) 58 (39)
   Moderately impaired 10 (7) 17 (12) 16 (11) 26 (18)
   Severely impaired 2 (1) 5 (3) 5 (3) 6 (4)
E/A ratio 1.8 ± 0.7 1.6 ± 0.5 1.7 ± 0.8 1.5 ± 0.6 0.009
E’ wave, cm/s 8.9 ± 2.5 8.5 ± 2.4 8.2 ± 2.7 7.1 ± 2.6 < 0.001
E/E’ ratio 10.5 ± 4.1 11.2 ± 5.1 11.6 ± 4.5 13.5 ± 6.2 < 0.001
Deceleration time, ms 206 ± 58 202 ± 56 209 ± 64 198 ± 54 0.491
Laboratory results      
Hemoglobin, mmol/L 9.3 ± 0.8 9.3 ± 0.8 9.2 ± 1.1 9.1 ± 1.2 0.083
Creatinine, μmol/L 76 ± 13 76 ± 12 74 ± 12 82 ± 27 0.008
Legend Supplemental Tables 1,2: Values are reported as median [IQ1–IQ3], otherwise as n (%) or mean ± SD. 
Diﬀerences across biomarker quartiles are analysed using the chi-square Mantel-Haenszel test for categorical 
variables, otherwise using linear regression. *Congenital diagnosis of aortic stenosis, aortic coarctation or 
arterial switch operation (0) versus tetralogy of Fallot, Rastelli, systemic RV or univentricular heart (1). †Left 
sided volumes were not measured in patients with a systemic right ventricle, functionally univentricular heart, 
pulmonary hypertension (n = 137) or a poor acoustic window. Abbreviations (Supplemental Tables 1,2): 
GDF-15, growth-diﬀerentiation factor 15, hs-TnT, high-sensitive troponin-T; LA, left atrial; LV, left ventricular; 
NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; RV, right ventricular.
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SUPPLEMENTAL TABLE 3 - Risk of the primary composite endpoint (cardiovascular event) and secondary composite 
endpoint (death or heart failure) for other baseline characteristics.
 
 
Cardiovascular event (n = 165) Death or heart failure (n = 50)
Crude HR (95% CI) P-value Crude HR (95% CI) P-value
Clinical characteristics     
Age, years 1.03 (1.02-1.05) < 0.001 1.07 (1.05-1.09) < 0.001
Sex, male 1.13 (0.83-1.53) 0.446 1.81 (1.03-3.16) 0.038
Surgical repair, yes 1.01 (0.59-1.72) 0.972 0.90 (0.36-2.28) 0.830
Age at surgical repair, years 1.02 (1.01-1.03) < 0.001 1.03 (1.02-1.05) < 0.001
Congenital diagnosis* 1.87 (1.35-2.59) < 0.001 3.99 (1.94-8.21) < 0.001
Cardiac medication use 3.41 (2.50-4.66) < 0.001 15.4 (6.57-36.2) < 0.001
Body mass index, kg/m2 1.02 (0.99-1.06) 0.225 1.09 (1.04-1.15) 0.001
Heart rate, beats/minute 1.00 (0.99-1.01) 0.837 1.02 (1.00-1.04) 0.125
Systolic blood pressure, mmHg 0.99 (0.99-1.00) 0.250 1.01 (0.99-1.02) 0.509
O
2
 saturation < 90% 2.54 (1.29-4.98) 0.007 4.51 (1.79-11.4) 0.001
NYHA class, II–III 4.63 (3.26-6.57) < 0.001 9.63 (5.52-16.8) < 0.001
Electrocardiogram     
Sinus rhythm 0.37 (0.26-0.53) < 0.001 0.21 (0.12-0.37) < 0.001
QRS duration, ms 1.01 (1.00-1.01) 0.004 1.01 (1.00-1.02) 0.052
Echocardiogram     
LA volume, mL/m2 1.03 (1.02-1.03) < 0.001 1.02 (1.01-1.03) < 0.001
LV end-diastolic volume, mL/m2 1.02 (1.01-1.03) 0.002 1.03 (1.01-1.05) < 0.001
LV end-systolic volume, mL/m2 1.03 (1.02-1.04) < 0.001 1.04 (1.03-1.06) < 0.001
LV ejection fraction, % 0.96 (0.94-0.98) < 0.001 0.92 (0.89-0.95) < 0.001
Interventricular septum, mm 1.11 (1.02-1.20) 0.011 1.17 (1.02-1.34) 0.021
Posterior wall, mm 1.06 (0.95-1.19) 0.312 1.13 (0.92-1.39) 0.243
RV fractional area change, % 0.98 (0.96-1.00) 0.024 0.94 (0.91-0.97) < 0.001
Systemic ventricular function, 0–3 1.60 (1.35-1.89) < 0.001 2.22 (1.68-2.94) < 0.001
E/A ratio 0.81 (0.58-1.11) 0.191 0.38 (0.15-0.97) 0.043
E’ wave, cm/s 0.77 (0.70-0.85) < 0.001 0.53 (0.42-0.68) < 0.001
E/E’ ratio 1.06 (1.02-1.09) 0.001 1.10 (1.04-1.16) 0.001
Deceleration time, ms 1.00 (1.00-1.00) 0.504 1.00 (0.99-1.00) 0.260
Laboratory results†     
Hemoglobin, mmol/L 0.94 (0.79-1.12) 0.498 0.74 (0.54-1.01) 0.057
Creatinine, μmol/L 1.16 (1.03-1.31) 0.017 1.20 (1.00-1.44) 0.047
*Congenital diagnosis of aortic stenosis, aortic coarctation or arterial switch operation (0) versus tetralogy 
of Fallot, Rastelli, systemic RV or univentricular heart (1). †Expressed per one standard deviation increase in 
biomarker. Abbreviations: as deﬁned in Supplemental Tables 1,2.
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2.533 unique patients with one or more visits to the adult congenital 
cardiology outpatient clinic (April 5, 2011 – April 16, 2013) 
602 patients enrolled in study cohort 
267 patients without echocardiogram not approached 
1.664  patients not approached due to: age < 18 years, pregnancy, mild cardiac 
lesion (isolated atrial or ventricular septal defect), not capable of understanding 
and signing informed consent, refusal to participate in study (< 5% of patients), 
no routine visit, random administrative reasons 
595 patients with  
NT-proBNPmeasurement 
589 patients with 
Troponin-T  measurement
589 patients with GDF -15 
measurement 
582 patients with NT-proBNP and Troponin-T and GD F-15 
measurement  
SUPPLEMENTAL FIGURE 1- Flowchart of the selection of patients.
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SUPPLEMENTAL FIGURE 2 - NT-proBNP, hs-TnT and GDF-15 levels in the different congenital diagnoses.
Abbreviations: REV, réparation à l’etage ventriculaire; ccTGA, congenitally corrected transposition of the 
great arteries; PAH, pulmonary arterial hypertension.
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SUPPLEMENTAL FIGURE 3 - Cardiovascular event-free survival and heart failure-free survival, stratified according to 
quartiles of NT-proBNP, hs-TnT and GDF-15. 95% confidence intervals are indicated.
NT-proBNP: First quartile < 6.8 pmol/L, n = 150, Second quartile 6.8-15.2 pmol/L, n = 148, Third quartile 15.2-
33.3 pmol/L, n = 148, Fourth quartile > 33.3 pmol/L, n = 149. Hs-TnT: First quartile < 3 ng/L, n = 196, Second 
quartile 3-4.8 ng/L, n = 131, Third quartile 4.8-7.7 ng/L, n = 131, Fourth quartile > 7.7 ng/L, n = 131. GDF-15: 
First quartile < 487 ng/L, n = 148, Second quartile 487-618 ng/L, n = 147, Third quartile 618-867 ng/L, n = 147, 
Fourth quartile > 867 ng/L, n = 147.
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SUPPLEMENTAL FIGURE 4 - Exploratory analysis of tertiary endpoints. 
Each component of the primary composite endpoint was separately assessed for NT-proBNP, hs-TnT and 
GDF-15. Skewed biomarker distributions were logtransformed. Hazard ratios are expressed per one standard 
deviation increase of the biomarker.
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SUPPLEMENTAL FIGURE 5 - Cardiovascular event-free survival and heart failure-free survival, stratified according to 
the number of elevated biomarkers. 95% confidence intervals are indicated.
No biomarkers elevated (n = 256): NT-proBNP < 14 pmol/L, hs-TnT < 14 ng/L and GDF-15 < 1109 ng/L. One 
biomarker elevated (n = 234): NT-proBNP > 14 pmol/L (n = 217) or hs-TnT > 14 ng/L (n = 4) or GDF-15 > 1109 
ng/L (n = 13).  Two biomarkers elevated (n = 70): NT-proBNP > 14 pmol/L (n = 70) and hs-TnT > 14 ng/L (n = 20) 
or GDF-15 > 1109 ng/L (n = 50). Three biomarkers elevated (n = 22): NT-proBNP > 14 pmol/L and hs-TnT > 14 
ng/L and GDF-15 > 1109 ng/L.
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SUPPLEMENTAL FIGURE 6 - Receiver Operating Characteristic-Curves showing the discriminative ability of NT-
proBNP, hs-TnT and GDF-15 for the primary composite endpoint (cardiovascular event) and secondary composite 
endpoint (death or heart failure). The sensitivity and 1-specificity for cut-offs according to quartiles of distribution is 
indicated. 
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ABSTRAC T
Background Galectin-3 is an emerging biomarker for risk stratiﬁcation in heart failure 
patients. This study aims to investigate the release of galectin-3 and its 
association with cardiovascular events in patients with adult congenital 
heart disease (ACHD).
Methods In this prospective cohort study, 602 consecutive patients with ACHD 
who routinely visited the outpatient clinic were enrolled between 2011 
and 2013. Galectin-3 was measured in thaw serum by batch analysis. 
The association between galectin-3 and a primary endpoint of all-cause 
mortality, heart failure, hospitalisation, arrhythmia, thromboembolic 
events, and cardiac interventions was investigated using multivariable 
Cox models. Reference values and reproducibility were established by 
duplicate galectin-3 measurements in 143 healthy controls.
Results  Galectin-3 was measured in 591 (98%) patients (median age 33 [25–41] 
years, 58% male, 90% NYHA I). Median galectin-3 was 12.7 [range 4.2–
45.7] ng/mL, and was elevated in 7% of patients. Galectin-3 positively 
correlated with age, cardiac medication use, NYHA class, loss of sinus 
rhythm, cardiac dysfunction, and NT-proBNP. During a median follow-up 
of 4.4 [IQR 3.9–4.8] years, the primary endpoint occurred in 195 patients 
(33%). Galectin-3 was signiﬁcantly associated with the primary endpoint 
in the univariable analysis (HR per two-fold higher value 2.05; 95% CI 
1.44–2.93, p < 0.001). This association was negated after adjustment for 
NT-proBNP (HR 1.04; 95% CI 0.72–1.49, p = 0.848).
Conclusions Galectin-3 is signiﬁcantly associated with functional capacity, cardiac 
function, and adverse cardiovascular events in patients with ACHD. 
Nevertheless, the additive value of galectin-3 to a more conventional risk 
marker such as NT-proBNP seems to be limited.
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INTRODUC TION
The protein galectin-3 belongs to an ancient lectin family, which is characterized by 
its binding capacity for beta-galactosides. It is present in numerous cell and tissue 
types, and plays an important role in cell adhesion, cell activation, cell growth and 
diﬀerentiation, and apoptosis. Given this wide variety of biological roles, galectin-3 
is known to be involved in a broad range of pathophysiological processes, including 
cancer, inﬂammation, and ﬁbrosis.1 Currently, galectin-3 is in the spotlight as an 
emerging biomarker in patients with cardiac disease. Circulating levels have been shown 
to provide prognostic information in patients with acute and chronic heart failure, 
independently of other established markers such as natriuretic peptides.2-4 Galectin-3 
has even been included in the ACCF/AHA guideline for additive risk stratiﬁcation of 
patients with acute and chronic heart failure.5
 In contrast to the “tsunami” of biomarker research in the heart failure realm,6 
biomarkers are only making their ﬁrst steps in the clinical management of patients with 
adult congenital heart disease (ACHD). Natriuretic peptides are now gaining increasing 
interest in these patients;7-9 however, data on emerging biomarkers such as galectin-3 are 
yet sparse. It is unknown whether galectin-3 provides prognostic information in patients 
with ACHD and whether it could be useful for risk stratiﬁcation beyond conventional risk 
markers. This study therefore investigated the release of galectin-3 and its association 
with cardiovascular events in patients with moderate and complex ACHD. In addition, we 
established reference values and reproducibility of galectin-3 in healthy controls.
METHODS
Study design and population
In this prospective cohort study, consecutive adults with moderate or complex congenital 
heart disease10 who routinely visited our ACHD outpatient clinic were included between 
April 2011 and April 2013. Exclusion criteria were: age < 18 years, pregnancy, mild 
cardiac lesion (isolated atrial or ventricular septal defect), kidney failure (creatinine > 
200μmol/L), or incapability of understanding and signing informed consent. According 
to the study protocol, patients underwent physical examination by a cardiologist, 12-
lead electrocardiography, echocardiography and venous blood sampling at the day of 
study inclusion. All patients were structurally followed-up during four years by annual 
visits to the ACHD outpatient clinic. The study conforms with the principles outlined in 
the Declaration of Helsinki, was approved by the Erasmus MC medical ethics committee 
and all subjects gave written informed consent to participate in the study. The study 
protocol and the echocardiographic image analysis have been described in more detail 
previously.9, 11
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Healthy controls
Self-declared healthy volunteers were prospectively recruited through an advertisement. 
Between January 2014 and December 2014, all participants underwent physical 
examination, electrocardiography, echocardiography and venous blood sampling on 
the same day at our outpatient clinic. Details of the study protocol and exclusion criteria 
have been published previously.12
Sample processing and analysis
Venous blood samples were obtained at the day of study inclusion for research purposes 
only, and decisions regarding patient management were made independently of any 
biomarker value. Venous blood samples were transferred to the clinical chemistry 
laboratory of the Erasmus MC within 2 hours. In study patients, serum N-terminal pro-B-
type natriuretic peptide (NT-proBNP) was directly measured in the fresh samples using 
a commercial electrochemiluminescence immunoassay (Roche Diagnostics, Rotkreuz, 
Switzerland). In both study patients and healthy controls, other serum was aliquoted 
and stored according to the same protocol at –80 degrees of Celsius until further 
analysis. In March and April 2017, samples were thawed in batches. Galectin-3 was 
directly measured on the ARCHITECT ci8200 analyser (Abbott Diagnostics, Hoofddorp, 
the Netherlands). Samples were subjected to a maximum of one freeze-thaw cycle. 
In study patients, we performed one galectin-3 measurement per patient. In healthy 
controls, we performed two galectin-3 measurements from the same aliquot in order 
to assess reproducibility of the galectin-3 assay in our centre. The ARCHITECT galectin-3 
assay is designed to have a limit of quantitation of ≤ 4.0 ng/mL, and an imprecision of 
≤ 10% total coeﬃcient of variation for samples with galectin-3 concentrations ranging 
from 4.0 to 114.0 ng/mL.
Definition and assessment of events
We deﬁned the primary endpoint prior to the collection of data as a composite of the 
following adverse (cardiovascular) events: all-cause mortality, heart failure (requiring 
initiation or change in heart failure medication, or requiring hospital admission), 
hospitalisation for cardiac reasons, arrhythmia (symptomatic and recorded, or 
requiring treatment), thromboembolic events (ischemic cerebrovascular accident, 
pulmonary embolism or myocardial infarction), and/or cardiac interventions (surgical 
or percutaneous). The secondary endpoint was deﬁned as a composite of all-cause 
mortality and/or heart failure. 
 Patients were prospectively and systematically followed for fatal and non-fatal 
events by a yearly clinical evaluation at our ACHD outpatient department until August 
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1, 2016. Survival status was also checked in the Municipal Population Register. Suspect 
endpoint events were adjudicated by two experienced investigators (VB and JR) without 
knowledge of biomarker levels.
Statistical analysis
Continuous patient characteristics are presented for the total cohort and per quartile 
of galectin-3 distribution as mean ± standard deviation or median [interquartile range], 
depending on the distribution of data. Comparisons across galectin-3 quartiles were 
performed using the Chi-Square Mantel-Haenszel test for trend (for categorical variables) 
or linear regression (for continuous variables). Galectin-3 had a skewed distribution and 
was therefore log 
2
 transformed for further analysis.
 Reference values for galectin-3 were stratiﬁed for sex and calculated as the 97.5th 
percentile of the distribution in the healthy controls. Reproducibility of the galectin-3 
assay was assessed by the R2, Bland-Altman plots with corresponding limits of agreement 
(mean diﬀerence of two repeated measurements ± 1.96 standard deviation), and 
coeﬃcient of variation which was calculated as the standard deviation of the diﬀerences 
of two measurements divided by the mean of two measurements *100%.
 Primary endpoint-free survival was deﬁned as the time from study inclusion to the 
occurrence of the ﬁrst event. Patients without any cardiovascular event were censored 
at the end of the follow-up duration. Survival curves were derived by the Kaplan-
Meier method and stratiﬁed for galectin-3 quartile; quartiles were compared using the 
log-rank test for trend. Cox regression was performed to investigate the association 
between continuous galectin-3 and the primary and secondary endpoint. We 
conducted multivariable analyses with adjustment for age, sex, congenital diagnosis, 
New York Heart Association (NYHA) functional class, cardiac medication use, rhythm, 
systemic ventricular function, and NT-proBNP. Data on NT-proBNP was 99% complete; 
imputation of the mean was used to account for missing data. All other covariates were 
100% complete. As a post-hoc analysis, we stratiﬁed patients according to the number 
of elevated biomarkers (NT-proBNP and/or galectin-3). The hazard ratios were estimated 
using Cox regression, by analyzing the number of elevated biomarkers as a categorical 
variable, with ‘no biomarkers elevated’ as the reference group. 
 Data analysis was performed using IBM SPSS Statistics for Windows, version 21.0 
(IBM Corp., Armonk, NY, USA). Two-sided p-values of < 0.05 were considered statistically 
signiﬁcant.
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RESULTS
Baseline characteristics
Of the 602 patients with moderate to complex ACHD who were included in the cohort, 
a galectin-3 measurement was available in 591 patients (98%). A ﬂowchart of the 
patient selection process is provided in Supplemental File 1. The median age was 33 
[interquartile range (IQR) 25–41] years and 343 (58%) were men. Surgical repair was 
performed in 539 patients (91%) at young age (3.8 [IQR 0.8–12.0] years). The majority of 
patients were in NYHA class I (90%). 
 Median galectin-3 was 12.7 [IQR 10.9–14.8, range 4.2–45.7] ng/mL. Galectin-3 was 
elevated (> 97.5th percentile of the reference population) in 16 of the 248 women 
(6.5%) and in 24 of the 343 men (7.0%). Patients in the highest galectin-3 quartile were 
signiﬁcantly older and underwent surgical repair at older age. In the highest quartile, 
a larger proportion of patients was female, had a complex congenital diagnosis, 
used cardiac medication, had a low oxygen saturation, and was in NYHA class II–III. In 
addition, higher galectin-3 was associated with loss of sinus rhythm, worse systemic 
ventricular function, lower E’ wave and higher E/E’ ratio, and higher NT-proBNP. Baseline 
characteristics are further detailed in Table 1. Galectin-3 levels are presented per 
congenital diagnostic group in Figure 1. This shows that the highest mean galectin-3 
levels were present in patients with pulmonary hypertension or a functionally 
univentricular heart.
Reference values and reproducibility
A total of 147 healthy volunteers were included. Galectin-3 measurements were 
performed twice in 143 volunteers (Supplemental File 1). In this cohort, galectin-3 was 
not signiﬁcantly associated with age (r = 0.137, p = 0.102) but was signiﬁcantly higher in 
women than in men (12.8 ± 3.2 versus 11.5 ± 2.6 ng/mL, p = 0.007). Age and sex speciﬁc 
galectin-3 levels are further detailed in Supplemental File 2. The 97.5th percentile of the 
distribution was 21.3 ng/mL in women and 16.9 ng/mL in men, which was used as a cut-
oﬀ to describe elevated levels of galectin-3 in the study population. Since galectin-3 was 
not signiﬁcantly associated with age in the healthy controls, we did not use age-speciﬁc 
cut-oﬀ values. The reference values that were found in this study are compared with 
previously published studies in Supplemental File 3.13-17 Reproducibility was excellent, 
with limits of agreement of –1.1–1.0 ng/mL and a COV of 4.5% (Supplemental File 4). 
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FIGURE 1 - Galectin-3 levels in the different congenital diagnostic groups.
The mean level in each diagnostic group is indicated with a black line.
Follow-up
Survival status and detailed follow-up data were available in 586 patients (99.2%). After 
a median of 4.4 [IQR 3.9–4.8] years of prospective follow-up, the primary endpoint 
occurred in 195 patients (33%) and the secondary endpoint occurred in 58 patients 
(10%). The separate components of the primary endpoint (in which patients were 
not censored at the time of another endpoint than the endpoint of interest) were all-
cause death (n = 16), heart failure (n = 52), hospitalisation for cardiac reasons (n = 148), 
arrhythmia (n = 110), thromboembolic event (n = 24), and cardiac intervention (n = 111).
Association between galectin-3 and clinical outcomes
Cumulative endpoint-free survival curves stratiﬁed per galectin-3 quartile are presented 
in Figure 2, showing that patients in the fourth quartile were clearly at highest risk 
of both the primary and secondary endpoint. As is shown in Table 2, higher levels of 
galectin-3 were also signiﬁcantly associated with the primary and secondary endpoint 
when analysed continuously. 
 Multivariable adjustment for age and sex attenuated the results, but galectin-3 
remained signiﬁcantly associated with the study endpoints. After full adjustment for 
age, sex, clinical characteristics and NT-proBNP, the associations between galectin-3 and 
the primary and secondary endpoint were no longer signiﬁcant. Adjustment for NT-
proBNP only yielded similar nonsigniﬁcant results (Table 2). 
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FIGURE 2 - Cardiovascular event-free survival and heart failure-free survival, stratified according to quartiles of 
galectin-3 distribution.
Q1, ﬁrst quartile (n = 153); Q2, second quartile (n = 147); Q3, third quartile (n = 148); Q4, fourth quartile (n = 143).
TABLE 2 - Univariable and multivariable associations of galectin-3 with the primary endpoint (cardiovascular event) 
and secondary endpoint (death or heart failure).
 HR per two-fold higher value 95% CI P-value
Cardiovascular event      
Galectin-3 (univariable) 2.05 1.44–2.93 < 0.001
   Adjusted for age and sex 1.59 1.09–2.33 0.017
   Adjusted for NT-proBNP 1.04 0.72–1.49 0.848
   Full model including all covariates* 0.84 0.58–1.22 0.354
Death or heart failure      
Galectin-3 (univariable) 6.01 3.51–10.3 < 0.001
   Adjusted for age and sex 3.19 1.69–6.03 < 0.001
   Adjusted for NT-proBNP 1.47 0.79–2.72 0.222
   Full model including all covariates* 1.00  0.52–1.91 0.991
*Adjusted for age, sex, congenital diagnosis, cardiac medication use, NYHA class II–III, sinus rhythm, systemic 
ventricular function, and NT-proBNP. Abbreviations: CI, conﬁdence interval; HR, hazard ratio; NT-proBNP, 
N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.
 As a post-hoc analysis, we divided patients in three groups: both NT-proBNP and 
galectin-3 low (n = 265), either NT-proBNP or galectin elevated (n = 291), and both NT-
proBNP and galectin-3 elevated (n = 31). In Figure 3, the Kaplan-Meier curves stratiﬁed 
according to these three groups are presented. The small group of 31 patients with both 
elevated levels of NT-proBNP and galectin-3 were clearly at highest risk of adverse events. 
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FIGURE 3 - Cardiovascular event-free survival and heart failure-free survival, stratified according to the number of 
elevated biomarkers.
No biomarkers elevated (n = 265): NT-proBNP < 14 pmol/L and galectin-3 < 21.3 ng/mL in women and < 16.9 
ng/mL in men. One biomarker elevated (n = 291): NT-proBNP > 14 pmol/L (n = 282) or galectin-3 > 21.3 ng/
mL in women and > 16.9 ng/mL in men (n = 9). Two biomarkers elevated (n = 31): NT-proBNP > 14 pmol/L and 
galectin-3 > 21.3 ng/mL in women and > 16.9 ng/mL in men.
TABLE 3 - Risk of the primary endpoint (cardiovascular event) and secondary endpoint (death or heart failure) 
according to the number of elevated biomarkers.
  Combination of NT-proBNP and galectin-3
 All (n = 587)
No biomarkers 
elevated
(n = 265)
One biomarker 
elevated
(n = 291)
Two biomarkers 
elevated
(n = 31)
P-value*
Cardiovascular event      
   No. Cases 195 45 128 22
   Person-years 2025 1022 928 75
   Crude HR (95% CI) Reference 3.05 (2.17–4.29) 6.14 (3.68–10.2) 0.003
   Adjusted HR (95% CI)† Reference 2.21 (1.51–3.24) 2.25 (1.24–4.08) 0.940
Death or heart failure      
   No. Cases 58 2 43 13
   Person-years 2407 1143 1165 98
   Crude HR (95% CI) Reference 21.0 (5.08–86.6) 70.0 (15.8–310) < 0.001
   Adjusted HR (95% CI)† Reference 7.80 (1.80–33.8) 9.11 (1.88–44.3) 0.662
Elevated galectin-3 was deﬁned as > 21.3 ng/mL in women and > 16.9 ng/mL in men, based on the 97.5th 
percentile of the distribution in our healthy controls. Elevated NT-proBNP was deﬁned as > 14 pmol/L. *The last 
two columns are compared (one versus two biomarkers elevated). †Adjusted for age, sex, congenital diagnosis, 
cardiac medication use, NYHA class II–III, sinus rhythm, and systemic ventricular function. Abbreviations: CI, 
conﬁdence interval; HR, hazard ratio, NT-proBNP, N-terminal pro-B-type natriuretic peptide.
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Table 3 also shows that patients with two elevated biomarkers (both NT-proBNP and 
galectin-3) carry a signiﬁcantly and substantially higher risk of adverse events compared 
with patients with only one elevated biomarker. However, because of the small size of 
the group with two biomarkers, the exact numbers should be interpreted with caution. 
Nevertheless, after adjustment for clinical variables, the diﬀerence between these two 
groups was no longer signiﬁcant. 
DISCUSSION
This is the ﬁrst large and prospective study that investigates the levels of galectin-3 
and its association with clinical characteristics and outcomes in patients with ACHD. 
Galectin-3 was elevated in only 7% of the study population and was highest in patients 
with pulmonary hypertension or a functionally univentricular heart. In addition, higher 
galectin-3 was related to higher age, cardiac medication use, higher NYHA class, loss 
of sinus rhythm, ventricular dysfunction (both systolic and diastolic), and higher NT-
proBNP. Galectin-3 was signiﬁcantly associated with both the primary endpoint 
(cardiovascular events) and the secondary endpoint (death or heart failure) in the 
univariable analysis. However, galectin-3 was not signiﬁcantly associated with study 
endpoints after adjustment for NT-proBNP. 
Comparison with previous studies
Previous reports have also indicated that galectin-3 probably shares some overlapping 
information with other variables, especially with NT-proBNP. In two studies in patients 
with chronic heart failure and a reduced left ventricular ejection fraction, galectin-3 was 
signiﬁcantly associated with cardiac events in the univariable analysis. However, this 
association did not persist after adjustment for other predictors such as NT-proBNP.18, 19 
In contrast, three other studies in patients with heart failure reported that galectin-3 
was associated with clinical outcomes independently of natriuretic peptides.2-4 These 
diﬀerences may depend on the patient population that was investigated. For instance, 
two of these three studies investigated patients during hospital admission for acute 
heart failure.2, 4 The mean left ventricular ejection fraction in two studies was clearly 
higher (≥ 40%) compared with the studies in which galectin-3 did not provide additional 
information on top of NT-proBNP.2, 3 This could be an important diﬀerence because de 
Boer et al.4 showed that galectin-3 might be more useful in patients with a preserved 
ejection fraction: while the average galectin-3 levels were comparable between patients 
with a reduced and a preserved ejection fraction, an identical rise in galectin-3 levels 
was associated with a much stronger increase in the risk of death or rehospitalisation in 
patients with a preserved ejection fraction. In addition, diﬀerences in sample processing, 
11G a l e c t i n - 3  i n  A C H D  -  C H A P T E R  11
233 
11
storage, and analysis, diﬀerences in disease severity (as reﬂected by varying mortality 
rates and median galectin-3 levels), and the number and type of other covariates that 
were included in the multivariable analyses could inﬂuence the results. 
 To our knowledge, there is only one study that previously investigated the 
association between galectin-3 and clinical outcome in adult congenital patients. In 70 
ambulatory adult Fontan patients, Opotowsky et al. showed that galectin-3 levels were 
associated with adverse outcomes.20 In this study, NT-proBNP was not measured and 
the association of galectin-3 with adverse outcomes was adjusted one by one for age, 
NYHA functional class, estimated glomerular ﬁltration rate, C-reactive protein and the 
presence of chronic comorbidities.
Galectin-3 release in healthy controls
Whereas galectin-3 was positively associated with age in our patients with ACHD, it was 
not associated with age in the healthy controls. Higher galectin-3 values may therefore 
be explained by the disease progression that occurs in the aging ACHD patients, 
rather than the increase in age itself. This implies that age-speciﬁc reference values are 
probably not required. Both in study patients and in healthy controls we found higher 
galectin-3 values in women, which was also previously reported in healthy controls14, 16, 21 
and in heart failure patients.19 However, the data is conﬂicting with regard to this point 
as some other studies have reported similar or even higher galectin-3 values in men.15, 17 
Although the age groups in our study were small, the diﬀerences between men and 
women were only signiﬁcant in the healthy controls aged 30–50 years. A previous study 
with in-vitro endometrial cells showed that galectin-3 was upregulated by estradiol and 
progesterone.22 Because these sex-speciﬁc hormonal diﬀerences are attenuated after 
the menopause, diﬀerences in baseline characteristics with regard to age may partially 
explain the conﬂicting results.
Clinical perspectives
Although most biomarker studies focus on the utility of a single biomarker measurement 
in diagnosis and risk stratiﬁcation, other important clinical applications of biomarkers 
are monitoring of disease progression and guidance of therapy in heart failure 
management. Galectin-3 is thought to be involved in a diﬀerent pathophysiological 
axis than natriuretic peptides. It is mainly related to changes in the extracellular matrix, 
leading to cardiac and non-cardiac ﬁbrosis.23 In our study, galectin-3 was signiﬁcantly 
associated with several echocardiographic parameters of diastolic dysfunction, which 
was also found in other studies.24 Galectin-3 has also been directly related to ventricular 
ﬁbrosis as assessed by late gadolinium enhancement in patients with non-ischemic 
dilated cardiomyopathy.25 In addition, repeated measurements of galectin-3 have 
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previously been shown to provide prognostic value in patients with heart failure.26, 27 
Interestingly, the normal intra-individual biological variability of galectin-3 is much 
lower compared with brain natriuretic peptide28 or NT-proBNP.29 It may therefore be 
worthwhile to evaluate if repeated galectin-3 measurements can be used to monitor 
ongoing ventricular remodelling, and if these are more useful than NT-proBNP to 
monitor heart failure progression in speciﬁc patient subgroups with more ventricular 
ﬁbrosis and diastolic dysfunction. In addition, galectin-3 might be useful to identify 
patient groups that possibly beneﬁt from new pharmacologic agents that target ﬁbrosis, 
as hypothesized previously.18
Study limitations
This is a relatively large cohort of patients with ACHD; however, it consists of a 
heterogeneous group of congenital diagnoses. It is interesting that galectin-3 
values are highest among patients with pulmonary hypertension or a functionally 
univentricular heart, and the prognostic value of galectin-3 may be stronger in these 
patients subgroups. In addition, although the average galectin-3 levels and the range 
of the galectin-3 values are roughly comparable between patients with a systemic RV 
and patients with a systemic LV, the prognostic value of galectin-3 might be diﬀerent in 
patients with a systemic RV. Unfortunately, diagnosis-speciﬁc analyses are limited by the 
relatively low sample size within speciﬁc diagnostic groups. In addition, in the post-hoc 
analysis according to the number of elevated biomarkers, the group of patients with 
both elevated levels of NT-proBNP and galectin-3 was relatively small and the results 
should therefore be carefully interpreted. Of note, patients with an isolated repaired 
atrial or ventricular septal defect were not included, because of the expected low 
number of events. This should be taken into account when extrapolating these results 
to other cohorts of patients with ACHD.
 No data on cardiopulmonary exercise testing was available to include in the current 
analysis. This may have further attenuated the association of galectin-3 with adverse 
outcomes, because it is known that exercise testing is of prognostic importance in 
patients with ACHD.18
CONCLUSIONS
In our cohort of patients with ACHD, galectin-3 was elevated in 7% of the study 
population. Higher galectin-3 level was related to higher age, higher NYHA class, loss 
of sinus rhythm, ventricular systolic and diastolic dysfunction, and higher NT-proBNP. 
In addition, galectin-3 was signiﬁcantly associated with adverse cardiovascular events 
in the univariable analysis. Nevertheless, the value of galectin-3 incremental to a more 
conventional risk marker such as NT-proBNP seems to be limited.
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SUPPLEMENTAL MATERIAL
 2.533 unique patients with one or more visitsto the 
adult congenital cardiology outpatient clinic
(April 5, 2011 – April 16, 2013) 
602 patients enrolled 
267  patients without echocardiogram not 
approached 
1.664  patients not enrolled due to: age <18 years, 
pregnancy, mild cardiac lesion (isolated ASD or 
VSD), not capable of understanding and signing 
informed consent, refusal to participate in study 
(<5% of patients), no routine visit, 
random logistical reasons 
591 patients with galectin-3 measurement  
155 self-declared healthy volunteers with one visit 
to the adult congenital cardiologyoutpatient 
clinic (January 6, 2014 – December 22, 2014) 
147 healthy volunteers enrolled 
8 volunteers excluded due to: prior 
cardiovascular disease (n = 1), 
hypertension (n = 1), BMI > 40 (n = 1), 
breast implants (n = 2), 
abnormal &$(	O
PS
BCOPSNBMFDIPDBSEJPHSBN	O

143  participants with galectin-3 measurement 
(duplicate measurements to assess 
reproducibility) 
SUPPLEMENTAL FILE 1 - Flowchart of the selection of patients (left panel) and healthy controls (right panel).
SUPPLEMENTAL FILE 2 - Galectin-3 levels in a healthy control population across different age and sex groups.
The mean level in each subgroup is indicated with a black line. *Two-sided P < 0.05 (Mann-Whitney U test).
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SUPPLEMENTAL FILE 4 - Reproducibility of galectin-3 on the ARCHITECT ci8200 analyser (Abbott Diagnostics).
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ABSTRAC T
Background Red cell distribution width (RDW) is a standard component of the 
automated blood count, and is of prognostic value in heart failure and 
coronary heart disease. We investigated the association between RDW 
and cardiovascular events in patients with adult congenital heart disease 
(ACHD).
Methods In this prospective cohort study, 602 consecutive patients with ACHD
and Results who routinely visited the outpatient clinic were enrolled between 2011 
and 2013. RDW was measured in fresh venous blood samples at inclusion 
in 592 patients (median age 33 [IQR 25–41] years, 58% male, 90% NYHA 
I) and at four annual follow-up visits. During 4.3 [IQR 3.8–4.7] years of 
follow-up, the primary endpoint (death, heart failure, hospitalization, 
arrhythmia, thromboembolic events, cardiac intervention) occurred in 
196 patients (33%). Median RDW was 13.4 (12.8–14.1)% versus 12.9 (12.5–
13.4)% in patients with and without the primary endpoint (p < 0.001). 
RDW was signiﬁcantly associated with the endpoint when adjusted for 
age, sex, clinical risk factors, CRP, and NT-proBNP (HR 1.20; 95% CI 1.06–
1.35; p = 0.003). The C-index of the model including RDW was slightly, 
but signiﬁcantly (p = 0.005) higher than the model without (0.74, 95% 
CI 0.70–0.78 versus 0.73, 95% CI 0.69–0.78). Analysis of repeated RDW 
measurements (n = 2449) did not show an increase in RDW prior to the 
occurrence of the endpoint.
Conclusions RDW is associated with cardiovascular events in patients with ACHD, 
independently of age, sex, clinical risk factors, CRP, and NT-proBNP. This 
readily available biomarker could therefore be considered as an additive 
biomarker for risk stratiﬁcation in these patients.
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INTRODUC TION
Red cell distribution width (RDW) is a marker of anisocytosis, which is automatically 
measured when a complete blood count is requested. RDW is calculated as the 
coeﬃcient of variation of the red cell volume distribution (standard deviation divided 
by mean cell volume). A high RDW indicates a greater variation in erythrocyte size, 
and a low RDW indicates a more homogeneous population of red blood cells.1 Various 
distinct pathophysiological mechanisms such as impaired iron mobilization, ineﬀective 
erythropoiesis, nutritional deﬁciencies, decreased hemoglobin level, oxidative stress, 
and inﬂammation have been related to an increased RDW.2-5 
 Interestingly, increased RDW has been reported to be closely related to the risk of 
adverse events  in the general population.6, 7 More speciﬁc, it has been shown to be a 
predictor of cardiovascular morbidity and mortality in patients with acute and chronic 
heart failure,2, 8-11 coronary heart disease12, 13 and pulmonary arterial hypertension.14 
Even an increase in RDW during hospitalization has been related to adverse outcome.15 
Despite these promising data, its current role in clinical practice still pertains to the 
diﬀerential diagnosis of anemia together with the mean cell volume, which was already 
described in 1983.16, 17 
 The number of patients with adult congenital heart disease (ACHD) is rapidly 
increasing and although many of these patients have no complaints, the incidence 
of cardiovascular events and need for (re)interventions is high. Prognostication is an 
essential component of the routine clinical care of patients with ACHD, and forms the 
basis of patient information, follow-up management and therapeutic strategies. To our 
knowledge, it is unknown whether RDW can enhance the prognostication of ACHD 
patients. The aim of this study was therefore to investigate the association between RDW 
and cardiovascular events in patients with ACHD. In addition, we evaluated repeated 
measurements to investigate the changes in RDW level over time.
METHODS
Study design and population
This is a prospective cohort study. We included consecutive adults with a moderate or 
complex type of congenital heart defect,18 who routinely visited our ACHD outpatient 
clinic with an echocardiogram between April 2011 and April 2013. We excluded patients 
with age < 18 years, pregnancy, a mild cardiac lesion (isolated atrial or ventricular septal 
defect), not capable of understanding and signing informed consent, or severe kidney 
disease (estimated glomerular ﬁltration rate < 30 mL/min at baseline). At the day of 
study inclusion, patients underwent physical examination by a cardiologist, 12-lead 
electrocardiography, echocardiography and venous blood sampling. All patients were 
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structurally followed-up during four years by annual visits to the ACHD outpatient clinic, 
including physical examination by a cardiologist, 12-lead electrocardiography, venous 
blood sampling, and echocardiography (every two years). During the follow-up, patients 
were treated in accordance with ESC guidelines.19 The study protocol was approved 
by the Erasmus MC medical ethics committee and all participants provided written 
informed consent. Other details of the study protocol and the echocardiographic image 
analysis have been described previously.20, 21
Laboratory measurements
An automated complete blood count was performed in fresh K2EDTA plasma samples 
at study inclusion and at the planned yearly follow-up visits in the clinical chemistry 
laboratory of the Erasmus MC, using a Sysmex XN-1000TM Hematology Analyzer (Sysmex 
Europe GmbH, Norderstedt, Germany). Up to ﬁve subsequent annual measurements per 
patient were collected. Samples were stored at room temperature and were analyzed 
within three hours of collection. RDW measurements were performed for research 
purposes only, and decisions regarding patient management were made independently 
of RDW measurements. The lower and upper limits of normal for RDW in our lab are 
12.0 and 16.0 %, respectively. Anemia was deﬁned as a hemoglobin level of < 139 g/L 
in men (< 8.6 mmol/L) and < 121 g/L (< 7.5 mmol/L) in women. N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) was directly measured in fresh serum samples, using 
a commercial electrochemiluminescence immunoassay (Roche Diagnostics, Rotkreuz, 
Switzerland). More details have been published previously.21
Definition and assessment of events
We deﬁned the primary endpoint prior to the collection of data as a composite of the 
following (cardiovascular) events: all-cause mortality, heart failure (requiring initiation 
or change in heart failure medication, or requiring hospital admission), hospitalization 
for cardiac reasons, arrhythmia (symptomatic and recorded, or requiring treatment), 
thromboembolic events (ischemic cerebrovascular accident, pulmonary embolism or 
myocardial infarction), and/or cardiac interventions (surgical or percutaneous). The 
secondary endpoint was deﬁned as a composite of all-cause mortality and/or heart 
failure. 
 According to the study protocol, patients were followed for the occurrence of fatal 
and non-fatal events by a yearly clinical evaluation at our institution. The end of the 
follow-up period was set at August 1, 2016. Survival status was also checked in the 
Municipal Population Register. Suspect endpoint events were adjudicated by two 
experienced investigators (VB and JR) without knowledge of RDW levels.
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Statistical analysis
Patient characteristics were described per quartile of the RDW distribution. Depending 
on the data distribution, these were presented as mean ± standard deviation or as 
median [interquartile range (IQR)]. Comparisons across quartiles of the RDW distribution 
were performed using the Chi-Square Mantel-Haenszel test for trend (for categorical 
variables) or linear regression (for continuous variables). 
 For patients with multiple events, event-free survival was deﬁned as the time from 
enrollment to the occurrence of the ﬁrst event. Patients without any cardiovascular 
event were censored at the end of the follow-up duration. Kaplan-Meier endpoint-free 
survival curves were presented for each RDW quartile separately. Cox regression was 
performed to investigate the association between baseline RDW and study endpoints. 
We analyzed RDW both as a categorical variable (in quartiles) and as a continuous 
variable (RDW was normally distributed and presented per % increase). We also 
investigated the association of the other components of the automated blood count 
(hemoglobin, hematocrit and mean cell volume) with the primary and secondary 
endpoint. Associations were adjusted for age, sex, congenital diagnosis, cardiac 
medication use, NYHA class, rhythm, and systemic ventricular function. Furthermore, 
we performed additional adjustment for C-reactive protein and NT-proBNP. Data on NT-
proBNP was 99% complete; imputation of the mean was used to account for missing 
data. All other covariates were 100% complete. We reported crude and adjusted hazard 
ratios (HR) and their corresponding 95% conﬁdence intervals (CI).
 In order to evaluate the potential added value of RDW for risk prediction, we 
determined C-statistics of models with and without RDW as a predictor. Models were 
compared using the likelihood ratio test.22
 We developed linear mixed-eﬀects (LME) models to analyze the temporal pattern 
of RDW throughout the follow-up, while accounting for the correlation between 
subsequent RDW measurements within individuals. The correlations in the repeated 
RDW measurements were modeled using a random intercept and a linear random 
slopes term. Within-subject variation was expressed as residual variance / total variance 
* 100%. Between-subject variation calculated as (total variance – residual variance) 
/ total variance * 100%. We evaluated diﬀerences in temporal evolvement of RDW 
between patients with and without the study endpoints by LME models including a 
time*endpoint interaction term in the ﬁxed part of the model. Because the temporal 
RDW evolution was similar in patients with and without study endpoints, we did not 
apply joint modeling to obtain hazard ratios for these relations.
 Data analysis was performed using IBM SPSS Statistics for Windows, version 21.0 
(IBM Corp., Armonk, NY, USA) and using the survC1, nlme and JMBayes packages in 
R statistical software, version 3.3.2 (available at: www.r-project.org).23, 24 Two-sided 
p-values < 0.05 were considered statistically signiﬁcant.
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RESULTS
Study cohort
Of the 602 patients with moderate to complex ACHD who were included in the cohort, 
a baseline RDW measurement was available in 592 patients. None of the patients had to 
be excluded because of severe kidney disease at baseline. The median age at inclusion 
was 33 [IQR 25–41] years and 342 (58%) were male. Surgical repair was performed in 
537 patients (91%) at young age (3.8 [IQR 0.8–11.9] years). The majority of patients 
were in NYHA class I (90%). Anemia was present in 28 patients (5%). Other baseline 
characteristics are described in Table 1.
Association of RDW with patient characteristics
Median RDW was 13.1 [IQR 12.7-13.7, range 11.3–20.7]%. The majority of baseline RDW 
measurements was within the normal range: only 17 patients (3%) had a RDW < 12.0% 
and only 15 patients (3%) had a RDW > 16.0%. In the highest RDW quartile, patients 
were signiﬁcantly older and underwent surgical repair at an older age. Moreover, a larger 
proportion was female, had a complex congenital diagnosis, used cardiac medication, 
had a low oxygen saturation and was in NYHA class II–III. In addition, in the highest RDW 
quartile a larger proportion of patients had loss of sinus rhythm, and patients had a worse 
systemic ventricular function and higher NT-proBNP levels. Baseline characteristics 
across quartiles of RDW distribution are further detailed in Table 1. RDW levels were 
higher in patients with pulmonary hypertension, a functionally univenticular heart or a 
congenitally corrected transposition of the great arteries (Supplemental File 1).  
Follow-up
Survival status according to the Municipal Population Register and detailed follow-
up data regarding non-fatal events were available in 588 patients (99.3%). After a 
median of 4.3 [3.8–4.7] years of prospective follow-up, the primary endpoint occurred 
in 196 patients (33%) and the secondary endpoint occurred in 57 patients (10%). The 
components of the primary endpoint are separately displayed in Table 2.
Relation between baseline RDW and study endpoints
Median RDW was 13.4 (12.8–14.1)% versus 12.9 (12.5–13.4)% in patients with and 
without the primary endpoint, respectively (p < 0.001). Median RDW was 13.9 (13.4–
15.0)% versus 12.9 (12.5–13.5)% in patients with and without the secondary endpoint, 
respectively (p < 0.001). The cumulative RDW distribution in patients with and without 
study endpoints is depicted in Supplemental File 2.
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Values are reported as median [IQR], otherwise as n (%) or mean ± SD. Diﬀerences across baseline RDW 
quartiles are analyzed using the Chi-Square Mantel-Haenszel test for categorical variables, otherwise using 
linear regression. aCongenital diagnosis of aortic stenosis, aortic coarctation or arterial switch operation 
(0) versus tetralogy of Fallot, Rastelli, systemic RV, univentricular heart or pulmonary arterial hypertension 
(1). bLeft sided volumes were not measured in patients with a systemic right ventricle, functionally 
univentricular heart, pulmonary hypertension (n = 137) or a poor acoustic window. cHemoglobin was 
converted from mmol/L to g/L by using the conversion factor 0.06202. Abbreviations: ACE, angiotensin 
converting enzyme; ARBs, angiotensin receptor blockers; eGFR, estimated glomerular ﬁltration rate; LA, 
left atrial; LV, left ventricular; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart 
Association; RDW, Red blood cell distribution width; RV, right ventricular.
FIGURE 1 - Kaplan-Meier curves stratified per baseline RDW quartile for the primary and secondary endpoint.
Q1, ﬁrst quartile; Q2, second quartile; Q3, third quartile; Q4, fourth quartile.
 Patients who were in a higher RDW quartile had a signiﬁcantly lower primary and 
secondary endpoint-free survival, as is shown in the Kaplan-Meier curves in Figure 1. 
When the RDW quartiles were analyzed in a multivariable Cox model including multiple 
clinical variables, C-reactive protein, and NT-proBNP, the association was partially 
attenuated but remained statistically signiﬁcant. Moreover, each separate component 
of the primary endpoint seemed to occur more frequently in patients in the highest 
RDW quartile (Table 2). As is shown in Table 3, similar conclusions were found when RDW 
was analyzed as a continuous variable. None of the other components of the automated 
blood count (hemoglobin, hematocrit and mean cell volume) were predictive of the 
primary endpoint; however, a decreased hemoglobin was signiﬁcantly associated with 
the secondary endpoint. We therefore conducted sensitivity analyses with additional 
adjustment of the associations between RDW and study endpoints for hemoglobin, 
which did not yield diﬀerent conclusions.
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TABLE 3 - Associations between baseline hemoglobin, hematocrit, mean cell volume, and red cell distribution and the 
primary and secondary endpoint, analyzed continuously.  
 
Crude HR 
(95% CI) P-value
Adjusted HRa 
(95% CI) P-value
Adjusted HRb 
(95% CI) P-value
Cardiovascular event
   Hb, g/L 1.00 (0.99–1.01) 0.572 ņ ņ ņ ņ
   Ht, L/L 2.15 (0.06–79.3) 0.678 ņ ņ ņ ņ
   MCV, fL 1.01 (0.98–1.04) 0.551 ņ ņ ņ ņ
   RDW, % 1.47 (1.34–1.62) < 0.001 1.26 (1.13–1.41) < 0.001 1.20 (1.06–1.35) 0.003
Death or heart failure
   Hb, g/L 0.98 (0.96–1.00) 0.024 0.98 (0.96–1.00) 0.020 0.98 (0.97–1.00) 0.011
   Ht, L/L 0.10 (0.00–13.0) 0.209 ņ ņ ņ ņ
   MCV, fL 0.99 (0.94–1.05) 0.731 ņ ņ ņ ņ
   RDW, % 1.81 (1.59–2.06) < 0.001 1.45 (1.23–1.70) < 0.001 1.38 (1.15–1.65) 0.001
aAdjusted for age (years), sex, congenital diagnosis (aortic stenosis, aortic coarctation or arterial switch 
operation (0) versus tetralogy of Fallot, Rastelli, systemic RV or univentricular heart (1)), cardiac medication use 
(yes/no), NYHA class II–III, sinus rhythm (yes/no), systemic ventricular function (0–3). bAdditionally adjusted 
for C-reactive protein and NT-proBNP (both log
2
-transformed) . Abbreviations: CI, conﬁdence interval; HR, 
hazard ratio.
 A basic risk marker model including age, sex, congenital diagnosis, cardiac 
medication use, NYHA class, rhythm, systemic ventricular function, and NT-proBNP 
yielded a C-index of 0.73 (95% CI 0.69–0.78) for the primary endpoint. The augmented 
model with RDW included as predictor yielded a C-index of 0.74 (95% CI 0.70–0.78), 
which was a modest but signiﬁcant improvement (p = 0.005). 
Repeated RDW measurements
During the follow-up, a total of 2449 RDW measurements were collected. Although 
the majority of the RDW measurements (n = 2085, 85%) were in the normal range, 
the RDW was clearly and consequently higher at baseline and throughout the entire 
follow-up duration in patients with a primary endpoint, compared with patients who 
remained endpoint-free. This diﬀerence was even more pronounced in patients with the 
secondary endpoint (Supplemental File 3). In Supplemental File 4 and 5, the individual 
measurements are displayed for each patient separately. Our data did not provide 
evidence for a steady increase in RDW prior to the occurrence of adverse events. The 
largest part of variation between the RDW measurements was attributable to between-
subject variation (76%) instead of within-subject variation (24%). 
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DISCUSSION
In this study, we have prospectively followed a large cohort of ACHD patients during 4.3 
years with annual repeated RDW measurements. RDW was higher at study inclusion and 
throughout the entire follow-up period in patients with a cardiovascular event, especially 
in patients who died or developed heart failure. Increased RDW at inclusion was 
signiﬁcantly associated with cardiovascular events during follow-up, independently of 
NT-proBNP and other prognostic markers. Adding RDW to a prognostic model including 
established clinical risk factors and NT-proBNP yielded a modest improvement. 
Previous reports 
To our knowledge, this is the ﬁrst large and prospective study that investigated the 
prognostic value of RDW in patients with ACHD. The ﬁndings of this study are in line with 
previous studies that have been performed in patients with acquired cardiac diseases, 
such as heart failure and coronary heart disease.2, 8-13 More speciﬁc, in a retrospective 
cohort study of Miyamoto et al. in 144 patients with ACHD who were hospitalized,25 
increased RDW was closely related to the risk of cardiovascular death. Comparable 
results were found in a retrospective cohort of 109 adult patients with Eisenmenger 
syndrome.26 Furthermore, RDW was found to be an indicator of iron deﬁciency in 
adult Fontan patients and correlated with lower exercise capacity.27 The remainder 
of studies that have been performed in congenital heart disease have only included 
pediatric patients. In a small cross-sectional study of pediatric patients with a Fontan 
circulation, increased RDW was related to a higher central venous pressure and a lower 
mixed venous oxygen saturation.28 In addition, preoperative RDW has been reported 
to positively correlate with the length of postoperative stay in children undergoing 
surgery for congenital heart disease.29, 30
Pathophysiological mechanisms
RDW likely reﬂects a broad range of pathophysiological processes, that could explain 
the association between RDW and cardiovascular events in patients with ACHD. 
First of all, RDW has been directly related to markers of impaired iron mobilization, 
decreased erythropoietin production, and nutritional deﬁciencies such as iron, folate, 
or vitamin B12.2, 3, 31 This may subsequently cause a decreased hemoglobin level, which 
is associated with a worse prognosis in chronic heart failure patients.32, 33 Nevertheless, 
data from previous studies and also from our cohort show that RDW provides prognostic 
information independent of hemoglobin level.10 Moreover, only 5% of patients had 
anemia in our study. 
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 Young red blood cells are relatively large and variable in size, and the erythrocytes 
shrink and become more equally sized during the natural aging process. Oxidative 
stress and inﬂammation are both known to decrease red blood cell survival.4, 5 The 
decreased lifespan of the erythrocytes will lead to relatively large amounts of both 
large and small red cells, which is reﬂected by an increased RDW.31 In addition, RDW 
has been related to endothelial function as assessed with ﬂow-mediated dilatation (as 
a measure of underlying metabolic derangements), and a high RDW is more frequently 
present in patients with kidney failure.34 Although in our study the average C-reactive 
protein, total cholesterol, low density lipoprotein and estimated glomerular ﬁltration 
were within the normal range, RDW seemed to be associated with these measures of 
inﬂammation, dyslipidemia and kidney function (Table 1).
 The heterogeneity of red blood cell size therefore could be an epiphenomenon 
that reﬂects several miscellaneous mechanisms, which are related to an individual’s 
prognosis. Previous studies have shown that risk prediction improves when multiple 
biomarkers are used together, that reﬂect distinct pathophysiological mechanisms.21, 35 
RDW may combine these diﬀerent mechanisms in one biomarker, and the red blood 
cell has therefore been previously proposed as an overall ‘barometer’ of cardiovascular 
health.2 
Clinical implications
The RDW is directly available as part of the automated blood count, which is a 
routine component of standard blood testing. The measurement is easy, inexpensive, 
rapid, does not require speciﬁc skills or instrumentation, and is readily available in 
virtually all clinical laboratories worldwide. In light of the accumulating evidence that 
emphasizes the prognostic value of RDW, the clinical role of RDW may be extended 
beyond the boundaries of the diﬀerential diagnosis of anemia. RDW could be a new 
tool to enhance the prognostication of ACHD patients, together with other functional, 
echocardiographic and biochemical markers, and can be easily implemented in routine 
clinical care. Accurate identiﬁcation of high-risk patients will enable more intensive 
follow-up with hopefully prevention of events in the future, and the identiﬁcation of 
low-risk patients will lead to reassurance, less intensive follow-up and cost savings.
Study limitations
Changes in RDW during a hospital admission for acute decompensated heart failure 
have been previously associated with all-cause mortality or readmission for heart 
failure.15 In this study with clinically stable ACHD patients, we did not observe an increase 
in RDW prior to the occurrence of adverse events. However, RDW measurements were 
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performed only once per year in this study. Therefore, it could be hypothesized that 
repeated measurements should be performed more frequently in order to ﬁnd an 
association between recent changes in RDW and an adverse event. 
 Imputation of the mean was used to account for the 1% missing NT-proBNP values. 
Although in general imputation of the mean could be considered as a limitation, it is 
considered acceptable for covariates with a very low percentage of missing data.
 In this cohort, patients with an isolated repaired atrial or ventricular septal defect 
were not included, due to the expected low number of events in these patients. This 
should be taken into account when extrapolating these data to other cohorts of patients 
with ACHD.
CONCLUSIONS
The RDW is signiﬁcantly associated with cardiovascular events in patients with ACHD, 
independently of NT-proBNP and other prognostic markers. This readily available 
biomarker, that can be reliably measured worldwide at a low cost, may therefore be a 
valuable additional tool in the risk stratiﬁcation of patients with ACHD.
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SUPPLEMENTAL MATERIAL
SUPPLEMENTAL FILE 1 - Baseline RDW levels in the different congenital diagnostic groups.
Actual RDW measurements are separately depicted. The median level in each diagnostic group is indicated 
with a black line.
Patients without study endpoint
Patients with study endpoint
SUPPLEMENTAL FILE 2 - Cumulative distribution of baseline RDW in patients with and without the primary and 
secondary endpoint.
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RDW measurement in patient with study endpoint
RDW measurement in patient without study endpoint
SUPPLEMENTAL FILE 3 - Average RDW evolutions in patients with and without the primary (A) and secondary 
endpoint (B).
Only the measurements that occurred prior to the primary endpoint (n = 2012) are displayed. One patient with 
an extreme outlier at year one (28.1%) who did not have an event is not displayed in the graphical illustrations 
of the results, but was included in all analyses. Lower and upper limits of normal are depicted by dashed lines. 
Time point zero is denoted as the moment at which patients either experienced an event, or when they were 
censored because of reaching the end of the follow-up duration without experiencing an event. We displayed 
all repeated RDW measurements as years before this moment (i.e., on a negative timescale). 
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SUPPLEMENTAL FILE 4 -  Individual RDW evolutions in patients with and without the primary endpoint.
The annual repeated measurements of each individual patient are connected with a separate line. RDW 
measurements after the event were deleted, therefore only the measurements that occurred prior to the 
primary endpoint (n = 2012) are displayed in these plots. 
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SUPPLEMENTAL FILE 5 - Individual RDW evolutions in patients with and without the secondary endpoint.
The annual repeated measurements of each individual patient are connected with a separate line. RDW 
measurements after the event were deleted, therefore only the measurements that occurred prior to the 
secondary endpoint (n = 2334) are displayed in these plots. 
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ABSTRACT
Background A single N-terminal pro-B-type natriuretic peptide (NT-proBNP) 
measurement is a strong prognostic factor in adult congenital heart 
disease (ACHD). This study investigates NT-proBNP proﬁles within ACHD 
patients and relates these to cardiovascular events.
Methods In this prospective cohort, 602 ACHD patients were enrolled at the 
and Results  outpatient clinic (2011–2013). NT-proBNP was measured at study 
inclusion in 595 patients (median age 33 [IQR 25–41] years, 58% male, 
90% NYHA I) and at subsequent annual visits. The primary endpoint 
was deﬁned as death, heart failure, hospitalization, arrhythmia, 
thromboembolic event, or cardiac intervention; the secondary endpoint 
as death or heart failure. Repeated measurements were analyzed using 
linear mixed models and joint models. During a median follow-up of 
4.4 [IQR 3.8–4.8] years, a total of 2424 repeated measurements were 
collected. Average NT-proBNP increase was 2.9 pmol/L the year prior 
to the primary endpoint (n = 199, 34%) and 18.2 pmol/L prior to the 
secondary endpoint (n = 58, 10%), compared with 0.3 pmol/L in patients 
who remained endpoint-free (p-value for diﬀerence in slope 0.006 and < 
0.001, respectively). In patients with elevated baseline NT-proBNP (> 14 
pmol/L, n = 315, 53%), repeated measurements were associated with the 
primary endpoint (HR per two-fold higher value 2.08; 95% CI 1.31–3.87; p 
< 0.001) and secondary endpoint (HR 2.47; 95% CI 1.13–5.70; p = 0.017), 
when adjusted for the baseline measurement. 
Conclusions NT-proBNP increased prior to the occurrence of events, especially 
in patients who died or developed heart failure. Serial NT-proBNP 
measurements could be of additional prognostic value in the annual 
follow-up of ACHD patients with an elevated NT-proBNP.
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INTRODUC TION
A congenital heart defect is the most prevalent congenital anomaly, with an occurrence 
of 9 per 1000 live births.1 Due to the success of pediatric cardiology and cardiothoracic 
surgery, the population of patients with adult congenital heart disease (ACHD) is rapidly 
growing. Currently around 2.3 million patients with ACHD are estimated to be alive 
in Europe, already outnumbering children with congenital heart disease.2 Although 
survival has improved, residual lesions may cause progressive exercise intolerance 
and late complications such as arrhythmia, heart failure and sudden death.3, 4 This 
expanding demographic phenomenon is causing serious issues concerning the optimal 
management of patients with ACHD. Accurate biomarkers that enable risk stratiﬁcation 
and monitoring of disease progression are therefore clearly needed. 
 Natriuretic peptides are ﬁrmly established diagnostic and prognostic tools in a variety 
of cardiovascular conditions, such as heart failure and coronary heart disease.5, 6 Previous 
studies have shown that N-terminal pro-B-type natriuretic peptide (NT-proBNP) is also a 
strong independent prognostic factor in patients with ACHD.7-9 However, NT-proBNP is 
known to have a considerable intra-individual biological variability10 and progression of 
disease may lead to substantial changes in the NT-proBNP level over time.11-14 Repeated 
NT-proBNP measurements could therefore provide additional prognostic information. 
The aim of this study was to investigate the temporal evolution of NT-proBNP within 
individual patients and to relate this to cardiovascular events in a prospective cohort 
study of patients with ACHD.
METHODS
The data, analytic methods, and study materials will be made available to other 
researchers for purposes of reproducing the results or replicating the procedure upon 
reasonable request.
Study design and population
This prospective cohort study was conducted at the outpatient clinic of a tertiary care 
center between April 2011 and April 2013, that is responsible for the clinical care of 
all patients with ACHD in the south-west region of the Netherlands. A total of 602 
consecutive patients with a moderate or complex type of congenital heart defect15 
who routinely visited the outpatient clinic were enrolled in the study cohort. Exclusion 
criteria were: age < 18 years, pregnancy, mild cardiac lesion (isolated atrial or ventricular 
septal defect), not capable of understanding and signing informed consent, or kidney 
failure (creatinine > 200μmol/L). 
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 According to the study protocol, participants underwent physical examination 
by a cardiologist, 12-lead electrocardiography, echocardiography and venous blood 
sampling at the day of study inclusion. During four subsequent years, all patients 
were structurally followed-up by yearly visits to the ACHD outpatient clinic, including 
physical examination by a cardiologist, 12-lead electrocardiography, and venous blood 
sampling. During follow-up, patients were treated in accordance with ESC guidelines.16 
Presence of pulmonary hypertension was deﬁned as a right ventricular systolic pressure 
of > 40 mmHg, as measured by the tricuspid valve regurgitation maximal velocity (in 
patients with a systemic left ventricle) or mitral valve regurgitation maximal velocity 
(in patients with a systemic right ventricle) and the estimated right atrial pressure, in 
accordance with the guidelines.17 In patients with pulmonary stenosis we subtracted 
the gradient across the pulmonary valve from the right ventricular systolic pressure.18 
The study protocol was approved by the Erasmus MC medical ethics committee and 
all participants provided written informed consent. Other details of the study protocol 
have been described previously.9, 19 
N-terminal pro-B-type natriuretic peptide
NT-proBNP was measured at inclusion and at the scheduled yearly follow-up visits. 
Therefore, a maximum of ﬁve subsequent measurements per patient were collected. 
NT-proBNP measurements were not part of standard clinical care at the time this 
study was conducted. All measurements were performed for research purposes only, 
and decisions regarding patient management were made independently of any NT-
proBNP level. NT-proBNP was directly measured in fresh serum samples at the clinical 
chemistry laboratory of the Erasmus MC, using a commercial electrochemiluminescence 
immunoassay (Roche Diagnostics, Rotkreuz, Switzerland). The limit of detection was 
0.6 pmol/L, and all values below the limit of detection were reported as < 0.6 pmol/L. 
Elevated NT-proBNP was deﬁned as > 14 pmol/L (approximately > 125 pg/mL), based on 
the recommended low cut-oﬀ for the diagnosis of heart failure in patients presenting 
with non-acute symptoms.20
Definition and assessment of events
The primary endpoint was deﬁned prior to the collection of data as a composite of the 
following adverse (cardiovascular) events: all-cause mortality, heart failure (requiring 
initiation or change in heart failure medication, or requiring hospital admission), 
hospitalization for cardiac reasons (including heart failure, arrhythmia, thromboembolic 
event, cardiac intervention, endocarditis, or other cardiac reasons requiring admission 
24 hours or longer), arrhythmia (symptomatic and recorded, or requiring treatment), 
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thromboembolic event (ischemic cerebrovascular accident, pulmonary embolism 
or myocardial infarction), or any cardiac intervention (surgical or percutaneous). The 
secondary composite endpoint was deﬁned as a composite of all-cause mortality or 
heart failure. 
 Patients were prospectively and systematically followed for fatal and non-fatal 
events by a yearly clinical evaluation at our institution according the study protocol 
until August 1, 2016. We retrieved information from electronic patient charts and also 
checked the survival status of patients in the Municipal Population Register. Suspect 
endpoint events were adjudicated by two experienced investigators (V.J.M.B. and 
J.W.R.-H.) without knowledge of NT-proBNP levels. 
Statistical analysis
Variables are presented as mean ± standard deviation or median [interquartile range 
(IQR)], depending on the distribution of data. NT-proBNP had a skewed distribution and 
was therefore log
2
 transformed for further analysis. 
 We adjudicated each component of the primary endpoint (death, heart failure, 
hospitalization for cardiac reasons, arrhythmia, thromboembolic event, and cardiac 
intervention) separately. In other words, patients were followed until the occurrence 
of the speciﬁc endpoint of interest and were not censored at another endpoint type. 
This was important because patients frequently experienced multiple event types 
simultaneously or subsequently. For patients with multiple events, event-free survival 
was deﬁned as the time from enrolment to the occurrence of the ﬁrst event. Patients 
without any cardiovascular event were censored at the end of the follow-up duration. 
Cox proportional hazards regression was performed to identify associations between 
baseline NT-proBNP and the study endpoints. We conducted multivariable analyses with 
adjustment for baseline age (years), sex, congenital diagnosis (moderate vs. complex), 
NYHA class (I vs II–III), cardiac medication use (angiotensin-converting-enzyme 
inhibitors, angiotensin II receptor blockers, ß-blockers, diuretics, calcium blockers, or 
anti-arrhythmic drugs), loss of sinus rhythm, systemic ventricular function (normal, 
mildly, moderately, or severely impaired), body mass index (kg/m2), saturation < 90%, 
≥ 1 re-intervention after initial corrective surgery, and estimated glomerular ﬁltration 
range (eGFR; mL/min, log 
2
-transformed). Data on covariates were 99.3% complete; we 
used imputation of the mean to account for missing values.
 We developed linear mixed-eﬀects (LME) models to describe the temporal NT-
proBNP evolution, while accounting for the correlation between subsequent NT-proBNP 
measurements within individuals. In patients with study endpoints, only NT-proBNP 
measurements prior to the study endpoint were used. The model building and selection 
strategy for NT-proBNP is further detailed in Supplemental Methods 1 and Supplemental 
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Table 1. We developed models with adjustment for the full set of covariates that were 
used in the Cox models. The proportion of within-subject variation was calculated as 
the residual variance of the LME model divided by the total variance. To illustrate the 
average NT-proBNP evolution in patients with and without events, an interaction term 
in the ﬁxed part of the model was used to allow diﬀerent slopes in patients with and 
without events. We additionally developed LME models with time point zero denoted 
as the moment at which patients experienced an event, or when they were censored 
because of reaching the end of the follow-up duration without experiencing an event. 
Repeated NT-proBNP measurements were denoted as years before this moment (i.e., on 
a negative timescale). These models were used to calculate the increase in NT-proBNP in 
the year prior to an event. To provide additional insight in the NT-proBNP dynamics over 
time, we expressed the association between baseline and follow-up NT-proBNP values 
by the Spearman rank correlation coeﬃcient. In addition, we calculated quartiles of the 
change in NT-proBNP concentration in the ﬁrst year (Δ Year 1 - Year 0) and related this to 
baseline patient characteristics and study endpoints. Hence, a positive value indicates 
an increase in NT-proBNP in the ﬁrst year, and a negative value indicates a decrease. 
 We used joint modeling (JM) to investigate the association between the individual 
NT-proBNP evolutions over time and the occurrence of study endpoints.21 JM combines 
the LME model estimating the NT-proBNP level of an individual patient at time t, with 
a Cox model to relate that estimated value with the incidence of study endpoints after 
time t. Results are presented as hazard ratios (HR) with 95% conﬁdence intervals (CI) 
for a two-fold higher value of the NT-proBNP level at any time t between 0 and 4 years 
follow-up. HRs were adjusted for the baseline NT-proBNP level by including baseline NT-
proBNP as a separate variable in the Cox model. In addition, we constructed multivariate 
LME models including both serial NT-proBNP and serial eGFR measurements, which 
were used in a multivariate joint model to investigate the additive value of serial NT-
proBNP measurements on top of serial eGFR measurements.
 We repeated the JM analyses when stratiﬁed for normal versus elevated NT-proBNP 
level at baseline, and stratiﬁed for the absence or presence of pulmonary hypertension. 
In addition, multiple explorative sub analyses were performed to check the robustness 
of speciﬁc assumptions with regard to endpoint deﬁnitions. Because a linear random 
slopes term did not signiﬁcantly improve the ﬁt of the model, we only used random 
intercepts and therefore did not calculate HRs for the slope. Finally, although the present 
study was not speciﬁcally designed to investigate NT-proBNP proﬁles in patients with a 
cardiac intervention, we performed explorative post-hoc analyses to evaluate whether 
we could detect a decrease in NT-proBNP levels after a surgical or percutaneous valve 
intervention among individual patients. 
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 We used IBM SPSS Statistics for Windows, version 21.0 (IBM Corp., Armonk, NY, USA), 
and the nlme and JMBayes packages in R statistical software, version 3.3.1 (available at: 
www.r-project.org).22 Two-sided p-values < 0.05 were considered statistically signiﬁcant.
RESULTS
Patient characteristics
A total of 595 patients underwent NT-proBNP measurement at study inclusion. The 
median age was 33 [IQR 25–41] years and 346 (58%) were male. Surgical repair of the 
congenital defect before study entry was performed in 540 patients (91%) at a median 
age of 3.7 [IQR 0.8–11.9] years), and 534 patients (90%) were in NYHA functional class 
I. The underlying congenital diagnoses were congenital aortic stenosis (n = 137), aortic 
coarctation (n = 109), repaired tetralogy of Fallot (including pulmonary atresia with 
ventricular septal defect, n = 177), transposition of the great arteries (TGA) corrected by 
atrial switch operation (Mustard, n = 65), TGA corrected by arterial switch operation (n = 
24), congenitally corrected TGA (n = 20), complex TGA with ventricular septal defect or 
double-outlet right ventricle corrected with a Rastelli type repair (n = 11), functionally 
univentricular heart (n = 43), and pulmonary arterial hypertension after a (corrected) 
atrial or ventricular septal defect (n = 9). The majority of patients were in sinus rhythm (n 
= 514, 87%). Systemic ventricular function was graded as normal (n = 298, 50%), mildly 
impaired (n = 210, 35%), moderately impaired (n = 69, 12%), or severely impaired (n = 
18, 3%). Right ventricular systolic pressure was available in 420 patients (71%), of whom 
33 patients (7.9%) had pulmonary hypertension. A ﬂowchart of the patient selection 
and detailed clinical, electrocardiographic and echocardiographic characteristics of the 
study cohort, also expressed per baseline NT-proBNP quartile, have been previously 
reported.9 
Cardiovascular events
Patients were followed-up during a median of 4.4 [IQR 3.8–4.8] years. Survival status 
according to the Municipal Population Register and detailed follow-up data regarding 
non-fatal events were available in 590 patients (99.2%). The primary endpoint occurred 
in 199 patients (34%) and the secondary endpoint in 58 patients (10%). In total, 16 
patients died. Causes of death were: end-stage heart failure (n = 8); cardiac arrest (n 
= 4); sudden death, presumed cardiac (n = 3); other (n = 1). Other components of the 
primary endpoint were heart failure (n = 52), hospitalization for cardiac reasons (n = 
151), arrhythmia (n = 110), thromboembolic event (n = 25), and cardiac intervention (n 
= 113).
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Prognostic value of baseline N-terminal pro-B-type natriuretic peptide
Baseline NT-proBNP was signiﬁcantly associated with the primary endpoint (crude HR 
per two-fold higher value 1.55 [95% CI 1.43–1.68], p < 0.001) and with the secondary 
endpoint (crude HR per two-fold higher value 2.30 [95% CI 1.97–2.68], p < 0.001). The 
Kaplan-Meier estimate of primary endpoint-free survival at four years of follow-up was 
84.1% in patients with normal baseline NT-proBNP (< 14 pmol/L) and 55.1% in patients 
with elevated baseline NT-proBNP. Secondary endpoint-free survival at four years of 
follow-up was 99.3% in patients with normal baseline NT-proBNP (< 14 pmol/L) and 
83.2% in patients with elevated baseline NT-proBNP. After complete adjustment for 
all covariates, the strength of the association was slightly attenuated but remained 
signiﬁcant for both the primary endpoint (adjusted HR per two-fold higher value 1.39 
[95% CI 1.23–1.57], p < 0.001) and the secondary endpoint (adjusted HR per two-fold 
higher value 1.80 [95% CI 1.42–2.28], p < 0.001). The prognostic value of baseline NT-
proBNP in this cohort has been previously published (using standardized HRs).9 Of 
note, baseline eGFR measurements were not predictive of the primary and secondary 
endpoint in these multivariable models (adjusted HR per two-fold higher value 1.00 
[95% CI 0.58–1.72], p = 0.993 and 2.49 [95% CI 0.78–7.89], p = 0.123, respectively). 
Temporal N-terminal pro-B-type natriuretic peptide evolution
During the follow-up, a median of four yearly repeated NT-proBNP measurements were 
collected per patient, resulting in a total of 2424 measurements. For the analysis of 
the primary endpoint 2009 measurements were available, and for the analysis of the 
secondary endpoint 2319 measurements were available. Figure 1 and 2 describe the 
average NT-proBNP proﬁles in patients with and without the primary and secondary 
endpoint, respectively. Individual NT-proBNP proﬁles are depicted in Supplemental 
Figure 1 and 2. Of the total variation in the NT-proBNP level, 89% was attributable to 
variation between subjects and 11% to variation within subjects. 
 The average baseline NT-proBNP (intercept) in patients who reached the primary 
endpoint was 30.6 (95% CI 25.8–36.2) pmol/L, compared with 10.6 (95% CI 9.6–11.8) 
pmol/L in patients who remained event-free during the follow-up (p-value < 0.001). The 
average NT-proBNP increase in the last year before the primary endpoint was 2.9 pmol/L, 
compared with 0.3 pmol/L in patients without the endpoint (p-value for diﬀerence in 
slope 0.006). 
 In patients who reached the secondary endpoint, the average baseline NT-proBNP 
was 73.7 (95% CI 56.1–96.8) pmol/L, compared with 12.9 (11.7–14.1) pmol/L in patients 
without the endpoint (p-value < 0.001). The average NT-proBNP increase in the last year 
before the secondary endpoint was 18.2 pmol/L, compared with 0.3 pmol/L in patients 
without the secondary endpoint (p-value for diﬀerence in slope < 0.001).
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FIGURE 1 - Average NT-proBNP evolution in patients with and without the primary endpoint.
NT-proBNP measurements after the event were deleted, therefore a total of 2009 measurements that occurred 
prior to the primary endpoint were used in this analysis. A, time point zero is denoted as the date of study 
inclusion (and ﬁrst NT-proBNP measurement). B, time point zero is denoted as the moment at which patients 
either experienced an event, or when they were censored because of reaching the end of the follow-up 
duration without experiencing an event. We displayed all repeated NT-proBNP measurements as years before 
this moment (i.e., on a negative timescale). 
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FIGURE 2 - Average NT-proBNP evolution in patients with and without the secondary endpoint.
NT-proBNP measurements after the event were deleted, therefore a total of 2319 measurements that occurred 
prior to the secondary endpoint were used in this analysis. A, time point zero is denoted as the date of study 
inclusion (and ﬁrst NT-proBNP measurement). B, time point zero is denoted as the moment at which patients 
either experienced an event, or when they were censored because of reaching the end of the follow-up 
duration without experiencing an event. We displayed all repeated NT-proBNP measurements as years before 
this moment (i.e., on a negative timescale).
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 The Spearman correlation coeﬃcient of the baseline NT-proBNP measurement with 
Year 1, 2, and 3, respectively, was 0.84, 0.85, and 0.86 in subjects without any event; 0.85, 
0.82, and 0.87 in subjects with the primary endpoint; and 0.88, 0.75, and 0.79 in subjects 
with the secondary endpoint (all p < 0.001). In Table 1, quartiles of the change in NT-
proBNP concentration in the ﬁrst year are related to baseline patient characteristics. 
Patients in the highest quartile (i.e., with the largest increase in NT-proBNP level within 
the ﬁrst year) were signiﬁcantly older, were more likely to be female, had a higher age at 
initial surgical repair, more frequently used cardiac medication, were in a higher NYHA 
class and had a worse systemic ventricular function. Of note, in this type of statistical 
analysis only a subset of the data is used and regression to the mean partly explains the 
diﬀerences in NT-proBNP levels between patient subgroups. The exact results should 
therefore be carefully interpreted.
Prognostic value of repeated measurements
The HRs of the repeatedly measured NT-proBNP value indicate the risk of the primary 
and secondary endpoint for a two-fold higher value of NT-proBNP, measured at any time 
t between 0 and 4 years of follow-up (Table 2). These HRs were consequently higher 
than the HRs of the single baseline NT-proBNP value, calculated using Cox regression (as 
reported in the text above). This indicates that the repeated NT-proBNP measurements 
that were taken during the follow-up were more predictive of the primary and secondary 
endpoint than the single baseline value. 
 The NT-proBNP level at any point in time during the follow-up was even stronger 
associated with the study endpoints when adjustment was performed for the baseline 
NT-proBNP level. I.e., when two patients with the same NT-proBNP level at baseline were 
compared, higher values during follow-up were strongly predictive of study endpoints 
(Table 2).
 The stratiﬁed analysis reported in Table 3 shows that the repeated measurements 
seem to carry additional prognostic value on top of the baseline value in both patients 
with a normal NT-proBNP level and patients with an elevated NT-proBNP level at 
baseline. However, this association is probably underpowered in the group of patients 
with a normal baseline NT-proBNP, since the event rates of the primary endpoint and 
especially the secondary endpoint (which may be considered as most clinically relevant 
in this matter) were very low in these patients. A stratiﬁed analysis based on the 
absence (n = 387) or presence (n = 33) of pulmonary hypertension showed repeated 
NT-proBNP measurements were associated with the primary and secondary endpoint 
in both groups (p < 0.001 for all analyses). Additional explorative sub analyses excluding 
cardiac interventions from the primary endpoint, and separately analyzing heart failure 
requiring hospitalization versus heart failure requiring medication change or initiation 
did not yield diﬀerent conclusions. 
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 Finally, in Figure 3, the association between the change in NT-proBNP level in the 
ﬁrst year (Δ Year 1 - Year 0) and the study endpoints is depicted. 
N-terminal pro-B-type natriuretic peptide response after cardiac intervention
Of the 113 patients with a cardiac intervention, 41 patients underwent a surgical 
intervention (valvular replacement, n = 35; valvular repair, n = 4; aortic surgery, n = 1; and 
defect closure, n = 1) and 72 patients underwent a percutaneous intervention (ablation, 
n = 21; pacemaker or ICD implantation, n = 20; valve replacement, n = 16; coronary 
intervention, n = 5; defect closure, n = 4; valvular balloon dilatation, n = 4; aortic stenting, 
n = 2). To explore whether interventions with a volume or pressure load reduction on 
the heart were followed by a decrease in NT-proBNP level among individual patients, 
we plotted the NT-proBNP proﬁles of all patients with a surgical valve intervention 
(valve replacement or valve repair) and with a percutaneous valve intervention (valve 
replacement or balloon dilatation) in Supplemental Figure 3. Within individual patients, 
large reductions in the NT-proBNP level were observed after the valvular intervention, 
especially in the surgical valve intervention group. Other exploratory analyses are 
shown in Supplemental Figure 4 (NT-proBNP proﬁles in patients with elective versus 
non-elective cardiac interventions) and in Supplemental Figure 5 (NT-proBNP proﬁles in 
patients with sudden cardiac death). 
FIGURE 3 - Association of the change in NT-proBNP concentration in the first year (Δ Year 1 - Year 0) with the primary 
and secondary study endpoint.
Only a subset of the data could be used for this conventional type of analysis, because all measurements after 
Year 1 were discarded, the time-to-event was recalculated from Year 1 onwards and patients with a study 
endpoint in the ﬁrst year were excluded. Hence, for the analysis of the primary and secondary endpoint, 488 
and 546 patients were available, respectively.
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TABLE 2 -  Hazard ratios per two-fold higher value of the biomarker, calculated using a joint model.
 HR (95% CI) P-value
Primary endpoint
Repeated NT-proBNP measurements* 1.63 (1.49–1.76) < 0.001
   Adjusted for baseline characteristics*† 1.55 (1.35–1.79) < 0.001
   Additionally adjusted for baseline NT-proBNP†‡ 2.05 (1.23–3.66) < 0.001
Repeated NT-proBNP and eGFR measurements§
   Repeated NT-proBNP measurements 1.60 (1.50–1.71) < 0.001
   Repeated eGFR measurements 0.88 (0.67–1.16) 0.266
Secondary endpoint
Repeated NT-proBNP measurements* 2.46 (2.04–2.87) < 0.001
   Adjusted for baseline characteristics*† 2.10 (1.64–2.75) < 0.001
   Additionally adjusted for baseline NT-proBNP†‡ 4.44 (1.50–13.7) < 0.001
Repeated NT-proBNP and eGFR measurements§
   Repeated NT-proBNP measurements 2.51 (2.20–2.92) < 0.001
   Repeated eGFR measurements 1.30 (0.87–2.11) 0.166
*HR for a patient with a two-fold higher NT-proBNP level than another patient at any point in time during 
the follow-up. †Adjusted for age (years), sex (0–1), congenital diagnosis (moderate vs. complex), NYHA 
class (I vs II–III), cardiac medication use (0–1), loss of sinus rhythm (0–1), systemic ventricular function (0–
3), body mass index (kg/m2), saturation < 90%, ≥ 1 re-intervention after initial corrective surgery, and eGFR 
(mL/min, log 
2
-transformed). ‡HR for a patient with a two-fold higher NT-proBNP level than another patient 
at any point in time during the follow-up, when two patients with the same baseline NT-proBNP level are 
compared. §Analyzed using a multivariate joint model (including both repeated NT-proBNP and repeated 
eGFR measurements). Abbreviations: CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; HR, 
hazard ratio; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
TABLE 3 - Hazard ratios per two-fold higher value of NT-proBNP, calculated using a joint model: stratified analysis in 
patients with baseline BNP < 14 pmol/L (normal) and > 14 pmol/L (elevated).
 Baseline NT-proBNP < 14 pmol/L (normal, n = 280)
Baseline NT-proBNP > 14 pmol/L 
(elevated, n = 315)
 No. Cases
Crude HR 
(95% CI) P-value
No. 
Cases
Crude HR 
(95% CI) P-value
Primary endpoint 50   149   
Repeated NT-proBNP measurements* 1.61 (1.10–2.52) 0.011 1.65 (1.46-1.86) < 0.001
  Adjusted for baseline NT-proBNP† 2.03 (0.88–4.71) 0.098 2.08 (1.31-3.87) < 0.001
Secondary endpoint 2   56   
Repeated NT-proBNP measurements* 3.67 (0.41–63.2) 0.284 2.30 (1.89-2.86) < 0.001
  Adjusted for baseline NT-proBNP† 6.62 (0.10–1026) 0.435 2.47 (1.13-5.70) 0.017
*HR for a patient with a two-fold higher NT-proBNP level than another patient at any point in time during 
the follow-up. †HR for a patient with a two-fold higher NT-proBNP level than another patient at any point 
in time during the follow-up, when two patients with the same baseline NT-proBNP level are compared. 
Abbreviations: CI, conﬁdence interval; HR, hazard ratio; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
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DISCUSSION
In this study, we describe yearly repeated NT-proBNP measurements in adult patients 
with congenital heart disease for the ﬁrst time. Baseline NT-proBNP levels in patients 
with an event were markedly higher, especially in patients who developed heart failure 
or died. In addition, NT-proBNP levels generally increased prior to the occurrence of 
an event, whereas patients without any cardiovascular event exhibited stable and low 
NT-proBNP levels. Consequently, when two patients with the same NT-proBNP level at 
baseline were compared, higher values measured during the follow-up were strongly 
indicative of events. Repeated measurements were especially of value in patients with 
an elevated NT-proBNP at baseline.
Repeated biomarker measurements
Repeated NT-proBNP sampling allows the quantiﬁcation of a change in levels over time. 
Although, in general, NT-proBNP concentrations were relatively stable over time and 
the average increase in patients with the primary endpoint was modest, the occurrence 
of death or heart failure was preceded by a substantial change in NT-proBNP level. The 
annual increase prior to the occurrence of death or heart failure was approximately 25% 
of the baseline value, and may therefore be considered clinically meaningful. This is in 
line with previous studies in patients with chronic heart failure, showing that changes in 
NT-proBNP level over time are associated with an individual’s prognosis.11-14 
 Using all repeated NT-proBNP measurements in the JM yielded a higher HR 
compared with using only the baseline value in the Cox model. This may be explained 
by the fact that the JM incorporates all NT-proBNP values that were subsequently taken 
during the follow-up, and were thus also measured closer to the occurrence of adverse 
events. A measurement close to the occurrence of an adverse event could better reﬂect 
an individual’s disease status at that time. Accordingly, in a study on chronic heart failure 
patients by Masson et al., a single NT-proBNP value at 4 months of follow-up was found 
to have a greater prognostic accuracy than baseline NT-proBNP.11 
 Although the exact results must be interpreted with great caution because only a 
subset of the data is used and regression to the mean can play a role, the conventional 
statistical analyses (Figure 3) conﬁrm our main analysis, and show that the 25% of 
patients with the largest increase in NT-proBNP during the ﬁrst year (> 5.1 pmol/L) 
were at highest risk of the primary and secondary study endpoint. Interestingly, the 
25% of patients with the largest decrease in NT-proBNP (< -4.1 pmol/L) also had a high 
risk of the study endpoints. These data suggest that variations in NT-proBNP level are 
associated with an increased risk of adverse events, and that the observed direction of 
change is dependent on the coincidental moment on which the biomarker is measured 
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(note that our patients were clinically stable). Furthermore, patients with more variation 
in their NT-proBNP level also appear to have higher baseline NT-proBNP levels (Table 
1). Comparable ﬁndings have been reported by Masson et al. in patients with chronic 
heart failure, showing that patients with the largest absolute change in NT-proBNP 
level within the ﬁrst 4 months had a higher all-cause mortality risk than patients with a 
relative stable level.11
 
Of note, the strength of evaluating more than two measurements 
per patient with LME models (as applied in this study), is that it becomes possible to 
adjust for this variation and to quantify gradual increases in the average NT-proBNP 
level over time.
Regression to the mean
An extreme measurement has the tendency to become less extreme when it is 
measured again, due to the intra-patient ﬂuctuations around a true mean. This statistical 
phenomenon is called regression to the mean, and especially occurs when an analyzed 
variable has a substantial within-subject variability over time.23-25 NT-proBNP is known 
to have a substantial intra-individual biological variation.10 Regression to the mean is 
therefore an important concept to consider when serial measurements are analyzed, 
and diﬀerences between two subsequent measurements cannot be directly translated 
into a true increase or decrease. Multiple (> 2) measurements provide more accurate 
estimations of an individual’s true average NT-proBNP level, and better allow analysis of 
biomarker evolution over time. 
 Most of the studies that have evaluated repeated NT-proBNP measurements so 
far, have assessed the diﬀerence between two subsequent NT-proBNP measurements 
and related relative, absolute and/or categorical changes to adverse events.11-14 This is 
the ﬁrst time that multiple repeated NT-proBNP values are investigated, and that JM 
techniques are applied. An important advantage of JM is that the LME model part 
takes into account the random within-subject variation (11% of the total variation in 
our study). Because this allows adjustment for the inherent biological variation and 
regression to the mean, this sophisticated statistical technique produces more reliable 
estimates of the true NT-proBNP proﬁle of individual patients. 
Clinical implications
Patients with an elevated NT-proBNP level at baseline are clearly at higher risk of 
adverse cardiovascular events.9 In these patients, it seems reasonable to regularly check 
the NT-proBNP level by an annual measurement, because especially the increase in the 
year prior to the occurrence of death or heart failure was substantial (~25%). Moreover, 
in this group the repeated measurements were independently associated with study 
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endpoints when adjustment was performed for the baseline NT-proBNP measurement. 
Patients with high NT-proBNP levels seem to have more biological variation; therefore, 
it could be important to perform multiple (> 2) measurements, in order to detect a 
gradual increase in the NT-proBNP over time. Patients with a high NT-proBNP level and 
patients with a substantial increase over time may require more frequent follow-up visits 
or timely initiation or expansion of heart failure medication. The optimal frequency of 
repeated measurements cannot be determined from these data and warrants future 
research.
 In contrast, in patients with a normal NT-proBNP level at baseline (< 14 pmol/L, 
47% of our study population) the NT-proBNP concentration was relatively stable and 
the event rates were much lower. Especially the risk of death and heart failure was 
extremely low, which emphasizes the high negative predictive value of NT-proBNP.9 
Due to these low event rates, no signiﬁcant additional value of repeated measurements 
could be shown in this group. Our pragmatic interpretation of these results is as follows: 
because the absolute risk of events is low in this group, even an increased relative risk for 
higher values during follow-up (which did not reach statistical signiﬁcance in our study) 
would add limited information. It therefore seems unnecessary to repeat NT-proBNP 
measurements annually in these patients to obtain additional prognostic information. 
The clinical implication of not needing annual repeated measurements in patients 
with normal NT-proBNP also includes a possible positive cost-eﬀect, because these 
measurements are relatively expensive. It may be advisable to update information on 
NT-proBNP levels at a lower frequency, for instance every four or ﬁve years. To provide 
evidence for this, studies with a much longer follow-up duration are needed. 
 Finally, NT-proBNP might be useful as a biomarker to detect a response to successful 
interventions, because we observed large NT-proBNP reductions among individual 
patients, especially after surgical valve interventions. Whether this could actually 
improve the patient selection and timing for re-intervention warrants future studies 
including more frequent NT-proBNP measurements that are scheduled at pre-deﬁned 
time points both before and after valvular interventions.
Study limitations
Although we performed multivariable adjustment for multiple covariates such as 
age, sex, congenital diagnosis, NYHA class, cardiac medication use, rhythm, systemic 
ventricular function, body mass index, saturation, re-intervention, and eGFR, this is an 
observational study and as such subject to residual confounding. For instance, our cohort 
consisted of a relatively heterogeneous group of multiple congenital diagnoses, and 
we could only adjust for a dichotomized variable indicating a moderate (0) or complex 
(1) type of congenital diagnosis. Other variables that were not taken into account in 
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this analysis may also play a role in the prognostication of patients with ACHD. Of note, 
patients with mild cardiac lesions such as isolated atrial or ventricular septal defect were 
excluded in this study, because the expected event rate in these patients is very low. 
This should be taken into account when these results are compared with other cohorts 
of ACHD patients. 
 In this study, only repeated NT-proBNP and repeated eGFR measurements were 
analyzed. However, also changes in other biomarkers with less day-to-day variations 
or other patient characteristics could play a role in the prognostication of ACHD 
patients. We did not take repeated two-dimensional echocardiographic measurements 
into account, because these are known to have a relatively large measurement error 
and we therefore did not consider these suitable for accurate quantiﬁcation of serial 
changes.26 Other repeatedly assessed clinical variables were not available. Ideally, 
updating multiple variables during each follow-up visit could lead to more precise and 
individualized dynamic predictions. 
 Finally, we used composite endpoints in this study, and it should be taken into account 
that the individual components are not all of similar clinical importance to the patient.
CONCLUSIONS
A single measurement of NT-proBNP at any time during the follow-up is of important 
prognostic value in patients with ACHD who routinely visit the outpatient clinic. 
In patients with a normal NT-proBNP level, it is not needed to annually repeat NT-
proBNP measurements to obtain additional prognostic information. In patients with an 
elevated NT-proBNP level, yearly repeated measurements were strongly predictive of 
study endpoints and provided signiﬁcant prognostic information beyond the baseline 
NT-proBNP level. In these patients, serial measurements may therefore aid in the further 
optimization of individual follow-up strategies, medical therapies and timing of re-
interventions.
CLINIC AL PERSPEC TIVE
What is new?
% NT-proBNP is associated with the risk of death or heart failure in patients with adult 
congenital heart disease (ACHD).
% ACHD patients without cardiovascular events during 5-year follow-up had stable 
and low NT-proBNP levels. 
% NT-proBNP levels generally increased prior to the occurrence of an adverse event in 
patients with ACHD, especially prior to death or heart failure.
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% Repeated NT-proBNP measurements were useful to improve prognostication in 
patients with elevated (> 14 pmol/L) baseline values, since higher values, as well as 
(large) variations were associated with an increased risk of adverse cardiovascular 
events.
What are the clinical implications?
% ACHD patients with low NT-proBNP concentrations (< 14 pmol/L) have a very 
favorable prognosis, and serial measurements will therefore be of limited additional 
value.
% ACHD patients with elevated NT-proBNP concentrations (> 14 pmol/L) have an 
increased risk of death or heart failure.
% ACHD patients with elevated NT-proBNP concentrations that have additional 
increments over time represent a population that should receive close follow-up.
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SUPPELEMENTAL MATERIAL
SUPPLEMENTAL METHODS 1 - Linear mixed-effects model building and selection. 
We used all NT-proBNP measurements that occurred prior to the primary endpoint (n = 2009), 
with a median of 4 measurements per patient. We started with a LME with linear and quadratic 
time evolutions, a nonlinear eﬀect of age using natural cubic splines with 3 degrees of freedom, 
the main eﬀects of sex, diagnosis, NYHA class, medication use, rhythm, systemic ventricular 
function, BMI, saturation, re-intervention and logeGFR, and the interactions of time with sex and 
diagnosis (Model 1).
 We ﬁrst expanded the random-eﬀects structure, while keeping the same ﬁxed eﬀects, in order 
to appropriately model the correlations in the repeated NT-proBNP measurements. We therefore 
included the linear random slopes term (Model 2) and tested whether this improved the ﬁt of the 
model by using a likelihood ratio test, which was not the case (p = 0.323). Therefore, we continued 
with a model with only random intercepts. 
 To deﬁne the ﬁxed part of the model, we subsequently tested whether the interaction terms 
had an important contribution to the ﬁt of the model. To this end, we reﬁtted Model 1 under 
maximum likelihood (instead of the default restricted maximum likelihood) and then ﬁtted 
another model without the interaction terms (Model 3). The results suggested that the eﬀects of 
time do not diﬀer between men and women, and between patients with a moderate or complex 
diagnosis (p = 0.249). We continued by performing the omnibus test for all nonlinear terms in the 
model. We therefore ﬁtted the model that excluded all nonlinear terms (Model 4) and compared 
this with Model 3 using the likelihood ratio test. This indicated that the nonlinear terms did not 
have a signiﬁcant contribution to the model (p = 0.096). 
 Therefore, the ﬁnal selected model for the log 
2
 transformed serial NT-proBNP measurements 
was a random intercepts LME with a linear time evolution, and main eﬀects of age (linear), sex, 
diagnosis, NYHA class, medication use, rhythm, systemic ventricular function, BMI, saturation, 
re-intervention and logeGFR. A schematic overview of the LME model building and selection is 
presented in Supplemental Table 1. This model was reﬁtted with restricted maximum likelihood 
and further used for the estimation of the temporal NT-proBNP evolution. Of note, the joint 
models were estimated using a Bayesian framework.
SUPPLEMENTAL TABLE 1 - Linear mixed-effects model building and selection. 
NT-
proBNP 
model
Fixed Random LRT
Compared 
with 
(method)
1 logBNP ~ (obstimeyr + I(obstimeyr^2)) * (sex + 
diagnosis) + ns(age,3) + NYHA + medication + rhythm + 
systfunc + BMI + saturation + reintervention + logeGFR
~ 1 | id   
2 Equal to model 1 ~ obstimeyr | id p = 0.323 Model 1 
(REML)
3 logBNP ~ (obstimeyr + I(obstimeyr^2)) + sex + diagnosis 
+ ns(age,3) + NYHA + medication + rhythm + systfunc + 
BMI + saturation + reintervention + logeGFR
~ 1 | id p = 0.249 Model 1 (ML)
4 logBNP ~ obstimeyr + sex + diagnosis + age + NYHA + 
medication + rhythm + systfunc + BMI + saturation + 
reintervention + logeGFR
~ 1 | id p = 0.096 Model 3 (ML)
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SUPPLEMENTAL FIGURE 1 - Individual NT-proBNP profiles in patients without and with the primary endpoint.
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SUPPLEMENTAL FIGURE 2 - Individual NT-proBNP profiles in patients without and with the secondary endpoint.
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Years before and after valve intervention
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SUPPLEMENTAL FIGURE 3 - NT-proBNP profiles in patients with a surgical or percutaneous valve intervention (at 
time point 0).
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SUPPLEMENTAL FIGURE 4 - NT-proBNP profiles in patients with elective versus non-elective cardiac interventions.
Of the 113 cardiac interventions, 17 were non-elective (pacemaker or ICD implantation, n = 10; surgical 
aortic valve replacement, n = 4; percutaneous pulmonary valve dilatation, n = 1; coronary intervention, n = 1; 
ablation, n = 1). No clear diﬀerences in the NT-proBNP proﬁles were observed, probably because the group of 
patients with a non-elective intervention was relatively small and heterogeneous.
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SUPPLEMENTAL FIGURE 5 - NT-proBNP profiles in patients with sudden cardiac death.
The 7 patients with sudden cardiac death had higher NT-proBNP levels at baseline that increased over time in 
all patients. Because of the low (expected) number of patients with sudden cardiac death, we did not aim to 
make predictions for this speciﬁc endpoint.
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ABSTRAC T
Aims  To evaluate diagnosis-speciﬁc biomarker proﬁles in patients with 
pulmonary hypertension and to investigate the association of these 
biomarkers with clinical outcomes. Additionally, we explored the 
prognostic value of a multi-biomarker approach. 
Methods In this study, 106 consecutive treatment-naïve patients with pulmonary
and results  hypertension conﬁrmed by right heart catheterization were prospectively 
included (median age 58.7 [IQR 47.0–69.2] years, woman, 64%). Venous 
blood sampling, performed during right heart catheterization, included; 
NT-proBNP, high-sensitive troponin-T, high sensitive-CRP, galectin-3, 
red blood cell distribution width and eGFR. During a median follow-up 
duration of 23.9 [IQR 15.1–40.0] months death or lung transplantation 
(primary endpoint) occurred in 29 patients and 37 patients reached the 
secondary endpoint (death, lung transplantation or heart failure). Cox 
proportional-hazards regression analysis showed signiﬁcant associations 
between all biomarkers and the primary and secondary endpoint with 
adjustment for age. A multi-biomarker approach including the number 
of elevated biomarkers per patient, demonstrated that patients were at 
higher risk of adverse events as more biomarker levels were elevated (HR 
for each extra elevated biomarker; 1.33, 95% CI 1.07–1.64, p = 0.01). The 
absence of any elevated biomarker (n = 11, 11%) ruled out the risk of any 
event up to 40 months. 
Conclusions Various biomarkers are associated with the event-free survival in adult 
patients with pulmonary hypertension. A single biomarker may not 
be suﬃcient to achieve optimal risk stratiﬁcation. This study provides 
evidence in favour of a multi-biomarker approach.
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INTRODUC TION
Pulmonary hypertension (PH) is a heterogeneous disease, characterized by an increased 
pulmonary vascular resistance leading to an elevated pulmonary arterial pressure. 
Eventually, compensatory mechanisms of the right ventricle may fail to cope with the 
increased afterload resulting in progressive right-sided heart failure (HF) and death.1, 2 
Although treatment options have expanded, morbidity and mortality rates remain high. 
Risk stratiﬁcation is crucial to identify patients at high risk and to optimize therapeutic 
management.
 The prognosis of PH varies widely and is besides aetiology,3 also based on clinical 
and hemodynamic characteristics including symptoms of HF, 6-minute walking 
distance, right atrial pressure and cardiac index, according to the European guidelines 
on PH4. Currently, the response to therapy and prognosis is often based on these factors. 
Biomarkers may provide objective measurements in a relatively non-invasive and easy-
accessible manner and the European guidelines on PH advise the use of N-terminal 
pro B-type natriuretic peptide (NT-proBNP) and troponin-T,4 which are known to be 
associated with outcomes in patients with PH.5, 6 Nevertheless, the search for novel 
biomarkers in PH is ongoing, resulting in new potential biomarkers reﬂecting various 
pathophysiological pathways.7, 8
 Because heterogeneous conditions involving diﬀerent pathophysiological 
pathways can give rise to the development and prognosis of PH, multiple biomarkers 
may potentially better reﬂect a patient’s condition. In addition, a combination of 
biomarkers could provide insight in the main pathophysiological mechanisms within 
PH subgroups. This study aimed to evaluate diagnosis-speciﬁc biomarker proﬁles and to 
investigate the associations of these biomarkers with clinical outcomes in patients with 
PH. Additionally, we explored the prognostic value of a multi-biomarker approach.
METHODS
Study design and population
In this prospective observational cohort study, we included all consecutive adult 
patients diagnosed with PH conﬁrmed by right heart catheterization between the 
15th of May 2012 and the 4th of October 2016 in our centre. A mean pulmonary artery 
pressure (mPAP) of ≥ 25 mmHg measured by right heart catheterization was used as 
cut-oﬀ value for the diagnosis of PH.4 Exclusion criteria were: patients with incomplete 
diagnostic work-up and therefore no conﬁrmed PH diagnosis, patients who already 
used PH-speciﬁc medication, patients aged < 18 years and patients not capable of 
understanding and signing informed consent. In addition, we excluded patients with 
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PH due to left heart disease because this cause of PH has a fundamental diﬀerent 
underlying pathophysiology than other PH groups9. The study protocol was approved 
by the medical ethical committee and written informed consent was provided by all 
patients. This study was performed conform the principles outlined in the Declaration 
of Helsinki. 
World Health Organization classification
Subgroups of PH were classiﬁed in accordance with the World Health Organization 
(WHO) classiﬁcation of PH:4, 10 pulmonary arterial hypertension (PAH), PH due to lung 
diseases/hypoxia, chronic thromboembolic pulmonary hypertension (CTEPH) and PH 
with unclear/multifactorial mechanisms (WHO5). Patients with a mixed clinical picture 
were grouped under WHO5. Group 1 patients (PAH) were further stratiﬁed in subgroups 
according to the WHO classiﬁcation. 
Data collection
During the inpatient screening visit for analysis of PH, all patients underwent physical 
examination by a cardiologist and pulmonary physician, 6-minute walking test, 12-
lead electrocardiography (ECG), echocardiography, venous blood sampling, chest 
computed tomography scan and right heart catheterization. Patient characteristics 
and vital signs were collected, including: age, sex, height, weight, blood pressure, heart 
rate and peripheral oxygen saturation. We used the New York Heart Association (NYHA) 
functional class to grade the severity of functional limitations by the presence of signs 
and symptoms of HF.
 During right heart catheterization, a Swan-Ganz catheter was inserted in the 
internal jugular vein. A standardized protocol for the work-up of PH was used to 
obtain hemodynamic measurements and thermodilution or Fick’s principle was used 
to measure the cardiac output. When the obtained capillary wedge pressure was 
ambiguous, a ﬂuid challenge was performed to distinguish between pre-capillary PH 
and PH due to left heart disease. 
 Data was collected and stored in PAHTool (version 4.3.5947.29411, Inovoltus, Santa 
Maria da Feira, Portugal), an online electronic case report form.
Echocardiography and cardiac computed tomography
Two-dimensional transthoracic echocardiography was performed using a commercially 
available ultrasound system (iE33, Philips Medical Systems, Best, the Netherlands). For 
the imaging analysis, we followed the guidelines for cardiac chamber quantiﬁcation by 
echocardiography from the American Society of Echocardiography and the European 
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Association of Cardiovascular imaging echocardiography.11 The systolic left ventricular 
function was visually graded as normal, mildly, moderately or severely impaired. We 
measured the left ventricular end-diastolic dimension in the parasternal long axis of 
the left ventricle. The 4-chamber view was used to measure the right atrial area, right 
ventricular basal dimension and right ventricular fractional area change. M-mode of 
the 4-chamber view was used to measure the tricuspid annular plane systolic excursion 
(TAPSE). The presence of pericardial eﬀusion was deﬁned as mild (< 10mm), moderate 
(10–20 mm) or severe (> 20mm) in one of the views. 
  Cardiac computed tomography was performed according to routine clinical 
practice. The central pulmonary artery diameter and the ascending aortic diameter 
were measured at the level of the pulmonary artery bifurcation.12
Clinical follow-up and definition of endpoints
Patients were prospectively followed-up by half-yearly scheduled visits to the outpatient 
clinic. Speciﬁc PH medications were prescribed when indicated in accordance with 
the ESC guidelines.4 Patients with CTEPH eligible for pulmonary endarterectomy or 
balloon pulmonary angioplasty were referred and treated when indicated. Patients who 
underwent one of the above procedures, were not censored afterwards. 
 The primary composite endpoint was deﬁned as all-cause mortality or lung 
transplantation. The secondary endpoint was a composite of all-cause mortality, lung 
transplantation or HF-related hospital admission that was deﬁned as any hospitalization 
due to symptoms or signs of HF requiring (additional) treatment with diuretics.  
 Survival status of all patients was checked in the Municipal Personal Records database. 
Suspected endpoint events were adjudicated by two independent researchers based 
on the electronic patient records. When necessary, we contacted referring hospitals and 
general practitioners to obtain additional information. Patients who did not reach the 
primary or secondary endpoint were censored at the 1st of June 2017. 
Biomarker assessment 
Venous blood samples were obtained during right heart catheterization for study 
purposes only and were at ﬁrst place not intended for clinical decision-making. 
Transference of the blood samples to the clinical chemistry laboratory took place within 
2 hours from withdrawal. NT-proBNP, estimated glomerular ﬁltration rate (eGFR) and red 
cell distribution width (RDW) levels were directly determined in the fresh blood samples. 
The lab-speciﬁc upper limits of normal (ULN) to deﬁne elevated levels were > 15 pmol/L 
(≈ 125 pg/mL) for NT-proBNP, > 16% for RDW, and < 60mL/min/1.73m2 for eGFR. 
 Other serum samples were aliquoted and stored at -80 degrees Celsius, until batch 
analysis was performed to determine high sensitive troponin-T (hs-TnT), high sensitive 
C H A P T E R  14  -  M u l t i - b i o m a r k e r  a p p r o a c h  i n  p u l m o n a r y  h y p e r t e n s i o n
298 
C-reactive protein (hs-CRP) and galectin-3. Defrosting of the samples took place in 
batches followed by immediate analysis, to ensure that samples were exposed to only 
one freeze-thaw cycle. A commercial electrochemiluminescence immunoassay (Roche 
Diagnostics, Rotkreuz, Switzerland) was used to determine the levels of hs-TnT and hs-
CRP with lower limits of detection (LoD) of 3 ng/L and 0.3 mg/L, respectively. The ULN 
was 14 ng/L for hs-TnT and 10 mg/L for hs-CRP. 
 Galectin-3 levels were measured with the ARCHITECT ci8200 analyser (Abbott 
Diagnostics, Hoofddorp, the Netherlands). The ARCHITECT assay is designed to have 
a limit of quantitation of ≤ 4.0 ng/mL. The ULN was based on the 97.5th percentile of 
a series of healthy volunteers, and was > 16.9 ng/mL for man and > 21.3 ng/mL for 
woman, as previously described.13 
Statistical analysis
Continuous variables were presented as mean ± standard deviation (SD) or median 
[interquartile range]. Biomarker levels were log
2
 transformed to correct for skewness. 
Biomarker values below the LoD were substituted with a value that was equal to 50% of 
the LoD, for analytical purposes. 
 Biomarker release was visualized in scatterplots. Comparisons of biomarker levels 
across PH subgroups were performed using a one-way ANOVA test or Kruskal-Wallis 
test. Correlations were reﬂected by the Pearson or Spearman correlation coeﬃcient, 
depending on the distribution of the data. Tertiles of the biomarker distributions were 
determined. The cumulative survival for the tertiles was calculated using the Kaplan-
Meier estimator; comparisons between survival tertiles were made using the log-rank 
test for trend. 
To compare the eﬀect sizes of the diﬀerent biomarkers, biomarker levels were 
standardized according to the mean and SD of their distribution, and the relation 
between the thus obtained Z-scores and study endpoints were evaluated by Cox 
proportional-hazards regression. Multivariable analysis was performed to correct for 
age as potential confounder in all further analysis. The corresponding C-index, reﬂecting 
the discriminative ability of each biomarker up to 40 months, was calculated. 
 Subsequently, all patients with complete biomarker proﬁles were included 
in a multi-biomarker model. Biomarkers were classiﬁed as normal or elevated 
according to the pre-speciﬁed cut-oﬀ value. The association of the number of 
elevated biomarkers with the study endpoints was evaluated by Cox regression. 
Statistical analysis was performed using IBM SPSS software (version 21.0.0.1). The 
C-index was calculated in R (version 3.3.3), packages SurvC1 and Survival. A two-sided 
p-value of < 0.05 was considered statistically signiﬁcant. 
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RESULTS
Baseline characteristics
A total of 164 consecutive patients underwent right heart catheterization as part of 
the screening for PH between 15th of May 2012 and 4th of October 2016, of which 106 
patients fulﬁlled the inclusion criteria and were enrolled in the study (Supplemental File 
1). Patients were classiﬁed as PAH (n = 54, 51%), PH-lung disease (n = 15, 14%), CTEPH (n 
= 21, 20%) and WHO5/multifactorial (n = 16, 15%). Baseline characteristics of all patients 
and speciﬁed for each PH diagnosis, are summarized in Table 1. Median age was 58.7 
[IQR 47.0–69.2] years, 68 (64%) were woman and 58 (55%) were in NYHA class III or IV. In 
8 patients, pericardial eﬀusion was present, of which 7 mild and one moderate. 
Follow-up 
The median follow-up duration was 23.9 (IQR 15.1–40.0) months. Follow-up data 
regarding mortality and other endpoints was 100% complete. During follow-up 
25 patients died and 4 patients underwent lung transplantation, so the primary 
endpoint was reached in 29 patients (27.4%). Causes of death included end-stage HF 
(n = 8), sudden death, presumed cardiac (n = 4), euthanasia in patients with end-stage 
cardiovascular and pulmonary disease (n = 3), multi-organ failure (n = 3), kidney and/
or liver failure (n = 2), myocardial infarction (n = 1), progression of systemic sclerosis (n 
= 1), hepatic encephalopathy (n = 1), malignancy (n = 1) and sudden death, presumed 
cerebral (n = 1). 
 Twenty-two patients were hospitalized for HF requiring (additional) diuretic 
treatment. This resulted in 37 (34.9%) patients who reached the secondary endpoint. Of 
the patients with CTEPH, three patients underwent balloon pulmonary angioplasty and 
three patients underwent pulmonary endarterectomy surgery. 
Biomarker release and PH classification 
Baseline levels of the six biomarkers stratiﬁed according to subgroups of PH are shown 
in Figure 1. Because of small numbers, heritable PAH, PAH induced by drugs and toxins, 
PAH associated with portal hypertension and PAH caused by pulmonary veno-occlusive 
disease were grouped as ‘other’.
 NT-proBNP signiﬁcantly diﬀered between the PH subgroups (p < 0.001). The highest 
levels of NT-proBNP were found in the patients with iPAH (median 205.0 pmol/L, IQR 
87.9–407.0 pmol/L) and PAH associated with connective tissue disease (median 190.0 
pmol/L, IQR 25.9–293.0 pmol/L). NT-proBNP was elevated in 82 (77%) patients. Of the 
patients with iPAH, all except one had an elevated NT-proBNP.
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FIGURE 1 - Biomarker release stratified according to the WHO classification of PH.
Biomarker levels are represented on the log 
2
 scale (except for eGFR; the skewness increased after log
2
 
transformation). Blue dotted line represents the biomarker-speciﬁc cut-oﬀ value. Red line represents the 
mean biomarker level in each group. For galectin-3, sex-speciﬁc biomarker cut-oﬀ values are represented 
(blue dotted line = men, pink dotted line = women). *Kruskal Wallis test, otherwise one-way ANOVA test.
 
14M u l t i - b i o m a r k e r  a p p r o a c h  i n  p u l m o n a r y  h y p e r t e n s i o n  -  C H A P T E R  14
303 
14
Hs-TnT also diﬀered signiﬁcantly between the PH subgroups (p = 0.03) and levels were 
lowest in CTEPH patients (median 9.0 ng/L, IQR 7.0–13.0 ng/L). In 43 patients (41%), an 
elevated level of hs-TnT was measured and found in particular in patients with PH-lung 
disease (64%). 
 We found no signiﬁcant diﬀerences in the levels of galectin-3, hs-CRP, RDW and eGFR 
between the subgroups of PH. Overall, 39% of the patients had an elevated level of 
galectin-3, this percentage was highest in those with PH-lung disease (65%) and iPAH 
(54%). 
Association between biomarkers and baseline characteristics
As shown in Table 2, all biomarkers signiﬁcantly correlated with the 6-minute walking 
distance, and all except hs-TnT and RDW showed a signiﬁcant correlation with NYHA class. 
NT-proBNP showed the strongest correlation with both the 6-minute walking distance 
(r = –0.46, p < 0.001) and NYHA class (r = 0.40, p < 0.001). NT-proBNP correlated with 
right ventricular and left ventricular function echocardiographic variables. In contrast, 
hs-TnT, hs-CRP, galectin-3 and RDW did not correlate with any of the echocardiographic 
ventricular function variables. In addition to NT-proBNP, only eGFR correlated with 
right atrial area, right ventricular basal dimension and left ventricular end diastolic 
dimensions. Hemodynamic measurements exclusively showed a signiﬁcant correlation 
with NT-proBNP levels. Mutual correlations between biomarkers were all signiﬁcant. 
The strongest correlation was found between hs-TnT and galectin-3 (r = 0.58, p < 0.001) 
(Supplemental File 2). 
Associations between biomarkers and clinical outcomes
The transplant-free survival according to tertiles of biomarker levels are visualized in 
the Kaplan-Meier curves (Figure 2). Patients in the highest tertiles of NT-proBNP, hs-TnT, 
galectin-3 and RDW had a signiﬁcantly higher risk of death or transplantation compared 
to patients in the lower tertiles.
 Concerning the secondary endpoint, patients in the highest tertiles of NT-proBNP, 
hs-TnT, galectin-3 and RDW, were at highest risk of death, transplantation or HF-related 
hospital admission. For eGFR, patients in the highest tertile of eGFR had a signiﬁcant 
worse event-free survival than patients in the lower tertiles (Supplemental File 3).
 Standardized hazard ratios for the association between the biomarker levels and the 
endpoints are shown (Figure 3). When analysed continuously, all biomarkers showed a 
signiﬁcant association with the primary endpoint, NT-proBNP, hs-CRP and hs-TnT had the 
highest hazard ratios. According to the C-index, NT-proBNP had the best discriminative 
power (C-index 0.69, 95% CI 0.58–0.81), followed by hs-TnT (C-index 0.67, 95% CI 0.56–
0.78) and galectin-3 (C-index 0.67, 95% CI 0.56–0.79) (Supplemental File 4).
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 All biomarkers were also signiﬁcantly associated with the secondary endpoint. For 
NT-proBNP and RDW, the standardized hazard ratio of the secondary endpoint increased 
relatively to the hazard ratio of the primary endpoint, as did the C-index.
TABLE 2 - Correlation coefficients of biomarkers with baseline characteristics.
NT-proBNP
n=106
Hs-TnT
n=104
Hs-CRP
n=104
Galectin-3
n=104
RDW
n=106
eGFR#
n=106
Clinical characteristics
Age, years#  0.10   0.36*** –0.19    0.28**  0.15    –0.43***
Sex, female  0.05   0.25* –0.11 –0.01  0.03  0.01
Body mass index, kg/m² –0.15 –0.04   0.24*  0.13 –0.01 –0.06
Heart rate, beats/minute  0.15  0.08  0.19    0.26**  0.13 –0.01
Systolic blood pressure, mmHg  –0.22* –0.18 –0.04 –0.13  –0.21*  0.04
Oxygen saturation < 90% –0.02 –0.06 –0.07 –0.02  0.07  0.13
NYHA class III/IV     0.40***  0.18   0.23*    0.30**  0.19   –0.38***
Electrocardiography
Loss of sinus rhythm 0.11 0.06 –0.13 –0.08 –0.05  0.01
QRS duration, ms# 0.11  0.24* –0.14  0.05  0.07 –0.01
6-minute walking test
Distance, m   –0.44***  –0.38**   –0.32**   –0.44***   –0.33**   0.40***
Echocardiography
RA area, cm²    0.41***  0.17 –0.13 –0.03 –0.01  –0.25*
RV basal dimension, mm    0.49***  0.18  0.13  0.03 –0.02  –0.28*
RV fractional area change, %   0.34** –0.17 –0.13 –0.19 –0.05  0.19
RV TAPSE, mm    0.43*** –0.19 –0.15  0.00 –0.06 –0.01
LV function, 0–3    0.35***  0.14  0.14  0.05  0.19 –0.08
LV end diastolic dimension, mm –0.31** –0.12 –0.16 –0.10  0.02     0.39***
Right heart catheterization
mPAP, mmHg#    0.42***  0.03  0.10 –0.01 0.07 –0.07
mRAP, mmHg     0.30**  0.16  0.18  0.16 0.13 –0.18
Capillary wedge pressure, mmHg –0.06 –0.03  0.01  0.07 0.03  0.02
Cardiac output, L/min#      0.46*** –0.17 –0.06 –0.01 0.03  0.18
Computed tomography
PA diameter, mm  0.03  0.11 –0.14 –0.05 –0.08 –0.03
PA/AO ratio –0.10 –0.13 –0.13   –0.26** –0.15  0.16
#Spearman, otherwise Pearson correlation coeﬃcient. Signiﬁcant values are presented in bold. Level of 
signiﬁcance is indicated by the number of asterisks. *indicates p < 0.05, **indicates p < 0.01, ***indicates p 
< 0.001. Abbreviations: RA, right atrial; RV, right ventricular; LV, left ventricular; mRAP, mean right arterial 
pressure; PA, pulmonary artery; AO, aortic artery.
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FIGURE 2 - Transplant-free survival according to tertiles of the biomarker levels.
NT-proBNP: ﬁrst tertile < 26.57 pmol/L, second tertile 26.57–150.0 pmol/L, third tertile > 150.0 pmol/L. Hs-TnT: 
ﬁrst tertile < 2.0 ng/L, second tertile 2.0–6.3 ng/L, third tertile > 6.3 ng/L. Hs-CRP: ﬁrst tertile < 2.0 mg/L, second 
tertile 2.0–6.3 mg/L, third tertile > 6.3 mg/L. Galectin-3: ﬁrst tertile ≤ 15.3 ng/mL, second tertile 15.3–19.9 
ng/mL, third tertile > 19.9 ng/mL. RDW: ﬁrst tertile ≤ 13.6%, second tertile 13.6–15.5%, third tertile > 15.5%. 
eGFR: ﬁrst tertile > 80.3 ml/min, second tertile 60.0–80.3 ml/min, third tertile ≤ 60 ml/min (tertiles of eGFR are 
inversed).
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FIGURE 3 - Standardized hazard ratios, reflecting the instantaneous risk of the primary and secondary endpoint per 
one standard deviation increase in the biomarker level.
Standardized hazard ratios adjusted for age with the corresponding 95% CI and p-value for each biomarker. 
*For eGFR the inverse hazard ratios are shown.
A
5 < 1
B
FIGURE 4 - Transplant-free and event-free survival stratified according to the number of elevated biomarkers.
Figure legend shows the number of elevated biomarkers (lowered for eGFR) with the corresponding line 
colour (detailed explanation of the diﬀerent groups is provided in Supplemental File 5).
Multi-biomarker approach
Figure 4A shows the Kaplan-Meier curve stratiﬁed according to the number of elevated 
biomarkers. Patients with zero elevated biomarkers were free of events after 40 months 
whereas of the patients with ﬁve or six elevated biomarkers, only 37% was alive and 
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free of transplantation. The age adjusted hazard ratio for the primary endpoint for one 
extra elevated biomarker was 1.33 (95% CI 1.07–1.64, p = 0.01). Multi-biomarker analysis 
concerning the secondary endpoint (Figure 4B) showed similar results (HR 1.33, 95% CI 
1.10–1.60, p = 0.003).
DISCUSSION
This study investigated diagnosis-speciﬁc biomarker proﬁles, the prognostic value of 
these biomarkers and the potential beneﬁt of a multi-biomarker approach in adult 
patients with PH. 
 A signiﬁcant diﬀerence in the biomarker release of NT-proBNP and hs-TnT among 
the diﬀerent subgroups of PH was found and only 11% of the patients was free of any 
abnormal biomarker level. All six biomarkers studied in this prospective cohort were 
associated with adverse clinical outcomes, independent of age. A multi-biomarker 
approach demonstrated that patients were at higher risk of events as more biomarkers 
were elevated, wherein the absence of any elevated biomarker ruled out the risk of any 
event up to 40 months. This study therefore shows the importance of involving multiple 
biomarkers in the risk stratiﬁcation of patients with PH. 
 Strengths of this study are its prospective design and the inclusion of only treatment 
naïve patients. The biomarkers therefore reﬂect a more natural state of disease severity, 
which is unaﬀected by treatment status. Additionally, this study evaluated the levels of 
six biomarkers measured at one point in time reﬂecting a patients’ underlying disease 
state at a single moment. Patients with PH due to left heart disease were excluded in this 
study, to prevent any interference in biomarker levels due to myocardial stress primary 
caused by the left ventricle. We aimed to base our conclusions merely on processes 
regarding failure of the right ventricle. 
New biomarker for PH: galectin-3
To our knowledge, this is the ﬁrst prospective cohort study investigating the association 
with galectin-3 and clinical outcomes in patients with heterogeneous types of pre-
capillary PH. Galectin-3 belongs to the beta-galactose-binding lectins and induces 
cardiac ﬁbroblast proliferation, a process associated with the development of HF.14 
Galectin-3 may particularly be appropriate to monitor right ventricular remodelling.15 
Previous studies investigating galectin-3 mainly focused on patients with PAH only 
and consisted of smaller cohorts.15-17 Calvier et al. found elevated levels of galectin-3 
in PAH patients, which correlated with NYHA class.17 Mazurek et al. demonstrated that 
galectin-3 was associated with mortality, however this study included both patients with 
PAH and patients with PH due to left heart disease.16 In our current study, we had the 
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unique opportunity to compare diﬀerent subgroups of PH. Only 38.5% of the patients 
with a galectin-3 level of > 19.9 ng/mL was alive and free of transplantation or HF after 
40 months. Galectin-3 should therefore be considered as a new promising prognostic 
biomarker in the pre-capillary PH population.
Cardiovascular health ‘barometer’: red blood cell distribution width 
Previous studies investigating the prognostic role of RDW in patients with PH already 
demonstrated that levels of RDW are associated with mortality,18 even independent 
of NT-proBNP.19 A variety of mechanisms have been hypothesized to elucidate the 
prognostic value of RDW in HF patients. Levels of RDW appear to reﬂect an underlying 
inﬂammatory state and an impaired iron metabolism. It has been suggested that RDW 
can be seen as an overall cardiovascular health ‘barometer’.20, 21
 In our study, elevated levels of RDW were observed in all subgroups of PH and were 
associated with death or transplantation, independent of age. Patients with RDW > 
15%, have a cumulative transplant-free survival of only 48.3% after 40 months. Adding 
HF-related hospital admission to the endpoints increased the hazard ratio as well as the 
C-index. This suggests that besides being able to predict mortality or transplantation, 
RDW may be even better in predicting HF. Since RDW is determined as part of the 
automated blood count, RDW is an inexpensive, easy-accessible and widely available 
biomarker. 
Heterogeneity across the PH population
A diﬃculty when studying the PH population is the major diversity in aetiology and the 
presence of PH-related comorbidities. The prognosis may be explained by the interaction 
between PH and the PH-related comorbidities, which diﬀers between individuals. Cause 
of death in our study were diverse, with only 8 patients dying merely due to end-stage 
HF. It is therefore not surprising that many (potential)biomarkers are suggested for the 
risk stratiﬁcation and that there is an increasing demand for a multi-biomarker approach 
that can capture more pathophysiological axes.7 Indeed, the diﬀerent biomarkers in this 
study demonstrate that the pathophysiology of PH is complex and that one should not 
merely focus on one all-encompassing biomarker.
Future perspectives
This multi-biomarker approach gives promising results regarding the prognostic value 
of combining multiple biomarkers. Especially, the negative predictive value was very 
good. However, a larger cohort of patients is needed to correct for the levels of the 
other biomarkers in a multivariable analysis and to investigate the diagnosis-speciﬁc 
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prognostic value of all diﬀerent biomarkers. Additionally, it would be of interest to 
investigate whether serial biomarker measurements may improve prognostic precision 
and can monitor therapy.  Eventually, a cost-eﬀectiveness study should be performed 
to determine which biomarkers should be included in the multi-biomarker approach to 
be most proﬁtable. 
Study limitations
NT-proBNP, RDW and eGFR were directly determined in the clinical laboratory and 
therefore these biomarker results were directly available for the treating physician of 
a patient. Particularly NT-proBNP is an established biomarker and is used for the risk 
assessment in PH.4 It was therefore inescapable and not ethical, to ignore NT-proBNP 
in the considerations of the clinical management. As a result, this may have diluted the 
association between NT-proBNP and clinical outcomes.
 Six patients with CTEPH underwent pulmonary endarterectomy or percutaneous 
transluminal pulmonary angioplasty. Patients were not censored after the procedure 
because this would have introduced bias. However, keeping this patients in the study 
may also have biased the association between biomarker levels and clinical events, 
most likely towards the null.
 Conclusions regarding the multi-biomarker approach should be treated with 
caution. This study demonstrates an association between the number of elevated 
biomarkers and the risk of events. 
 However, we could not correct for the underlying biomarker correlations in a 
multivariable-analysis due to limited numbers of events. The biomarkers may share 
some common prognostic eﬀect; hence the exact additive prognostic value of each 
biomarker is diﬃcult to compute. Also, the number of elevated biomarkers is analysed 
continuously instead of categorical due to limited degrees of freedom. Due to the 
relatively small sample size and limited number of events, the power of this study was 
not suﬃcient to correct for the diﬀerent PH subgroups. 
CONCLUSIONS
This study showed that a wide range of biomarkers reﬂecting diﬀerent pathophysiological 
pathways are signiﬁcantly associated with an increased risk of mortality, lung 
transplantation and HF in patients with PH. Combining multiple biomarkers is beneﬁcial 
in detecting patients at higher risk of events.
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SUPPLEMENTAL MATERIAL
Consecutive patients screened 
for PH including a RHC in the 
Erasmus MC between the 15th of 
May 2012 and the 4th of October 
2016 (n = 164) 
Patients diagnosed with PH 
confirmed by RHC and 
biomarker level measurements 
at baseline (n = 106) 
Exclusion (n = 58) 
 No informed consent (n = 8)  
 No PH (mPAP  < 25 mmHg) (n  = 29) 
 PH due to left heart disease (n  = 7) 
 Incomplete diagnostic work-up (n = 11) 
 Not treatment naive (n = 3) 
x PAH (n = 54) 
Ͳ iPAH (n  = 13)  
Ͳ Hereditary PAH (n  = 2) 
Ͳ Drug and toxin induced (n  = 1) 
Ͳ PAH -connective tissue disease (n  = 17) 
Ͳ PAH -portal hypertension (n = 7) 
Ͳ PAH -congenital heart disease (n  = 12) 
Ͳ PVOD (n  = 2) 
x PH-lung disease (n = 15) 
x CTEPH (n = 21) 
x WHO5  / multifactorial (n = 16) 
SUPPLEMENTAL FILE 1 - Flowchart of the patient selection process.
SUPPLEMENTAL FILE 2 - Mutual correlations between the different biomarkers in patients with pulmonary 
hypertension.
NT-proBNP Hs-TnT Hs-CRP Galectin-3 RDW
r r r r r
Hs-TnT 0.51***
Hs-CRP 0.37*** 0.43***
Galectin-3 0.40*** 0.58*** 0.48***
RDW 0.28** 0.36*** 0.29** 0.26**
eGFR# -0.52*** -0.42*** -0.22* -0.43*** -0.21*
#Spearman correlation coeﬃcient, otherwise Pearson correlation coeﬃcient. Level of signiﬁcance is indicated 
by the number of asterisks (*); *indicates p < 0.05, **indicates p < 0.01, ***indicates p < 0.001.
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SUPPLEMENTAL FILE 3 -Event-free survival according to tertiles of the biomarker levels. 
NT-proBNP: ﬁrst tertile < 26.57 pmol/L, second tertile 26.57–150.0 pmol/L, third tertile > 150.0 pmol/L. Hs-TnT: 
ﬁrst tertile < 2.0 ng/L, second tertile 2.0–6.3 ng/L, third tertile > 6.3 ng/L. Hs-CRP: ﬁrst tertile < 2.0 mg/L, second 
tertile 2.0–6.3 mg/L, third tertile > 6.3 mg/L. Galectin-3: ﬁrst tertile ≤ 15.3 ng/mL, second tertile 15.3–19.9 
ng/mL, third tertile > 19.9 ng/mL. RDW: ﬁrst tertile ≤ 13.6%, second tertile 13.6–15.5%, third tertile > 15.5%. 
eGFR: ﬁrst tertile > 80.3 ml/min, second tertile 60.0–80.3 ml/min, third tertile ≤ 60 ml/min (tertiles of eGFR are 
inversed).
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ABSTRAC T
In order to adequately manage the rapidly expanding population of patients with 
adult congenital heart disease (ACHD) and to optimize patient outcomes, accurate 
prognostication is of paramount importance. A large part of the risk stratiﬁcation 
of patients with ACHD is based on the underlying anatomical defect, concomitant 
lesions and type of corrective surgery that was performed. In addition, components 
of the medical history, physical examination and further diagnostic tests (including 
ECG, echocardiography, cardiac magnetic resonance imaging, exercise testing, and 
biomarkers) can provide prognostic information. This chapter provides a narrative 
review of the factors that have been identiﬁed as predictors for heart failure and other 
late complications in the entire cohort of patients with ACHD and within speciﬁc 
congenital subgroups.
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INTRODUC TION
The population of adult patients with congenital heart disease is steadily growing and 
aging, thanks to the major advances in cardiothoracic surgery and pediatric cardiology 
in the past decades. Although survival has improved and most of these patients 
have no complaints, today it is widely acknowledged that congenital heart disease is 
palliated, not cured. Residual or recurrent structural heart defects are common, and 
may result in late complications such as heart failure and early demise. Therefore, these 
patients require lifelong surveillance and care in specialized cardiac centers.1 In order 
to adequately manage this rapidly expanding population and to optimize patient 
outcomes, accurate prognostication is of paramount importance. 
 The etymology of the word ‘prognosis’ dates back from the ancient Greek civilization, 
and is literally translated as ‘foreknowledge’. As a medical term, it is used to indicate the 
likely course and outcome of a disease. We aim to determine this forecast by a range 
of patient characteristics and tests, in order to make individualized risk predictions as 
accurate as possible. This chapter is therefore structured by a range of components that 
can be useful to stratify the risk of heart failure and other late complications in patients 
with ACHD. Although state-of-the-art prognostication and treatment in patients with 
ACHD is often based on extrapolated data from patients with chronic heart failure, this 
chapter aims to focus on the evidence that is available from congenital patients.
MEDIC AL HISTORY
Congenital defect and corrective surgery
The congenital heart defects can be grouped into mild, moderate and complex lesions.2 
This classiﬁcation is important, because it is well known that the survival of patients 
with a complex heart defect is substantially worse than the survival of patients with a 
mild type of heart defect.3-6 Patients with repaired patent ductus arteriosus and atrial 
or ventricular septal defects have the lowest all-cause mortality, being only slightly 
higher than or even comparable to the general population.4, 6, 7 In contrast, the long-
term survival of patients with a cyanotic defect, Fontan circulation, systemic ventricular 
heart or other complex congenital heart disease is clearly diminished with a substantial 
morbidity.4, 5, 8 The most frequent cause of death in these patients is chronic heart failure.4
Among patients with the same congenital defect at birth, it is very important which type 
of corrective surgery was performed. In patients with transposition of the great arteries 
(TGA), major diﬀerences in ventricular function and functional capacity exist between 
those with a systemic right ventricle after a Mustard or Senning procedure compared 
with those who underwent anatomical correction by an arterial switch operation in a 
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more recent surgical era.9 Consequently, the survival of patients with TGA has markedly 
improved.10 Also the pre-operative anatomy may vary in severity, and concomitant 
congenital lesions in other organs may be present. For instance, in patients with a Fontan 
circulation, the pre-operative anatomy signiﬁcantly impacts patient outcomes, with the 
lowest overall survival in patients with hypoplastic left heart syndrome11 and heterotaxy 
syndrome.12 The presence of concomitant lesions that require more extensive surgical 
correction, such as atrioventricular valve replacement at the time of Fontan correction, 
is also related to a higher risk of morbidity and mortality during long-term follow-up.12
 Among patients with the same congenital defect and type of repair, the practice of 
repair has undergone major changes over the past decades. Apart from improvement 
in surgical experience and quality of postoperative care, today’s surgical techniques 
are diﬀerent from those in the past and are adapted based on the late sequelae we 
now observe more than three decennia after repair. For instance, in patients with 
tetralogy of Fallot, later age at initial repair and the use of a palliative shunt have been 
shown to be associated with worse outcomes.13-15 Corrective surgery is now seldom 
performed beyond the ﬁrst half of infancy, and palliative shunts are almost no longer 
used. Modern strategies that include the avoidance of the use of a transannular patch 
and pulmonary valve-sparing approaches may improve patient outcomes,15 although 
comparisons are diﬃcult because of era diﬀerences and the lack of long-term follow-up 
data of newer approaches.16 In patients with a Fontan circulation, the overall survival 
has also greatly improved in later surgical eras, with the worst outcomes in patients 
with an atriopulmonary connection (the original technique),11, 17 and probably the best 
outcomes in patients with an extracardiac conduit. Fontan patients with a longer bypass 
time also have an increased risk of mortality.12
 In conclusion, the severity of the congenital heart disease is not only based on the 
type of defect, but also strongly inﬂuenced by the type of corrective surgery, presence 
of concomitant lesions, and surgical era. Based on these diﬀerences, a suggested 
modiﬁcation of the original Bethesda classiﬁcation is provided in Table 1, which could 
be useful for the further guidance of follow-up schemes.
Genetics
The identiﬁcation of a genetic syndrome or mutation is important, not only because it 
provides implications for future oﬀspring, but also because speciﬁc genetic variations 
are related to the risk of developing associated cardiac complications, such arrhythmias 
and heart failure. For instance, ASD patients with an associated NKX2.5 syndrome have 
a higher risk of the development of atrioventricular block and ventricular dysfunction,18 
and may even develop dilated cardiomyopathy. TBX5 is a gene which is involved 
in Holt-Oram syndrome, which includes atrioventricular node disease, and also 
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modulates diastolic dysfunction.19 MYH6 mutations are associated with various forms 
of congenital heart disease, but also with hypertrophic, dilated and noncompaction 
cardiomyopathy.20 In addition, a cardiac congenital abnormality as part of a genetic 
syndrome (such as Down, Patau, Edward, DiGeorge, Turner, Williams-Beuren, Noonan, or 
Alagille syndrome) can also involve non-cardiac malformations.21 These may impact peri-
operative morbidity, and can have long-standing ramiﬁcations on neurodevelopment 
and overall health.22
TABLE 1 - Modified Bethesda classification.
Mild congenital 
heart disease
Moderate congenital 
heart disease
Complex congenital
heart disease
Unrepaired PFO or small ASD  
(no associated lesions)
Unrepaired PDA, ASD II, SVD, VSD 
(with signiﬁcant shunt)
Congenitally corrected TGA
Unrepaired small VSD  
(no associated lesions)
AVSD (partial or complete, 
repaired or unrepaired)
Systemic right ventricle after 
Mustard/Senning repair for TGA
Repaired PDA PAPVR with signiﬁcant 
hemodynamic shunt or TAPVR
Truncus arteriosus
Repaired ASD II or SVD without 
residual shunt
Ebstein’s anomaly Conduits, valved or nonvalved
Repaired VSD without residual 
shunt
Aortic coarctation Double inlet left ventricle or 
double outlet right ventricle
Mild congenital aortic valve 
disease
Moderate/severe congenital aortic 
disease (subvalvar, valvular or 
supravalvar)
Hypoplastic left or right heart 
syndrome
Mild congenital mitral valve 
disease (no associated lesions)
Moderate/severe mitral valve 
disease (including parachute 
valve, cleft leaﬂet)
Mitral or tricuspid atresia
Mild pulmonary valve disease Moderate/severe pulmonary valve 
disease or RVOT obstruction
Fontan procedure
 Arterial switch operation for TGA PAH-CHD
Repaired tetralogy of Fallot Eisenmenger syndrome
 Pulmonary atresia with 
biventricular repair
Cyanotic congenital heart disease
Abbreviations: ASD, atrial septal defect; AVSD, atrioventricular septal defect; PAH-CHD, pulmonary arterial 
hypertension due to congenital heart disease; PAPVR, partial anomalous pulmonary venous drainage; PDA, 
patent ductus ateriosus; PFO, patent foramen ovale; RVOT, right ventricular outﬂow tract; SVD, sinus venosus 
defect; TAPVR, total anomalous pulmonary venous drainage; TGA, transposition of the great arteries; VSD, 
ventricular septal defect.
Age
The presence of chronic pressure or volume overload and cyanosis, as a result of valvular 
dysfunction, shunts, or other residual lesions, carry long-term eﬀects that steadily 
increase over time. These eﬀects include atrial and ventricular dilatation, dysfunction, 
ﬁbrosis, and other forms of disease progression. Accordingly, observational studies 
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show that the risk of heart failure and death continues to increase with age in patients 
with ACHD.4, 23, 24 Apart from disease progression, the oldest patients also originate from 
an earlier surgical era, with a corresponding median later age at corrective surgery 
and possibly outdated surgical methods.5 The oldest patients with ACHD therefore 
carry multiple risk factors for the development of heart failure. However, the strong 
positive correlation between age and age at initial corrective surgery makes it diﬃcult 
to distinguish their separate eﬀects, and to foresee the rate of disease progression with 
age in the infants that are operated today with newer techniques.
Sex
Within the general population, men have a shorter life expectancy than women. 
Leading explanations can be classiﬁed social/environmental (such as risky behavior, 
smoking, alcohol, homicide, suicide) and biological (such as eﬀects of estrogen versus 
testosterone).25 This sex gap is also observed in patients with ACHD26 and within speciﬁc 
diagnostic subgroups such as Fontan palliation.11 It is unknown whether this can be 
directly translated from the general population, or whether other factors such as 
medical therapy adherence also play a role. 
Previous (re)interventions
Patients with multiple previous surgical or percutaneous (re)interventions are more 
frequently followed-up in a tertiary referral center. These patients are likely to represent 
a more complex congenital group and/or are in a worse clinical condition, with a 
subsequent higher mortality risk.3 Multiple previous sternotomies may be present in 
congenital patients and can also be a risk factor on its own, because these increase the 
risk of complications during surgery. Nevertheless, the absolute risk of reentry injury 
during repeat sternotomy for congenital heart disease is low.27
Previous heart failure or arrhythmia
A history of heart failure is associated with higher mortality rates, for instance in 
patients with repaired tetralogy of Fallot.15 A history of arrhythmias is also signiﬁcantly 
associated with worse outcomes, such as the occurrence of heart failure, late 
arrhythmias or mortality in patients with tetralogy of Fallot,14, 28 Mustard5 and Fontan 
palliation.12, 17 The association between early arrhythmias and heart failure may be 
explained by surgical damage to the conduction system and post-operative scarring. 
In addition, the presence of a pacemaker has been identiﬁed as a risk factor for 
mortality.29 Pacemaker implantation in young adults with congenital heart disease 
is related to higher NT-proBNP levels, lower peak oxygen uptake, and a longer QRS 
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duration, indicating that longstanding abnormal ventricular activation in patients with 
a pacemaker may contribute to progressive ventricular dysfunction and the occurrence 
of heart failure.30
Cardiac medication use
Patients who do not use any cardiac medication such as an ACE-inhibitor, angiotensin 
receptor blocker, beta blocker, diuretic or anti-arrhythmic are more likely to be in a 
good clinical condition, and have a much lower risk to develop heart failure.23 Patients 
who do use cardiac medication may have a history of heart failure or arrhythmia, with a 
subsequent higher risk of recurrence. In addition, the chronic use of negative inotropic 
antiarrhythmic drugs may negatively aﬀect ventricular function. In patients after Fontan 
correction, diuretic therapy was strongly related to death, transplant31 or hospitalization 
for cardiac reasons.17
 Also, the lack of adequate medical therapy may increase the risk of complications. 
In many centers, all Fontan patients are routinely treated with systemic anticoagulation 
in order to manage the high thromboembolic risk due to low ﬂow in the Fontan circuit, 
reduced cardiac output, possible Fontan obstruction and atrial arrhythmias. Fontan 
patients lacking thromboprophylactic therapy (warfarin or aspirin) have been shown to 
carry a higher risk of death or transplant.31
Clinical symptoms of heart failure
Most patients with ACHD have no complaints and do not readily report symptoms. 
Patients often do not recognize subtle changes in functional class and may have no typical 
symptoms of heart failure. When present, symptoms of heart failure in congenital heart 
disease include symptoms of systemic ventricular failure (fatigue, dyspnea, dry cough, 
reduced exercise tolerance, orthopnea, paroxysmal nocturnal dyspnea, wheezing) and 
symptoms of sub-pulmonary ventricular failure (fatigue, bloating, weight gain, loss of 
appetite, reduced exercise tolerance, increased abdominal girth).32 Clinical heart failure 
based on history, examination and further investigations is documented in 22% of 
patients with Mustard repair for TGA, in 32% of patients with congenitally corrected 
TGA, and in 40% of patients after Fontan operation.32 Early recognition and diagnosis 
of clinical heart failure is very important. New York Heart Association (NYHA) functional 
class can be used to classify symptoms of heart failure, with patients who report no 
limitation in ordinary physical activity considered as NYHA functional class I. NYHA class 
is known to be signiﬁcantly associated with adverse outcomes in the overall population 
of patients with ACHD4 and also for instance in subgroups of patients with repaired 
tetralogy of Fallot33 and Fontan palliation.34
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PHYSIC AL EX AMINATION
Clinical signs of heart failure
Signs of systemic ventricular failure on physical examination in patients with ACHD 
include a third or fourth heart sound, a laterally displaced apical impulse, basal crackles, 
absent breath sounds and dull percussion at the lung basal ﬁelds. Signs of sub-pulmonary 
failure are elevated jugular venous pressure, hepatomegaly, ascites, pitting leg, sacral or 
scrotal edema.32 Of note, arrhythmias could also be a ﬁrst clinical manifestation of heart 
failure. In addition, worsening of cyanosis could be present in patients with intra- or 
extra-cardiac shunts or fenestrations. 
Oxygen saturation
Pulse oximetry is routinely carried out alongside clinical examination mostly for 
diagnostic purposes. However, it also provides prognostic information. Systemic oxygen 
desaturation is related to a higher risk of cardiovascular events, death or heart failure in 
the entire ACHD population23 and also predicts mortality risk in speciﬁc subgroups such 
as Eisenmenger patients24 and Fontan patients.29
ELEC TROC ARDIOGRAPHY AND HOLTER MONITORING
Most patients with ACHD have abnormal electrocardiograms (ECGs). Therefore, 
comparison with previous ECGs in order to detect intra-individual changes in ECG 
morphology are most relevant to detect underlying disease progression with a higher 
risk of adverse events.
 In concordance with a history of arrhythmia, also the loss of sinus rhythm at standard 
electrocardiographic evaluation is a strong predictor for clinical outcomes, for instance 
in patients with Eisenmenger syndrome.24 Additional evaluation of arrhythmias is 
primarily performed in symptomatic patients, and may require ambulatory ECG 
monitoring (Holter), event recorders or implantable loop recorders. A grade II or greater 
ventricular arrhythmia on ambulatory ECG (which includes ≥ 30 unifocal or multifocal 
premature ventricular complexes per hour, non-sustained or sustained ventricular 
tachycardia) has been shown to be a risk marker of sudden death in some cohorts of 
patients with repaired tetralogy of Fallot,35 but not in all.15, 36
 Increased QRS duration has been shown to be associated with the occurrence 
of heart failure in ACHD patients with a pacemaker.30 Also in patients with repaired 
tetralogy of Fallot, a prolonged QRS duration was predictive of ventricular tachycardia 
and death;15, 37 however, conﬂicting data have been reported.14
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 Although the current survival of patients after arterial switch operation for TGA 
is excellent, the most frequent cause of morbidity and mortality is coronary artery 
obstruction, which is present in 5 to 7% of survivors. Annual ECG evaluation for signs of 
ischemia (with advanced imaging if indicated) is therefore recommended in all arterial 
switch patients with ostial stenosis identiﬁed in childhood.10
TRANSTHORACIC ECHOC ARDIOGRAPHY
Echocardiography is a widely available, portable, cheap, and non-invasive imaging 
technique that plays a key-role in the clinical follow-up of patients with ACHD. However, 
the quality of echocardiographic measurements are highly user-dependent and 
ventricular function and volumes can be challenging to assess in adults with complex 
congenital heart diseases such as univentricular hearts or systemic right ventricles.38 An 
overview of some important echocardiographic predictors that are discussed below is 
also provided in Figure 1.
Systolic ventricular function
The systolic ventricular function is one of the most important prognostic parameters 
obtained by echocardiography in the ACHD population. A moderately to severely 
impaired systemic ventricular function (as expressed by an ejection fraction below 40%) 
is an independent predictor for sudden cardiac death in the overall ACHD population.39 
This is also the case in speciﬁc ACHD subpopulations such as in patients with repaired 
tetralogy of Fallot40 and in patients with a systemic right ventricle after Mustard 
procedure.41 Also the right ventricular (or subpulmonary) systolic function has been shown 
to be of prognostic importance, for instance as quantiﬁed using fractional area change.42
 The tricuspid annular plane systolic excursion (TAPSE) quantiﬁes the longitudinal 
right ventricular function in M-mode. In patients with pulmonary arterial hypertension 
the TAPSE is frequently reported as an important predictor for adverse clinical 
outcomes.43 Accordingly in patients with Eisenmenger syndrome, one study showed 
that TAPSE was associated with the risk of mortality;44 however, contradictory results 
have been published in this patient group.24 In patients with a systemic right ventricle 
after the Mustard procedure, the prognostic value of the lateral versus the septal TAPSE 
may diﬀer.45 Nevertheless, the TAPSE was not associated with the right ventricular 
ejection fraction as measured by cardiac magnetic resonance imaging (CMR) in these 
patients,46 and the contraction pattern of the systemic right ventricle is thought to shift 
from longitudinal to circumferential shortening.47 Therefore, the prognostic value of 
TAPSE may be limited in this patient group. Although less often used, the mitral annular 
plane systolic excursion (MAPSE) was found to be associated with sudden cardiac death 
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and ventricular arrhythmias in patients with repaired tetralogy of Fallot, even beyond 
the left ventricular ejection fraction.42
 Other measures of the global ventricular function are the myocardial performance 
index (Tei index) and systolic to diastolic duration ratio. The systolic to diastolic duration 
has been reported as independent predictor of mortality in patients with a Fontan 
circulation and is relatively easy to measure, despite of the complex anatomy of the 
heart.48
FIGURE 1 - Echocardiographic predictors of adverse clinical outcome in patients with ACHD.
A, measurement of left ventricular ejection fraction using the biplane method of disks (modiﬁed Simpson’s rule) 
in a patient with aortic coarctation. B, mildly reduced TAPSE (< 16 mm) in a patient with tetralogy of Fallot. C, 
severe pulmonary valve regurgitation visualized using color ﬂow Doppler in a patient with tetralogy of Fallot. 
D, severe biatrial dilatation and E, D-shaped left ventricle in a patient with pulmonary arterial hypertension 
after surgical repair of a sinus venosus defect and partial anomalous pulmonary venous return. F, pericardial 
eﬀusion in a patient with pulmonary arterial hypertension. G, global longitudinal left ventricular strain as 
quantiﬁed with speckle tracking echocardiography (courtesy of R.W.J. van Grootel). H, 3D echocardiography 
analyzed using automated software (Heart Model).
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Ventricular and atrial dilatation 
In patients with a systemic right ventricle, the ejection fraction may not always be a 
good indicator for the systolic ventricular function due to the frequent occurrence of 
atrioventricular valve regurgitation, which paradoxically increases the ejection fraction. 
One study has reported the systemic right ventricular end-diastolic volume to be a 
better parameter for adverse outcomes in patients with a systemic right ventricle.49 In 
patients with repaired tetralogy of Fallot, right ventricular dilatation is often used to in 
the timing of pulmonary valve replacement, because it is thought that a severely dilated 
right ventricle is unable to reverse remodel. 
 Heart failure may lead to atrial dilatation due to chronic diastolic dysfunction.50 
Several studies have shown that both left and right atrial enlargement is related to a 
worse clinical prognosis.51 In patients with pulmonary hypertension and in patients with 
Eisenmenger syndrome, increased right atrial area was found to be a strong predictor for 
adverse clinical outcomes.43, 44, 52 Its association with disease severity can be explained 
by the failure of the right heart to overcome the high pulmonary pressures. As a result, 
the pressures in the right ventricle and right atrium will increase, which is often reﬂected 
by enlargement of the right atrium. 
Shunt lesions and valve disease
Doppler echocardiography can also be used to detect shunt lesions and to grade the 
severity of valve disease. The presence of a substantial shunt lesion or a hemodynamically 
signiﬁcant residual shunt after ASD or VSD repair is important to detect and may require 
transoesophageal echocardiography to be adequately visualized, because it impacts 
the classiﬁcation of the severity of the heart defect and the follow-up strategy.2 The 
presence of a pretricuspid shunt has been reported to be an independent predictor of 
death in Eisenmenger patients.24
 The grade of valvular stenosis or regurgitation also determines the severity of the 
heart defect 2, and is important to regularly assess during the routine echocardiographic 
follow-up of patients with valvular disease. For instance, in patients with repaired 
tetralogy of Fallot, a moderate or severe tricuspid or pulmonary valve regurgitation 
has been reported to be associated with an increased risk of sudden cardiac death and 
arrhythmias.15
Pulmonary arterial hypertension 
A substantial proportion of patients with ACHD develops pulmonary arterial 
hypertension and ultimately Eisenmenger syndrome.53 Doppler echocardiography can 
be used to estimate pulmonary pressures based on the maximal tricuspid regurgitation 
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velocity (together with the estimated right atrial pressure, based on inferior vena cava 
diameter and collapse) or the pulmonary regurgitation maximal and end-diastolic 
velocity. Long-standing pressure overload of the right ventricle may lead to progressive 
right ventricular heart failure. Therefore, it is not surprising that elevated pulmonary 
pressures are strongly indicative of a poor prognosis, and it is important to regularly 
follow-up right ventricular systolic pressures and function in patients with pulmonary 
hypertension to timely detect further deterioration.
 Pericardial eﬀusion may develop in patients with elevated ﬁlling pressures of the 
right side of the heart.54 In patients with pulmonary arterial hypertension, pericardial 
eﬀusion is the most extensively documented parameter that is known to be of 
prognostic importance.43 In a multicentre study including patients with Eisenmenger 
syndrome, in 9.2% of the patients pericardial eﬀusion was present. The presence of 
pericardial eﬀusion was found to be a strong predictor for all-cause mortality, even after 
adjusting for other risk factors such as age, NYHA class, pretricuspid shunt, sinus rhythm 
and oxygen saturation.24
 Another speciﬁc prognostic parameter in pulmonary arterial hypertension is the 
septal shift during systole due to elevated pressures in the right ventricle,52 which is also 
known as the ‘D-sign’ visible on the echocardiography. 
Novel echocardiographic techniques
Speckle tracking echocardiography is a technique which can be used to obtain the 
ventricular function based on the quantitative assessment of myocardial deformation 
(strain) and myocardial displacement of displacement rate (velocity) with a high 
temporal resolution.55, 56 One study has shown that systemic right ventricular two-
dimensional longitudinal strain was associated with adverse clinical outcomes such 
as death, arrhythmias and an increase in NYHA class in patients with a systemic right 
ventricle.45 In patients with tetralogy of Fallot, the left ventricular longitudinal strain was 
related to sudden cardiac death or life threatening arrhythmias and was associated with 
a higher NYHA class.42 
 Three-dimensional (3D) echocardiography is an excellent imaging technique to 
visualize complex congenital anatomies and the technique has improved impressively 
over the past years. Unfortunately, it is still not widely available and mainly relies 
on manual input, making it a time consuming echocardiographic technique. New 
software has been developed to automatically analyze 3D images to shorten analysis 
time and to make it more feasible for routine practices. This novel software has been 
shown to measure the left atrial volume, left ventricular volume and the left ventricular 
ejection fraction in strong agreement with CMR measurements,57, 58 also within speciﬁc 
subgroups such as patients with bicuspid aortic valve disease.59 3D echocardiography 
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may signiﬁcantly contribute to the risk stratiﬁcation of ACHD patients in the future 
when the image quality has further improved.
C ARDIAC MAGNETIC RESONANCE IMAGING
Cardiac magnetic resonance imaging (CMR) is generally accepted as the reference 
standard when it comes to measurement of the volume, mass and ejection fraction of 
both the right and the left ventricle. CMR also has its limitations such as higher costs, less 
availability and limited ability to scan patients with intra-cardiac devices, but it is very 
useful when echocardiography is unable to provide images of suﬃcient quality or when 
echo measurements are borderline or ambiguous.53, 60 CMR is therefore highly suitable 
in patients with complex congenital abnormalities in whom it is often diﬃcult to obtain 
good echocardiographic images of the cardiac anatomy. A graphical illustration of the 
CMR predictors that are discussed below is provided in Figure 2.
Ventricular function and volumes 
In accordance with the studies that evaluated ventricular function in echocardiography, 
CMR-derived ejection fraction is strongly predictive of mortality or adverse cardiac 
events in several subgroups of patients with ACHD, including patients with a 
systemic right ventricle, repaired tetralogy of Fallot, Eisenmenger syndrome and 
pulmonary hypertension.45, 61-63 In addition, higher ventricular end-diastolic volumes 
are independently associated with a higher mortality risk in patients with a Fontan 
circulation64 and in patients with repaired tetralogy of Fallot.62
Myocardial fibrosis
With the help of gadolinium enhancement technique in CMR, myocardial scarring and 
ﬁbrosis can be detected. Increased late gadolinium enhancement of the left ventricle 
in patients with repaired tetralogy of Fallot is related to myocardial dysfunction and 
is associated with adverse outcomes after correcting for age.65 The presence of late 
gadolinium enhancement located at the right ventricular insertion points is also 
thought to reﬂect a more advanced disease and poor prognosis in patients with 
tetralogy of Fallot and in patients with pulmonary arterial hypertension.66 Therefore, 
myocardial ﬁbrosis quantiﬁed by late enhancement could a valuable additional tool 
for risk stratiﬁcation. Myocardial T1 mapping is a relatively novel technique that is able 
to detect diﬀuse ﬁbrosis as reﬂected by prolonged T1 times, and to determine the 
extracellular volume.67 In patients with a systemic right ventricle after correction of TGA, 
higher septal extracellular volumes correlate with other prognostic parameters such as 
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NT-proBNP levels and the chronotropic index during CPET,68 suggesting that it may be 
of prognostic value in these patients. 
FIGURE 2 - Cardiac magnetic resonance imaging parameters that are reported to be of prognostic importance in 
patients with ACHD.
A, left and right ventricular ejection fraction as measured by multi-slice short axis cine imaging in a patient 
with congenital aortic stenosis. B, right ventricular dilatation and pronounced trabecularization as visualized 
on the four-chamber view in a patient with tetralogy of Fallot. C, late gadolinium enhancement at the right 
ventricular insertion points. D, feature tracking to derive regional and global left ventricular strain in a patient 
with tetralogy of Fallot (courtesy of R.W.J. van Grootel).
Deformation imaging
The deformation imaging technique that is available in CMR is known as feature 
tracking. Longitudinal and circumferential global left ventricular function measured by 
feature tracking closely agree with the same parameters measured by speckle tracking. 
Moreover, right ventricular feature tracking parameters showed to be associated with 
exercise capacity in patients with repaired tetralogy of Fallot, suggesting that it may 
be useful as prognostic parameter.69 Also left ventricular dyssynchrony assessed by 
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myocardial deformation imaging was found to be associated with adverse outcomes 
in patient with repaired tetralogy of Fallot.62 However, contradictory results on strain 
measurements in patients with repaired tetralogy of Fallot have been reported, 
showing no association between strain measurements and deterioration in left and 
right ventricular function.70 Hence, more research is needed to prove the prognostic 
value of this promising new technique. 
C ARDIAC COMPUTED TOMOGRAPHY
Computed tomography (CT) angiography has a very high spatial resolution and can 
therefore reliably evaluate the aortic size and small vasculature of the heart. Therefore, 
patients with an intrinsic higher risk of aortic dilatation and eventually dissection 
of the aorta, such as patients with a bicuspid aortic valve, Marfan syndrome or a 
SMAD3 mutation, require follow-up by cardiac CT to timely detect any progression 
in aortic dilatation.71 An ascending aortic area/height ratio of more than 10 cm2/m is 
independently associated with in increased cardiovascular mortality risk in patients 
with a bicuspid aortic valve.72
 Nevertheless, in the overall population of patients with ACHD, serial cardiac CT 
measurements are unattractive due to the need of high dosages of ionizing radiation, 
and are therefore not widely used for the risk stratiﬁcation in patients with ACHD.53 
However, as the population of adults with congenital heart disease are aging, coronary 
heart disease may begin to develop in this population, which possibly expands the role 
for CT angiography in the follow-up and risk stratiﬁcation of elderly patients with ACHD 
in the future.
C ARDIOPULMONARY EXERCISE TESTING
Cardiopulmonary Exercise Testing (CPET) consists of the assessment of exercise 
intolerance and ventilatory gas exchange during exercise, and can be considered part 
of the regular follow-up in ACHD patients. Chronic heart failure is characterized by an 
impaired cardiac output response to exercise and therefore CPET is widely used in the 
clinical follow up for the development of heart failure in patients with ACHD.73
Peak oxygen uptake
The peak oxygen uptake (peak VO
2
) is one of the most important measures to quantify 
exercise capacity.74 Peak VO
2
 is diminished in symptomatic as well as asymptomatic 
ACHD patients,75 with the lowest peak VO
2
 found in Eisenmenger syndrome and other 
cyanotic patients.76 The majority of patients with a Fontan circulation fail to reach 
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> 80% of the predicted peak VO
2
, independently of the type of Fontan operation.17 
Lower peak VO
2
 is associated with a higher risk of hospitalisation or death,75 the 
development of heart failure, and independently predicts mortality,76 indicating that 
it is a powerful prognostic tool within the entire ACHD population. Studies in speciﬁc 
ACHD populations such as tetralogy of Fallot, transposition of the great arteries (TGA) 
corrected by atrial switch procedure, and Ebstein’s anomaly, report comparable results 
regarding the prognostic importance of peak VO
2
.37, 77, 78 Peak VO
2
 may also be suitable 
for the assessment of perioperative risk in patients with repaired tetralogy of Fallot 
undergoing surgical pulmonary valve replacement.79 
 In patients with a Fontan circulation, contradictory results regarding the predictive 
ability of the peak VO
2
 have been reported. Some studies found an increased risk for 
mortality or morbidity in patients with a lower peak VO
2
, even independent of other risk 
factors.80 Others suggest that the impaired peak VO
2
 in Fontan circulation does not arise 
from failure of univentricular circulation, but from the intrinsic inability to adequately 
react to exercise, and therefore has no predictive ability.17
Ventilatory efficiency
Ventilatory eﬃciency can be expressed by the slope of the minute ventilation versus 
the CO
2
 production (VE/VCO
2
) assessed during CPET. An elevated VE/VCO
2
 slope (> 30) 
indicates a pulmonary ventilation-perfusion mismatch due to an adequate ventilation 
but a poor perfusion due to the inability of the heart to adequately increase the cardiac 
output during exercise. In the overall ACHD population, a higher VE/VCO
2
 slope was 
found to be associated with a higher risk of mortality; however this association was 
negated after adjustment for peak VO
2
.76 Nevertheless, studies that investigated 
speciﬁc diagnostic subgroups such as tetralogy of Fallot, Fontan circulation and TGA 
corrected by Mustard or Senning procedure did report that VE/CO
2
 slope independently 
predicted heart failure related hospitalisation or cardiac related death.37, 78 Combined 
interpretation of the VE/CO
2
 slope together with the peak VO
2
 may further increase the 
accuracy of risk predictions.
Heart rate reserve
The chronotropic response is the ability of the heart to respond to exercise by increasing 
the heart rate. Most studies use the failure to achieve ≥ 80% of  the heart rate reserve 
as a cut-oﬀ for chronotropic incompetence.81 In a large cohort of 727 ACHD patients, 
chronotropic incompetence was present in 62% of the patients and was associated with 
severity of heart failure symptoms as expressed by NYHA class.82 The heart rate reserve 
and peak heart rate are both predictors for hospitalisation or mortality in the overall 
ACHD population.82 The heart rate reserve in patients with a Fontan circulation is a 
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strong prognostic parameter to predict mortality or heart transplantation, independent 
of age, type of Fontan surgery and the use of antiarrhythmic drugs. However, the 
prognostic value of heart rate reserve in this population seems to be inferior to other 
non-CPET identiﬁed risk factors such as signs and symptoms of heart failure, non- total 
cavopulmonary connection type of Fontan circulation and a medical history of clinically 
relevant arrhythmia.17 Also in patients with Ebstein’s anomaly the heart rate reserve was 
shown to be a signiﬁcant predictor of adverse outcomes.77
Other prognostic parameters
In addition to the clearest prognostic parameters as previously mentioned, there are a 
couple of other CPET parameters that may be of prognostic importance. The peak load 
(Watt) as a measure for the exercise capacity is relatively easy to obtain in comparison to 
the peak VO
2
, as no gas exchange measurements are required. Peak load may therefore 
be easier to use in daily clinical practice. Although less extensively investigated, peak 
load was shown to be associated with a higher risk of mortality in patients with a 
systemic right ventricle due to congenitally corrected TGA or TGA corrected by the atrial 
switch procedure.49 Furthermore, a saturation drop of more than 5% during exercise 
is a predictor of all-cause mortality in the overall ACHD population76 and a lower peak 
exercise systolic blood pressure is associated with an increased risk of adverse cardiac 
outcomes in patients with a systemic right ventricle.49
BLOOD BIOMARKERS
Standard laboratory testing
Basic laboratory testing should be performed in congenital patients that are suspected 
of heart failure, which includes a full blood count, iron, kidney function, liver function, 
protein and albumin, and thyroid function.32 Anemia is not uncommon in patients with 
ACHD, and is associated with a 3-fold higher risk of death. Low MCV and diuretic use are 
related to the presence of anemia in these patients, suggesting that iron depletion and 
the heart failure syndrome play a role in its pathogenesis. Iron deﬁciency has also been 
directly related to adverse outcomes in patients with Eisenmenger syndrome,83 and iron 
replacement therapy may even improve exercise capacity in these patients.84
 Renal dysfunction is more frequently observed in patients with cyanotic heart 
disease and is related to a worse prognosis. For instance, Fontan patients with post-
operative renal insuﬃciency or a higher creatinine level have a signiﬁcantly poorer 
outcome.12 Liver dysfunction is most frequently reported in patients with a failing 
Fontan circuit, and is known to have a direct eﬀect on morbidity and mortality. The 
MELD-XI score, calculated from creatinine and total bilirubin which was originally 
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developed for patients with end-stage liver disease, also predicted cardiac mortality 
and transplantation in Fontan patients.85
 Fontan patients who develop protein-losing enteropathy (PLE), as diagnosed by 
enteric loss of alpha-1-antitrypsin or the presence of low serum total protein/albumin 
in addition to persistent or intermittent edema, are especially at high risk of death.12, 
31 PLE is diﬃcult to treat, however with recent advances the ﬁve-year survival after the 
diagnosis of PLE has improved from 50% to 88%.86
Natriuretic peptides
In patients with heart failure, natriuretic peptides are ﬁrmly established prognostic 
tools. Neurohormonal activation of the natriuretic, endothelin, sympatho-adrenergic, 
and renin-aldosterone systems also occurs in all types of congenital heart disease.87 
Accumulating evidence shows that N-terminal pro-B-type natriuretic peptide (NT-
proBNP) is related to disease severity and that it is useful for risk stratiﬁcation in patients 
with clinically stable ACHD, even beyond conventional risk markers.23, 88 Importantly, 
normal levels of NT-proBNP (< 14 pmol/L) can accurately rule out the risk of death and 
heart failure with a high negative predictive value.23 Therefore, natriuretic peptides have 
increasingly gained interest and are currently suggested as a component of the clinical 
work-up of patients with ACHD.32 No published data is available yet to conﬁrm that 
changes in natriuretic peptides over time can be used as a marker for outcome; however, 
data from acquired heart failure patients suggests that disease progression is related to 
substantial changes in NT-proBNP over time.89 A position paper from the working group 
of grown-up congenital heart disease and the heart failure association of the European 
Society of Cardiology has therefore suggested that a two-fold increase of baseline NT-
proBNP within 6 months is regarded as a signiﬁcant increase which indicates the need 
for optimization of heart failure medical therapy.32
Novel biomarkers 
Biomarkers that reﬂect other pathophysiological mechanisms which are involved in 
the heart failure syndrome, such as high-sensitive troponin-T (hs-TnT) and growth-
diﬀerentiation factor 15 (GDF-15) are also related to the occurrence of heart failure in 
ACHD patients. In a prospective cohort of 595 patients with moderate and complex 
ACHD, elevated levels of hs-TnT (> 14 ng/L, 8% of patients) and GDF-15 (> 1109 ng/L, 15% 
of patients) could predict outcomes in ACHD patients with elevated levels of NT-proBNP, 
suggesting a potential beneﬁt of a multi-marker approach.23 Other promising novel 
cardiac markers are red cell distribution width, galectin-3 and ST-2, but longitudinal 
studies in patients with ACHD are not available yet.
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C ARDIAC C ATHETERIZ ATION
In patients with ACHD, cardiac catheterization is usually performed for speciﬁc 
anatomical, diagnostic, or physiological questions or for intervention. Some studies 
have reported hemodynamic variables as predictors for clinical outcome. As described 
in more detail above, the presence of pulmonary arterial hypertension is an important 
predictor of mortality.90 Also in Fontan patients, elevated preoperative pulmonary 
artery pressures,91 elevated Fontan pressure, portal hypertension,29 and elevated right31 
and left atrial pressure12 have been identiﬁed as risk factors for mortality.
RISK STRATIFIC ATION IN PREGNANC Y
Although many women with heart disease may be in a stable clinical condition, 
pregnancy is associated with substantial hemodynamic changes that carry an increased 
risk of cardiac complications. The risk of complications is strongly inﬂuenced by the type 
of heart defect and presence of residual lesions. The modiﬁed World Health Organization 
(mWHO) classiﬁcation seems to be the most accurate tool in predicting these risks.92 It 
stratiﬁes patients based on their underlying diagnosis into four groups from very low 
risk patients (mWHO I), to high risk patients in whom a pregnancy is thought to be life 
threatening and therefore contraindicated (mWHO IV).93 Pregnancy is contraindicated 
(mWHO IV) in women with pulmonary hypertension, severe cyanosis, reduced left 
ventricular function, previous peripartum cardiomyopathy with incomplete recovery, 
symptomatic left ventricular outﬂow tract obstruction, and Marfan patients with a 
dilated aortic root.
 The most frequently encountered complications are heart failure and arrhythmia. 
Heart failure occurred in 13% of patients in the Registry Of Pregnancy And Cardiac 
disease (ROPAC), a large worldwide registry on patients with cardiac disease becoming 
pregnant. Heart failure occurred more often at the end of the second trimester and 
around delivery. At higher risk were patients with cardiomyopathy or presented with 
heart failure before pregnancy.94 Although supraventricular ectopy and supraventricular 
tachycardia are seen often in normal pregnant women, atrial ﬁbrillation or ﬂutter are 
very rare. In ROPAC, atrial ﬁbrillation or ﬂutter occurred in 1.3% of the pregnant women 
with structural heart disease and was associated with a marked increase in maternal 
mortality and low birth weight.95 Ventricular tachyarrhythmia’s occurred in 1.4% of 
pregnant women with cardiovascular disease in ROPAC, mainly in the third trimester, 
and was associated with heart failure during pregnancy and impacted fetal outcome.96
Contraceptive advice and careful planning of the pregnancy is essential for women with 
cardiac disease.92 Pre-pregnancy counselling should be performed in all women with 
known cardiac disease in an expertise center. An experienced multidisciplinary team 
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should be available to provide care, before, during and after pregnancy and should 
timely discuss the mode of delivery. A vaginal delivery is the preferred mode of delivery 
in most patients, when needed with epidural anesthesia and assisted second stage. A 
caesarean section is only preferred in speciﬁ c high risk groups such as patients with a 
dilated aorta or severe heart failure.97
RISK PREDIC TION
Few studies have attempted to develop risk prediction models speciﬁ cally for patients 
with ACHD76, 98 or to validate existing models designed for the general heart failure 
population.99, 100 The Seattle Heart Failure Model (SHFM) allows prediction of survival with 
the use of easily obtained clinical characteristics, such as age, sex, weight, NYHA class, 
systemic ejection fraction, systolic blood pressure, cardiac medication use, laboratory 
values, and presence of a device. In patients with heart failure, the model provides an 
accurate estimate of mean, 1-, 2-, and 3-year survival and allows estimation of eﬀ ects of 
adding medications or devices to a patient’s regimen. Although the predicted mortality 
risks by the SHFM do not represent actual ACHD survival, it may help to identify subjects 
with ACHD at risk for adverse outcome and poor cardiopulmonary eﬃ  ciency.100
CONCLUSIONS AND RECOMMENDATIONS
This chapter aimed to provide a comprehensive review of the factors that can be used in 
day-to-day clinical practice for the risk stratiﬁ cation of patients with ACHD. An overview 
of the most important reported prognostic factors is provided in Figure 3. Of note, 
accurate risk stratiﬁ cation does not rely on a single parameter. An integral perspective 
of the patients’ clinical prospects should always be based on a combination of all 
available information, that is composed of the medical history, physical examination, 
imaging, exercise testing and biomarkers. The frequency at which individual patients 
should be monitored at the outpatient clinic and the type and frequency of additional 
investigations is based on expert opinion in specialist centers. A suggested follow-up 
scheme of clinically stable patients with ACHD is provided in Table 2. Nonetheless, 
considering the enormous heterogeneity of the ACHD population, the lack of evidence, 
and the diﬀ erences in the availability of additional investigations among centers, it 
remains challenging to standardize the monitoring and follow-up of individual patients 
with ACHD.
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Medical History Physical Examination and ECG 
• Complexity of the congenital heart defect 
• Type of corrective surgery 
• Pre-operative anatomy and concomitant lesions 
• Surgical era and surgical technique 
• Genetic syndrome or mutation 
• Age and sex 
• Previous (re)interventions 
• Previous heart failure or arrhythmia 
• Cardiac medication use 
• Clinical symptoms of heart failure 
• Clinical signs of heart 
failure 
• Saturation 
• Changes in ECG 
morphology 
• Loss of sinus rhythm 
• QRS duration 
 
Regular follow-up 
Additional investigations 
Echocardiography 
• Systolic ventricular 
function (LVEF, RVFAC, 
TAPSE, eyeballing) 
• Ventricular and atrial 
dilatation 
• (Residual) shunt lesions 
• Severity of valvular disease 
• Right ventricular pressure 
• Pericardial effusion 
• Novel techniques (strain, 
3D echocardiography) 
 
 
Cardiac MRI (CT) 
• Systolic ventricular 
function (LVEF, RVEF) 
• Ventricular dilatation 
• Novel techniques (late 
gadolineum 
enhancement, feature 
tracking) 
 
 
Biomarkers 
• Full blood count, iron, 
kidney function, liver 
function, protein and 
albumin, thyroid function. 
• NT-proBNP 
• High-sensitive Troponin-T 
• Growth-differentiation 
factor 15 
• Potential novel biomarkers 
(galectin-3, ST-2) 
 
 
Exercise testing 
• Peak oxygen uptake 
(peak VO2) 
• Ventilatory efficiency 
(VE/VCO2 slope) 
• Heart rate reserve 
(chronotropic 
incompetence) 
• Peak load (Watt) 
 
 
FIGURE 3 - Risk factors for heart failure and mortality in patients with ACHD.
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ABSTRAC T
Aims  To develop and validate a clinically useful risk prediction tool for patients 
with adult congenital heart disease (ACHD).
Methods A risk model was developed in a prospective cohort of 602 patients with 
and Results  moderate/complex ACHD who routinely visited the outpatient clinic of 
a tertiary care centre in the Netherlands (2011–2013). This model was 
externally validated in a retrospective cohort of 402 ACHD patients 
(Czech Republic, 2004–2013). The primary endpoint was the 4-year 
risk of death, heart failure, or arrhythmia, which occurred in 135 of 602 
patients (22%). Model development was performed using multivariable 
logistic regression. Model performance was assessed with C-statistics 
and calibration plots. Of the 14 variables that were selected by an expert 
panel, the ﬁnal prediction model included age (OR 1.02, 95% CI 1.00–1.03, 
p = 0.031), congenital diagnosis (OR 1.52, 95% CI 1.03–2.23, p = 0.034), 
NYHA class (OR 1.74, 95% CI 1.07–2.84, p = 0.026), cardiac medication 
(OR 2.27, 95% CI 1.56–3.31, p < 0.001), re-intervention (OR 1.41, 95% CI 
0.99–2.01, p = 0.060), BMI (OR 1.03, 95% CI 0.99–1.07, p = 0.123), and NT-
proBNP (OR 1.63, 95% CI 1.45–1.84, p < 0.001). Calibration-in-the-large 
was suboptimal, reﬂected by a lower observed event rate in the validation 
cohort (17%) than predicted (36%), likely explained by heterogeneity 
and diﬀerent treatment strategies. The externally validated C-statistic 
was 0.78 (95% CI 0.72–0.83), indicating good discriminative ability.
Conclusion The proposed ACHD risk score combines six readily available clinical 
characteristics and NT-proBNP. This tool is easy to use and can aid 
in distinguishing high- and low-risk patients, which could further 
streamline counselling, location of care, and treatment in ACHD.
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INTRODUC TION
Over the past decades, the treatment and intervention strategies for children with 
congenital heart disease have enormously improved. This had led to the dawning of a 
new era, in which nowadays the patient population with adult congenital heart disease 
(ACHD) outnumbers children with congenital heart disease,1 and we are confronted 
with new challenges. Today’s clinicians face a continuously increasing and aging 
population of patients with ACHD, who require specialized cardiac care, are at risk of 
serious adverse events, and in whom monitoring and treatment strategies are largely 
based on expert opinion.2 Evidence-based risk stratiﬁcation would be an important step 
forward towards individualized management strategies that could lead to better use of 
health resources, cost savings and improvement of patient care.
 To date, many studies have shown that variables such as the complexity of the heart 
defect,3-5 age,5-7 cyanosis,4, 5, 7 New York Heart Association (NYHA) functional class,5, 8 
ventricular function,9, 10 or biomarkers (N-terminal pro-B-type natriuretic peptide; NT-
proBNP)6, 11 are related to adverse outcomes in patients with ACHD. The combination of 
multiple risk predictors into a tool that provides clinically useful risk predictions is most 
relevant. For instance, in patients with atrial ﬁbrillation12 or coronary heart disease,13 risk 
calculators have been developed which are successfully used in daily clinical practice 
worldwide. In patients with ACHD, few studies have developed risk models7, 14 or 
validated existing prediction models designed for the general heart failure population 
in patients with moderate or complex ACHD;15, 16 however, none of these are widely 
used in daily clinical practice.
 The aim of this study was to develop and validate a clinically useful, easy-to-use 
risk prediction tool that predicts the individualized 4-year risk of death, heart failure or 
arrhythmia in patients with ACHD. This may aid clinicians in determining the adequate 
follow-up frequency to monitor patients at the outpatient clinic, to establish the level 
of care needed for this patient, to provide reliable patient information, and to support 
clinical judgment when initiating medical therapy.
METHODS
Derivation cohort
We developed a multivariable prediction model by using the data of a prospective 
cohort of 602 consecutive patients with moderate or complex congenital heart 
disease.3 Patients were aged 18 years and older, and routinely visited the outpatient 
clinic of a tertiary referral centre in the Netherlands (the Erasmus MC, Rotterdam). 
Patients were enrolled during a 2-year period (April 2011<April 2013) and underwent 
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clinical assessment, electrocardiography, echocardiography, and venous blood drawing 
with NT-proBNP measurement at baseline. According to the study protocol, patients 
were yearly evaluated at our institute during a 4-year period. The primary endpoint was 
deﬁned as the 4-year risk of all-cause mortality, heart transplant, heart failure (requiring 
hospital admission or initiation/uptitration of diuretics), or arrhythmia (requiring 
treatment, or symptomatic and recorded). Follow-up status at year 4 regarding fatal and 
non-fatal events was complete in 600 patients (99.7%). The institutional review board 
of the Erasmus MC approved the study protocol and written informed consent was 
obtained from all patients included in the cohort. A detailed description of the study 
protocol, participants and data collection has been previously published.6
Model development
The primary endpoint was deﬁned prior to the data analysis as a composite of all-cause 
mortality, heart failure (requiring hospitalization, or initiation or change in heart failure 
medication), or arrhythmia (symptomatic and recorded, or requiring treatment). In order 
to prevent overﬁtting and preserve external validity, we constructed the multivariable 
models with the use of ≈ 10 events per degree of freedom. Therefore, we evaluated 
a maximum of 14 variables that were deemed to be of clinical interest by an expert 
panel of adult congenital cardiologists in our centre. These variables were speciﬁed 
in advance and were 98.6% complete. We used single imputation of covariates based 
on all covariates considered for the model and based on outcome data to account for 
missing values; outcome data were not imputed. Continuous variables were analysed 
continuously, with the exception of oxygen saturation, which was dichotomized at 90 
% because we considered this as a clinically meaningful threshold value. Highly skewed 
variables were log 
2
-transformed (NT-proBNP). With regard to the categorical variables, 
we collapsed categories with small numbers (NYHA II–III), we analysed ordinal variables 
as linear terms, and related variables were grouped (congenital diagnosis, cardiac 
medication use), in order to use only one degree of freedom per categorical variable.
 The main eﬀects were ﬁrst evaluated using univariable binary logistic regression. 
Nonlinear eﬀects and interaction terms were disregarded. Variables were selected 
using Akaike’s Information Criterion (p < 0.157), and were subsequently entered in a 
multivariable binary logistic regression model. The ﬁnal prediction model was retrieved 
using a stepwise backward selection method (p < 0.157). Internal validation (in order 
to obtain the optimism-adjusted C-statistic of the ﬁnal model) was performed using 
bootstrap resampling. Shrinkage of model coeﬃcients to adjust for optimism and to 
improve external calibration was performed using penalized regression.17, 18 
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Validation cohort
The model was externally validated by using the data of a cohort of 402 patients that 
routinely visited the outpatient clinic of the Hospital Na Homolce, Prague, Czech Republic 
(2004–2013). This centre was chosen because it is routine practice to obtain all clinical 
parameters and also NT-proBNP levels in this hospital. Patients were selected based on 
retrospective review of medical records. All patients with a moderate or complex type 
of diagnosis were included. In all patients, NT-proBNP had been determined in fresh 
serum samples. Exclusion criteria were: referral for hospitalization with manifest heart 
failure or arrhythmia, age < 18 years, mild cardiac lesion (isolated atrial or ventricular 
defect), or kidney failure (creatinine > 200 μmol/L). In order to compare the results with 
the derivation cohort, the occurrence of the primary endpoint as deﬁned above was 
registered during a period of 4 years from study inclusion.
External validation
Discrimination of the ﬁnal prediction model was described using the concordance 
(C)-statistic, which ranges from 0.5 for non-informative models to 1 for perfectly 
discriminating models.19 Calibration was visualized by plotting the predicted risks 
against the observed risks in a validation plot, and further described with the calibration 
slope (ideally equal to 1) and intercept (ideally equal to zero).20 Finally, the regression 
coeﬃcients were reﬁtted on a combined dataset including all patients of the derivation 
cohort and validation cohort (n = 1004).
 Statistical analyses were performed in IBM SPSS Statistics for Windows, Version 21.0 
(IBM Corp., Armonk, NY, USA) and using R statistical software, Version 3.3.4, package 
rms. Development of the web application was performed in the R Shiny package.
RESULTS
Derivation and validation cohorts
The baseline patient characteristics of the derivation cohort (n = 602) and validation 
cohort (n = 402) are detailed in Table 1. The validation cohort additionally included 
patients with Ebstein anomaly and atrioventricular septal defect, and no patients after 
arterial switch operation. Moreover, the validation cohort included fewer patients with 
congenital aortic stenosis or aortic coarctation and more patients with pulmonary 
arterial hypertension. In the validation cohort 195 patients (49%) with a complex heart 
defect were included, compared with 149 patients (25%) in the derivation cohort. 
Furthermore, in the validation cohort the average NYHA class was higher, and more 
patients used cardiac medication. Age, sex, body mass index, heart rate, smoking, oxygen
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TABLE 1 - Baseline characteristics of the derivation and validation cohort.
Variable Derivation cohort (n = 602)
Validation cohort 
(n = 402)
Age, years 32.5 [24.7–41.2] 28.3 [22.5–36.2]
Sex, male 348 (58) 206 (51)
Congenital diagnosis
   Congenital aortic stenosis 138 (23) 23 (6)
   Aortic coarctation 112 (19) 21 (5)
   Arterial switch operation 24 (3) 0 (0)
   Tetralogy of Fallot 179 (30) 106 (26)
   Rastelli/REV 11 (2) 7 (2)
   Atrial switch operation 65 (11) 87 (22)
   Congenitally corrected TGA 21 (4) 22 (5)
   Fontan 36 (6) 33 (8)
   Functionally univentricular heart 7 (1) 3 (1)
   Pulmonary arterial hypertension 9 (1) 43 (11)
   Ebstein anomaly 0 (0) 37 (9)
   Atrioventricular septal defect 0 (0) 20 (5)
NYHA functional class
   I 541 (90) 109 (27)
   II 56 (9) 198 (49)
   III 5 (1) 94 (24)
   IV 0 (0) 1 (0)
Cardiac medication use 212 (35) 233 (58)
≥1 re-interventions after corrective repair 317 (53) 143 (36)
Body mass index, kg/m2 24.7 ± 4.4 23.8 ± 4.3
Heart rate, beats/min 74 ± 13 72 ± 14
Current smoking 56 (9) 49 (12)
Oxygen saturation < 90% 17 (3) 21 (5)
Loss of sinus rhythm 81 (13) 43 (11)
Systemic ventricular function
   Normal, 0 303 (50) 224 (56)
   Mildly impaired, 1 212 (35) 84 (21)
   Moderately impaired, 2 69 (12) 57 (14)
   Severely impaired, 3 18 (3) 37 (9)
Presence of severe valvular dysfunction 86 (14) 185 (46)
NT-proBNP, pmol/L* 15 [7–33] [12-51]
Values are presented as n (%), mean ± standard deviation or median [interquartile range]. *This variable was 
log
2
-transformed for further analysis. Abbreviations: NT-proBNP, N-terminal pro-B-type natriuretic peptide; 
NYHA, New York Heart Association functional class; REV, Réparation à l’Etage Ventriculaire; TGA, transposition 
of the great arteries.
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saturation, rhythm, systemic ventricular function and NT-proBNP levels were comparable 
between both cohorts. 
 After 4 years of follow-up, the primary endpoint occurred in 135 patients (22%) in 
the derivation cohort and in 67 patients (17%) in the validation cohort. All individual 
components of the primary endpoint occurred less frequently in the validation cohort 
(Table 2).
TABLE 2 - Composites of the primary endpoint in the derivation and validation cohorts. 
Variable Derivation cohort (n = 602)
Validation cohort 
(n = 402)
Primary endpoint 135 (22) 67 (17)
   Death 14 (2) 5 (1)
      End-stage heart failure 7 (1) 5 (1)
      Sudden death / cardiac arrest 6 (1) 0 (0)
      Other 1 (0) 0 (0)
   Heart transplant 0 (0) 1 (0)
   Heart failure 52 (9) 20 (5)*
      Requiring hospital admission 23 (4) 9 (2)
      Requiring initiation or change in diuretics 29 (5) 10 (3)
   Arrhythmia 112 (19) 55 (14)
      Ventricular ﬁbrillation 7 (1) 1 (0)
      Ventricular tachycardia 18 (3) 6 (2)
      Atrial ﬂutter/ﬁbrillation 51 (9) 22 (6)
      Supraventricular tachycardia (unspeciﬁed/other) 26 (4) 17 (4)
      Other 10 (2) 9 (2)
*Treatment of heart failure was missing in one patient.
Model development
The majority of the 14 variables that were evaluated were predictors of the primary 
endpoint in the univariable analysis (Table 3). Only heart rate (p = 0.833), smoking (p 
= 0.410) and severe valvular dysfunction (p = 0.343) were not related with the primary 
endpoint, and were therefore excluded from the multivariable model. The ﬁnal 
prediction model included all variables that were associated with the primary endpoint 
in the multivariable analysis: age, congenital diagnosis, NYHA class, cardiac medication 
use, re-intervention, BMI, and NT-proBNP. Of note, the backward selection method 
resulted in the same ﬁnal prediction model as a forced entry method of variables with 
p < 0.157 in the multivariable model. The internally validated (optimism-adjusted) 
C-statistic was 0.85. 
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TABLE 3 - Main effects in derivation cohort (n = 602). 
Variable Univariable OR (95% CI) P-value
Multivariable OR 
(95% CI) P-value
Age, years 1.07 (1.05–1.09) < 0.001 1.03 (1.01–1.06) 0.005
Sex, male 0.73 (0.50–1.07) 0.111 1.27 (0.76–2.13) 0.354
Complex congenital diagnosis 3.28 (2.17–4.95) < 0.001 1.73 (0.90–3.34) 0.100
NYHA class II–III 8.90 (5.02–15.79) < 0.001 2.75 (1.33–5.72) 0.007
Cardiac medication use 7.06 (4.62–10.80) < 0.001 2.52 (1.49–4.24) 0.001
≥ 1 re-interventions after corrective repair 2.30 (1.54–3.45) < 0.001 1.67 (0.99–2.80) 0.055
BMI, kg/m2 1.06 (1.01–1.10) 0.009 1.05 (1.00–1.11) 0.059
Heart rate, beats/min 1.00 (0.98–1.01) 0.833 - -
Current smoking 0.76 (0.39–1.46) 0.410 - -
Oxygen saturation < 90% 4.67 (1.71–12.80) 0.003 1.12 (0.29–4.29) 0.874
Loss of sinus rhythm 4.35 (2.67–7.10) < 0.001 1.18 (0.61–2.30) 0.622
Systemic ventricular function, 0–3 2.09 (1.65–2.65) < 0.001 0.95 (0.66–1.37) 0.787
Presence of severe valvular dysfunction 1.29 (0.76–2.17) 0.343 - -
log
2
 NT-proBNP, per two-fold higher value 2.12 (1.82–2.47) < 0.001 1.62 (1.34–1.97) < 0.001
Eﬀect sizes represent the increased 4-year risk of the primary endpoint (death/transplant, heart failure, 
arrhythmia). Abbreviations: OR, odds ratio; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, 
New York Heart Association functional class.
External validation
Similar eﬀects were found for most variables in the validation cohort, except for age and 
re-intervention.  The ﬁnal prediction model was ﬁtted in the validation dataset to obtain 
the externally validated C-statistic, which was 0.78 (95% CI 0.72–0.83). Hence, the ﬁnal 
model discriminated well between patients with and without a primary endpoint in the 
validation dataset. 
 A calibration plot is presented in Figure 1. The calibration-in-the-large was 
suboptimal: the prediction model systematically overestimated the risk in the validation 
dataset. The overall proportion of patients with an event in the validation cohort was 
lower (17%) than would be expected based on the average predicted risk of our model 
(36%). However, the calibration slope was acceptable, indicating that the predicted risks 
were not too extreme or too close to the baseline risk. Therefore, when reﬁtting the 
ﬁnal coeﬃcients of the model on the combined dataset, we included a correction factor 
to adjust for the systematic overestimation in the validation dataset (derivation cohort 
= 0, validation cohort = 1). After shrinkage of the coeﬃcients, the results of the ﬁnal 
prediction model were: age (OR 1.02, 95% CI 1.00–1.03, p = 0.031), congenital diagnosis 
(OR 1.52, 95% CI 1.03–2.23, p = 0.034), NYHA class (OR 1.74, 95% CI 1.07–2.84, p = 0.026), 
cardiac medication (OR 2.27, 95% CI 1.56–3.31, p < 0.001), re-intervention (OR 1.41, 95% 
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CI 0.99–2.01, p = 0.060), BMI (OR 1.03, 95% CI 0.99–1.07, p = 0.123), and NT-proBNP (OR 
1.63, 95% CI 1.45–1.84, p < 0.001). We implemented the ﬁ rst version of our model in a 
prototype of a web-based ACHD risk calculator (Figure 2). Based on six clinical variables 
and the NT-proBNP level, it can provide an estimation of the absolute 4-year risk of 
death, heart failure, or arrhythmia, as deﬁ ned in this study. The risk calculator is directly 
available online at https://achdwebcalculator.shinyapps.io/achdwebcalculator/. The 
absolute risk estimations of this model can be further improved, and we therefore gladly 
invite other investigators to share their data in order to further improve the current 
version of the model.
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FIGURE 1 - Calibration plot for the prediction of the primary endpoint in the validation cohort (n = 402). 
The calibration slope indicates whether the model is overﬁ tted (estimated risks too extreme, value < 1) or 
underﬁ tted (estimated risks too close to baseline risk, value > 1). The calibration intercept (calibration-in-the-
large) indicates whether predicted probabilities are systematically too low (value > 0) or too high (value < 
0). The linear bar chart shows the distribution of patients with (1) or without (0) a primary endpoint for each 
predicted probability.
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FIGURE 2 - Web-based ACHD risk calculator, using the coeffi  cients of the fi nal prediction model.
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DISCUSSION
To our knowledge, this is the ﬁrst study that aimed to develop and validate a risk 
prediction model speciﬁcally for patients with ACHD. The ﬁnal model was developed 
in 602 patients with ACHD and included six readily available clinical variables (age, 
congenital diagnosis, NYHA class, cardiac medication use, re-interventions, BMI) 
and NT-proBNP. External validation in a diﬀerent ACHD population (n = 402) with an 
independent treatment strategy showed that the model could discriminate well 
between patients with death, heart failure, or arrhythmia within 4 years of follow-up 
and patients without an event during that period. The results are presented in a web-
based ACHD risk calculator that is directly suitable for implication in clinical practice.
Comparison with other risk scores
Another risk score for congenital patients was previously developed by Yap et al. in 
378 patients with ACHD and atrial arrhythmias at baseline.14 Of the 9 variables that 
were found to be of importance in univariable analysis, in a multivariable model 
NYHA class, single ventricle physiology, pulmonary hypertension, and valvular heart 
disease remained signiﬁcantly associated with mortality (n = 40). These variables were 
combined in a risk score, which was visualized in a Kaplan-Meier curve; however, no 
model performance characteristics (discrimination, calibration) were evaluated. The 
deﬁnition of the study population and endpoint was slightly diﬀerent from our study, 
but the similarity with our study is that we also included NYHA class and congenital 
diagnosis (where single ventricle physiology and pulmonary hypertension were both 
deﬁned as a complex diagnosis) in the ﬁnal model.
 Kempny and colleagues recently presented a multivariable mortality risk stratiﬁcation 
model that was developed in a retrospective cohort of 1098 adults with Eisenmenger 
syndrome.7 The model included age, pretricuspid shunt, oxygen saturation, presence 
of sinus rhythm and presence of pericardial eﬀusion. In our cohort of ACHD patients, 
a pretricuspid shunt or presence of pericardial eﬀusion was uncommon, and oxygen 
saturation and presence of sinus rhythm were not signiﬁcantly related to study 
endpoints in the multivariable analysis. Hence, Eisenmenger patients reﬂect a distinct 
disease entity in which other variables may be more important. However, NT-proBNP 
measurements were not included in this study.
 The Seattle Heart Failure Model was developed in a cohort of 1125 patients with 
heart failure, and allows prediction of survival with the use of easily obtained clinical 
characteristics, such as age, sex, weight, NYHA class, systemic ejection fraction, systolic 
blood pressure, cardiac medication use, laboratory values, and presence of a device.21 In 
patients with heart failure, the model provides an accurate estimate of mean, 1-, 2-, and 
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3-year survival. This model was validated in a cohort of 153 patients with ACHD, and was 
able to identify subjects with adverse outcome; however, the predicted mortality risks 
by the Seattle Heart Failure Model did not represent actual ACHD survival.15 Still, the 
type of variables that are included are largely overlapping with our prediction model 
(age, weight (BMI), NYHA class, cardiac medication use, and laboratory values such as 
NT-proBNP).
Other variables of potential interest
Inuzuka and colleagues comprehensively demonstrated that a combination of peak 
oxygen uptake and heart rate reserve are strong predictors of midterm mortality in 
patients with ACHD, in addition to clinical parameters such as age, low oxygen saturation, 
and use of negative chronotropic agents.22 It has also been shown by other studies that 
exercise testing provides prognostic information in patients with ACHD.23-25 In addition, 
various cardiac magnetic resonance imaging measurements have been reported to 
be valuable for risk stratiﬁcation. It is known that cardiac magnetic resonance imaging 
provides the most reliable measurements of right ventricular volumes and function, 
which are also predictors of clinical outcome.26 
 Because cardiopulmonary exercise testing and cardiac magnetic resonance imaging 
are relatively expensive and time-consuming, they were not routinely performed in all 
patients of our cohort and were therefore not investigated in this study. These variables 
could perhaps further improve the prediction of our model. However, we believe the 
current set of variables better reﬂects clinical practice, is readily available and very easy 
to use. Therefore, this model may be directly suitable for implementation in day-to-day 
clinical practice.
Calibration
Although the validation cohort included more patients with complex congenital 
diagnoses, a higher NYHA class, and cardiac medication use (Table 1), they had a 
better outcome compared with patients in the derivation cohort (Table 2). Because 
these variables were part of the prediction model, the risk in the validation cohort was 
systematically overestimated. This resulted in a suboptimal calibration-in-the-large 
(reﬂected by a calibration intercept < 0), which is a common problem when externally 
validating risk models.19 This may be explained by a diﬀerence in the deﬁnition and 
classiﬁcation of endpoint events. The deﬁnition of heart failure included ‘initiation 
or uptitration of diuretics’ and the deﬁnition of arrhythmia included ‘symptomatic 
and recorded’. As a result, diﬀerent clinical strategies among centres with regard to 
treatment with diuretics or holter monitoring could result in a diﬀerent proportion 
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of events. Furthermore, misclassiﬁcation of (non)events may have occurred, although 
every attempt was made to avoid this by assuring completeness of follow-up in both 
cohorts and independent review of the events by two investigators. Second, a diﬀerent 
classiﬁcation of baseline covariates may have occurred. The deﬁnition for NYHA class 
I in the derivation cohort was ‘no limitation in ordinary physical activity’, but this can 
be subjective and may have been assessed in a stricter way in the validation cohort. 
The diﬀerences in treatment strategies among centres as described above may also 
impact cardiac medication use and the number of re-interventions. Finally, there may 
be additional important prognostic factors which explain this diﬀerence, and that are 
not part of the current model.
Clinical implications and future perspectives
In this study, we aimed to combine various risk predictors in order to derive individualized 
risk predictions. The model provided a good discrimination between high-risk and low-
risk patients, and this may serve to optimally inform and, in case of low-risk, reassure 
patients. High-risk patients should be followed-up in a tertiary care centres, while low-
risk patients may be managed in a shared-care model with for instance check-ups every 
other time in a non-tertiary care centre. In addition, it could support clinical judgment 
in determining the window in which the next outpatient follow-up visit needs to be 
scheduled, in assessing the need of initiation or change in medical therapy, planning an 
intervention, or even considering heart transplantation. 
 Because the absolute predicted risks were not in accordance with the observed 
risks in the validation cohort, the absolute risks provided by our model in other cohorts 
of patients with moderate/complex ACHD must be interpreted with caution. Future 
research is warranted to evaluate whether the implementation of such a risk prediction 
tool actually can improve a patients’ prognosis, and thus leads to clinical beneﬁt. Finally, 
it should be investigated how much costs can be saved by implementing such a risk 
prediction tool.
Study limitations
Although a prospective cohort of 600 patients with ACHD may be considered 
relatively large in this patient population, it is rather small in comparison with other 
cohorts in which well-known risk prediction models were developed. Nonlinear terms 
and interaction terms had to be disregarded in the multivariable prediction model, 
because we considered it more relevant to analyse the potential additive eﬀects 
of the highest possible number of diﬀerent covariates, instead of fully exploring 
nonlinearity and interactions at the risk of overﬁtting the model. With larger datasets, 
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it could be worthwhile to explore these potential eﬀects in order to further improve 
risk prediction.
CONCLUSIONS
We developed and validated an ACHD risk calculator, which was based on readily 
available clinical characteristics (age, congenital diagnosis, NYHA class, cardiac 
medication use, re-interventions, BMI) and NT-proBNP. External validation showed that 
calibration-in-the-large was suboptimal, which is likely explained by the heterogeneity 
in patient cohorts and diﬀerent treatment strategies across centres. Nonetheless, the 
ﬁnal prediction model was able to accurately discriminate between patients at high and 
low risk of death, heart failure, or arrhythmia within 4 years, and could therefore support 
clinical judgment in day-to-day practice. Other investigators are welcome to share their 
data in order to further improve the absolute risk estimations of the current model.
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SUMMARY
Thanks to the improvements in the medical care of children with congenital heart 
disease, today’s cardiologists are confronted with a growing population of adults with 
congenital heart disease (ACHD). These patients are mostly young adults, may want 
to become pregnant or parent, participate in sports, and aim to live their life as close 
to normal as possible. In order to maximize their quality of life for as long as possible, 
early detection of late complications and risk stratiﬁcation is an essential component of 
routine clinical care. This thesis aimed to establish novel prognostic tools that can be 
used for the risk stratiﬁcation of adults with congenital heart disease and/or pulmonary 
hypertension. In Chapter 1, an introduction and overview of the patient populations, 
potential prognostic tools, outcomes, and study designs is provided. 
Part I – Imaging biomarkers
Right ventricular volumes and function are important prognostic parameters in ACHD 
and pulmonary hypertension patients. Although the most accurate measurements are 
obtained with cardiac magnetic resonance imaging (CMR), the course trabeculae that 
are often present in these patients hamper reproducible right ventricular endocardial 
alignment. Chapter 2 describes a new method to deal with these trabeculae. Eighty 
patients (pulmonary hypertension, transposition of the great arteries after arterial 
switch operation and after atrial switch procedure and repaired tetralogy of Fallot) and 
20 controls underwent CMR. Two methods of measuring right ventricular volumes and 
function were compared. We found that exclusion of trabeculae from the blood volume 
with a semi-automatic pixel-intensity based software was highly reproducible, and 
resulted in a substantial change in right ventricular volumes and function, compared 
with the conventional manual method. 
In Chapter 3, we describe the cross-sectional association between CMR ﬁndings and 
exercise capacity in 71 adults after arterial switch operation for transposition of the 
great arteries. Especially main pulmonary artery area was closely related to peak oxygen 
uptake, indicating that this is an important determinant of limitation in functional 
capacity and thus a potential prognostic factor. In Chapter 4, the association of left 
atrial size and function with clinical events in 134 adults with repaired tetralogy of Fallot 
is described. All patients underwent echocardiography with measurement of left atrial 
maximal, minimal and pre-A wave volume, area and length, and were prospectively 
followed for the occurrence of cardiovascular events. Higher left atrial volumes, 
larger left atrial length and decreased total and active emptying fraction were found 
to be associated with cardiovascular events, indicating that these echocardiographic 
measurements can provide prognostic information.
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The development or persistence of pulmonary arterial hypertension (PAH) after atrial 
septal defect (ASD) closure at adult age is associated with a poor prognosis. To establish 
the prevalence of PAH before and after ASD closure and to explore factors that are 
associated with PAH after ASD closure, we performed a systematic review of all studies 
that reported the prevalence of PAH or data on pulmonary artery pressures both before 
and after surgical or percutaneous ASD closure in an adult population in Chapter 5; 
and retrospectively assessed echocardiograms before and after ASD closure in 198 
adult patients who underwent ASD closure in our own center between 2000 and 2014 
in Chapter 6. The reported prevalence of PAH after ASD closure widely varied between 
5 and 50%, and was higher in older studies, smaller study cohorts, and studies with 
a large proportion of patients lost to follow-up. We therefore assumed that the “true” 
prevalence was more towards the lower limit of the reported range, which was indeed 
conﬁrmed in our own study (5%). The prevalence of PAH and mean pulmonary pressures 
decreased in all studies after ASD closure, and in all but one patient in our own cohort. 
Whereas in previous studies age at closure was reported as predictor for PAH, we found 
that NYHA functional class, presence of pulmonary disease, cardiac medication use, and 
impaired RV function were associated with for PAH after ASD closure.
In Chapter 7 and Chapter 8, the echocardiographic ﬁndings and CMR ﬁndings that 
provide prognostic information in patients with pulmonary arterial hypertension are 
systematically reviewed. Among 37 papers that investigated 51 echocardiographic 
ﬁndings, the presence of pericardial eﬀusion, enlarged right atrial area, and decreased 
tricuspid annular plane systolic excursion were the most well-investigated and robust 
predictors of mortality or transplant. Of the 21 CMR ﬁndings that were described in 
eight papers, decreased right ventricular ejection fraction was the strongest and most 
well-established predictor of mortality. 
Part II – Blood biomarkers
Chapter 9 presents the cross-sectional association of matrix metalloproteinase (MMP)-
2, -3, -9 and tissue inhibitor of matrix metalloproteinase-1 with cardiac function and 
exercise capacity, in a subset of 425 patients with ACHD from the BioCon study. MMP-
2 was found to have a modest correlation with decreased exercise capacity (peak 
workload), decreased ventilatory eﬃciency (carbon dioxide equivalent) and decreased 
left ventricular deceleration time, independently of NT-proBNP. However, peak 
workload and carbon dioxide were only available in 126 and 40 patients, respectively, 
and reproducibility and reference values were not assessed in this study. 
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In Chapter 10 the most important results of the BioCon study are presented. We 
investigated the association of NT-proBNP, high-sensitive troponin-T, and growth-
diﬀerentiation factor 15 with cardiovascular events in 595 patients with ACHD. 
During a prospective follow-up of median 42 months, the primary endpoint of any 
cardiovascular event occurred in 165 patients. NT-proBNP was strongly associated with 
the primary endpoint, independently of multiple clinical, electrocardiographic and 
echocardiographic variables. The risk of death or heart failure was extremely low (~1%) 
in patients in the lowest two NT-proBNP quartiles (< 15.2 pmol/L). The risk of patients 
with an elevated NT-proBNP level could be further diﬀerentiated by the combined use of 
hs-TnT and GDF-15. Patients with elevated levels of all three biomarkers were at highest 
risk of cardiovascular events. In Chapter 11, we describe the galectin-3 measurements 
that were performed in the BioCon study. Galectin-3 is an emerging biomarker for 
risk stratiﬁcation in heart failure patients, and was also signiﬁcantly associated with 
functional capacity, cardiac function, and adverse cardiovascular events in our cohort of 
patients with ACHD. However, the additive value of galectin-3 to a more conventional risk 
marker such as NT-proBNP was limited. In Chapter 12, we propose red cell distribution 
width (RDW) as an additive biomarker for risk stratiﬁcation. We found that RDW was 
signiﬁcantly associated with cardiovascular events when adjusted for age, sex, clinical 
risk factors, CRP, and NT-proBNP. In addition, the C-index of the model including RDW 
was slightly, but signiﬁcantly higher than the model without (0.74, 95% CI 0.70–0.78 
versus 0.73, 95% CI 0.69–0.78). Analysis of repeated RDW measurements (n = 2449) did 
not show an increase in RDW prior to the occurrence of the primary endpoint; therefore, 
repeated measurements were not further analyzed in this study.
In Chapter 13 we investigated repeated measurements of NT-proBNP, as this appeared 
to be the most promising biomarker of the BioCon study. We analyzed 2424 repeated 
annual NT-proBNP measurements that were collected during a median follow-up of 4.4 
years with linear mixed eﬀect models and joint models. NT-proBNP increased prior to 
the occurrence of an event, especially death or heart failure, whereas patients without 
any event exhibited stable and low levels. The high-risk group of patients with an 
elevated baseline NT-proBNP (> 14 pmol/L, n = 315, 53%) could be further diﬀerentiated 
by repeated NT-proBNP measurements, since these were signiﬁcantly associated with 
cardiovascular events when adjusted for the baseline level.
In Chapter 14, we describe the ﬁrst results of the BioPulse study. We prospectively 
included 106 consecutive treatment-naïve patients with pulmonary hypertension 
conﬁrmed by right heart catheterization. During a median follow-up duration of 24 
months, the primary endpoint of death or lung transplantation occurred in 29 patients 
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(27%). At baseline, we measured NT-proBNP, high-sensitive troponin-T, high sensitive-C-
reactive protein, galectin-3, red blood cell distribution width and estimated glomerular 
ﬁltration range, all of which were found to be associated with the primary endpoint. In 
addition, this study supports the idea of a multi-biomarker approach to optimize risk 
stratiﬁcation, as an analysis which included the number of elevated biomarker in each 
patient demonstrated that patients were at higher risk of events as more biomarker 
levels were elevated. The absence of any elevated biomarker ruled out the risk of any 
event up to 40 months.
Part III – Risk prediction 
Chapter 15 provides a narrative review of the factors that have been identiﬁed as 
predictors for heart failure and other late complications in the entire cohort of patients 
with ACHD and within speciﬁc congenital subgroups. We describe that a large part of the 
risk stratiﬁcation of patients with ACHD is based on the underlying anatomical defect, 
concomitant lesions and type of corrective surgery that was performed. In addition, 
components of the medical history, physical examination and further diagnostic tests 
(including ECG, echocardiography, cardiac magnetic resonance imaging, exercise 
testing, and biomarkers) can provide prognostic information.
Finally in Chapter 16 we developed and validated a multivariable logistic regression 
model to predict the 4-year risk of death, heart failure or arrhythmia in patients with 
moderate or complex ACHD. The model was derived in the BioCon study (n = 602), and 
externally validated in a retrospective cohort of 402 ACHD patients from a tertiary care 
center in Prague, Czech Republic. The ﬁnal prediction model included six readily available 
clinical characteristics (age, congenital diagnosis, NYHA class, cardiac medication use, 
re-interventions, BMI) and NT-proBNP. The externally validated C-statistic was 0.78 (95% 
CI 0.72–0.83), indicating a good discriminative ability. The calibration-in-the-large was 
suboptimal, reﬂected by the calibration intercept (< 0) and a lower observed event 
rate in the validation cohort (17%) than predicted (36%). This is likely explained by 
the heterogeneity in patient cohorts and diﬀerent treatment strategies across centers. 
Nevertheless, the proposed tool could be clinically useful as it aids in distinguishing 
patients with a high or low risk of death, heart failure, or arrhythmia, which could further 
streamline care in tertiary care centers.
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GENERAL DISCUSSION
Clinical implications of this thesis
Imaging biomarkers
Part I outlines the potential prognostic value of various cardiac magnetic resonance 
and echocardiographic measurements. Measurements of right and left ventricular 
volumes and function,1-3 main pulmonary artery area,4 left atrial size and function,5 
right ventricular pressure, pericardial eﬀusion, and right atrial area6 were shown to 
be associated with patient characteristics, surrogate study endpoints and/or clinical 
endpoints. Therefore, these measurements can be of prognostic value in speciﬁc 
subgroups of the ACHD population. 
 When generalizing these results, it is important to take into account that the 
diﬀerent studies were performed in various patient cohorts with diﬀerent congenital 
diagnoses and a widely varying cardiac anatomy. For instance, precise quantiﬁcation of 
right ventricular function is important;1, 2 however, this cannot be obtained in patients 
with a single ventricle physiology, and in patients after Mustard correction the anatomic 
right ventricle serves as the systemic ventricle. In patients after arterial switch operation 
the main pulmonary artery area seems to be an important determinant in the limitation 
of functional capacity,4 as is likely opposed to patients with a congenital aortic stenosis. 
In patients with tetralogy of Fallot, left atrial area measurements provide prognostic 
information and this could also be useful for the assessment of diastolic function, 
because the value of E’ is questionable due to the presence of the interventricular patch.5 
In contrast, in patients after Mustard correction, pulmonary venous return is directed 
towards the systemic ventricle through a noncompliant baﬄe and the left atrium does 
basically not exist.7 
 Because of the widely varying cardiac anatomy among the diﬀerent congenital 
diagnoses, we did not aim to combine or directly compare the diﬀerent imaging ﬁndings 
across the entire ACHD population. Instead, the value of these imaging measurements 
should be appreciated within the investigated speciﬁc diagnostic subgroups.
Blood biomarkers
In contrast to imaging biomarkers, blood biomarkers can be obtained in all patients, 
regardless of the underlying congenital anatomy. We displayed diagnosis-speciﬁc 
biomarker proﬁles and adjusted the analyses for the complexity of the congenital 
diagnosis. In Part II, the (potential) value of matrix metalloproteinases,8 NT-proBNP, 
troponin-T, GDF-15,9 galectin-3,10 and RDW is described in separate chapters. In Table 
1, we provide an overview of all biomarkers that were investigated in the BioCon study, 
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a prospective study of the value of biomarkers in 602 adult patients with congenital 
heart disease. In order to allow better comparison of the prognostic value of all available 
biomarkers, we analyzed the biomarkers according to the statistical analysis method 
and endpoint deﬁnition as described in Chapter 16 (4-year risk of death, heart failure, 
or arrhythmia). Skewed biomarker distributions were log
2
-transformed and odds ratios 
were presented per one standard deviation increase in the biomarker. 
 From these results, it can be concluded that almost all biomarkers were signiﬁcantly 
associated with the endpoint in the univariable analysis, except for MMP-2 and 
hemoglobin. NT-proBNP has the highest standardized odds ratio, indicating that this 
biomarker is most strongly associated with adverse events. Furthermore, NT-proBNP 
has the highest discriminatory value (C-statistic). When all available biomarkers 
were analyzed together in a multivariable logistic regression model, only NT-proBNP, 
troponin-T and GDF-15 remained signiﬁcantly associated with the endpoint. This 
is explained because although the biomarkers reﬂect diﬀerent pathophysiological 
pathways, one biomarker can also be involved in multiple pathways, so there is a 
considerable overlap. This is reﬂected by the correlation coeﬃcients as shown in Table 
2. Although the eﬀect of RDW was partly negated when adjustment was performed for 
all biomarkers (including GDF-15), it was signiﬁcantly associated with clinical endpoints 
when only adjusted for NT-proBNP. Because this is a very inexpensive and worldwide 
readily available biomarker, RDW could also be clinically useful to obtain additional 
prognostic information.
 Of all investigated biomarkers, NT-proBNP was the strongest and most important 
prognostic marker. It is therefore recommended that at least one measurement of 
NT-proBNP is performed in all patients with moderate or complex ACHD to obtain 
prognostic information, preferably when they are in a stable situation when visiting 
the outpatient clinic for a routine check. Patients with a low NT-proBNP level may be 
reassured and can be monitored at a lower follow-up frequency, for instance every 
2-4 years (also depending on other patient characteristics, such as age and congenital 
diagnosis) instead of yearly. In patients with an elevated NT-proBNP, it is probably 
useful to additionally measure other biomarkers, such as troponin-T, GDF-15, or RDW. 
Furthermore, in these patients annual repeated NT-proBNP measurements should 
be considered. This can be useful to identify high-risk patients who should be strictly 
followed-up in a tertiary care center, may beneﬁt from timely initiation or expansion 
of heart failure medication, cardiac rehabilitation training, or possibly early cardiac 
interventions in order to pre-empt the onset of late complications.
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TABLE 1 - Increased 4-year mortality, heart failure, or arrhythmia risk per one standard deviation increase in the (log2-
transformed) distribution of the biomarker.
Biomarker
Univariable 
standardized OR 
(95% CI)
P-value C-statistic
Multivariable 
standardized OR 
(95% CI)
P-value
MMP-2, ng/L* 1.10 (0.88–1.37) 0.416 - - -
NT-proBNP, pmol/L* 3.82 (2.90–5.02) < 0.001 0.80 2.55 (1.82–3.55) < 0.001
hs-TnT, ng/L* 2.18 (1.76–2.70) < 0.001 0.71 1.35 (1.03–1.76) 0.029
GDF-15, ng/L* 2.36 (1.91–2.92) < 0.001 0.73 1.41 (1.07–1.86) 0.014
RDW, % 1.88 (1.53–2.30) < 0.001 0.69 1.26 (0.97–1.62) 0.079
Hb, g/L 0.96 (0.79–1.16) 0.660 - - -
Galectin-3, ng/mL* 1.77 (1.44–2.18) < 0.001 0.65 1.01 (0.77–1.32) 0.942
hs-CRP, mg/L* 1.26 (1.03–1.55) 0.023 0.58 0.93 (0.72–1.19) 0.562
Sodium, mmol/L 0.70 (0.57–0.86) 0.001 0.57 0.86 (0.67–1.09) 0.214
Ureum, mmol/L* 1.68 (1.37–2.06) < 0.001 0.63 1.29 (0.96–1.73) 0.087
eGFR, mL/min* 0.60 (0.48–0.74) < 0.001 0.61 1.14 (0.83–1.57) 0.419
*Biomarker was log2-transformed before further analysis because of a skewed distribution.
TABLE 2 - Pearson correlation coefficients representing the correlation between the biomarkers in the BioCon study.
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MMP-2 0.15 0.07 0.10 0.09 –0.04 0.15 –0.04 –0.03 0.00 –0.07
NT-proBNP 0.42* 0.50* 0.37* –0.13 0.30* 0.24* –0.15* 0.21* –0.33*
hs-TnT 0.31* 0.19* 0.14 0.23* 0.05 0.02 0.37* –0.28*
GDF-15 0.40* –0.12 0.40* 0.20* –0.23* 0.27* –0.48*
RDW –0.20* 0.32* 0.18* –0.18* 0.18* –0.27*
Hb –0.04 –0.12 0.17* 0.08 0.18*
Galectin-3 0.22* –0.20* 0.21* –0.43*
hs-CRP –0.16* –0.01 –0.12
Sodium –0.09 0.18*
Ureum –0.52*
eGFR
*P < 0.001. Correlations with r > 0.40 are printed in bold.
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From risk factor, to risk prediction, to clinical benefit and cost savings
The majority of chapters aims to identify risk factors that are associated with clinical 
outcome in (speciﬁc subgroups of ) ACHD, and are therefore regarded as prognostic 
factor research.11 A factor’s prognostic value over existing prognostic factors should 
not only be reﬂected with the eﬀect size and conﬁdence interval (p-value) of the 
multivariable odds ratio or hazard ratio, but preferably also with the improvement in 
discrimination (C-statistic), and reclassiﬁcation (net reclassiﬁcation index, integrated 
discrimination improvement). 
 Chapter 16 aimed to combine multiple prognostic factors to predict the absolute risk 
of future clinical events in individual patients, which is regarded as prognostic model 
research.12 We validated the model in an external cohort, showing that it had a good 
discrimination and could thus well separate low- and high-risk patients. The calibration-
in-the-large was suboptimal, indicating that the model systematically overestimated 
the absolute risk in the validation cohort.13 Our risk prediction model may therefore be 
further improved by including larger datasets from other centers.
 In addition, more evidence is ideally required beyond external validation before 
a model can be regarded as clinically useful.14 Impact studies are needed to assess 
the eﬀect the implementation of a prediction model on the physician’s behavior and 
patient outcome (net clinical beneﬁt, e.g. the gain in 10-year event-free survival).15 
The reference standard for the evaluation of biomarkers (or prediction models) by 
clinical outcomes is the assessment in a randomized controlled trial which compares 
the outcomes of patients for whom clinical decisions are driven by the biomarker (or 
prediction model) versus usual practice. The challenge of these trials is that a relatively 
large sample size is required to show a beneﬁt on clinical endpoints. To illustrate this, 
we calculated the required sample size of a trial in which patients are randomized 1:1 
into biomarker decision-based therapy and usual practice. Biomarker decision-based 
therapy could for instance be that patients with an elevated NT-proBNP (~50%) receive 
intensive treatment with optimization of heart failure medication, cardiac rehabilitation 
training, frequent follow-up visits, and/or early re-interventions; while patients with a 
normal NT-proBNP level receive standard treatment or even less frequent follow-up.
 Based on an overall event rate of 22% (the 4-year event rate of death, heart failure, 
or arrhythmia in Chapter 16) and a 2-sided α = 0.05 and ß = 0.80, a sample size of ~2800 
patients would be needed to demonstrate a hazard ratio of 0.80 for the occurrence of 
the primary endpoint in the biomarker decision-based treatment group.16 It may be 
therefore more feasible to design a biomarker decision-based trial with a lower required 
sample size by using surrogate endpoints such as the improvement in exercise capacity 
or ventricular function.
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 Finally, the cost-eﬀectiveness of the implementation of a biomarker (or risk model) 
should be studied. The measurement costs of the diﬀerent biomarkers that are studied 
in this thesis are widely varying, with most biomarkers ranging from €1 to €20 per 
measurement (Table 3). Especially GDF-15 is very expensive (€60-80 depending on 
the costs of pre-clinical assays). Furthermore, NT-proBNP and galectin-3 are relatively 
expensive, while other routinely available ‘standard’ biomarkers such as RDW (as part of 
the automated blood count) and kidney function are almost for free, also because these 
measurements may be already performed for other clinical reasons. This could be an 
important reason to consider hs-TnT or RDW as more suitable biomarkers for add-on risk 
stratiﬁcation on top of NT-proBNP, in contrast to GDF-15. Cost-eﬀectiveness is typically 
expressed as a ratio of the gain in health (such as QALY, quality-adjusted life years) and 
the cost associated with that health gain. In theory, this could be analyzed as part of 
the trial as proposed above. The average costs per patient in the biomarker decision-
based therapy arm should be compared with the average costs per patient in the usual 
practice arm. However, in order to demonstrate a substantial gain in health as expressed 
in QALYs in the biomarker decision-based therapy arm, probably a long follow-up and 
large patient numbers would be required (as shown above). Therefore, it might be a 
more feasible option to evaluate cost-eﬀectiveness by using microsimulation modeling 
techniques.17 These computer modeling techniques are suitable for estimating the 
eﬀects of proposed interventions before they are implemented, and are for instance 
used in highway traﬃc ﬂowing through an intersection, ﬁnancial transactions, but also 
in healthcare.18, 19
TABLE 3 - Costs for each biomarker measurement in the clinical laboratory of the Erasmus MC (2016–2017).
Biomarker Costs
MMP-2 €  7,50*
NT-proBNP € 19,45
hs-TnT €  7,87
GDF-15 € 60-80*
RDW €  0,98
Hb €  0,98
Galectin-3 € 18,31*
hs-CRP €  1,54 
Sodium €  0,86 
Ureum €  0,89
eGFR (Creatinin) €  1,06 
*Depending on the costs of pre-clinical assays and measurements in the trial laboratory (incl. BTW). 
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Bias in observational studies: pitfalls and how to deal with it
All chapters in this thesis are based on observational studies, or a review of observational 
studies. Although this type of studies can be useful to answer many questions in 
health research, they are subject to a number of potential limitations that must be 
acknowledged, in order to appropriately deal with it and/or to justly interpret the 
obtained results.20 
Selection and selection bias
Patients with mild ACHD (isolated repaired septal defect without PAH) were not included 
in the BioCon study. These patients have lower levels of NT-proBNP21, 22 and much lower 
event rates;23 therefore, the association that was found between NT-proBNP and events 
may be weaker or even absent in these patients. This is due to selection of the study 
cohort and does not aﬀect the internal validity of the conclusions of the BioCon study 
for patients with moderate and complex ACHD; however, it does imply that the results 
may not generalizable to patients with mild ACHD. 
 Selection bias arises when the study participants (i.e., the BioCon study cohort) 
would not be a representative or random sample of the target population for which a 
statement is to be made (i.e., clinically stable patients with moderate or complex ACHD).20 
In that case, the relation between the studied exposure and outcome is diﬀerent for 
those who participate in the study, compared with all of those who were theoretically 
eligible for the study. The BioCon study was a single-center study performed at the 
outpatient clinic of a tertiary care center. Therefore, we cannot exclude referral bias (a 
type of selection bias); however, almost all patients with moderate or complex ACHD 
are under tertiary care. Selective non-response or selective loss to follow-up may also 
result in selection bias, which can be minimized a prospective study design, a high 
participation rate or ‘consecutive’ sample (i.e., all eligible patients who are seen within 
a speciﬁc time window are included), and careful study planning. In order to assess the 
potential impact of selection bias, the rate of non-participants must be reported (e.g. 
with a ﬂowchart of the study cohort selection process), preferably the most important 
baseline characteristics of the non-participants should be presented, and sensitivity 
analyses can be conducted. The BioCon study had a prospective design, aimed to 
included consecutive patients, and had a high completeness of patient data and follow-
up. Therefore, the impact of selection bias on the overall results of the BioCon study (as 
described in Chapter 4, Chapter 9–13) is probably limited. 
 In contrast, selection (bias) probably did aﬀect the results of the observational studies 
that were included in the systematic review in Chapter 5. We found that the reported 
PAH prevalence after atrial septal defect closure was widely varying (5–50%). This was 
highest in older studies and in studies which included a small number of patients. It is 
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likely that the oldest study cohorts are not generalizable anymore to the population of 
adults with an ASD closure nowadays, because ASD closure is now usually performed 
percutaneously, and therefore probably with a lower threshold (i.e., in less severe 
patients). Furthermore, the rate of non-participants was generally not reported and 
the overall loss to follow-up (i.e., patients with echocardiographic data on pulmonary 
pressures after ASD closure) was high. Therefore, a probable explanation for the wide 
range of the reported PAH prevalence is that the inclusion of more severe patients and 
the selective echocardiographic follow-up of more severe patients has resulted in an 
overestimation of the PAH prevalence in some studies.
Information bias
Incorrect or inaccurate recording of patient characteristics or study outcomes results in 
information bias. These variables can be continuous (referred to as measurement error) 
or categorical (referred to as misclassiﬁcation). When these errors are independent of 
other variables, these ‘random mistakes’ will result in less precise measurements and 
thus an underestimation of the diﬀerence between groups (bias towards the null).20, 24 
An example where non-diﬀerential measurement errors may have resulted an 
underestimation of the eﬀect is Chapter 9. Because we did not assess the reproducibility 
of the matrix metalloproteinase measurements by duplicate measurements, it could be 
possible that the detected biomarker levels were not precise enough. This may explain 
why the correlation between MMP-2 and variables reﬂecting LV diastolic dysfunction 
and exercise capacity was only weak, and not related to study endpoints. We have tried 
to improve this in other studies by ﬁrst performing duplicate measurements of novel 
biomarkers in a healthy control cohort. The galectin-3 measurements were found to 
be highly reproducible and in accordance with normal values that were previously 
published (Chapter 11). However, the initial duplicate ST-2 measurements with a novel 
rapid test were varying to such a degree that we decided to cancel the scheduled 
measurements in the BioCon cohort, and start over with a more conventional ST-2 
analysis method (ELISA; results not available yet and therefore not included in this 
thesis).
 When misclassiﬁcation or measurement errors are dependent of other variables, the 
true association may be either over- or underestimated. This could for instance occur if 
patients with a low NT-proBNP level are not as thoroughly assessed for clinical events as 
patients with a high NT-proBNP level (either during the clinical follow-up by the physician, 
or during review of the electronic patient record the researcher), or vice versa. We aimed 
to avoid this by blinding the event adjudication for biomarker levels. Furthermore, not 
any biomarker was part of the clinical patient work-up during the conduct of the BioCon 
study. Therefore, we expect that bias due to diﬀerential misclassiﬁcation is minimal.
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Confounding
Many epidemiologists, but not all, regard confounding as another type of bias. 
Confounding occurs when the association between exposure and outcome is (partially) 
explained by a third variable (the confounder) that is related to both the exposure and 
the outcome, and is not in the causal chain itself. 
 Confounding is a causal concept, and can be dealt with in the data-analysis by 
stratiﬁcation or multivariable adjustment for confounders. 
 In prognostic studies, it is not the main question whether biomarkers have a causal 
relationship with the disease.25 Biomarkers can play a pathophysiological role in the 
development of disease, but can also be so-called ‘innocent bystanders’ – surrogates 
of causal factors that may be easier to measure but do not have a causal association 
with the disease itself. A clear example of this is NT-proBNP, the biologically inactive 
terminal fragment of the brain natriuretic peptide prohormone.26 Because it does not 
matter if the prognosis is based on causal variables, surrogates of causal variables, or 
confounders, prognostic research focuses on association rather than causation and there 
is strictly speaking no need to ‘control for confounders’ (although it is often described in 
this way).25, 27 Still, in prognostic studies multivariable adjustment is performed, in order 
to investigate whether speciﬁc biomarkers can provide prognostic value incremental to 
other variables that are known to be of prognostic importance (Chapter 4, Chapter 9-13), 
and in order to combine multiple predictors to derive clinically useful risk predictions 
(Chapter 16).
Repeated measurements: regression to the mean
Most studies that investigate serial biomarker measurements only assess the diﬀerence 
between two subsequent measurements, and relate relative, absolute and/or categorical 
changes to adverse events. This is convenient, because it is easy to analyze and interpret, 
and requires less data per patient. However, a problem is that these changes cannot 
be adjusted for the baseline measurements, because this will introduce a bias due to 
regression to the mean. 
 Changes between subsequent measurements can be (partially) the result of 
analytical imprecision and biological variation. Due to this day-to-day variation, every 
patient has a certain ‘normal distribution’ of biomarker values that are (hypothetically) 
measured within a very short time period, with a ‘true mean level’ and a standard 
deviation. The standard deviation will be larger for biomarkers with a relatively large 
biological variation, such as NT-proBNP.28 In Figure 1, an example is presented in which 
the actual levels of a patient with a high mean NT-proBNP level (depicted in red), and of 
a patient with a low mean NT-proBNP level (depicted in blue), do not change between 
Year 0 and Year 1. When evaluating two subsequent measurements of Year 0 and Year 
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1, a decrease or increase can be (partially) explained by regression towards the mean 
NT-proBNP level within a patient. Because regression towards the mean has the same 
theoretical chance to occur in either direction (upward or downward), it may attenuate 
the true changes that can be detected, but it does not directly bias the results. However, 
when the change is adjusted for the baseline measurement as is shown in the right 
panel, basically two patients with the same baseline NT-proBNP level are compared. 
Now, the eﬀect of an increase over time is positively biased due to the regression 
towards the mean eﬀect. 
 This is a very important concept when analyzing two repeated measurements within 
the same patient, especially when there is a large intra-individual biological variability, 
and even more so when adjustment for baseline levels is performed. We believe this 
concept deserves much more scientiﬁc attention, because most studies that have 
investigated serial measurements do not take this into account. The solution for this 
problem is the analysis of multiple measurements (> 2) with a linear mixed eﬀects 
model.29 We believe this provides a more reliable of the true biomarker evolution over 
time. Moreover, it adjusts for regression to the mean by including a random eﬀects term 
for each patient, which takes into account the random within-subject variation.
Year 0 Year 1 
EŽƌŵĂůĚŝƐƚƌŝďƵƚŝŽŶŽĨEdͲƉƌŽEWǁŝƚŚŝŶĂƉĂƚŝĞŶƚǁŝƚŚĂŚŝŐŚƚƌƵĞŵĞĂŶůĞǀĞů
EŽƌŵĂůĚŝƐƚƌŝďƵƚŝŽŶŽĨEdͲƉƌŽEWǁŝƚŚŝŶĂƉĂƚŝĞŶƚǁŝƚŚĂůŽǁƚƌƵĞŵĞĂŶůĞǀĞů
Unadjusted 
Year 0 Year 1 
Adjusted for baseline level 
FIGURE 1 - Conceptual model of the bias that is introduced when adjustment is performed for the baseline level, due 
to biological variation and regression to the mean.
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Big data
Today, the calculation of a p-value is just a few clicks away in easily accessible point-and-
click software such as SPSS. We can hardly imagine that back in the 1970s researchers 
had to manually calculate the signiﬁcance of a statistical test with the use of calculators 
and distribution tables.30 The computer has greatly accelerated medical research 
methods by enabling data management and analysis in a more accurate and less time-
consuming way. 
 Along the same line, in one or two decades from now, we can probably hardly imagine 
that the majority of data harvesting was still manually performed around the year 2017. A 
large part of the data that is described in this thesis was collected by manually including 
patients, analyzing echocardiographic images and double-checking electronic patient 
records. Consequently, cohorts of 600 patients with more than 100 variables per patient 
such as used in this thesis could be considered as reasonably large datasets nowadays. 
There are also much larger cohorts such as the Rotterdam study,31 but these involve 
major budgets and many researchers to appropriately deal with the amount of work. 
 An enormous amount of data is continuously generated in all medical ﬁelds, from 
the intensive care unit to the general practice. These data are incredibly valuable, if we 
would take full advantage of it; however, in medicine we are only at the very beginning 
stages of this information revolution. Information-power companies such as Google, 
Amazon, Netﬂix, and Facebook already know how to predict what kind of shoes you 
would like to buy or what kind of movies you would like to watch, based on self-learning 
algorithms and extremely large datasets known as ‘big data’. In medicine, big data could 
be very useful to further improve risk predictions for individual patients. Although all 
patient information is entered in the electronic patient record at every outpatient clinic 
visit (or even continuously during hospital admissions), including clinical characteristics, 
imaging ﬁndings and laboratory measurements, we do not have an automatic 
framework to further take advantage of this data. We already know how to analyze 
repeatedly collected data in continuously updating dynamic prediction models,32 but 
if we can automatically collect all the data that is generated, machine-based learning 
techniques might be able to further improve the prediction of clinical outcome and to 
aid in clinical decision making.
 The use of big data in medical research is currently hampered by concerns about 
informed consent; protection of patient privacy, conﬁdentiality, and harm; data quality 
and re-identiﬁcation; the reporting of faulty inferences;33 data sharing and intellectual 
property rights; and practical issues such as electronic patient records that are not 
suitable for electronic data collection and the lack of resources to analyze increasingly 
large datasets.34 In addition, concern exists that big data in medicine will lead to the 
(partial) replacement of human doctors by computers. 
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 Nevertheless, artiﬁcial intelligence is already transforming the world as we know it 
and the potential of big data in medicine is huge. Together with wearable devices and 
mobile health apps this will change how people manage their health. Responsible big 
data research should take into account the complex ethical issues that are involved, 
acknowledge that data are people, reduce the change of harm resulting from big data 
research practices, make sure that the work is sound and accurate, and contribute to 
building best practices in medicine.35
CONCLUSIONS
This thesis aimed to establish novel prognostic tools that can be used for the risk 
stratiﬁcation of adults with congenital heart disease and/or pulmonary hypertension. 
Measurements of right and left ventricular volumes and function, main pulmonary 
artery area, left atrial size and function, right ventricular pressure, pericardial eﬀusion, 
and right atrial area are important imaging features that can be of prognostic value 
within speciﬁc diagnostic subgroups. Blood biomarkers can be measured in all patients; 
especially NT-proBNP should be measured at least once in all patients with moderate 
or complex ACHD. In patients with an elevated NT-proBNP level it is probably useful 
to obtain annual repeated NT-proBNP measurements and other biomarkers such as 
hs-TnT and RDW, while patients with a low NT-proBNP level can be reassured and may 
require less frequent follow-up. Finally, a simple risk calculation tool consisting of six 
easy to obtain clinical variables and NT-proBNP is proposed, which could be useful 
to discriminate high- and low-risk patients. Selection bias and information bias are 
inherent types of bias to these observational studies and should be acknowledged 
when interpreting these results. The novel biomarkers that are outlined in this thesis 
are a next step towards better risk stratiﬁcation of patients with ACHD. This may serve to 
optimally inform and reassure patients, to aid clinical judgment in determining optimal 
monitoring and management strategies, to better utilize medical resources and save 
costs, and ultimately to improve the clinical outcome of these patients.
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NEDERL ANDSE SAMENVAT TING
Dankzij de vooruitgang van de medische zorg voor kinderen met een aangeboren 
hartafwijking, wordt de groep volwassenen met een aangeboren hartafwijking alsmaar 
groter. Deze patiënten zijn met name jongvolwassenen, die misschien moeder of 
vader willen worden, deelnemen aan sport en streven naar een zo normaal mogelijk 
leven. De dagelijkse klinische zorg voor deze patiënten is erop gericht om niet alleen 
de levensverwachting, maar ook de kwaliteit van leven te optimaliseren. Hierbij is het 
essentieel om het risico op complicaties, zoals het optreden van ritmestoornissen of 
hartfalen, zo nauwkeurig mogelijk te voorspellen. Het doel van dit proefschrift is het 
onderzoeken van bekende en nieuwe biomarkers bij volwassenen met een aangeboren 
hartafwijking en bij patiënten met pulmonale hypertensie. Biomarkers zijn structuren 
of stoﬀen die gemeten worden in het lichaam middels beeldvorming (zoals MRI en 
echocardiograﬁe) en in het bloed, die het risico op complicaties kunnen voorspellen. 
Hoofdstuk 1 is de algemene inleiding, waarin de achtergrond en indeling van dit 
proefschrift wordt beschreven. 
Deel I – Beeldvorming
Het hart bestaat uit een rechter- en linker hartkamer, en een rechter- en linker 
hartboezem. De grootte en functie van de rechter hartkamer zijn sterke voorspellers 
voor klinische uitkomsten bij volwassenen met een aangeboren hartafwijking en bij 
patiënten met pulmonale hypertensie. Cardiale MRI wordt beschouwd als de gouden 
standaard voor deze metingen. Door de hoeveelheid spiervezelbundels (“trabekels”) 
in de rechter hartkamer is een handmatige meting van het volume van de rechter 
hartkamer echter minder nauwkeurig. In Hoofdstuk 2 wordt een nieuwe meetmethode 
beschreven om met deze trabekels om te gaan. Een MRI van het hart werd verricht bij 
tachtig patiënten (met pulmonale hypertensie, transpositie van de grote vaten met 
arteriële switch operatie of met atriale switch operatie, of gecorrigeerde tetralogie van 
Fallot) en 20 gezonde vrijwilligers. Twee methoden om rechter hartkamervolumes en 
-functie te meten werden vergeleken. De exclusie van trabekels van het bloedvolume 
met een semi-automatische methode, gebaseerd op de pixel intensiteit, bleek zeer 
reproduceerbaar te zijn. Tevens resulteerde dit in een substantiële verandering in 
rechter hartkamervolumes en -functie in vergelijking met de handmatige methode, 
waarbij trabekels werden geïncludeerd in het bloedvolume. Deze nieuwe methode met 
exclusie van trabekels lijkt daarom superieur te zijn aan de oude handmatige methode.
In Hoofdstuk 3 wordt de associatie tussen cardiale MRI-metingen en 
inspanningscapaciteit beschreven bij 71 volwassenen met een arteriële switch operatie 
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op de kinderleeftijd. Met name de grootte van de longslagader was sterk gerelateerd 
aan de maximale zuurstofopname. Dit geeft aan dat een vernauwing van de 
longslagader waarschijnlijk een sterk beperkende factor is van de inspanningscapaciteit 
bij deze patiënten, en vermoedelijk ook een prognostische (voorspellende) factor. In 
Hoofdstuk 4 wordt de associatie tussen linker hartboezemgrootte en -functie met 
klinische uitkomsten beschreven in 134 volwassenen met gecorrigeerde tetralogie van 
Fallot. Middels echocardiograﬁe werden bij alle patiënten het volume, de oppervlakte, 
de lengte en de functie (ledigingsfractie) van de linker hartboezem gemeten. Grotere 
linker hartboezemvolumes, -lengte, en verminderde totale en actieve ledigingsfractie 
waren signiﬁcant geassocieerd met klinische uitkomsten, wat betekent dat deze echo-
metingen van prognostische waarde kunnen zijn bij deze patiënten.
Volwassenen met een gat in het tussenschot van de hartboezems (atriaal septum defect, 
ASD) lopen risico op het ontwikkelen van een verhoogde bloeddruk in het longvaatbed 
(pulmonale arteriële hypertensie, PAH), omdat er door het ASD continue te veel bloed 
terugstroomt naar de longen. PAH is geassocieerd met een slechte prognose. Het ASD 
wordt daarom meestal gesloten met een ingreep via de lies of met een hartoperatie. 
Het is echter niet precies duidelijk hoe vaak er sprake is van PAH bij volwassenen voor en 
na de ASD-sluiting. In Hoofdstuk 5 wordt een systematisch overzicht gegeven van alle 
studies die de bloeddruk in het longvaatbed en/of het percentage volwassenen met 
PAH voor én na ASD-sluiting hebben beschreven. Vervolgens hebben we in Hoofdstuk 
6 van 198 volwassenen die een ASD-sluiting in ons eigen centrum ondergingen tussen 
2000 en 2014, retrospectief alle echo’s beoordeeld voor en na de ASD-sluiting. Uit het 
literatuuronderzoek bleek dat er een grote spreiding was in de prevalentie van PAH na 
ASD-sluiting: tussen de 5 en 50%. De prevalentie was met name hoog in oudere studies, 
studies met een klein aantal patiënten en studies waarbij de echo na ASD-sluiting miste 
bij relatief veel patiënten. We concludeerden in Hoofdstuk 5 daarom dat de “werkelijke” 
prevalentie waarschijnlijk meer richting de benedengrens van deze range zou liggen, 
wat inderdaad werd bevestigd in ons eigen onderzoek (5%). Het aantal patiënten met 
PAH en de gemiddelde drukken in het longvaatbed verminderden in alle studies na de 
ASD-sluiting en bij (op één na) alle patiënten in ons eigen onderzoek. Tevens hebben 
we onderzocht welke factoren een risico vormen voor PAH na ASD-sluiting. Hoewel in 
eerdere onderzoeken de leeftijd ten tijde van ASD-sluiting als belangrijke voorspeller 
werd gerapporteerd, was in ons onderzoek de NYHA-klasse, aanwezigheid van een 
longziekte (OSAS of COPD), gebruik van cardiale medicatie en een verminderde rechter 
hartkamerfunctie gerelateerd aan PAH na ASD-sluiting. Deze patiënten moeten dus na 
de ASD-sluiting extra goed in de gaten worden gehouden.
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In Hoofdstuk 7 en Hoofdstuk 8 wordt een systematisch overzicht gegeven van alle 
echocardiograﬁsche en cardiale MRI-metingen, die van prognostische waarde kunnen 
zijn bij patiënten met PAH. In 37 artikelen werden in totaal 51 verschillende echo-
metingen onderzocht. Hiervan bleken de aanwezigheid van pericardeﬀusie (vocht 
in het hartzakje), een grotere rechter hartboezem en een lagere TAPSE (maat voor 
rechter hartkamerfunctie) de meest onderzochte en sterkste voorspellers voor sterfte 
of longtransplantatie. In 8 artikelen werden 21 cardiale MRI-metingen beschreven: 
hiervan was een verminderde rechter hartkamer ejectiefractie (maat voor functie) de 
belangrijkste voorspeller voor sterfte. 
Deel II – Biomarkers in het bloed
De BioCon studie is een groot project waarbij 602 volwassenen met een matige of 
ernstige aangeboren hartafwijking gedurende 5 jaar zijn gevolgd op de polikliniek van 
het Erasmus MC. Jaarlijks werden deze patiënten gecontroleerd door de cardioloog met 
een bloedafname, hartﬁlmpje en (elke 2 jaar) een echo van het hart. In Hoofdstuk 9 
wordt de associatie van vier biomarkers (MMP-2, -3, -9, en TIMP-1) met de hartfunctie en 
het inspanningsvermogen in een subgroep van 425 volwassenen met een aangeboren 
hartafwijking uit de BioCon studie onderzocht. Van deze vier biomarkers had alleen 
MMP-2 een zwakke associatie met enkele metingen van een inspanningstest of echo. 
Dit zijn echter nog zeer experimentele biomarkers. De nauwkeurigheid van de metingen 
en de normaalwaarden moeten nog worden onderzocht.
In Hoofdstuk 10 worden de belangrijkste resultaten van de BioCon studie beschreven. 
In 595 volwassenen met een aangeboren hartafwijking hebben we de associatie van 
NT-proBNP, hoog-sensitief troponine-T en GDF-15 met het optreden van complicaties 
onderzocht. Tijdens een periode van (mediaan) 42 maanden trad er bij 165 
patiënten een cardiovasculaire complicatie op (gedeﬁnieerd als overlijden, hartfalen, 
ziekenhuisopname, ritmestoornis, trombo-embolie of re-interventie). NT-proBNP was 
zeer sterk gerelateerd aan het optreden van complicaties, onafhankelijk van meerdere 
klinische gegevens en echocardiograﬁsche metingen. Het risico op overlijden of hartfalen 
was extreem laag (~1%) bij de patiënten met een normale NT-proBNP-concentratie 
(ongeveer de helft van de totale groep). Het risico van patiënten met een verhoogde 
NT-proBNP-concentratie kon verder worden bepaald door het gecombineerd gebruik 
van hoog-sensitief troponine-T en GDF-15: patiënten bij wie alle drie de biomarkers 
verhoogd waren, hadden het hoogste risico op een complicatie. In Hoofdstuk 11 worden 
de galectine-3 metingen van de BioCon studie beschreven. Galectine-3 is een mogelijke 
nieuwe biomarker voor patiënten met hartfalen. In ons cohort van volwassenen met 
een aangeboren hartafwijking bleek galectine-3 signiﬁcant geassocieerd te zijn met de 
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hartfunctie (gemeten op echocardiograﬁe) en met het optreden van complicaties. De 
toegevoegde waarde van galectine-3 bovenop een meer bekende biomarker zoals NT-
proBNP bleek echter beperkt. In Hoofdstuk 12 wordt beschreven dat RDW, een meting 
die standaard wordt verricht bij het bepalen van het hemoglobinegehalte, mogelijk wel 
van toegevoegde waarde kan zijn bij het voorspellen van cardiovasculaire complicaties, 
onafhankelijk van leeftijd, geslacht, andere klinische risicofactoren, CRP en NT-proBNP. 
De C-index (maat voor hoe goed een onderscheid gemaakt kan worden tussen hoog- 
en laag-risico-patiënten) van het model mét RDW was net iets hoger dan het model 
zonder (0.74, 95% CI 0.70–0.78 vergeleken met 0.73, 95% CI 0.69–0.78). Uit de analyse 
van 2449 herhaalde RDW-metingen bleek dat er geen duidelijke stijging was aan te 
tonen in de RDW-waarde vlak voor het optreden van een complicatie. 
In Hoofdstuk 13 hebben we 2424 herhaalde jaarlijkse NT-proBNP-metingen 
geanalyseerd, die werden verzameld gedurende 4.4 jaar in de 602 patiënten van 
de BioCon studie. Hierbij hebben we gebruik gemaakt van gevorderde statistische 
methoden (liner mixed eﬀect models, joint models). De NT-proBNP-concentratie steeg 
voorafgaand aan een complicatie, met name bij overlijden of hartfalen. Patiënten 
zonder een complicatie hadden juist stabiele en lage NT-proBNP concentraties. Binnen 
de hoog-risicogroep met een verhoogd baseline NT-proBNP (> 14 pmol/L, n = 315, 53%) 
konden jaarlijks herhaalde NT-proBNP-metingen aanvullende prognostische informatie 
opleveren, omdat herhaalde metingen (ook na correctie voor de baseline waarde) nog 
steeds signiﬁcant geassocieerd waren met het optreden van complicaties.
In Hoofdstuk 14 worden de eerste resultaten van de BioPulse studie beschreven. 
De BioPulse studie is een project waarin tot nu toe 106 patiënten met pulmonale 
hypertensie (een verhoogde druk in het longvaatbed) zijn geïncludeerd. Deze patiënten 
worden elke 6 maanden gecontroleerd door zowel de cardioloog als de longarts, met 
een bloedafname, hartﬁlmpje, longfunctietest, inspanningstest en (jaarlijks) een echo 
van het hart. Gedurende 24 maanden trad er bij 29 patiënten (27%) een complicatie 
op (overlijden of longtransplantatie). Verschillende biomarkers op baseline (NT-
proBNP, hoog-sensitief troponine-T, CRP, galectine-3, RDW en eGFR) waren signiﬁcant 
geassocieerd met het optreden van een complicatie. Hoe meer biomarkers verhoogd 
waren, hoe hoger het risico was op een complicatie. Deze gegevens pleiten dus voor 
een aanpak waarbij meerdere biomarkers tegelijk worden gebruikt. Alle patiënten 
met normale waarden van alle biomarkers waren na 40 maanden nog in leven zonder 
longtransplantatie.
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Deel III – Risico voorspellen
Hoofdstuk 15 geeft een literatuuroverzicht van alle gerapporteerde factoren die 
mogelijk kunnen bijdragen aan het voorspellen van hartfalen en andere complicaties 
bij patiënten met een aangeboren hartafwijking in het algemeen of binnen subgroepen 
met een speciﬁeke aangeboren hartafwijking. Het risico op complicaties is voor een 
groot deel afhankelijk van de precieze anatomie van de onderliggende hartafwijking 
en de soort hartoperatie of ingreep die is gedaan. Verder kunnen componenten van 
de anamnese, lichamelijk onderzoek en aanvullende diagnostische testen (inclusief 
hartﬁlmpje, echograﬁe of MRI van het hart, inspanningstest en bloedbiomarkers) 
informatie opleveren over het risico dat een patiënt heeft op een complicatie.
Tot slot hebben we in Hoofdstuk 16 een model ontworpen en gevalideerd, waarmee 
het 4-jaars risico op dood, hartfalen of een ritmestoornis bij volwassenen met een 
matig tot ernstige aangeboren hartafwijking kan worden voorspeld. Dit model werd 
ontwikkeld in de Biocon studie (n = 602) en extern gevalideerd in een database van 
402 patiënten met een aangeboren hartafwijking uit een tertiair ziekenhuis in Praag, 
Tsjechië. Het uiteindelijke model bestond uit zes direct beschikbare klinische variabelen 
(leeftijd, congenitale diagnose, NYHA-klasse, cardiaal medicatiegebruik, re-interventies, 
BMI) en NT-proBNP. De extern gevalideerde C-index was 0.78 (95% CI 0.72–0.83), wat 
betekent dat het model een goed onderscheid kan maken tussen hoog- en laag-
risicopatiënten. Wel maakte het model een systematische overschatting van het risico in 
de Tsjechische groep: de kalibratie kan derhalve wellicht nog verder verbeterd worden 
in de toekomst. Hoe dan ook zou dit model klinisch bruikbaar kunnen zijn bij het maken 
van een onderscheid tussen patiënten met een hoog of laag risico op complicaties.
CONCLUSIE
Het doel van dit proefschrift was het onderzoeken van bekende en nieuwe biomarkers 
die gebruikt kunnen worden bij het voorspellen van risico’s bij volwassen met een 
aangeboren hartafwijking en bij patiënten met pulmonale hypertensie. Verschillende 
MRI en echo-metingen worden beschreven die van prognostische waarde kunnen 
zijn, zoals rechter hartkamervolumes en -functie, longslagader grootte, linker 
hartboezemgrootte en -functie, verhoogde drukken in het longvaatbed, pericardeﬀusie 
en rechter hartboezemgrootte. Vanwege de verschillen in de anatomie van het hart moet 
de waarde van deze metingen per diagnose apart worden onderzocht en beoordeeld. 
NT-proBNP was de belangrijkste voorspellende biomarker in het bloed en zou bij elke 
volwassene met een matige of ernstige aangeboren hartafwijking op zijn minst éénmaal 
gemeten moeten worden. Bij patiënten met een verhoogde NT-proBNP-concentratie is 
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het waarschijnlijk zinvol om deze meting jaarlijks te herhalen en ook andere biomarkers 
te meten, zoals hoog-sensitief troponine-T en RDW. Patiënten met een normale NT-
proBNP-concentratie kunnen worden gerustgesteld en hoeven waarschijnlijk minder 
vaak gecontroleerd te worden door de cardioloog. Tot slot wordt een eenvoudige 
rekentool gepresenteerd, die bruikbaar zou kunnen zijn om onderscheid te maken 
tussen hoog- en laagrisicopatiënten. 
 De biomarkers die in dit proefschrift worden beschreven kunnen bruikbaar zijn voor 
het informeren en geruststellen van patiënten, bijdragen aan het klinische oordeel 
van de arts bij het bepalen van de optimale behandeling en kunnen mogelijk kosten 
besparen doordat medische zorg beter kan worden ingezet waar dat nodig is, met als 
uiteindelijk doel de zorg en klinische uitkomsten van volwassenen met een aangeboren 
hartafwijking verder te verbeteren.
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het bijzonder Cindy, Memento en Donna; en dames van de functieafdeling longziekten, 
in het bijzonder Leonoor, Wilma, en Carla: dank voor jullie hulp en enthousiasme bij 
alle ECGs, bloedafnames, formulieren, pakketjes en het plannen van afspraken in het 
kader van de BioCon en BioPulse studies. Collega’s van de longziekten: Dr. Boomars, 
Dr. van den Toorn, Peter en Thomas, bedankt voor de ﬁjne samenwerking en voor jullie 
expertise op het gebied van pulmonale hypertensie.
Lieve Ba-308tjes, door jullie was het altijd gezellig op werk. Eerst de oude garde: Jannet, 
je hebt alle projecten zo gestructureerd opgezet en overgedragen, dankzij jou had ik een 
vliegende start, ik ben ontzettend blij dat ik het stokje van jou heb mogen overnemen. 
John, met jou is het altijd lachen, het ESC-congres in Barcelona en het SFG-skiweekend 
waren legendarisch. Dan de ‘Avant-garde’: Myrthe, Iris en Allard. Als je 5 dagen in 
de week met elkaar datasets, computerleed en publicatietaart deelt en meerdere 
koﬃezetapparaten verslijt, kan het niet anders dat collega’s ook goede vrienden worden. 
Wij hadden ons eigen jargon ontwikkeld: pingelen, lengelen, deddelen, plensje, todelen. 
Samen hebben we heel wat congressen afgestruind, geknald, getroost, dinertjes gehad, 
tijdschriften gemaakt en mokken bedrukt. Myrthe, wat was het gezellig met jou op de 
kamer, zullen we binnenkort weer een rondje ﬁetsen (en vooral koﬃedrinken)? Iris, 
harde werker en lieve collega, ik bewonder jouw doorzettingsvermogen en ik ben 
blij dat je nu ook mijn buddy bent in het SFG. Allie. Wat ben jij een topper, ik kan zo 
lachen met jou. Je sportprestaties, kookkunsten en dancemoves zijn ongeëvenaard en 
ik weet zeker dat we nog veel meer mooie momenten zullen meemaken. Tot slot de 
nieuwe garde met talentvolle onderzoekers: Roderick, Lidia, Lucia, Laurie, en Carlijn. 
De fotowand vol met mooie herinneringen is door jullie meeverhuisd naar de nieuwe 
locatie. Ro, de nieuwe kamer-oudste en echo-expert, Lidia, doorzetter pur sang en 
nationaal beachvolleybal-ster, en Lucia, ik ken niemand met zoveel paar schoenen als 
jij, dank voor alle gezelligheid, koﬃetjes, biertjes, en niet te vergeten ons heerlijke tripje 
naar Davos: wat hebben we daar gelachen, de stofwolk van Lucia staat me nog helder 
voor de geest. Laurie, ik ben ontzettend blij dat jij de studies hebt overgenomen, ik weet 
zeker dat het bij jou in goede handen is. Bedankt aan alle studenten die een bijdrage 
hebben geleverd aan dit onderzoek, in het bijzonder Roxy, ook jouw eerste publicatie 
is inmiddels een feit!
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Andere collega-onderzoekers van de cardiologie: Lennart, jij bent vliegensvlug 
gepromoveerd, ik twijfel er niet aan dat jij een fantastische carrière als cardioloog 
tegemoet gaat. Hannah, dankzij jou zijn we inmiddels bijna 3 jaar geleden verhuisd 
naar een prachtig plekje in Rotterdam. Sara, bedankt voor jouw onmisbare hulp met 
R. Eva, Christoph, Lennart, Lida, Jaap, Maxime, Anne-Sophie, Raﬁ, bedankt alle mooie 
congressen, NVVC challenges, vrimibo’s, onze wekelijkse krokettenlunches, en andere 
ongein op de werkvloer. Alle andere onderzoekers, staf, en assistenten cardiologie in 
het Erasmus MC, dank voor de mooie tijd. 
Dr. Maarten-Jan Cramer, jouw enthousiasme heeft destijds de deur voor me geopend 
om onderzoek te gaan doen bij de GUCH, ik kijk met veel plezier terug op de tijd in het 
Harapan Kita Hospital. Rasa sayang! Dr. Folkert Meijboom, Dr. Gert-Jan Sieswerda, Dr. 
Hans Breur en Mieke Driessen: onder jullie supervisie ben ik als geneeskundestudent 
begonnen in het onderzoek bij de congenitale cardiologie. Ik ben jullie dankbaar voor 
alle begeleiding en voor de ﬁjne tijd in het UMC Utrecht.
Graag wil ik al mijn vrienden bedanken die de hoogtepunten en hobbels van de 
afgelopen jaren van dichtbij hebben meegemaakt. Dankzij jullie kreeg ik genoeg 
aﬂeiding, of dat nou in Rotterdam, Amsterdam, Utrecht, Eindhoven, Nuenen, Den Haag, 
Edinburgh, Texel, Rome, Uganda, Londen, Berlijn of het hockeyveld was, waardoor ik 
genoeg ruimte in mijn hoofd overhield om dit proefschrift te kunnen volbrengen. Lot 
en Fem, jullie zijn fantastisch. Ik word helemaal vrolijk van de gedachte dat jullie op 18 
september aan mijn zijde zullen staan als paranimfen, heel veel dank daarvoor!! 
Verder wil ik graag mijn lieve familie en schoonfamilie bedanken voor alle ﬁjne 
momenten van de afgelopen jaren en hun oprechte interesse in hoe het ervoor stond 
met mijn onderzoek. Pap, mam, Dirk en Guus, in Nuenen kwam ik altijd mijn batterij 
opladen. Ik ben een geluksvogel dat ik mocht opgroeien in een warm en gezellig gezin 
zoals dat van ons. Pap en mam, jullie zijn de liefste en beste ouders die ik me kan wensen 
en ik geniet ervan om te zien dat jullie, nu wij allemaal uit huis zijn, aan je tweede jeugd 
begonnen zijn. Duizendmaal dank voor jullie onvoorwaardelijke support en warmte. 
Lieve Emil, samen hebben we Rotterdam drie jaar geleden ons eigen thuis gemaakt. 
Niet alleen het voltooien van de inhoud, maar ook de cover van dit proefschrift heb 
ik aan jou te danken! Dankjewel voor je eindeloze interesse, relaxte steun en continue 
bron van aﬂeiding die jij voor mij bent geweest. Ik hou van jou.
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